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FOR CAROLYN, 
MARTIN AND ALEXANDER 
AND OUR FUTURE LIVES 
IN THE NEW WORLD 
Culture is concerned with establishing ideas. 
Education is concerned with communicating those 
established ideas. Both are concerned with 
improving ideas by bringing them up to date. 
The only available method for changing ideas is 
conflict which works in two ways. in the'first 
way there is a head on confrontation between 
opposing ideas. One or other of the ideas 
achieves a practical dominance over the other 
idea which is suppressed but not changed. In 
the second way there is a conflict between new 
information and the old idea. As a result of 
this conflict the old idea is supposed to be 
changed. This is the method of science which 
is always seeking to generate new information 
to upset the old ideas and bring about new ones. 
It is more than the method of science 
- 
it is 
the method of human knowledge. 
Edward de Bono 
"Lateral Thinking" 
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ABSTRACT 
This study has been undertaken to determine what pseudo-proprietary 
information and patenting activity statistics could be derived from an 
online patents database. 
To achieve this, a thorough investigation uas made of patenting in the 
field of an important group of beta-lactam antibiotics, the. Cephalospo- 
rins. Patents data was retrieved from the World Patents Index online 
files of Derwent Publications Limited, and the bibliographic details of 
each patent application retrieved analysed according to numbers of 
patents per patentee, priority and publication dates, types of patents, 
etc. 
A review of technological advances in this subject was conducted, 
demonstrating the value of patents literature for such purposes. 
The relationship between sales volumes and patenting activity for 
Cephalosporins patentees has been investigated and found to show a. 
significant correlation between these parameters. As an extension, the 
USA patenting and sales activity for the leading USA Industrial Corpor- 
ations (the 1981 Fortune 500) was studied; overall a high correlation 
was exhibited, but there were notable differences. between different 
industries. 
A number of bibliometric studies have been undertaken with a variety of 
patents data. for a number of techhologies. These studies include the 
application of Bradford-Zipf plots, other productivity studies and 
Vector Analysis to patents. 
Whilst previous studies on journal literature have investigated the 
applicability of frequency distributions as measures of author product- 
ivity, this study has for the first time applied Lotka's Law, Price's 
Pareto-type Distribution, Simon-Yule Distribution, Shockley's Lognormal 
Distribution, Borel-Tanner Distribution, Williams Geometric Series, 
Fisher's Logarithmic Series and the Negative Binomial Distribution to 
patents data. Theoretical distributions were ascertained using a 
series of microcomputer programs written in BASIC programming' language. 
The results indicate that of the distributions investigated, the 
Negative Binomial most closely fits the observed data when goodness-of- 
fit is measured by the Kolmogorov-Smirnov Test. 
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1: INDUSTRIAL INNOVATION AND INFORMATION FLOW 
According to Usher1, there are three general theories of invention: the 
transcendentalist, the mechanistic and the cumulative synthesis. The 
transcendentalist approach attributes invention to the inspiration of 
genius. Rare and infrequent flashes of insight yield brilliant idea 
which become path-making inventions. This is the traditional picture, 
where the individual plays a crucial role. The lone inventor makes a 
great impact on technology by a single creative thought. His flash of 
genius is largely independent of economic forces. Curiosity and 
fortuitous events are major elements. 
The mechanistic approach adopts the view that invention proceeds under 
the stress of necessity. Needs dictate the direction of change and 
inventions emerge. In this approach economic forces predominate. 
Invention is not visualised as an autonomous process yielding to 
unpredictable events. Costs and revenue considerations become crucial. 
The individual and lone genius revolutionising technology are rejected 
as the typical source of invention. 
The last approach sees major invention emerging from the cumulative 
synthesis of what has preceded. These inventions require an act of 
insight to overcome resistance or discontinuity. They are likely to 
occur to individuals who are directly concerned with the problem and 
its solution. The requirement of the act of insight reduces the 
predictability of the event. It is not certain that it will occur. 
Unlike the mechanistic approach, the individual is not merely an 
instrument of an inevitable historical process. He has an important 
role to play. His role is not that of the transcendentalist's genius 
who is struck by a brilliant idea, but rather of the mind engaged in 
the solution of technical problems. An act of insight will be condi- 
tioned by the specific problems encountered; if and when it occurs it 
will be through a synthesis of previous knowledge. This approach is 
probably the most realistic. Invention is not dependent on the emer- 
gence of genius. There are too many examples of multiple invention for 
this to be a realistic view of the process. Furthermore "it is clear 
from the analysis of patent statistics..... that invention in general 
and significant technical advances in particular, are not random 
2 
oecurences". 
-1- 
Nor is it an inevitable process dictated by the passage of time and 
economic pressures. Certainly, necessity will promote invention; 
wartime experience confirms this. Similarly great men emerge to make 
great inventions, but these occurences are not typical. Theories of 
invention must describe the usual, not the rare. In these terms, the 
cumulative synthesis approach is probably the most plausible. 
In 1968 the SAPPHO project (Scientific Activity Predictor from Patterns 
with Heuristic Origins) was launched to study the success and failure 
of industrial innovation3. Two important factors emerged from this 
study. The first is that it was noted that in introducing new products 
and processes to the market there is a high failure rate. It varies 
from 60 to 90%, depending on the sector of industry and the nature of 
the market. The second fact is allied to this. Innovations appear to 
happen in clusters, very seldom in isolation. Thus, when the world 
market for a particular chemical expands and forces up its price, 
several firms in the industry will encourage research into cost re- 
ducing or quantity increasing processes. Of this group of innovating 
firms, one or two will succeed commercially with a process, others will 
succeed technologically but not commercially, and some will fail on 
both counts. 
The SAPPHO team investigated why some companies succeeded outstandingly 
where others failed. By conducting a series of interviews with key 
personnel 
-in the chemical and scientific instruments industries the 
investigators hoped to find a group of characteristics that would 
effectively discriminate between a successful and a less successful or 
failed innovation, thus throwing light upon the necessary and suffi- 
cient conditions for commercial success, given technical success. 
The variables which were found to show the greatest differences between 
successful and less successful innovations (in both industries) were as 
follows. Successful innovators showed the following characteristics: 
- 
- 
they have better understanding of user needs, sometimes by colla- 
borating closely with potential customers; 
- 
they do thorough market research or possess the necessary exper- 
ience of user requirements; 
- 
they pay more attention to marketing; 
- 
their development work is more efficient, but not necessarily 
quicker than that of the failure cases; 
2 
- 
they remove technical snags from the product or process before 
they launch it, not after customer complaints; 
- 
they usually have a larger development team on the project and 
therefore spend more money on it, even when the successful firm is 
smaller than the failure; 
- 
they make more effective use of outside technological and scien- 
tific advice and information sources, even though they carry out 
most of the work in-house; and 
- 
they have better contacts with the outside scientific community in 
the specific area concerned and not merely in a general way. 
The responsible individuals in the successful attempt are. usually more 
senior and have greater authority than their counterparts who fail. In 
the instrument industry they have more diverse experience including 
experience abroad. The greater authority of the key individuals in the 
successful attempts is a factor in providing the scale of effort which 
is needed as well as the cooperation of R&D and marketing. 
In the SAPPHO results it emerged that although most firms involved with 
innovations tend to have good contacts with the scientific and techno- 
logical community, the discriminating factor, a subdivision of this 
one, is that the successful innovators make use of this connection with 
specific reference to the innovation project itself. Not only do they 
have constant and high quality information flows, they pay special 
attention to those relevant to the project. 
Hill ü, in discussing the place of patents in the field of scientific 
and technical literature, has drawn attention to the SAPPHO report 
conclusions and has commented upon the difficulties in the use of 
patents as an information source for technological developments. 
T. J. Allen5 has shown a correlation betwen successful innovative 
effort and systematic literature searches and staff consultations. 
Allen and Cohen6 found that R&D teams with a poor innovative record 
spent more time than successful teams on initial data gathering but 
neglected information seeking at later stages of a project, or at best 
fluctuated in their attention to information gathering during the life 
of the project. Teams with better results tended to be more consistent 
in the proportion of effort they put into data collection. 
-3- 
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Allen also found that high performance by teams tended to correlate 
with the use of internal sources of information. Comparatively poor 
performers not only tended to rely on outside sources but also to 
overrate the quality of those sources. Relevant literature was under- 
used by the poorer performers, and where they did use the printed word 
it was frequently "low grade", meaning that it was not academic nor 
professional but commercial, therefore outside the control of the 
professional institutes and "open to the temptation of distortion 
towards the products of the heavy advertisers". 
Carter and Williams7, who investigated about two hundred firms in a 
wide range of industries, defined twenty-four characteristics of the 
"technically progressive" firm (these may also be regarded as condi- 
tions for successful industrial innovation as it is a reasonable 
assumption that progressive firms will also be innovative). Six of 
these characteristics dealt with information flow: 
- 
- 
high quality incoming information 
- 
regular surveying of ideas 
- 
willingness to buy "know-how" and enter into joint ventures 
- 
knowledge sharing with other firms 
- 
an outward looking tendency 
- 
effective internal communication and coordination. 
Grace8 has presented a' hypothetical model of innovation as in Figure 
1. 
From the foregoing, there is a clear indication that the innovative 
process, to result in commercially viable and successful products and 
processes, relies to a very large extent on the careful gathering and 
dissemination of pertinent information. 
It is in this scenario that patents information plays a vital role. To 
satisfy questions such as: should a research project be carried out, or 
should the necessary know-how be acquired in another way, or should the 
project be abandoned, requires an efficient and continuing survey of 
patents information. 
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2: INVENTIONS AND PATENTS 
An invention is a novel idea resulting from inventive activity and is 
capable of industrial application. Under most legislations, therefore, 
an idea, to be protected by law (i. e.,. "patentable"), must be new in 
the sense that there is no evidence that the idea has already been 
published or publicly used before; it must be non-obvious in the sense 
that it would not have occurred to any specialist in the particular 
industrial field, had such a specialist been asked to find 
-a solution 
to the particular problem; and it must be applicable in industry in the 
sense that it can be industrially manufactured or used. 
A patent is a document, issued by a government office, which describes 
the invention and creates a legal situation in which the patented 
invention can normally only be exploited (made, imported, sold, used) 
with the authorisation of the patentee. This protection of the inven- 
tion is limited in time 
- 
generally for 15 to 20 years. The term 
"patents" is derived from "literae patentes", open letters, used by the 
Crown to confer rights or status. A patent for an invention is a form 
of industrial property, and is similar in many ways to private pro- 
perty. Thus, the owner can sell all or part of his private property, 
and equally the owner of industrial property can sell all or a part of 
it. Similarly, just as an owner can rent or lease private property for 
a period, so the owner of industrial property can grant licenses to 
others to use it. Normally the consideration for such a licence is a 
royalty. 
A further point of resemblance is that the owner of private. property 
can sue deliberate trespassers, while with industrial property the 
owner can sue for infringement of his rights. Both forms of property 
are part of the owner's estate and would on his death pass to the 
person specified in his will; in the case of industrial property owned 
by a company this means little as usually the company outlives most 
people. 
In the case of private property the document which specifies the 
ownership (title deed) defines the boundaries of the property. 
Similarly, in the case of a patent specification for an invention there 
are the "claims". These are brief statements which define the 
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boundaries of the monopoly of the patent. In both cases the documents 
are subject to the laws of interpretation of documents. Thus it can be 
seen that a patent specification is both a technical document and a 
legal document. 
PATENTS 
-A DEFINITION OF THEIR PURPOSE 
The primary intention of the patent system is the encouragement of new 
industries. The theory of the system has been succinctly described by 
Blanco White9 in his discussion of the British system: 
The basic theory of the patent system is simple and reasonable. 
It is desirable in the public interest that industrial techniques 
should be improved. In order to encourage improvement, and to 
encourage also the disclosure of improvements in preference to 
their use in secret, any person devising an improvement in a 
manufactured article, or in machinery or methods of making it, 
may upon disclosure of his improvement at the Patent Office 
demand to be given monopoly in the use of it for a period of 
sixteen years. [Blanco White was referring to the former UK 
regulations; under the terms of the Patents Act (1977) a maximum 
of 20 years is permitted. ] After that period it passes into the 
public domain; and the temporary monopoly is not objectionable, 
for if it had not been for the inventor who devised and disclosed 
the improvement nobody would have been able to use it at that or 
any other time, since nobody would have known about it. Further- 
more, the giving of the monopoly encourages the putting into 
practice of the invention, for the only way the inventor can make 
a profit from it (or even recover the fees for his patent) is by 
putting it into practice: either by using it himself, and deriv- 
ing an advantage over his competitors by its use, or by allowing 
others to use it in return for royalties. 
Parker10 has stated that patents are intended to raise the incentive to 
devote resources to technological change and that they are designed to 
combat the awkward properties of knowledge and speed the rate of its 
dissemination. 
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HISTORICAL ASPECTS OF PATENTS 
Many authors have written on the history of patent systems, tracing 
their development from antiquity through to present day legislation. 
Two of these accounts have been given by Skolnik11 and Capsey12; their 
works are quoted extensively in the following paragraphs, as the 
clarity and conciseness of their accounts would be difficult to improve 
upon. 
Records of early civilisations disclose a series of discoveries and 
inventions. Thousands of years before the development of writing, 
which occured about 2500 BCE, fire and its many applications had been 
discovered, the wheel had been conceived, animals had been domesti- 
cated, tools had been introduced, and humans had engaged in activities 
such as agriculture, mining, metallurgy, construction and boat buil- 
ding. From the dawn of history until humans learned to write, broad- 
based civilisations were dependent on the discovery of nature's secrets 
and on technological inventions and improvements. 
The pace of discovery and invention, extremely slow throughout most of 
antiquity, accelerated appreciably with the emergence and development 
of the Greek civilisation. Some of, the many inventions which came 
forth during the height of the Greek civilisation were the water clock 
(Ktesibios); balance, lever, endless screw (Archimedes); surveyor's 
instruments, water level, screw press (Hero-of Alexandria); and others 
such as the water wheel for pumping water and grinding grain, and the 
catapult as a military weapon. History tells us that the governing 
body in Athens granted franchises to those who invented or introduced 
new products, such as a new dish based on a special recipe for which 
the chef was given a six months monopoly 
- 
the so-called "food patents" 
of Sybaris. 
From the Roman empire came the introduction of road construction, 
public hygiene with the construction of aqueducts and sewers, a com- 
pletely new concept of architecture, and hydraulic cement for construc- 
ting buildings. The hydraulic cement was made possible by the presence 
of pozzalana sand near Rome; with the downfall of Rome the quality of 
this cement could not be matched until the introduction of Portland 
cement in the 19th. century. 
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Over the thirteen centuries of the Greek and Roman cultures, from about 
900 BCE to 1100+ CE, Western society was transformed from small agricul- 
tural communities to states with large cities. This new social struc- 
ture was based on extensive trade between cities and states and requi- 
red services such as fresh water and sewers, transportation facilities 
and industries. Thus arose a class of artisans with technical skills 
and technological knowledge. Even during the Middle Ages, from about 
the 5th. to the 14th. century, which we think of as the Dark Ages 
(especially from the 5th. to the 9th. century), inventions continued to 
come forth, such as fireplaces with chimneys, hot air stoves, the horse 
stirrup, wheeled plow, horse harness (which led to oxen being replaced 
by horses for agricultural tasks), carriages with springs for transpor- 
ting people, canal-lock chambers, windmills, ship rudders, the compass 
and weight driven clocks. 
Monopolies as such existed as long ago as the Byzantine Empire 
- 
but 
they were not for inventions. One example of the early use of privi- 
leges for technology occured in 1331 when Edward III wished to attract 
Flemish weavers to England. He issued letters of protection, analogous 
to a passport, but not giving exclusive rights. 
The bait offered to the Flemish weavers was a promise of "good beer, 
good beds and still better company, English girls being renowned for 
their beauty". This worked so well that the Flemish authorities had 
to make arrangements to prevent the excessive "export" of weavers. 
By the end of the 13th. century, the beginning of the Renaissance, the 
concept of patents for inventions had emerged. The Mediterranean 
area, and especially Italy, was dominant during the early part of the 
Renaissance. Outstanding metal, glass and textile artisans and gun- 
smiths were centered in various cities such as Florence and Venice. 
The first record of a granted patent for invention was that by the 
Republic of Florence in 1421 for a barge fitted with hoisting gear to 
load and unload marble. This first granted patent rewarded the inven- 
tor, Filippo Brunelleschi, with an exclusive three-year monopoly. The 
grant included the following wording: 
- 
-9- 
Because Brunelleschi did not want to give the invention to public 
use for fear of being robbed of the reward of his labours, the 
privilege is granted with the express intention not only that the 
invention may be made useful as well as for himself as for the 
generality but particularly also that he himself may be urged to 
further exertion, and stimulated to achieve greater inventions; 
the Government agrees to protect the inventor against unautho- 
rised working and to grant the author an immediate monopoly for 
the period stated by prohibiting the use of every form of tran- 
sport ship not in use at the date of the privilege unless it be 
built by Brunelleschi himself or with his consent. 
The Republic of Venice, one of the most industrially and commercially 
active sites in Europe during the 15th. century, granted similar 
monopolies to foster new enterprises.. These monopolies were called 
"privileges" and the first was granted by the State of Venice to John 
Speyer in 1469 for a printing process. 
However, in spite of such grants of privilege, no formal patents system 
was set up. Venice also granted what we would now call patents, and in 
1474 this led to the Venetian senate voting the first patent legisla- 
tion by a considerable majority. The main portion of the law reads as 
follows: 
- 
It is enacted by the authority of the present Council that 
whoever will make in the. City any new and ingenious artifice, not 
previously made in our State, will be obliged to register it at 
the office of our provediters of the Commune, as soon as it will 
be reduced to perfection so that it will be possible to use and 
apply it. It shall be forbidden to anyone else in our land and 
place to make any other artifice to the image and similarity of 
that one without consent and licence of the author during the 
term of ten years. And if nevertheless someone did it, the 
aforesaid author and inventor would be free to cite before any 
office of this City, and the said who would have imitated would 
be compelled to pay one hundred ducats, while the artifice would 
be immediately destroyed. But our Government will be free, at 
its complete discretion, to take over and use for its needs any 
of the said artifices and instruments, under the condition, 
however, that others than the authors may not employ them. 
- 
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This was not strictly applied, and some of the patents lasted more than 
ten years 
- 
usually in multiples of five years. Note in this Venetian 
law the preservation of the State's rights to use the invention. 
By 1550 over one hundred patents had been granted in Venice under its 
patent law of 1474, which, as Capsey12 observed, was more like our 
concept of copyrights than patents. 
The industrial and commercial dominance of the Mediterranean area did 
not last long. Two factors contributed to the diffusion of Italian 
technology. Italian craftsmen were persuaded or induced by lucrative 
offers of privileges of monopoly to bring their skills and knowledge to 
other European states. Religious persecution and warfare in Italy 
further stimulated the migration of Italian craftsmen. During most of 
the period from the 15th. century through to the 17th. century, crafts- 
men and technologists were a highly mobile group throughout Europe and 
many settled in the newly established American colonies, going where 
the rewards were greatest. 
The granting of monopolies was the primary reward, but the reward was 
highly localised and no invention of merit remained confined to one 
locality for long. Johann Gutenberg's invention of movable type in the 
1450s, for example, spread from Mainz where Gutenberg had his printing 
plant, throughout Europe within 30 years 
- 
all without gain to Gutenberg. 
Other countries also developed patent systems. In Antwerp there was a4 
well established patent system in the 16th. century and as early as 
1551 we find a patentee criticised for not working his patent. This is 
one historical precedent for the inclusion in the patent laws of many 
countries provisions making it obligatory for a patentee to work his 
invention or be willing to grant licences to others to work it. There 
were also patents valid in Brabant and Liege, and a flourishing Dutch 
patent system before 1550. 
France also had an early patent system, and here it was usual practice 
to examine the inventions for which a monopoly was sought and also to 
perform experiments. Thus, in 1609, Le Coure and Thouyn petitioned 
for patents for furnaces which they claimed they had invented. A 
practical examination before the minister Sully was imposed to decide 
the issue. In spite of all these rather' advanced ideas, the French 
system was apparently without any formal legal basis. 
- 
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Many other countries entered the field of patents for inventions at an 
early time; these included the German States. In 1535 the Margrave of, 
Brandenburg-Onalzbach, who owned Tarnowice in Silesia, granted an 
eight-year monopoly for a pump to be used in mines. Austria, Poland, 
Berne, Zurich and Russia also granted patents in the 16th. and 17th. 
centuries. One interesting point about the early Dutch system was that 
in the 16th. and early 17th. centuries written descriptions of the 
inventions were consistently required; this was not always so in other 
countries. 
Colonial America was predominantly agricultural. Less than 10% of the 
population was employed-in manufacturing processes. Because there was 
a need for new industries, colonial legislatures invoked the exercise 
of monopoly, but generally without the abuses of the European prac- 
tices, to encourage manufacturing and to induce European artisans to 
settle in the colonies. The first patent in colonial America was 
granted in 1641 by the Massachusetts General Court to Samuel Winslow 
for making salt "after a method invented by himself" for a period of 
ten years provided the process was operable within one year. Salt, 
being a necessity, was the subject of other granted patents in Plymouth 
(1641), Massachusetts (1652), Virginia. (1660), New York (1661), Connec- 
ticut (1691) and South Carolina (1725), each. presumably by a new 
process, but without the need to prove it. Pennsylvania, which had 
more industries than the other colonies, surprisingly granted no 
patents until after the-Revolution. 
The Continental Congress adopted a resolution in 1783 recommending the 
enactment by each state of Copyright Acts. ý All but one state did so 
by 1787. These acts were superseded by the United States Constitution 
of 1789 which empowered the Federal government "to promote the progress 
of science and useful arts by securing for limited times to authors and 
inventors the exclusive right to their, respective writings and discove- 
ries". 
Congress passed the first US Patent Act on 10 April, 1790, which 
granted patents for up to 14 years and placed administrative responsi- 
bility for the granting of patents on the State Department. The first 
board of examiners consisted of Thomas Jefferson (Secretary of State), 
Henry Knox (Secretary of War) and Edmund Randolf (Attorney General). 
The Act required inventors to file a specification in writing, a 
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drawing, and 
- 
if feasible 
-a model. The first patent granted under 
the Act was to Samuel Hopkins on 31 July, 1790, for "Making Pot and 
Pearl Ashes". 
THE BRITISH SYSTEM 
Monopoly,. not invention, was the underlying principle of the patent 
concept, and originally the word patent referred to the grant of a 
special license or privilege issued under the Great Seal by the Monarch 
to one of his subjects, usually one of the nobility. English rulers, 
over a period of about two centuries, exercised the monopoly principle 
as a right of the crown to grant charters, commissions, offices titles, 
favours, sanctions and the exclusive right to practice an art or trade, 
to the making using or selling of a product and to the regulation of 
trade. For example, in 1449, Henry II granted to John Utyman, who came 
to England to make stained glass windows for Eton College chapel, a 
monopoly for stained glass manufacture. This art had long been prac- 
tised in Europe, but not in England, thus a monopoly was granted for 
introducing a new technology into the country. 
The practise of granting monopolies led to many abuses and hampered or 
prevented the introduction of new industries by anyone not of the 
favoured class. This had led to complaints in Parliament as long ago 
as 1347, when a foreigner named Tidman had been given an exclusive 
right to export Cornish tin without paying tax. This abuse apparently 
got worse, so that in her last Parliament, Elizabeth I was forced to 
revoke a number of her letters patent which related to such offensive 
monopolies. This event, in 1601, was also significant in English 
constitutional history; it was the first time that a Parliament made an 
unwilling sovereign do something that he or she did not wish to do 
- 
well before the Civil War. Such patents, however, continued to be 
granted in the early years of the reign of James I, including one 
giving the sole right to make cigars. In view of the King's views on 
smoking this monopoly is rather surprising. 
The agitation caused by such abuse of monopolies led Parliament in 1623 
to pass the Statute of Monopolies (although it was not, in fact, signed 
by James I until the following year), which made all monopolies illegal 
except for those relating to "Manners of New Manufacture". The word 
"new" in this exception is significant, and this part of the Statute of 
Monopolies became the foundation of the British patent system. In fact 
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the words of Section 6 of this statute continued to appear in the 
definition of invention in legislation even up to the Patents Act 
(1949); this definition read as follows: 
- 
"invention means any manner of new manufacture the subject of 
letters patent and grant of privilege within section six of the 
Statute of Monopolies and any new method or process of testing 
applicable to the improvement or control of manufacture, and 
includes an alleged invention. " 
In the above quotation from Section 101(1) of the Patents Act (1949), 
the reference to methods of testing was newly inserted to previous 
definitions in earlier legislation. 
One of the main features of the Statute, the protection of inventions, 
was the major exception to the prohibition against the crown's granting 
of special privileges. Until recently, English law considered the 
granting of a patent to be the prerogative of the crown, i. e., a 
privilege not a right of the inventor; however, the Patents Act (1977) 
in contrast implies a right for the inventor. 
In the 1640s, after the crown's monopoly power was eliminated, English 
patents were granted for a period of 14 years (two generations of 
apprentices) with the requirement that they be directed to the creation 
of new industry. Written descriptions or drawings were not required. 
Specifications, written under the inventor's initiative, gradually 
became a relatively common practice. Specifications became a consis- 
tent practice, indeed, a requirement, as a result of a patent suit in 
1770, and not by statute. 
During the years which followed the enactment of the Statute of Monopo- 
lies, patents were granted fairly frequently and there were actions for 
infingement of these patents. These included a famous one in which 
James Watt successfully sued Cornish mine owners for infringing his 
patent on a condensing steam engine. However, it was very expensive to 
get patents, and separate patents were needed for England (including 
Wales), Scotland and Ireland. With the approach of the Great Exhibi- 
tion in 1851, acts were passed to produce a unified United Kingdom 
patent system, and also to reduce the costs to applicants. 
- 
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The patent specification reached something like its present form with 
the provision in the 1883 Act that the specification which described 
the invention must end with claims defining that invention. In 1905, 
after an investigation which showed that a large proportion of the 
granted patents were invalid in view of what was known before they were 
applied for, the Patent Office was instructed to carry out searches in 
the prior art to see if anything which was the same as that claimed as 
the invention could be found. This put the patent system on the basis 
on which it stands today. It is of interest to note that such "novelty" 
searches were introduced in the USA in 1790, but were abandoned in 1836 
following a fire on 15 December of that year which destroyed the Patent 
Office and its search file of about 1,000 patents; novelty searching 
was reintroduced in the USA in 1872 following the introduction of a new 
classification system. 
Under the present UK system [Patents Act (1977)) a patent may only be 
granted for an invention provided that (a) the invention is new, (b) it 
involves an inventive step, and (c) it is capable of industrial appli- 
cation. An invention is taken to involve an "inventive step" if it is 
not obvious to a person skilled in the art. Excluded from patentable 
inventions are such things as mathematical models, computer programs 
and literary, musical or artistic works. In deciding whether an 
application for a patent meets the regulatory criteria, a novelty 
search is carried out. Such a search involves an examination of all 
matter 
- 
whether a product, a process, ý information about either, or 
anything else 
- 
which has been made available to the public by written 
or oral description, by use or in any other way. This, naturally, 
includes matter contained in patent applications published on or after 
the priority date, i. e., the date upon which the details of the invent- 
ion were first filed as a patent application, as well as all previously 
published patent applications. 
In many countries the patent applications are published, or "laid open 
to public inspection" (OPI), before examination, usually eighteen 
months from the priority date (see below]. If the applications are 
proceeded with, then 
- 
following examination 
- 
they are republished, 
usually about twelve months after the unexamined document. This is now 
the case in the United Kingdom, the unexamined published applications 
being designated the "A" documents, the examined ones are designated 
the "B" documents. Because of, the examination process, the examined 
documents often differ from the unexamined - for example, the claims 
may be narrower in scope. 
- 
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In 1967 the Banks Committee was appointed to investigate changes needed 
to the patent system, especially as a result of Britain's entry into 
the Common Market and various international arrangements for patent 
cooperation. The Banks Committee presented their report in July 
197013. Following this, report the Government issued a White Paper on 
Patent Law Reform in April 1975; this was the precursor to the revised 
Patent Act (1977), the details of which were published in December 1976 
and which became effective from 1978. 
INTERNATIONAL ARRANGEMENTS 
The laws of a country relating to industrial property are generally 
concerned only with acts accomplished or commited in the country 
itself. Consequently, a patent, an inventor's certificate, a trademark 
registration, or the registration of an industrial design, is effective 
only in the country where the government agency effected the grant or 
registration; it is not effective in other countries. Therefore, if 
the owner of a patent, an inventor's certificate, etc., desires protec- 
tion in several countries, such protection must be obtained in each of 
them separately. 
It was mainly to facilitate the obtaining of this protection abroad for 
their own citizens that, in 1883, eleven countries established the 
International Union for the Protection of Industrial Property by 
signing the Paris Convebtion for the Protection of Industrial Property. 
Since that time the number of contracting States has been constantly 
growing, and now stands at ninety. The Convention has been revised 
several times, and additional agreements have been concluded among some 
of the member States on special problems. Gradually, provisions have 
been written into the Convention to ensure better protection. 
Consultations amongst member States on all kinds of practical problems 
have become more and more frequent, and the international Secretariat 
of the Union (WIPO 
- 
World Intellectual Property Organisation; one of 
the fourteen specialised agencies of the United Nations Organisation) 
has been given new tasks, particularly in the field of assistance to 
developing countries, finding solutions for some of the complex pro- 
blems of technical cooperation among the patent offices of the various 
countries, in matters of standardisation of document format, and search 
and patent documentation matters. 
- 
16 
- 
The Paris Convention, concluded on 20 March, 1883, was revised at 
Brussels in 1900, at Washington in 1911, at The Hague in 1925, at 
London in 1934, at Lisbon in 1958 and in Stockholm in 1967. 
The Convention is open to all States. Instruments of ratification or 
accession are deposited with the Director General of WIPO. 
The Convention applies to industrial property in the widest sense, 
including not only inventions, trademarks, service marks and industrial 
designs, but also trade names (designations under which an industrial 
or commercial activity is carried on), indications of source, apella- 
tions of origin and the repression of unfair competition. 
The substantive provisions of the Convention fall into three main 
categories: national treatment, right of priority and common rules. 
Under the provisions on national treatment, or assimilation, the 
Convention provides that, as regards the protection of industrial 
property, each contracting State must grant the same protection to 
nationals of the other contracting States as it grants to its own 
nationals. Nationals of non-contracting States are also protected by 
the Convention if they are domiciled or have a real and effective 
industrial or commercial establishment in the contracting State. These 
provisions guarantee not only that foreigners will be protected but 
also that they will not be discrimated against in any way. 
The Convention provides for the right of priority in the case of 
patents and inventor's certificates, trademarks and industrial designs. 
This right means that, on the basis of a regular first application in 
one of the contracting States, the applicant may, within a certain 
period of time (twelve months in the case of patents), apply for 
protection in all the other contracting States; these later applica- 
tions will then be regarded as if they had been filed on the same day 
as the first application, termed the "priority date". In other words, 
these later applications will have priority (hence the expression 
"right of priority") over applications which may have been filed during 
the said period of time by other persons for the same invention. 
Moreover, later applications, which are based on the first application, 
will not be invalidated by. any acts accomplished in the interval, such 
as, for example, publication or exploitation of the invention, the sale 
of copies of the design, or use of the trademark, and these acts cannot 
give rise to any rights for the benefit of third parties. 
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One of the great practical advantages of this provision is that when an 
applicant desires patent protection in several countries he is not 
required to present all his applications at the same time but has 
twelve months at his disposal to decide in which further countries he 
wishes protection and to organise with due care-the steps he must take 
to secure protection. 
These later applications are known as "priority" applications, because 
they quote the date of the first one as "priority". They are also 
known as "convention" applications because of the International Conven- 
tion. The resulting set of equivalent applications or granted patents, 
one from each country, is known as a "patent family"; indexes of such 
families are usually known as concordances. It should be remembered, 
however, that national law requirements may make minor variants neces- 
sary or desirable and that the descriptions of the invention in each 
family member document may not be identical; for example, - it may be 
possible to make a more extensive claim in one country than another. 
Furthermore, because of the twelve month period during which convention 
applications can be made, a later application may describe a more 
advanced stage than, or improvement of, the, original, or priority, 
invention. 
The Convention, in relation to patents, lays down a few common rules 
which all the contracting States must follow. Some of the more 
important of these ruleu are as follows: 
- 
(a) Patents granted in different countries of the Union for the 
same invention are independent of each other: the granting of 
a patent in one country does not oblige the other countries 
to grant a patent; a patent cannot be refused, annulled or 
terminated in any country on the grounds that it had been so 
dealt with in any other country. 
(b) The grant of a patent in one country of the Union may not be 
refused and a patent may not be invalidated on the grounds 
that the sale of the patented product, or of a product 
obtained by means of the patented process, is subject to 
restrictions or limitations resulting from domestic laws in 
another contracting State. 
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(c) Each country of the Union must maintain a special industrial 
property service and a central office for the communication 
to the public of patents, trademarks and industrial designs. 
An official periodical journal must be published by this 
office; the journal must contain the names of the owners of 
the patents granted, with a brief description of the patented 
inventions. 
It is to be noted that, except for the provisions with which each 
contracting State must comply, the most important of which are given 
above, the Convention leaves every contracting State free to legislate 
as it wishes in industrial property matters. In particular, each State 
is free: to exclude certain kinds of products or processes from patent- 
ability; to decide whether patents should be granted with or without an 
examination as to their novelty and patentability; to fix the duration 
of patents; to fix all the details of procedure and administration. 
The flexibility of the international protection of industrial property 
has allowed the member States of the Union to, maintain or establish 
their legislations in conformity with local conditions and concepts. 
The Convention further expressly provides that all or any of the 
member States may conclude separate, special agreements on particular 
aspects of industrial property. Such special agreements may not, of 
course, be in conflict with any of the provisions of the "general", 
i. e., Paris, Convention. 
PCT AND EUROPEAN PATENTS 
One of the special agreements entered into by members of the Paris 
Union, or Convention, is the Patent Cooperation Treaty, commonly 
referred to as its acronym "PCT", which was signed at Washington on 
19 June, 1970, by 35 States. 
The treaty provides for the filing of an "international application" 
where protection is sought for an invention in several countries. 
The formalities of the international application are regulated in 
detail. Filing of, such applications has the same effect as if applica- 
tions had been filed separately in each of the countries in which 
protection is desired. On filing an application the applicant desig- 
nates the countries in which protection is sought. 
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The international application is then subjected to a search to discover 
"prior art" and also, if specially requested by the applicant, to a 
preliminary examination to establish whether the invention seems to be 
new, non-obvious and industrially applicable. 
Once the relevant reports are established, and not before, the applica- 
tion is processed separately in the various countries, each of which 
will then grant or refuse protection. 
The international application, together with the international search 
report, is published generally upon the expiration of 18 months from 
the date of filing of the first application. 
This procedure has great advantages over other (national) procedures, 
not only for the applicant and the national patent offices, but also 
for the general public. 
It offers advantages to the applicant because it allows him to decide 
whether he wishes to pursue his application in several countries at a 
time when, thanks to the international search report, he is in a better 
position to judge whether the expense of proceeding in those countries 
is justified. The procedure under PCT, which is administered by WIPO 
in Geneva, is also to the advantage of the national patent offices 
because receiving an international search rport, or even an interna- 
tional preliminary search report, together with the application greatly 
reduces, if it does not entirely eliminate, their tasks of searching or 
examining. For the general public the advantage lies in being able to 
see the application published together with the international search 
report and thus be in a position to understand the invention and 
evaluate the chances it has of protection. The first PCT applications 
were published in October, 1978; during 1980 about 3,500 PCT applica- 
tions were filed. 
A further special agreement is the European Patent Convention (EPC) 
which was signed in Munich in 1973. This Convention involves only 
European countries and provides for early publication, as with PCT, but 
goes beyond the PCT in providing for central examination, grant and 
opposition proceedings. 
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It too provides for designation of States in which protection is 
sought. The grant of a European Patent in effect represents a bundle 
of national patents; and revocation and post-grant procedures, other 
than opposition, take place before national offices. All EEC countries, 
plus Monaco, Norway Switzerland, Liechtenstein and Sweden are likely 
to be involved eventually. The EPC is administered by the European 
Patent Office (EPO) in Munich (with branch offices in Berlin and at 
Riswijk in the Netherlands); the first filings under EPC were in June, 
1978; the first applications were published, in December, 1978, within 
the time scale of this study; a few such documents were thus included 
in the retrievals of patents data sets described later in this work. 
During 1980 a total of 17,505 European Patent Applications were rec- 
eived by the EPO; 47.9% were in English, 36.8% were in German, 13.8% 
were in French and 1.5% were in other languages. Some 94.1% were based 
on an earlier priority document. The average number of states design- 
ated was 6.67 per application 
- 
the UK being the most frequently 
designated with 943 designations per 1,000 applications. 
The majority of these applications (54.4%) were filed at the EPO, 
mainly at the Munich branch, the remainder being. filed at the national 
offices of the member states (27.3% in the UK, 12.0% in France). 64.8% 
of these applications originated from EPC member states (29.1% from 
Germany, 8.5% from UK, 11.6% from France, 5.8% from Switzerland, 3.1% 
from The Netherlands and the remaining 6.6% from Austria, Belgium, 
Luxembourg, Sweden and Italy). Of the 35.2%, originating outside EPC 
member states 23.9% originated in the USA, 8.3% from Japan with, the 
residual 3% being derived from 40 states. 
, 
In addition, 1980 saw some 2,435 international applications filed under 
PCT which designated EPO (approximately 69% of all PCT applications 
filed in that year). Of these 49.4% were filed in the USA, 8.6% in 
Japan, 10% in Sweden, 6.5% in UK and 3.4% in France. 
Thus 1980 saw a total of about 19,940 European Patent Applications 
filed, which at 6.67 designations each represents the equivalent of 
133,000 national patent applications. It is expected that when operat- 
ing fully some 26,000 applications per, year will be processed. 
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Reviews of recent changes in patent law in the UK and on an interna- 
tional basis have been given by Murphy 
14 
and Oppenheim15, the latter 
concentrates on the likely effect of these changes on information 
scientists and commercial information services. 
COSTS AND BENEFITS OF THE PATENT SYSTEM 
Without doubt the most important benefit expected of the patent system 
is the stimulation of invention and development of new products and 
processes. The monopoly power conferred by patent grants is the price 
which society pays for this. In simplest terms, the most important 
issue of patent policy is whether the costs of the system outweigh the 
benefits. On a more sophisticated plane the problem is to design a 
system, e. g., by adjusting the length or strength of patent grants, 
that will yield the maximum surplus of benefits over costs. 
Inventions and innovations bestow benefits on society. How beneficial 
they are depends on how fully they-are utilised: this is one of the 
paradoxes of the patent system. 
- 
Under the system inventors are given 
the right to control and restrict the use of their inventions, so 
outputs may be lower and prices may be higher than they would have been 
if the inventions were utilised under fully competitive conditions. 
Normally patentees can choose between alternative methods of control- 
ling utilisation. They can reserve exploitation of the invention 
exclusively to themselves, calling upon the courts to censure anyone 
who attempts to infringe upon that right. In this way, the profit 
maximising price can be set directly. Alternatively, they can license 
as many or as few companies as they please to exploit the invention, 
charging royalties for the privilege. In fixing the royalty rate the 
patentees can in theory achieve the same price-quantity outcome and 
profits as they could by retaining exclusive exploitation, other things 
being equal 16. In many countries patentees can also strengthen their 
control over licensees by prescribing prices at which the product can 
be controlled, imposing production quotas and limiting licensees to 
particular markets or fields of use. 
That patent owners exercise their power to set prices exploiting what 
ever monopoly power their patents confer does not mean that society is 
denied the advantages arising from invention and innovation. On the 
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contrary, society gains at least from the resources that cost-saving 
innovations release for alternative uses, less the research and deve- 
lopment cost of achieving that saving. 
Additionally, consumers other than the patentee benefit directly in two 
ways: firstly, after the patent has expired the patent holder should in 
principle have no further power to restrict production; thus, competi- 
tive pricing will prevail and consumers will reap the full benefits of 
the invention. Ideally, the life of a patent should be no longer than 
it needs to be to encourage the optimal amount of invention, so that 
monopolistic restrictions are terminated as soon as possible17. 
Secondly, consumers may also realise immediate gains even when innova- 
tions are exploited monopolistically; according to Scherer 
18 
several 
theoretical cases must be distinguished: 
- 
Case 1: A new and superior consumer product is introduced. It can be 
shown that the 
-innovation necessarily increases consumers' surplus 
unless the innovator is able to practice perfect first-degree price 
discrimination. Consumers therefore benefit directly even when the 
product is priced monopolistically. Whether overall social welfare is 
enhanced depends upon the costs of the innovation, the impact of the 
innovation on substitute products and other considerations. 
Case 2: A new and more efficient production process is introduced by a 
firm already exercising monopoly power. Here the effect is to shift 
the monopolist's marginal cost curve downwards, inducing a decrease in 
price if the marginal revenue curve is continuous. Consumers enjoy 
lower prices and higher consumers' surplus. 
Case 3: A substantially more efficient production process is introduced 
under patent protection into a previously competitive industry. The 
company controlling the new process will find it worthwhile to mono- 
polise the industry, computing its marginal revenue and setting a 
price that drives existing producers out of business. Alternatively, 
it will license the invention at a per-unit royalty equal to the 
difference between cost of production and price. In either case 
consumers benefit from the lower price. This result is more likely the 
greater the reduction in costs are and the more elastic demand is at 
outputs exceeding the pre-innovation levels other factors being equal. 
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Case 4: A slightly more efficient production process is introduced 
under patent protection into a competitive industry. If the patentee 
could monopolise the industry without restraint by virtue of his 
patent, he would like to set the price, but he cannot do this because 
of competition from the pre-innovation process. He must therefore 
either set a slightly lower price and 
, 
drive others out, or license 
others at a per-unit royalty slightly less than he desires. Here the 
reduction 
-in price will be insignificantly small-and consumers gener- 
ally will not benefit from the innovation until its patent protection 
has expired and competitive pricing commences. Then the innovator's 
profits are redistributed to consumers and, in addition, the welfare 
loss is transformed into consumers' surplus. 
In three cases out of the four, consumers gain immediately to some 
extent from the introduction of a, patented invention, though they enjoy 
the full price reduction benefits only after its patent protection has 
expired. Except when innovator's profits come largely from cannibali- 
sation of the profits that would otherwise have been enjoyed by the 
producers of substitute products, it is likely that society as a whole, 
i. e., including both consumers and producers, gains from inventions and 
innovations induced or hastened by the grant of patent rights. 
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3: 'THE NEED FOR PRODUCT DEVELOPMENT AND INNOVATION 
Product development refers not only to' the creation of new products, 
but also to the alteration or improvement of existing products. 
Unquestionably the need for continual product development is great, for 
society's needs are always changing, and different products must be 
forthcoming to fulfil those needs. All products have certain defi- 
ciencies, for they are the result of a great many compromises: the 
perfect product is yet to be made. Research makes possible the reduc- 
tion of these deficiencies resulting in improved products. However, 
there are other reasons underlying the temendous impetus behind product 
development efforts in modern industry. 
Figure 2 is a visualisation of the concept of the product life cycle, 
which holds that every product has a natural lifespan, varying from a 
very short time for certain "fads" to a relatively long time for 
certain stable products, and that it moves through its lifetime by 
stages. 
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The first portion of a product's life cycle is the pioneering stage in 
which competition is slight or non-existant, prices are relatively 
high, distribution and market are limited, and rapid improvements are 
being made in its technology. As the product grows in popularity it 
moves into the second phase of its life cycle: the growth stage, in 
which demand rapidly expands, prices fall, more companies enter the 
market, thereby making competition more intense, distribution is 
greatly broadened and good profits are being made. As competition 
intensifies and the market becomes saturated, the product moves into 
its maturity and saturation stages at the top of its cycle, where 
prices have bottomed out because of competition and technology. The 
product is well recognised in the market and has maximum distribution. 
Saturation may last for a long period, as in the case of many products 
with long-run demand characteristics. But sooner or later demand for 
the product begins to decline as new products replace it. With sales 
declining, competition becomes more ferocious. Marginal competitors 
fall by the wayside. Profits become almost non-existant. And so the 
life of the product comes to its end, prolonged perhaps for a while by 
a few hard-core users. 
The concept of the product life cycle is extremely important, for it 
indicates that sooner or later all products die and that if management 
wishes to sustain its revenues it must replace the declining products 
with new ones. The product life cycle concept also indicates what can 
be expected in the marketplace for a new product at various stages of 
its development. 
Continual innovation of new products renders existing ones obsolete. 
For that reason management has become accustomed to the fact-that no 
matter how good its product is today, someone will bring out a better 
one tomorrow. IBM's bringing out of a copier to match that of Xerox 
is a case in point. Xerox management realised that sooner or later 
some large company was bound to come after their lucrative copier 
market. But Xerox's management was not sitting idly by, for no sooner 
did IBM management announce its new copier than Xerox announced the 
introduction of a superior product;, one could surmise that Xerox was 
undoubtedly aware of IBM's intentions and had been withholding the 
announcement of its new development in order to top IBM's new product 
introduction. 
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Continual research on new product innovation is now regarded as a 
constant function of business. It is a mistake to wait until one has 
been defeated in the marketplace before tooling up to meet the competi- 
tive challenge. Market position is such an important asset that few 
intelligent managements wish to risk losing it by resting on the 
laurels with the same old products. 
Modern management operates on the theory that sooner or later- and it 
will probably, be sooner 
- 
someone is going to make its products obso- 
lete, so let it be us; we will be our own toughest competitor. 
Many organisations have growth as one of their objectives. While some 
growth can be realised as a result of normal expansion in the market, 
and additional growth may be realised if one's products are in a 
segment of the market that is growing rapidly, still many concerns are 
not satisfied to grow only at the rate of their markets; they want 
faster growth. To obtain it they see the introduction of new products 
to be a good strategy. So new product development has become one of 
the cornerstones underlying the strategy of growth. 
Companies are therefore motivated to conduct research and development 
(R&D) activities and to devote sufficient- resources, both money and 
manpower, in the quest for innovation leading to new products which 
leads in turn to larger market share and increased products. 
FIRM SIZE, INVENTION AND INNOVATION 
Several authors (see for example Scherer18) have addressed the ques- 
tion: are large firms in general more effective than small firms in 
making technological inventions and introducing them into commercial 
practice? 
A number of a priori hypotheses favourable to big business exist. One 
of the best known is that by Galbraith19 who asserts that the costs of 
technological innovation in modern times are so great that they can be 
borne only by'large corporations: 
There is no more pleasant fiction than that technical change is 
the product of the matchless ingenuity of the small man forced by 
competition to employ his wits to better his neighbour., Unhappily 
it is fiction. Technical development has long since become the 
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preserve of the scientist and engineer. Most of the cheap and 
simple inventions, have, to put it bluntly and unpersuasively, 
been made.... Because development is costly, it follows that it 
can be carried on only by a firm that has the resources which are 
associated with considerable size. 
Furthermore, it is argued, R&D projects are risky as well as expensive. 
Small companies place themselves in a dangerous position when they 
invest all their resources in a single innovative project whose pros- 
pects for technical and commercial success are far from guaranteed. 
This, combined with the risk aversion to which business managers and 
investors are supposedly prone, is said to discourage technical pione- 
ering by small companies. On the other hand, the large corporation 
can afford to maintain a balanced portfolio of R&D projects, letting 
the profits from successes more than counterbalance the losses from 
those that fail. The ability to average out losses and gains may lead 
large firms to consider innovative opportunities on their "best guess" 
merits, without being constrained unduly by risk aversion. 
18 
There may also be economies of scale in the conduct of R&D. A big 
laboratory can justify purchasing all sorts of specialised equipment, 
making experimentation easier. It can employ specialists in many 
disciplines to cross-fertilise one another and to lend temporary 
assistance when a team working on some development project encounters a 
technical problem outside its normal sphere of expertise. This latter 
advantage might be minimised if small firms called upon the services of 
outside consultants, but it is not clear whether such outside assis- 
tance is sought as willingly and speedily as internal expertise. 
18 
R&D projects may benefit from economies of scale realised in other 
parts of the large firm's operations. Large corporations can attract 
additional capital at lower cost and inHgreater quantity than their 
smaller cousins 
18, 
and may thus be better able to finance ambitious 
R&D projects. They have well established marketing channels and may 
enjoy certain economies of scale in promotion and distribution. Their 
- 
promotional advantages often permit them to penetrate markets more 
rapidly with new products, thus affecting the profitability of develo- 
ping a new product. 
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Large producers have an advantage in making process innovations. A new 
process that reduces costs by a given percentage margin yields total 
larger savings to the company producing on a large scale that to the 
company producing smaller quantities. As a result the large firm 
presumably has stronger incentives to develop such improvements. 
The disadvantages of size must, however, be contrasted with the above 
real and/or apparent advantages20. Decisions to bear the risks of R&D 
projects are made by individual managers, not by impersonal organisa- 
tions and so the argument on risk spreading may not hold water. In a 
small company, the decision to go ahead with an ambitious project typi- 
cally involves a small number of people who know one another well. In 
a large corporation, the decision must filter through a whole chain of 
command. Each member of the chain is risking his or her reputation, 
if not money, in backing the project. Under these circumstances there 
is a distressingly high probability that some member of the chain 
- 
from the person who had the idea to the corporate vice-president for 
research 
- 
will block the idea18. 
A direct consequence of this problem is a bias away from really imagin- 
ative innovations in the laboratories of large corporations. But more 
important, inability to get ideas approved by higher management drives 
many of the most creative individuals out of large company laboratories 
to go it alone in their own ventures. Thousands of researched based 
new enterprises have been founded by frustrated technicians from 
leading corporations such as IBM, Sperry-Rand, Hughes Aircraft, Western 
Electric and Texas Instruments21. 
A related malady is the propensity for research in large laboratories 
to become over organised. If too many people are involved in a project 
they spend a disproportionate amount of their time writing memoranda 
and reports to each other at the expense of more creative endeavour. 
Also, the quickest and surest path to higher status and pay in a large 
company's R&D establishment often lies in giving up work "at the bench" 
and becoming a member of the management team. Although some companies 
have tried to combat this tendency by creating well paid positions for 
senior research workers, it is still commonplace to find the most able 
workers in a laboratory devoting nearly all their time to supervising a 
swarm of drones. This is not the way truly creative work gets done. 
16 
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4: ECONOMIC ASPECTS OF R&D 
Sehumpeter22 first gave prominence to innovation in theories of econo- 
mic progress. Schumpeter identified innovation as one of the principal 
internal promotors of economic growth. His definition of innovation 
included not only the introduction of new products and new techniques 
of production, but also the opening up of new markets and supply 
sources, the improvement of management techniques and the introduction 
of new distributive methods. The person responsible for doing these 
and other "different things" was the entrepreneur. Schumpeter emphas- 
ised that the inventor and innovator need not be the same person, and 
in his view it was even highly improbable that the two functions would 
be combined. 
In describing the actual process of innovating, Schumpeter was rather 
more interested in important, large step innovations. He assumed, 
firstly, that the innovation would require "new plant"; secondly, that 
the innovation will be carried out in a "new firm" established for the 
purpose. He extended this second assumption to argue that the firm, 
after achieving its purpose, will, like a human being, have completed 
its alloted span and decay and die. A third, related assumption was 
that the innovation, embodied in the "new plant" of the "new firm", 
will be accompanied-by the coming to the forefront of "new men", the 
entrepreneurs. These are assumptions, Schumpeter says, about which 
"there is no lack of realism". 
Schumpeter admitted an exception to his second assumption in the case 
of the large corporation through which a continuous stream of "new men" 
pass with their respective innovations. He named this phenomenon 
"Trustified Capitalism" in comparison with the "Competitive Capitalism" 
of his model. The increasing predominance of Trustified Capitalism in 
the economy, ' together with the establishment of permanent R&D teams 
within companies forced Schumpeter to reconsider his third assumption 
also: "This social function [entrepreneurship] is already losing its 
importance:... innovation itself is being reduced to routine. Technolo- 
gical progress is increasingly becoming the business of teams of 
trained specialists who turn out what is required and make it work in 
predictable ways"23. 
Solo 1 criticises Schumpeter's'theory of innovation. She rebuts his 
assumption about "new firms" on the grounds that R&D is a normal 
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business activity. Other things being equal, the more-the efficient 
innovating firm competes, the less efficient innovator is forced out of 
existence, not just the non-innovating firm as Schumpeter suggests. 
The assumption of "new men" is also question by Solo; the R&D team of 
the modern company builds up its stock of knowledge and ability over 
time. As this ability grows so does the confidence of management in 
the work of R&D teams and in the Research Manager concerned. Rising 
confidence will lead to an increasing propensity to innovate by general 
management. Solo postulates, therefore, that innovation is possibly 
more likely to be connected with a previously successful R&D department 
than with "new men". 
Such criticism of Schumpeter's model, however, is possibly unnecessary 
in view of his own later admission of the obsolescence-of entrepreneur- 
ship itself. However, Schumpeter's earlier model of the process of 
innovation has proved, and may continue to prove, its worth in the case 
of really major innovations in a few selected fields. 
Schumpeter's entrepreneur, having acted with enterprise and carried out 
innovation, must like other factor inputs, be rewarded. It is this 
payment for entrepreneurial services that forms Schumpeter's well known 
concept of profit as a reward for innovation: "It is the premium put 
upon a successful innovation in a capitalist society and is temporary 
by nature; it will vanish in the subsequent process of competition and 
adaptation"22. 
Entrepreneurial profit is assumed to be one of the main motivating 
factors in bringing about innovation. The innovating firm in the era 
of trustified capitalism will also be, by definition, a monopolist, or 
at least an imperfect competitor, of the product or technique it has 
introduced. Consequently the reward which the innovating firm of 
trustified capitalism can be presumed to seek will be a composite of 
entrepreneurial profits and monopoly earnings. This introduced 'the 
classic policy maker's dilemma of weighing the social benefits of 
perfect competition against the cost of losing economies of scale. To 
this problem is now added the social cost of losing innovatory effort 
if one of the possible rewards of innovation, namely monopoly earnings, 
is removed or lessened. 
Schumpeter defends these monopoly earnings. The balance of advantages 
is poised in favour of the consumer; he postulates that big business 
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and imperfect competition have done more to advance than to retard the 
consumer's standard of living. Monopoly earnings, accumulated in the 
past, act as a lubricant to innovation and in practice may well be the 
most convenient way of financing further innovatory steps. No one is 
more cautious than a lender and nothing appears riskier than novel, 
untried ideas. 
Monopoly earnings as well as financing innovation can induce innova- 
tions. In the dynamic capitalist society as pictured by Schumpeter 
there exists a "perennial gale of creative destruction". This is the 
appearance of competitors. with improvements to, or imitations of, the 
original innovation. Should the perennial gale appear too quickly or 
blow too strongly profits might be "washed away" discouraging innova- 
tion. A monopoly-or imperfect competitive position can give the 
innovator's profits some protection, and so in the long run will 
encourage more general economic expansion than it discourages. As 
Schumpeter tritely remarks: "cars are travelling faster... because they 
are provided with brakes"23. 
Many economists have argued and developed the merits and demerits of 
Schumpeter's theories. Some have misinterpreted Schumpeter and, as 
Markham indicates25, it is important that we do not confuse the theses 
of the "neo-Schumpeterians" with Schumpeter's. Schumpeter merely 
implies a "threshold" theory. That there is a minimum firm size with 
a minimum amount of market power which is necessary to facilitate and 
induce innovation in a market economy., The neo-Schumpeterians state 
that the innovatory effort, as measured by the R&D input of a firm, 
will be a continuously increasing function of market power, size of 
firm and/or. of retained monopoly earnings. 
The dichotomy perceived by Schumpeter between the innovator and the 
entrepreneur has often ceased to exist (because of large and formalised 
in-house R&D efforts). According to Reekie26 R&D can be either offen- 
sive, defensive, a business status symbol or a department set up for 
trouble shooting. 
The status symbol R&D department has never been so prominent in the UK 
as in the USA. The annual announcement in the corporation's report 
that the firm spent $X million on R&D in the preceding year is used to 
enhance the firm's standing with the investment analyst and with 
existing and potential customers27. 
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Application of results, if any, would be the exception and not the 
rule. 
The trouble shooting R&D department has a rather more positive role to 
play in the company but its activities tend not to be R&D in the sense 
used here. The function of such a department is to primarily investi- 
gate technical faults or complaints brought to the attention of manage- 
ment by production or sales departments. 
Offensive R&D is directed at discovering entirely new products or pro- 
cesses, either as additions to or replacements for an existing range. 
This is often begun because of an entrepreneurial hope of expansion. 
Defensive R&D is R&D conducted to improve the quality or cheapen the 
procedures of existing products or processes, often this is initiated 
for fear of being supplanted. 
Where R&D is conducted of course, all four motives for performing it 
will be operating to a greater or lesser degree. Rarely will R&D be 
conducted for any one of these motives alone. 
Arguments that represent applied research as routine, while conceding 
that there are many technical difficulties, maintain that industrial 
laboratories pursue projects the outcome of which is less uncertain 
than that of basic research. This description is especially true of 
some types of industrial research concerned with problems of design and 
engineering development. Thus, Mansfield28 found that in more than 
three quarters of the projects undertaken by the laboratories of an 
electrical equipment manufacturing company, the probability of techni- 
cal success was estimated at about 0.8. Only 44% of the projects 
actually resulted in technical success, but even this percentage 
suggests that the degree of uncertainty is not very high compared with 
that in basic research. In short, industrial laboratories limit their 
research to the application of known principles discovered elsewhere to 
practical problems, the solution of which is relatively routine after 
the basic'research is completed. 
The argument goes on to say that because profit-maximising companies 
are reluctant to undertake risky, innovative R&D projects, individual 
inventors,. as'pointed out by Jewkes et al20, are prominent'in lists of 
important inventions. 
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Most of the discussion of applied versus basic research in economic 
literature refers to research other than pharmaceutical research. 
Pharmaceutical research, which is highly dependent on exploration, does 
not fit into the standard model well; the line between basic and 
applied research is especially indistinct in this field. While the 
very definition of basic research would exclude any deliberate search 
for specific drugs, pharmaceutical discoveries take the form of new 
drugs. 
Economists have suggested that increased expenditures on research other 
than basic research would not increase the number of inventions. The 
inventor draws on his knowledge of previous basic research, but his own 
efforts do not closely correspond to the amount of funds he has at his 
disposal. The efforts depend more on the prospect of economic reward 
resulting from the patent on a product and on the natural curiosity of 
the inventor. Examples given suggest that the inventor does not 
require the resources of the large firm and that economies of scale are 
unimportant in the research preceding the Invention 
1,18 
. 
The large firm's advantages, it is suggested, are more likely to be 
present in the development stage following the invention,. including the 
development of the design of the product and of production processes. 
The advantages'of scale in this stage come from the need for the skills 
of many specialists in different aspects of the problems of manufactur- 
ing a new product. Since small firms have difficulty in raising large 
amounts of capital, particularly when the investments do not produce 
any collateral, they may be unable to develop a product because of the 
large expense of making many designs, the practicality of which must be 
tested through numerous trials. If the project fails, as many do, the 
inventor may, not be able to recover his funds. In addition the small 
firm cannot support the large number of different specialists necessary 
for the development of a product. (See also the section on Firm Size, 
Invention and Innovation in Chapter 31. 
Schmookler29 extended the model to analyse the forces influencing the 
rate of innovation. This extension employed the traditional tools of 
demand and supply. Schmookler conceived of a supply curve of innova- 
tions which shifts to the right with reductions in the cost of innova- 
tion. Nevertheless, Schmookler's own emphasis is on the importance of the 
demand for innovation rather than on the supply. In his view, innova- 
tions respond to increases in demand which are the result in the rise 
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in the level of income, the growth of population, changes in prices of 
competing products and changes in factor costs. 
Schmookler maintained that accumulated knowledge only influences the 
rate of innovation by limiting the scope of inventions. He did not 
accept the idea that scientific discoveries alone stimulated inven- 
tions. In other words, a shift in the supply curve of innovations to 
the right would not result in an increase in the number of innovations. 
There had to be an increase in demand for this to happen; apparently 
Schmookler believed that the demand for innovations was inelastic with 
respect to their price. His evidence consisted of the record of 
inventions in four industries: petroleum refining, paper making, 
railroading and farming. In these industries the demand for innovation 
determined the number of innovations. According to Schmookler hundreds 
of inventions could be traced to the recognition of a problem and the 
use of available knowledge to solve it. In addition, he showed that in 
railroading the number of inventions increased historically with the 
amount of investment. 
Schmookler argued that even in the more science-based fields, R&D 
expenditures are not greatly influenced by individual scientific 
discoveries. He recognised that discoveries in pure science sometimes 
provide the stimulus for invention, but most of the inventions, even in 
science-based industries, derive from the same stimuli as in the 
industries which he examined in detail. He therefore concluded that 
the number of inventions depends more on the expected sales of products 
embodying the invention. 
Salter3° has given greater credit to the growth of knowledge. Salter 
suggested that when a new Technology arises, it will bring forth 
a flow of significant improvements and modifications. Salter also 
suggested that as a technology matures, significant advances become 
less frequent. 
Schwartzman37 points out that both Schmookler and Salter ignore certain 
other conditions influencing the quantity of resources employed in 
applied industrial research. Other factors include those affecting the 
cost of research, such as. the prices of resources used in industrial 
research; the degree of protection provided by patents; and regulatory 
requirements, which in the case of the pharmaceutical industry are most 
- 
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important. Thus, restrictions by the FDA in the USA on clinical 
testing and regulatory requirements governing proof of the efficacy and 
safety of drugs raise the costs of research, delay marketing of drugs, 
and thus reduce the expected rate of return from investment in R&D. 
Another important factor affecting the amount of resources devoted to 
applied research is the amount of protection patents give to manufac- 
turers of new products. 
Schwartzman31 states that hitherto analysis of the sources of innova- 
tion has been far too general. In some fields, for example, physics, 
where practical applications may follow fairly quickly on the growth cf 
basic scientific knowledge, the underlying theory may be, sufficiently 
complete for additions to knowledge to be readily translatable into 
practical devices. Industrial research, which utilises the results of 
such fields, in that case, may not diminish significantly with reduc- 
tions in the protection provided by patents. In addition, secrecy of 
production processes may adequately protect innovators against rapid 
imitation and loss of sales. In fact, one study suggests that in many 
industries firms would not reduce the extent of their research if 
patents were not available18. The much more important consideration 
may be the availability of a sufficiently large market at prices which 
provide some profit. Drugs, like all chemical inventions, however, are 
too easily imitated by too many firms for patent protection to be 
ignored. The pharmaceutical industry differs from others in that 
patents almost invariably refer to products rather than to processes, 
and it is relatively easy to imitate the product once it is available 
on the market and chemists can analyse its composition. 
- 
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RELATIONSHIPS BETWEEN GNP, R&D AND PATENTS 
The Gross National Product (GNP) is the total money value of all goods 
and services produced in a nation in some specified period of time, 
usually one year. It is widely used as an indicator of the well-being 
of that society and is largely Used for measuring prosperity and 
diagnosing economic ills. 
In 1969, Price32 investigated the relationship between the size of the 
national scientific effort and a number of national socio-economic 
variables such as GNP and GNP per capita. Price's measure of "scienti- 
fic size" was the number of authors producing scientific papers in a 
given time period. He concluded that national scientific effort was 
closely associated with GNP levels, and produced a graph showing a 
clear log-linear relationship between the two. 
Davidson-Frame33 investigated whether there was a relationship between 
the size of a country's scientific effort and the size of its resource 
base. He used counts of scientific papers, the data being drawn from 
Science Citation Index (SCI, published by the Institute for Scientific 
Information Inc., Philadelphia). Of the 271,435 papers covered, 95.4% 
could be attributed to 33 developed countries and only 4.6% to 74 
underdeveloped countries. SCI does not cover all underdeveloped 
country publications, but, probably includes most significant work from 
such sources. Davidson-Frame produced a log-log plot of GNP against 
number of scientific papers and found a relation between 1973 SCI data 
and 1972 GNP data, thus confirming the relationship described by Price. 
The regression equation for Davidson-Frame's graph had the form: 
- 
In y= 
-26-34'+ 1.383 In x 
where y is the number of scientific papers and x is the GNP. The 
correlation coefficient, r, was found to be 0.91. Davidson-Frame then 
separated the developed from the underdeveloped countries; he then 
found the following results: 
- 
Developed countries : in y= 
-18.063 + 1.066 In x (r2 = 0.799) 
Underdeveloped countries : In y= 
-20.849 + 1.115 In x (r2 = 0.655) 
Davidson-Frame concluded from this that quite a high percentage of the 
variation in the dependent variable could be explained by the GNP 
levels. 
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Slute31{ has carried out a similar study. She used a count of scienti- 
fic and technical journals currently being published in 1961 in 40 
countries, adjusted by United Nations mid-year population estimates for 
that year, to give an index of the number of publications per million 
of population. She correlated this against an index of economic 
development: this was per capita GDP (Gross Domestic Product) at factor 
cost in 1963 in hundreds of US dollars. Blute found that production of 
scientific and technical periodicals was a positive function of the 
economic index. Using the least squares method she found that the best 
mathematical expression for her results was the power formula: 
- 
b 
y= ax 
The studies of Price, Davidson-Frame and Blute did not consider pa- 
tents, only journal literature. 
The patent system, as it operates in both developed and underdeveloped 
countries, has not been without its critics; this is especially true of 
the underdeveloped nations. Many of these countries are considering 
changes, or have made changes, to their national patent laws which 
weaken the strength of their national patents, for example, by shorten- 
ing the maximum lifetime of a patent. Furthermore, there has been 
considerable pressure from the underdeveloped countries for changes to 
the Paris Convention; these countries believe that the Convention was 
written by developed countries for developed countries and has an 
implicit bias against the underdeveloped nations. 
R&D-based companies and other corporations which undertake significant 
patenting activities are concerned with the anti-patent policies 
adopted by a number of underdeveloped countries. Such companies will 
obviously be reluctant to apply for patents in countries which are 
likely to adopt anti-patent legislation in the near future. One of the 
principle arguments used to justify the attitude by the underdeveloped 
countries is that patents do not help their economic development 
- 
indeed, quite the reverse. They claim that patents hinder their 
development since multi-national corporations gain monopoly rights on 
key inventions in their country, but satisfy demand by importation from 
elsewhere. As a result, no local employment is created and no local 
factories are built. Instead, valuable foreign currency is lost. 
Duffy and Oppenheim35 have carried out research to assess the relation- 
ship between patenting activity and national prosperity in the hope 
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that such research would shed light on the arguments as to whether 
patents help or hinder economic development. 
In their studies, for the years 1961 to 1977, GNP and GNF per capita 
data were correlated in turn with patents indexes for the year in 
question. The patent indexes used were the total number of patent 
applications to a country, the number of applications by nationals of 
the country and the number by non-nationals. The data was divided into 
two sets: one each for the developed and the underdeveloped nations. 
The 33 developed countries were the western nations, Eastern European 
nations, South Africa, Israel, Rhodesia, Japan, Australia and New 
Zealand. The underdeveloped countries were 66 non-western nations. 
Correlations were carrid out using both linear and double log plots. 
GNP or GDP was the independent variable, patenting activity the depen- 
dent variable. 
In addition to this, the same manipulations were carried out with the 
GNP or GDP data lagged two years behind the patent data; two years was 
chosen as being the average time between a patent application and the 
time that the work leading to the patent was carried out. The authors 
felt that economic conditions two years before a patent application 
more closely represented the prevailing economic conditions when the 
inventive activity was carried out than at any other lime. In each 
case, r, the correlation coefficient was calculated, as was also the 
coefficient of determination, r2. On the basis of the least squares 
method, the values of the parameters a and b were calculated for the 
following equations: 
y=a+ bx (for the linear plot) 
In y= In a+b In x (for the log plot) 
These expressions represent the equation of the regression line which 
best fits the given data. 
For the developed countries, Duffy and Oppenheim found that the coeffi- 
cient of determination, r2, for a plot of log-GNP againt log-patenting 
was high; the r2 values were all greater than 0.75, thus implying a 
significant relationship between a developed nation's GNP and its 
inventive activity. As GNP can be interpreted as a nation's gross 
economic demand for technological change, it appears that the level of 
inventive activity is related to this demand. However, there is still 
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a certain inventive activity that is not linked to the level of GNP. 
This could be due to scientific activity which is not affected by 
economic conditions-, in other words scientific developments which 
36 progress independently. 
The values of r2 for log plots of GNP against domestic patenting were 
signifiently higher than the corresponding values for foreign patent- 
ing. This result was interpreted to mean that once countries have 
achieved a certain wealth they seek to maintain it by using a large. 
amount of resources to perform research, thus leading to a significant 
amount of inventive activity. 
The values for r2 were lower for linear plots of GNP against patenting 
than were the r2 values for the log plots. For GNP against total 
patenting, r2 varied from 0.49 to 0.64, indicating a signifcant rela- 
tionship between GNP and inventive activity. The r2 values were higher 
for GNP against domestic patenting than for GNP against foreign patent- 
ing, even with linear plots. 
The r2 values for log and linear plots of GNP per capita against 
patenting were much lower, varying from 0.15 to 0.46 (log plot) or from 
0.03 to 0.20 (linear plot). If GNP per capita is interpreted as the 
level of national affluance, then the authors conclude that the indivi- 
dual personal economic status has less effect on a nation's inventive 
activity than that nation's total wealth. , 
These authors also investigated whether the level of GNP in a given 
year influenced patenting activity in that year, or two years later by 
comparing the log-log plots for GNP against patenting and GNP two years 
earlier against patenting. They found that the r2 values were 
slightly higher for the lagged plot of GNP against foreign and total 
patenting, but not for the domestic patenting plot and conclude that 
there is little evidence for patenting lagging behind the economic 
variable. 
As with the developed countries the r2 values for a double log plot of 
GNP against patenting were high for the underdeveloped countries. For 
plots of GNP against total patenting, the r2 value varied from 0.70 to 
0.80, most being >0.75. The r2 values for linear plots of GNP against 
patenting were lower, but still indicted a relationship, varying from 
0.44 to 0.81; however most of the values were <0.70. 
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In contrast to the developed countries, the values of r2 for both the 
linear and log plots of GNP against patenting for the underdeveloped 
countries were higher for the foreign patenting than for the domestic 
patenting. This implies that GNP has a greater effect on foreign 
inventive activity than it does on domestic inventive activity. It 
appeared that the higher the level of GNP, or wealth, of an underdeve- 
loped country, the greater the number of investors who are patenting in 
that country, wealth being used as an indicator of the potential size 
of the market. 
The r2 values of double log plots of GNP per capita against patenting 
activity were very loci. The same applied to the linear plots of GNP 
per capita against patenting. It appeared that in the underdeveloped 
countries, affluance had no influence on inventive activity. 
In looking at differences between the developed and the lesser develo- 
ped countries double log plots of GNP against domestic patenting for 
both groups of countries were compared. The plots showed that for a 
given level of GNP underdeveloped countries produce less inventive 
activity. This may be because underdeveloped countries devote less of 
the GNP to inventive activities; they also lack the infrastructure of 
research. 
The authors observed that the graphs were essentially parallel. For a 
double log plot, this Was taken to indicate that underdeveloped coun- 
tries are proportionately as far behind the developed countries at one 
level as they are at another. This means that for increases in econo- 
mic size, there is little 
-'progress in narrowing the gap. Moreover, 
over the fifteen years analysed, there seemed to be no indication of a 
trend toward the closing of this gap. 
II 
The double log plots of GNP per capita against domestic patenting were 
also compared. Both sets of results were low; but the r2 values of the 
developed countries were much higher than those of the underdeveloped 
countries. Duffy and Oppenheim state the results imply that the level 
of inventive activity in underdeveloped countries is not responsive to 
changes in the level of national affluence. National affluanee 
appeared to have more effect on inventive activity in the developed 
countries. Inventive activity flourishes where there is an economic 
surplus. In the underdeveloped'countries, quite major shifts of 
affluance still leave the majority of the population very poor. 
- 
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Duffy and Oppenheim conclude that increases in GNP in underdeveloped 
countries leads to increasing use of the patent system by foreigners 
rather than by nationals. In contrast, for developed countries, the 
greater the GNP, the greater the domestic patenting. For neither set 
of countries was GNP per capita found to be significantly linked with 
any patenting variable. Overall, these authors could find little 
evidence to support the view that patenting helps underdeveloped 
countries' economies to prosper; even if the economies do prosper it is 
foreign patentees who benefit. 
Jonason37 has used patent statistics of the number of patent applica- 
tions as a basis for discussing and explaining the industrial develop- 
ment trend in Sweden during the period 1925 to 1936. 
She comments that the interest that has grown up recently in using 
statistics on filed patent applications as an aid to technological 
forecasting could be extended and diversified if other aspects that 
these figures help to explain are taken into consideration. The 
pattern of patent applications can be studied, such as by different 
categories of applicant or different forms of influence between groups 
and countries. She states, for example, that the distribution of 
families of patents technically and geographically, can serve to 
demonstrate the varying spread of different economic interests. 
Statistics of this kind for recent years can easily be compiled since 
today most patent applications, Jonason observes, are published within 
a fixed period from the date of filing or priority. 
Knowledge of this kind about the pattern of patent applications could 
be of some help in considerations of what measures can be taken in 
order to stimulate or improve the climate of innovation, and how and 
towards what such measures should be directed. She concludes that 
insofar as the patents system is regarded as an integral part of the 
industrial development trend, it should be possible to study various 
aspects of this trend through the patents system. 
Kleinknecht38 has used patent application statistics in similar ways 
to study the industrial economics of The Netherlands. It is envisaged 
that as economists become more aware of patents statistics, and as such 
statistics are made more readily available to them further studies, 
especially in macroeconomics, will be undertaken. 
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5: 1 ASUREMENT OF R&D EFFORT 
Three of the most frequently used measures of R&D effectiveness are 
numerical counts of (i) publications produced, (ii) of patents issued, 
and (iii) of new products introduced. Each of these measures has 
advantages and disadvantages and each has its own sphere of maximum 
applicability in the R&D spectrum. Each measure has the advantage that 
the individual components which go to make up the counts are readily 
identifiable, easily obtainable and obviously verifiable. Each measure 
has the disadvantage that there will almost certainly be an inevitable 
lack of uniformity and value between any two individual components 
going to help make up a count. 
(i) Publications Produced 
Some research workers may publish a flood of papers, each having but a 
minimum effort behind it, while others for the same aggregate effort 
will publish only a few really important papers. Also in some industr- 
ies much R&D effort will never be indicated by publications (or patent- 
ing) but only the ultimate new product. If an interindustry study is 
to be undertaken, account must be taken, therefore, of the varying 
propensities to publish and to patent'if either of these measures are 
being used. Similarly, an R&D effort may be successful but because of 
commercial developments elsewhere, the results of the effort may be 
obsolete and so possibly no new product will be introduced. 
Lipetz39 deemed it most probable that publications are produced by 
research workers working towards the basic research end of the R&D 
spectrum rather than those at the development end. If this is the 
case, then to the qualifications already mentioned must be added a 
restriction in applicability to research efforts predominantly con- 
cerned with the earlier stages of the R&D spectrum. 
In dealing with the matter of publications specifically by the pharma- 
ceutical industry, Schwartzman31 has commented that scientists in 
pharmaceutical laboratories want to publish their work, and their 
employers, who share some of the benefits, encourage publication. 
Acceptance by a journal signifies that the work meets the usual scien- 
tific standards, so it provides an outside check on the quality of the 
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work in the laboratory. Research-orientated firms willingly risk 
revelations that may aid competitors, since their success depends more 
on a well-developed programme of research, an accumulation of knowledge 
and a highly motivated team of scientists than on secret bits-of 
information. Rarely is a single publication of crucial importance, and 
encouraging publication stimulates greater effort. 
The number of publications is an index of output, and therefore of 
input. Scientists themselves regard articles as the end-product of 
research whether or not they report drug discoveries, and reports of 
findings related to physiological processes may be more valuable 
ultimately to those directly concerned with individual drugs. The 
research-orientated firm, in fact, may turn out many valuable scienti- 
fic reports and few drugs; other firms may profit from drugs which 
eventually result from the reports. To the extent that scientists 
seeking advancement publish articles reporting trivial experiments,. the 
measure is, as Reekie says, deficient 
- 
but the error need not bias the 
estimate of the effect of firm size on research effort. 
Using Derwent's Ringdoc service, Schwartzman examined the numbers of 
publications produced by forty USA pharmaceutical companies between 
1965 and 1970; these numbers he compared with the size of the firms as 
measured by sales of ethical drugs (and thus as a measure of ß&D, 
success). The results showed that the number of publications increases 
more than proportionately with sales size. An increase of 1% in sales 
size he estimated to yield an increase in research effort of 1.62%. 
(ii) Patents Issued 
The patent count as a measure of R&D effort effectiveness has received 
the stamp of respectability by its fairly prevalent use by some 
prominent economists such as Schmookler29, Freeman 
40, Scherer41 and 
26 Reekie. 
However, it should be noted that the propensity to patent varies from 
industry to industry and from firm to firm. Certain industries and 
firms may, therefore, be either inadequately represented or over-repre- 
sented by patent statistics. 
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Kuznets42 points out advantages in the use of patent count methods. 
Firstly, patent law ensures in theory that any invention which is 
granted a patent is original, non-obvious and is a technical possibi- 
lity. Secondly, since the obtaining of patents requires both time and 
money it can safely be surmised that the invention which is patented is 
expected, at least, to be commercially worthwhile. Unfortunately 
"commercially worthwhile" inventions include those which may be paten- 
ted solely for the purpose of restricting entry into a given market and 
blocking the innovation of the invention or similar imitation by others 
rather than for protecting the innovation of the patenting inventor, 
i. e., patents solely for the purpose of "disclosure". As Kuznets-says, 
however, unless the numbers of patents issued for the purpose of such 
unfair marketing strategies is both large and variable, then this 
qualification is of minor importance. 
Patent statistics are also defective as an index of the inventive 
output of an R&D effort in that they include patents taken out by the 
organisation concerned but which need not relate to inventions emanat-, 
ing from the official R&D department. Schmookler29 indicates that an 
organisation's patents will reflect inventive activity on the part of 
the scientist, engineers and administrators in other departments of the 
organisation as well as inventive activity in the, R&D department. 
Similarly many individual inventors, working alone or in academic 
institutions may well assign their commercial rights in an invention to 
an organisation which-in turn will apply for a patent in its own 
right. 
Furthermore, there is no certainty that the patents taken out by firms 
in period "t" can be definately 'ascribed to some specific R&D effort 
conducted in time "t-k" where "k" is a constant period. For example, 
administrative delays at the Patent Office may vary. Conversely it 
could be suggested that similar delays prior to acceptance will con- 
front each patentee, and while this will alter over time the changes 
will be gradual and probably not erratic and irregular from month to 
month. 
In opposition to this rationalising, however, intra-firm delays to 
provide a complete specification will vary from firm to firm, and 
invention to invention, depending on the inventive step itself and on 
the resources of the firm to perform the necessary R&D in the "race 
to patent". However, since the gap between the filing of an application 
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and the provision of the complete specification is fixed by law this 
latter factor may not be of great importance. 
A further difficulty in using patent counts as a measure of R&D 
appears to be that not all inventions are patented. A declining 
percentage of inventions are being patented29 and there appear to be 
fewer inventions to patent. Many reasons for this have been put 
forward. Schmookler noted that corporate patenting was not increasing 
at anything like the rate expected from the increased funding of 
corporate R&D. He suggested that this was due to a shift of attention 
away from empirical and towards more scientific research. It seems 
that firms are finding increasingly that being without a patent is not 
so dangerous as they had feared. They are still able to reap most of 
the benefits from an invention. The firm may well rely on secrecy to 
protect the invention rather than risk exposing it to competitive 
imitation. 
Like journal publications, patent statistics are also limited in their 
applicability to one part only of the R&D spectrum. Edwards){3 indicates 
that patent grants give no protection or property rights to the inform- 
ation provided by a basic research effort. Scientific knowledge is not 
patentable, and hence patents give no index of the success of basic 
research effort, despite the fact that it is at this stage that the 
bulk of R&D effort is expended, and it is here that the production and 
marketing constraints essential for success of the R&D project as a 
whole are applied with greatest stringency. 
Angilley44 has argued that patent counts are of little value in examin- 
ing research performance at either international levels or at indivi- 
dual compapy levels. His arguments to support these claims are, 
firstly, that different sized companies display different propensities 
to patent, managerial attitudes often affect the decision on whether to 
patent a potentially useful compound. Secondly, the types of invention 
which are patentable vary from country to country, for example between 
UK and USA, and, since USA industrial counterparts are typically larger 
that UK companies, any resultant bias would be of importance. 
In commenting on patent statistics and corporate policy on whether or 
not to patent, Christian 
45 
points out that the utility of a scheme for 
classifying and aggregating patents depends on more than its consis- 
tency with certain theoretical propositions. A scheme is ultimately 
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judged by its ability to meet the needs of different users at a 
reasonable cost. Users of classified and aggregated patent data 
include, among others, those who analyse and predict the rate and 
direction of technological change, prospective or actual patent appli- 
cants who wish to identify competing patents and analysts of the 
relationship between patented inventions and other economic variables. 
These latter users wish to analyse the role of invention in the systems 
of scientific advance, technological change and economic performance. 
Inventions cannot be measured directly: therefore, analysis focuses on 
patent activity, particularly by the private profit-seeking firms who 
dominate industrial consumer-oriented innovation. Much of the knowledge 
that these firms develop in their research and development efforts to 
develop new goods can be described as a "free good": it may be approp- 
riated without payment by other agents who have not performed costly 
R&D projects. Immediate imitation of innovations would prevent the 
inventing firm from reaping profits and earning a return to its R&D 
investment; it designs an innovation strategy around the development 
and at least partial maintenance of a monopoly over the new product. 
Patent systems permit one such strategy: a government grants rights 
over the use of an invention for a certain period of time in exchange 
for disclosure of the invention's crucial knowledge, a registration 
fee, and sometimes maintenance fees. 
, 
The firm, which has already made 
an invention and has evaluated its market potential, will weigh the 
costs and benefits of patent protection against the costs and benefits 
of other available strategies. 
Christian observes that the analyst of the economics of science, 
technology and innovation seeks an indicator that directly reflects 
calculable inventive output, which is jointly determined by the techni- 
cal per-unit reduction in service costs and demand conditions in the 
markets where invention is applied. These factors enter the firms 
decision to patent: other things being equal, an invention that is 
worth more to society will be worth more to the inventing firm, provid- 
ed it can maintain a monopoly over the relevant innovations. But other 
facts intrude as well: the decision to patent implies costs, including 
the cost of strategies foregone. If the value of alternative strategies 
varies systematically, then the relationship between the number of 
patents taken out and actual inventive output will also vary. There 
are good reasons to believe that the attractiveness of patent protect- 
ion does vary systematically, as a function of the effectiveness of 
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other strategies, including secrecy, the maintenance of a technological 
lead, and shelter behind other non-technological barriers to enter. 
Use of patent statistics as indicators of inventive activity therefore 
requires that account be taken of these systematic influences which are 
separate from the value of inventive. output. Two aspects of market 
structure seem likely to influence the decision to patent. Concentrat- 
ion in an industry suggests the existence of other advantages to 
existing firms which deter entry by new firms; these barriers may 
adequately protect the exploitation of new knowledge so that patent 
protection becomes redundant. Vertical integration, particularly 
between the equipment supply stage and the production stage, may permit 
a strategy of secrecy, offering the innovator the monopolist's differ- 
ential cost-price structure without the costs and risks of patenting. 
These non-technical factors and others flavour the economic analysts's 
choice of patent statistic methodology. To account for the variability 
in the firm's decision to patent and analyse the effect of changing 
technology independantly of market structure and other influences 
requires that patents be. divided into groups where the non-technologi- 
cal factors vary little. The prominence of market structure variables 
in the analysis of patent decision suggests that patents be broken down 
by industry. Such a breakdown has been attempted for the resources 
devoted to private sector research and development, according to the 
principal economic ectivity of the performing firm. This scheme is 
conservative, and it assumes that firms will only innovate in their 
current activity, and not enter new fields. An alternative approach, 
currently practiced by OTAF, divides patents according to their likely 
use; this is the product field approach. From the perspective of the 
ecomomic analyst, such a system should classify a patent in only one 
group, that containing the component furthest upstream that the patent- 
ed invention changes. In principle, the analyst would then compare 
this data with R&D data broken down by the product group of the goal 
of R&D; whether such data can ever be available is a separate question. 
Another question is whether the (ideal) product group classification 
scheme for patents discussed here can be compared with the currently 
available industrial breakdown of the resources devoted to R&D. 
Reekie46, whilst defending patent counting as a valid technique, admits 
it has three major disadvantages: patents do not differentiate between 
inventive steps of differing economic and/or 
-technical magnitude; 
Angilley's second argument concerning differences in patentable inven- 
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tions in differing countries applies; and, patents only refer to the 
creation of new technology, yet they are often used to assist in the 
understanding of the total morphology of an industry. 
The effect on patent counting techniques of variations in the quality 
of patents has been commented upon. Some patents may contain struc- 
tural inventions whilst others contain highly significant inventions, 
yet they are equal in numerical terms. Federico 
47 
claims that the 
patent laws of some countries encourage the filing of hasty and prema- 
ture applications. This can be done to establish the applicant as the 
first applicant, for example. Applications may thus be filed for 
inventions which are subsequently found to be worthless. Bosworth 
48 
claims that patents have increased in quality in the last few years. 
He agrees with Lutz 
49 
that the courts in the US have raised the stand- 
ard of invention. In addition, a higher proportion of patented items 
seem to he exported. This could be interpreted as implying an increase 
in the quality of the inventions. Scherer 
41 
believes it may be possible 
to correct for the variation in quality and suggests a method of this. 
This is an important deficiency of patent-based indices, for if the. 
quality variations become great, central trends may be obscured. 
Another factor which may affect patent-count indices is that of nov- 
elty. The same invention should only receive one patent in a particular 
country. This means that, if two groups of workers invest in research 
which leads to the same invention, their effort would only be recorded 
once. R&D input measures would show up both efforts. However, this is 
not felt to be a serious defect on the part of patent-based indices. 
Overall the number of multiple inventions is not great. 
Some workers feel that patent-based indices should not contain patents 
that are unworked. They think that only patents" worked for at least 
part of their lifetime should be included. As Encel and Inglis50 
point out, patents may not be used for a variety of reasons. The 
inventions may be useless, too novel, not in demand and the inventors 
may have no cash backing. However, all patents represent inventive 
activity of a kind and are, therefore, part of the output of the 
system. In addition, obtaining information on working would very much 
complicate the collection 
. 
of patent data. Bosworth 
48 has suggested a 
possible solution to this problem. Bosworth felt that a simple index 
of patent sealings was an inadequate proxy for changes in technology. 
He thought that the renewal of a patent indicated that it was of some 
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commercial use. He therefore developed a new index of patent sealings 
weighted by the number of renewals. He claimed that the new index was 
more realistic. 
Sanders51 believes that, for patents to serve as a useful index of 
inventive activity, the following conditions must be observed: 
i) The proportion of inventive activity resulting in patented inven- 
tions must have remained essentially invariate over the span of 
time during which patents are deemed to serve as a useful index. 
ii) The input of effort per average patent must have remained invariant. 
Sanders thinks that neither of these conditions holds. He thinks that, 
since the inclination to patent varies widely from one industry to 
another, and since ascendancy of different industries has varied widely 
over the decades, it is reasonable to assume that the proportion of 
inventive activity to patenting has not been constant. Sanders also 
thinks that the average input per patent is different for assigned and 
unassigned patents. As the proportion of individual to corporate paten- 
ting has changed, he believes input per average patent has changed. 
Despite this, Sanders believes that patents provide a valuable resource 
for the study of the innovative process. 
Schmookler52 believes that the forces which cause variation in the 
input per average patent are long term in nature. He, therefore, 
recommends that in an analysis using patent statistics, periods which 
are not too far apart should be compared. This should reduce the 
effects of these long term trends. He agrees that there is no guaran- 
tee that the proportion of inventive activity devoted to producing 
patented inventions has remained constant. He claims, however, that 
the use of patents as an index of inventive activity can be justified 
by the assumption that the average application in one period represents 
"a quantum of activity of all kinds which is equal to the amount of 
inventive activity of all kinds represented by the average application 
in any other period". Gifillan53 does not agree with this. 
Schiffel and Kitti5! { also considered the two points put forward by 
Sanders. They think that his second point is less important when 
comparing countries through time, since one would expect input per 
patent to change in a somewhat similar manner across 'countries because 
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of the international character of science. They also believe that, if 
the effect of patent law revisions could be controlled, that the first 
point would be of reduced importance. 
Comanor and Scherer55, using data concerning USA companies, have 
illustrated that the numbers of patents filed correlate more closely 
with R&D rianpower than with new product sales. They suggested that 
patents may be a better index of innovative input rather than output, 
and, if they are correct, this adds weight to the weakness of patent 
counting as a measure of innovative output. 
In their investigation, Comanor and Scherer used several indices: 
a) Sales during the first two years following the introduction of new 
chemical entities (NCEs) 1955-1960. 
b) Sales during the first two years following the introduction of all 
new products 1955-1960. 
c) Number of patent applications 1952-1957. 
d) Number of patent grants 1955-1960. 
e) Average number of professional people employed 1955-1960. 
f) Average number of total research employees 1955-1960. 
They found high correlations between the two measures of new product 
introduction and the two patent variables. However, firm size was 
found to correlate highly with both the new product introduction 
measure and patent variables. Therefore, they calculated partial 
correlations with the firm size constant. Patenting and firm size were 
found to account for 67 to 83 per cent of the total variation in the 
indexes of new product introduction. 
They next tried correlating the new product indices against the number 
of R&D personnel. As indicated above, they found higher correlations 
than before. If, however, the effects of firm size where removed, the 
patent-based indices were found to be as good at predicting new product 
introduction as were the indices of R&D personnel. 
They found a higher correlation between the total number of research 
employees and the patent indices than between the number of profes- 
sional people employed and the patent indices. They interpreted that 
as meaning that patents are more likely to indicate the total size of a 
research effort than to indicate the rate of significant innovation. 
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Schmookler52 tested the relationship between the number of technologi- 
cal workers in the US and patent applications for the period 1870-1940. 
He used Census data to obtain the number of technological workers. He 
found that the increases in the number of technological workers was 
matched by an increase in the numbers of patent applications. He took 
this as evidence that patent statistics could be used as measures in 
inventive activity. 
Schiffel and Kitti54 report that various studies have demonstrated that 
the number of patents granted to a firm is correlated, after a time- 
lag, with the firm's inputs in terms of R&D expenditure, the number of 
R&D employees and the industry in which a firm operates. 
Frecman56 also reports that several studies in the US and Europe have 
shown fairly strong correlation between R&D expenditures and patenting 
behaviour. 
Machlup57 has expressed the opinion that patent statistics are a useful 
index of investment innovation. He believes that they are best used in 
conjunction with other indices, when they provide valuable evidence 
about the relation between invention and economic progress. 
These imprecisions can, however, be modified in certain circumstances. 
For example, if the patents of the companies examined refer only to one 
industry, or to closely allied technologies, the inter-industry diffe- 
rences in the propensity to patent will be minimal. This is probably 
true especially of the pharmaceutical industry which regards patents as 
being of prime importance, thus making inter-company differences in 
patenting attitudes insignificant. Reekie46 thus argues that patent 
activity is a valid guide to industrial morphology and, whilst it 
cannot replace measures such as employee counts, sales records, market 
share and profit figures, the technique serves as a useful complimen- 
tary measure 
- 
especially as patents are an easily available and 
underutilised source of information. 
Schumpeter23 has asserted that, since modern industrial research 
requires large resources, large firms would do proportionately more 
research than small ones and so produce proportionately more innova- 
tions. Scherer18 has suggested three additional reasons for expecting 
large firms to be more innovative relative to their size: (1) by 
undertaking several reserch projects simultaneously they can reduce 
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their risks; (2) their diversification permits them to exploit the 
unexpected benefits of research; and (3) they can achieve economies of 
scale in research. 
Some studies of pharmaceutical research have disagreed with Schumpeter. 
According to Mansfield28 and Grabowski 
58, large drug companies do not 
spend proportionately more money on research than smaller ones. 
Comanor59 has observed diseconomies of scale in research. Schnee60 has 
concluded that leading companies do not produce proportionately more 
innovations than other firms. 
Confirmation of Schumpeter's thesis, however, has been provided in 
studies by Schwartzman31. This worker studied, for forty US pharmaceu- 
tical companies, the relationship between the numbers of laboratory 
workers (exclusive of auxilliaries) and numbers of US patents issued 
between 1968 and 1970. His results showed large, and increasing, 
economies of scale with increase in company size. He also showed that 
sales-size is less closely correlated to the number of patents than 
with other measures of research output. He concludes that large firm 
size encourages innovation in the pharmaceutical industry. 
It is of interest to note that, in considering the possible implicat- 
ions of a merger between the UK pharmaceutical companies Beecham Group 
Limited and Glaxo Holdings Limited the Monopolies Commission61 reported 
in 1972 that: " But, while we accept that 'large' research organisat- 
ions may have some advantage because of the resources at their disposal 
we think it necessary to distinguish between size achieved by growth 
within a company and size achieved by joining together two previously 
independent and, in some fields, competitive organisations, marked by 
some differences in approach. Success in pharmaceutical research 
depends primarily on the ability to generate promising novel ideas and 
on the possession of the scienfitife resources to develop from these 
ideas valuable products. There are no grounds for believing that the 
merging of Beecham and Glaxo would result in more promising ideas than 
if the two continued to work independently. Indeed, the elimination of 
competition seems more likely to lead to fewer ideas in their large 
field of common interest, the anti-bacterials. Nor do we believe that 
the merger would facilitate the processes of developing valuable 
commercial property from novel ideas. Each company has adequate 
resources to do this without the aid of the other and should be able to 
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generate or obtain such funds as it may need to increase its resources. 
Neither company needs to acquire another research organisation for this 
purpose". 
Scherer 41 examined 418 of the largest corporations in the USA using a 
patent count for R&D output and sales as an index of size. He showed 
that whil:; t patents were an increasing function of company size, the 
relationship did not rise more than proportionally; in other words the 
larger company was not relatively more productive in R&D than the 
smaller. Mansfield62 in a similar, but by industrial classification 
more restricted, study came to more specific but similar conclusions to 
Scherer. Mansfield examined companies in the chemical, petroleum and 
iron and steel industries. He "tentatively" concluded that, holding 
R&D expenditure constant, the effects of firm size on the average 
productivity of such expenditure was negative in each industry. In 
other words R&D productivity was lower in the largest firms than in the 
large and medium sized ones. In all three industries R&D expenditure 
ceased to be an increasing function of firm size after a certain point. 
However, holding firm size constant, Mansfield discovered that in the 
petroleum and iron and steel industries, R&D productivity fell after 
a point as R&D expenditure was raised. No such falling off in product- 
ivity was observed in the chemical industry. In certain industries, 
therefore, the largest R&D effort size may not have such a negative 
effect on R&D productivity as does the largest firm size. 
In his studies Reekie26 concluded that patents obtained in R&D are a 
function of the level of R&D effort. He also found economies of 
scale in the companies investigated, i. e., the larger is the R&D 
effort, the more efficient it is. He also observed that despite the 
presence of continuing scale economies in R&D effort, that the most 
productive size of firm (as opposed to the size of R&D effort) were the 
"very smallest" and "medium to large" companies. There the combination 
of R&D intensity and efficiency was such as to maximise patent output 
per unit of pharmaceutical output. 
Steward, Peters and Wibberley63 have pointed out that Reekie's proposi- 
tion that "patenting activity is a useful indicator of an industry's 
technological progress" is not based on a demonstrated relationship 
with the rate of new product introduction. Instead it relies on a 
convergence between certain features of patent data and i"iori 
reasoning based on more qualitative knowledge of pharmaceutical innova- 
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tion. Reekie's recognition of the 'major disadvantage' that patents 
"do not differentiate between inventive steps of differing economic 
and/or technical magnitude" does not lead to an attempt to empirically 
investigate the significance of this. Inter-industry and inter-firm 
variations in propensity are considered to be minimal due to the 
selection of one industry and the 'prime importance' of patenting 
within the industry. 
The data on patenting activity used by Reekie are the total numbers of 
patents within certain categories accepted at the UK Patent Office 
between 1900 and 1966 which he presents in time-series form. He 
concludes that patenting activity as a reflection of "technological 
advance 
... 
is displaying classic exponential growth and in 1966 was 
still showing no sign of having reached a ceiling or reverting to the 
more familiar S-shaped ogive or logistic curve". The question as to 
how precise or distorted a reflection is being shown by these data is 
not pursued and instead the post-1935 growth is simply correlated with 
the onset of the "therapeutic revolution" following Domagk's discovery 
of Prontosil. 
Steward et al. doubt the validity of the methodology pursued by Reekie, 
especially as regards the value of his data as a measure of 'technical 
advance'. These doubts concern the following points: 
(1) The universe of technical activity covered by British patents 
The sample of firms covered are by definition operating in the U. K. 
market and include'many foreign firms. It is considered that"there are 
good reasons to believe that any patenting activity which such firms 
will have indulged in in their home countries will be repeated in 
England" due to their presence in the U. K. market and the status of 
Britain as "one of the world's principal patenting countries". While 
this may be true it is by no means certain that the actual extent of 
international pharmaceutical research activity underlying patent 
activity remains unclear. There will also be imprecision concerning 
the U. K. patent data and their relation to the research preceding 
them. 
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(2) Awkwardness of U. K. data for time-series analysis 
The arbitrary and variable time-periods in which patent data at the UK 
Patent Office are available for convenient counting places constraints 
on the precision with which fluctuation over time can be assessed. 
This problem is compounded by the dates identified being for accept- 
ances rather than applications. 
(3) Arbitrary selection of relevant patents 
The classifications selected: A5B (pharmaceutical compositions), C2A 
(antibiotics), C2U (steroids) and C2V (vitamins) are very broad and do 
not refer with precision to pharmaceutical patenting alone. Although 
attempts to "minimise these imperfections were made by disregarding in 
certain instances companies with little or no pharmaceutical R&D" 
Reekie himself is led to conclude that "the findings in the study must 
consequently be viewed with not a little scepticism in view of the. 
inevitable inclusion of non-pharmaceutical patents". 
A further criticism of this work is that patents assigned to class C2C 
(Organic Chemistry) were included; although selecting those in this 
class which relate to pharmaceuticals would be a formidable task. 
Walsh et a164 adopted an approach to the measurement of pharmaceutical 
patent activity which overcame some of the defects of Reekie's study. 
They achieved a more comprehensive coverage of international activity 
and a more useful and precise measure of patent dates (though still 
acceptance rather than application dates) by counting the total patents 
included under the category of 'Pharmaceuticals' in Chemical Abstracts. 
They went on to examine the relationship between this data series and 
the numbers of annual introductions of NCEs into the U. S. market. The 
results pose an interesting problem. These authors point out: 
"The trends of patenting activity appear to follow very roughly the 
trends of NCE introduction with a time lag of the order of 5 years 
for the period following the war until about 1960, although a 
'bump' in the overall increase in patents immediately after the war 
is not mirrored in the trend in NCE output. This Is to be expected 
as many patents not published during the war appeared when it was 
over. The 5 year time lag would correspond approximately to the 
sequence patent application, patent publication and drug introduc- 
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tion. After 1960 however, the trends change. The number of 
patents continues a general upward trend. Although a short drop 
occurs after 1960, the general upward trend is resumed after a few 
years. The number of NCEs introduced, on the other hand, declines 
to about war-time level and (with fluctuations) remains low for the 
rest of the period". 
Three reasons are suggested for the possible explanation that patent 
applications are being made for an increasing number of compounds which 
have not yet been introduced as drugs in the U. S. market: 
(a) there is now a greater delay between discovering a new drug 
and FDA approval, 
(b) more compounds are now being produced which are not found to 
be commercially worth marketing, and 
(c) a higher proportion of compounds being produced are perform- 
ing unsatisfactorily in the required biological, clinical and 
toxicity tests. 
Steward and Wibberley65 have provided evidence to support each of these 
propositions. To reduce the impact of the peculiarities of the U. S. 
market a better comparison for the later period is with Reis-Arndt's66 
measure of world introductions of NCEs. Although reducing the diver- 
gence, it still remains apparent. The conclusion drawn concerning the 
value of patent data as an indicator is that "If it is correct that an 
increasing number of compounds continue to be discovered and patented 
in the course of drug R&D, but that fewer of them are reaching the 
market as drugs, the implication is that trends in patenting (for 
pharmaeuticals) provide an indicator of inventive activity rather than 
innovative activity". 
There remains the possibility, however, that the technical characteris- 
tics of what is being measured by the patent statistics is changing, 
reflecting a change either in R&D activity or in propensity to patent. 
Reekie's data on product and process patents indicated such a change, 
although if the trend he demonstrated is applicable worldwide and has 
continued after 1966, it would leave the above questions unresolved. 
The difficulty of tackling the problem is that the Chemical Abstracts 
database encompasses an enormous technical variety of patents of which 
those referring to NCEs are only a proportion. It cannot be assumed 
that trends in this patent activity are neceassarily being accurately 
reflected in the gross patent figures. 
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Steward et a163 have also reported on an extension to their studies, 
in which patenting activity was measured by two methods: 
(i) U. K. Patents granted to a named company were identified using the 
Patent Office "Name Index to Complete Specifications" searching 
primarily classifications A5B and C2C. Scrutiny of the specifica- 
tion was undertaken to select patents which are linked to research 
activity oriented toward novel chemicals. 
(ii) Priority applications for patents were identified using the 
Derwent WPI/WPIL online database. Patents were selected from 
Derwent classes B1 
- 
B6 (Pharmaceuticals). Again these were 
scrutinised to select the technically relevant patents. 
Preliminary results of the work indicate that, although these data 
require further detailed analysis, they do illustrate interesting 
fluctuations in patenting activity. Correlation with NCE introductions 
must bear in mind the increasing lag between patenting and marketing. 
There does seem to be some relationship between patenting activity and 
NCE introduction. 
Aggregation of the data indicates that there appears to be a relation- 
ship between the rate of product introduction in the 1970's and a rise 
in patenting activity between 1966 and 1969. A comparison of patenting 
activity in the U. K. owned research intensive section of the pharmaceu- 
tical industry with R&D expenditure of the U. K. owned pharmaceutical 
industry indicates a high correlation. 
These early results suggest that the more precise methods adopted may 
be of value, not only for casting light on the validity of patent data 
as an indicator, but also for the analysis of changes in technical 
activity in the industry in a changing regulatory and scientific 
environment. 
Aries 67 has used data concerning patents obtained internationally 
(i. e., patents obtained by companies in their country of domesticity 
together with their non-domestic counterpart parents) as a measure of 
R&D activity. lie does point out that patents alone cannot be used as 
an index of successful R&D. He suggests that the "patent balance" 
- 
a measure of the success of one country's inventors in obtaining 
non-domestic'patents as compared to the success of foreigners in 
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obtaining patents in his own country 
- 
is a better measure. He reports 
on a study that showed that some countries, such as France, have a very 
low patent balance, and some researchers do not even bother filing 
applications overseas. As an example he quotes a key cephalosporin 
patent of Smith, Kline and French Laboratories Inc. which was filed in 
only two European countries, thus permitting highly ethical companies 
like Ciba-Geigy to enter the market without an NRDC license and with 
the aid of Montedison and its affiliate Lark SpA. 
Aries also draws attention to a particular problem which is applicable 
to all parameters used as indices of R&D effort; this is the fact that 
companies frequently employ subsidiaries to publish, 
-file patent 
applications and market new products overseas, and thus it is difficult 
to attribute figures from "counts" to a parent company in a reliable 
manner. Furthermore, the complexity of licensing arrangements also 
makes collection of some of these figures unreliable. 
Whilst acknowledging that time series of patent data give a very useful 
indication of the strength and direction of secondary and induced 
innovative activity associated with the take-off of a new industry, 
sector or product group, and they therefore provide an important 
analytical tool for a study of the economics of industrial sectors, 
Walsh 
68 
has cautioned that in studying patenting activity it is neces- 
sary to contextualise the statistical data in terms of the evolution of 
industrial sectors and "new technology systems". Aggregate patent data 
do not reflect the appearance of major or radical inventions or innova- 
tions of the kind that may lead to new industries, beacause their 
numbers would be too small to show up in the aggregate trend. In 
practise, such innovations have appeared at the same time as the first 
indication of upsurge in patenting activity in each of the dye, plast- 
ics and pharmaceutical sectors; but in other sectors a major patent 
might appear several years earlier, and not be signalled by any 
perturbation in the aggregate trend. 
From her investigation, Walsh concludes that it is essential to use 
qualitative material, and possibly other statistical indicators, in 
addition to patent statistics to study trends in invention and innova- 
tion over a whole industry life cycle, or in a comparison between a 
cross section of sectors (possibly each at an unknown stage in their 
life cycles). Thus, for example, a simple comparison between patent 
output in different sectors of the chemical industry during the 1930s 
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might suggest that the dyestuffs area was more inventive or innovative 
than the plastics sector. In terms of the absolute number of new 
chemical compounds that became commercially viable products, then it 
probably was; but in terms of signficance, plastics patents at that 
time represented more radical innovations and inventions, which later 
gave rise to a much greater upsurge of secondary product innovations 
and process, fabrication, end use and machinery innovations. 
Simiarly a study of patent output in the pharmaceutical sector in the 
mid 1960s and 1970s might suggest a continuing rapid rate of innova- 
tion. In fact, the continued rapid state of invention was not reflected 
in an equivalent number of innovations. The industry was becoming 
subject to diminishing returns on R&D. 
The use of patent and other data, conversely modifies case study or 
historical material and in particular "conventional wisdom" about 
innovation in general or the development of a particular innovation. 
Thus, the traditional view of the dye industry for example, has been 
strongly modified by the patent and demand statistics. The implication 
of this for policy makers is that "conventional wisdom" and case 
history material about a particular industrial sector may prove to be 
misleading or selective unless considered in the context of patent and 
other statistical material. Government policy is increasingly consi- 
dered at the sector level (e. g., policies to promote biotechnology, the 
electronics industry) 
-and relies on an examination and analysis of 
developments in that particular sector. 
Soete and Wyatt69 have compared foreign patents across a number of 
different major world "patent systems" at the global and industrial 
sectoral level. As well as data on US patents collected by OTAF, they 
have used patent data collected by WIPO and the EEC. 
Using data for the late 1970s they have compared gross national R&D 
expenditure (a science and technology input proxy) with various patent 
measures across several OECD countries. The patent measures included 
the number of domestic patent applications and patents granted; and the 
number of foreign patents obtained in the USA, Japan, West Germany, 
France and UK. They have also compared, across industrial sectors, the 
domestic patenting activity of the USA, West Germany, France and UK 
with their patenting activity in each of the other three countries. 
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Using foreign patents as a science and technology output indicator, 
Soete and Wyatt have studied the evaluation of a number of countries' 
technological performances across a broad range of industrial sectors. 
The analysis performed by these workers indicates that science and 
technology output indicators based on foreign patenting activity has 
considerable advantages over other indicators: it is easily available; 
it is collected in a reliable well publicised manner; and has been 
collected for many decades. 
(iii) New Products 
The third measure of the effectiveness-of an R&D effort mentioned 
earlier was the new product count. Some of the disadvantages applicable 
to patent statistics and publications also apply in this case. Again 
there is a lack of uniformity from one new product to another. Again 
this parameter does not indicate how much part R&D effort on other 
products has been used in the product in question, nor how much of the 
R&D effort incurred on the new product will be utilised in the future 
on other projects. However, the general advantages of ease of obtain- 
ment and objectivity are both present. The commercial worth of the R&D 
effort as measured by new products is more certain than when measured 
by patents. Companies do not introduce new products without at least 
the hope that they will enhance or consolidate their market position. 
The major disadvantages are the need to avoid including imitations, as 
opposed to innovations, in the count and the danger of including 
innovations which are a result of an R&D effort elsewhere, such as 
licensed products. A new product count is strictly merely an index of 
a company's innovatory effort not of its R&D effort. However, if the 
count can be restricted to those innovations proceeding from the com- 
pany's own efforts it could prove to be most useful. If the new prod- 
ucts count is so restricted then it will account for all new products 
emanating from the development end of the R&D spectrum within the firm 
and for the proportion, varying from firm to firm, of the new products 
emanating originally from the basic or applied research sectors of the 
R&D spectrum within the firm. Other sources of invention outside the 
company's official R&D unit have already been mentioned in the discus- 
sion on patents; basic research information leading ultimately to new 
products could come also from research associations, university cont- 
acts and others. 
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Thus while a new product is basically an innovative index, not an R&D 
output index, if it is restricted as suggested above, then, since by 
far the greatest part of R&D is expended at the development end of the 
R&D spectrum, then a known R&D effort can be asserted to be responsible 
for a very major part of the output gauged by this index. 
A major problem associated with new product counts is the definition of 
what is a "new product". A new salt or ester of an existing drug may 
represent a useful therapeutic advance, most often through inmproved 
pharmacokinetics, which can permit greater convenience in dosage 
schedules and improvement in safety. However, the market launch of 
such derivatives may require much smaller research investment compared 
to basic new agents for the same or similar therapeutic indications. 
Similarly a new derivative which represents a new use of a drug which 
is already available may not necessarily be considered a significant 
innovation. 
A National Economic Development Office Pharmaceutical Working Party 
concluded in its report published in 197270 that the numbers of new 
chemical entities, or NCEs (defined as those unique compounds which 
become ingredients in one or more products), marketed provide a more 
meaningful measure of innovative activity than a count of new products. 
Schwartzman31 has also examined the introduction of NCEs as a measure 
of R&D effort. His results demonstrate that the largest firms, with 
the greater R&D expenditure, discover relatively more new drugs than 
do smaller firms. Ile also provides evidence that smaller firms devote 
their R&D resources disproportionately to the design of new dosage 
forms and combination preparations than do the larger companies. Ile 
points out that the leading twenty USA pharmaceutical firms by sales in 
1965 accounted for 82% of new single entities between 1966 and 1972, 
and for only 36% of the new combination preparations. In addition, 
these twenty firms produced only half of all new dosage forms. Most of 
the new dosage forms produced by large companies followed shortly after 
the introduction of an NCE. Small firms, on the other hand, produce 
new formulations of old drugs whose patents have expired. The R&D work 
performed by small companies is thus limited to developmental projects 
where the degree of uncertainty of technical failure is small. They 
choose old, standard drugs for new combination and new dosage forms, so 
the toxicology and clinical tests 
- 
which are extremely expensive to 
conduct 
- 
are either unnecessary or perfunctory. 
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Reekie26 has stated that because of the lack of understanding of 
disease causes, most pharmaceutical research in R&D is of of a random, 
rather than rational, nature. This renders the R&D a relatively 
expensive "suck-it-and-see" process using a series of costly animal 
screens which in turn do not provide definite evidence of the reaction 
of man to the new drug. 
This author goes on to say that while most new products are either 
re-presentations or combinations of existing drugs this does not 
reflect the distribution of the industry's R&D effort. Most R&D 
expenditure is directed at obtaining new preparations. Whether or not 
more resources are devoted to obtaining re-presentations or combina- 
tions than is required to obtain the advantages that such products 
possess is a question which can possibly only be answered by the 
medical profession. In any event, he concludes, the R&D effort 
involved is absolutely small. 
Reekie goes onto suggest that approximately half of all new prepara- 
tions may be "molecular manipulations". These will have been the 
subject of considerable R&D effort and are often condemned as being 
clinically equivalent to existing preparations. He indicates that each 
"manipulation" must be judged on its merits. On the one hand the 
tetracycline variants may have been the result of vast and needless R&D 
expenditure, whilst on the other hand there are the examples of 
cortisone and semi-synthetic penicillin derivatives. 
In another publication Reekie71 has elaborated on the subject of 
"molecular manipulation" (sometimes also known as "molecular roulette") 
and offers the process as a particular criticism of drug patents 
inasmuch as competitors are encouraged to search for "me-too" products 
which are similar chemically to a profitable but patented drug, and 
which have similar therapeutic properties. 
Grabowski, Vernon and Thomas72 have used the measurement of NCEs as an 
index of R&D effort in a study to estimate the effects of governmental 
regulations on innovation. These workers showed that innovation in the 
pharmaceutical industry has been subject to a number of adverse struct- 
ural developments in recent years. They observed a sharp decline in 
the number of introductions of NCEs and rapid increases in costs and 
risks. They listed five hypotheses to explain their observations: (1) 
increased regulation of the industry, especially in the USA, associated 
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with the 1962 amendments to the Federal Food, Drug and Cosmetic Act is 
the cause; (2) the decline is illusory since only ineffective NCEs have 
declined; (3) a depletion of research opportunities has taken place: 
(4) the thalidomide incident has made firms and physicians more cau- 
tious; and (5) costs have risen as a result of advances in the techno- 
logy of safety testing. 
In order to separate the effects of regulations from other factors, 
these workers developed an international comparative analysis of R&D 
productivity changes in the USA and UK. 
A principal-finding that emerged from this analysis was that US "rprod- 
uctivity" 
- 
defined as the number of NCEs discovered and introduced 
into the USA per dollar of R&D expenditure 
- 
declined about sixfold 
between 1960-1961 and 1966-70. The corresponding decrease in the UK 
was threefold. Clearly, they state, some worldwide phenomenon, which 
might be labelled a "depletion of research opportunities" - but which 
probably includes the effects of other factors such as the thalidomide 
incident and higher costs due to new developments in safety testing 
- 
seems to hold for pharmaceutical R&D. However, they found strong 
support for the hypothesis that an additional factor had been at work 
in the USA industry. 
They conclude that this additional factor, which has lowered USA 
productivity at a significantly higher rate, is the increased regula- 
tions resulting from the 1962 amendments. On the basis of their' 
analyses the authors estimate that the introduction of the 1962 amend- 
ments, at a minimum, double the cost of an NCE. 
As far as could be ascertained, no studies have been conducted on the 
effect on the UK industry of the establishment of the Committee of 
Safety of Drugs set up under the Medicines Act, 1968. 
A study in 1970 reported by Meinhardt73 showed that the chemical and 
related industries (including as a major component the pharmaceutical 
industry) tended to patent more, and market products based on such 
patents more than for other industries. Unfortunately in this work the 
pharmaceutical industry weis not separated out for special consideration. 
In a two part study, Nolan, Oppenheim and Withers 
74 initially studied 
how the proportion of patents in the UK relating to pharmaceuticals has 
-6u- 
grown in the period 1941 to 1977. Over the period studied pharmaceuti- 
cal patenting in the UK grew exponentially up to 1961 and, after a 
small drop in 1961-3, has grown arithmetically ever since. This is in 
contrast to total patenting in the UK where a decline has been observed 
since 1969. The authors also showed that 28% of a random sample of 500 
UK drug patents published in 1951 and 1964 were kept in force for their 
full lifetime of sixteen years. This contrasts with the corresponding 
figure for patents in all subjects for which only 13 
- 
15% are kept in 
force for the full term. 
Using a random sample of 21 pharmaceutical companies from a number of 
countries, and using the Derwent CPI service, the authors examined the 
correlation between patents, profits, turnover and sales. ' They found 
that overall, patenting is positively correlated with profits and with 
sales, but for certain companies, there was a significant negative 
correlation, whilst for others there was no significant positive or 
negative correlation. They also found that turnover was significantly 
correlated with both R&D and patenting activity. However, no conclu- 
sion could be drawn from this study about cause-effect relationships. 
It was not clear whether high patenting activity causes high sales, 
high sales cause high patenting, or whether, in fact, both are control- 
led by other variables. 
In the second part of their study, Nolan et al found that the marketing 
activities of pharmaceutical companies had declined in the period from 
1974 to 1975; although this trend was not confined to any particular 
area other than that of the CNS-active drug market. They state that 
this decrase may in part be due to increasing costs of developing new 
drugs and in part to increased legislation concerning safety, which 
factors they argue tend to lengthen the time interval between patenting 
and marketing of drugs. 
The majority of drugs (73%) considered in their study were covered by 
patents. However, they were not able to ascertain an obvious reason as 
to why some drugs were successful in terms of sales volumes. 
These authors found differences in corporate attitudes and approach 
towards patenting amongst the 21 companies selected for special study. 
The levels of patent applications and publications were sporadic, but 
on the whole they observed a decrease in patenting activity levels. 
This is in contrast to the overall patenting activity where a steady 
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increase in patenting levels may be observed. They also observed that 
some companies have a propensity to offer their patents to be endorsed 
licenses of right rather than exploit the patents themselves and that 
those companies active in patenting do not usually market a large 
number of products. 
Nolan et al. pointed out that their investigation revealed that most 
companies did not utilise their own patents in developing products, but 
relied upon licensing arrangements 
, 
or to a greater extent, on manu- 
facturing drugs or compositions now out of patent cover. They found 
that only up to 18% of patents (depending on the company) led to 
marketed products. 
On looking into licensing arrangements, these authors found that, for 
the small sample studied, the majority of companies which were involved 
in such agreements with other companies did so without marketing a 
novel product based on the same patent themselves. A small number of 
companies did manufacture drugs in direct competition with the drugs 
based on the patents so licensed. They also found that over half of 
the products identified through the Monthly Index of Medical Speciali- 
ties, published by Haymarket Publishing Limited, London, consisted of 
drugs no longer covered by patents, and that of the remainder over half 
consisted of products marketed subject to licensing arrangements; only 
the smallest group consisted of products which were protected by 
patents. 
The authors were not able to find any general criteria for the relative 
success of the companies studied in this second part of their study, 
although the earlier part indicated a correlation between patenting and 
profits. Neither were they able to find correlations, significant or 
otherwise, when patent, marketing or profit data were tested. From 
this they conclude that their studies indicate that profitability lies 
in marketing products under license rather than carrying out large 
amounts of R&D and marketing the drugs resulting from that effort. 
Oppenheim75 has observed that the pharmaceutial industry is particu- 
larly active in protecting its patenting rights as indicated by the 
fact that during the period 1974 to 1977, out of a total of twenty 
seven patent infringement actions in the UK, ten related to pharmaceu- 
tical products; this is a very high figure when taken in the context 
that only 1 to 2% of all patents relate to pharmaceuticals. Further- 
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more, Oppenheim points out that a number of pharmaceutical companies 
have applied for an extension of term of their patents on some major 
drugs; indeed six out of fourteen extension cases in the same chronolo- 
gical period related to pharmaceutical patents. 
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6: THE IMPORTANCE OF PATENTS INFORMATION 
As stated earlier, a patent is a document, issued by a patent office, 
which provides a description of an invention. Furthermore, the 
patent, if granted, creates a legal situation in which the invention 
disclosed can be exploited, for example by manufacture or use, only 
with the specific consent of the patentee. The patent is thus a legal 
exclusive right in the form of a contract between the State and the 
creator of some technology. The inventor has to provide detailed 
knowledge of his invention and, for making this knowledge public, the 
State grants to the inventor the sole rights to what he has invented 
for a limited period of time. 
The patent is thus a publication which constitutes a source of informa- 
tion. Because of the incentive given by the exclusive rights granted 
by a patent, the inventor is encouraged to disclose his invention or, 
in other words, to disseminate information. Provided that the invention 
is clearly described in the patent, others can utilise the ideas to 
develop further improvements or to find better ways of accomplishing 
the same result. That is to say, technology may advance by building on 
technology. The disclosure of an invention in a patent may also 
prevent a duplication of research and the needless expenditure of 
efforts and funds. 
Kronz and Grevink 
6 have stated that, if it is accepted that the main 
purpose of patents is to promote technical and industrial innovation, 
and not only to create monopoly rights, a distinction should be made 
between three groups of innovation-related factors: - 
A- factors reflecting the need to innovate, 
B- factors reflecting the capacity to innovate, and 
C 
- 
factors reflecting the incentive to innovate. 
The principle components of type A factors appear to be: - 
Al 
- 
the number and characteristics of scientific and technical 
problems to be solved without having recourse to imitation, 
and 
A2 
- 
the degree and character of national and international com- 
petition imposed on or demanded by the economy. 
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In essence there is a need for social progress and thus a need for 
innovation. 
The principal components of type B factors appear to be: 
- 
B1 
- 
the number of entrepreneurs (firms and skilled individ- 
uals) engaged in the production of technology (goods, 
devices, processes), 
B2 
- 
the capital and labour engaged in R&D, and 
B3 
- 
the extent and character of the economic and industrial 
structures of a given country. 
In essence there is a capacity in existence able to bring about innova- 
tion. 
The principal components of type C factors appear to be: 
- 
C1 
- 
the mental disposition and environmental constraints for 
improving the standards of life by technical innovation, 
and 
C2 
- 
the existence and the quality of an economic order and a 
body of law favouring innovation. 
In essence there is an incentive for advancing the state of the art by 
innovation. 
Parker10 has emphasised that the information resource which patents 
represent provides a significant economic advantage to society. For an 
economy to grow, it is axiomatic that there must be innovative indivi- 
duals in that society; but for these persons to innovate they must be 
well informed and the society of which they are part must be able to 
produce, disseminate, retrieve and use knowledge efficiently. Patents 
as a source of knowledge thus constitute one of the building blocks of 
economic progress. 
It follows from this that in a highly competitive industry, or one 
subject to rapid growth, or to rapid technological advance, or, indeed 
to any combination of these, patents and the information they contain 
are of vital importance. If maximum. use of this information is to be 
attained, then the patents and/or the information have to be organised. 
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Before considering how this organisation has been brought about and how 
various products have developed with which to manipulate patents data, 
some appreciation of file size is important. Marmor77 has reported 
that the United States Patent and Trademark Office (USPTO) receives 
about 600,000 non-USA patents each year Under the exchange provisions 
of the PCT. These, together with the 70,000 to 80,000 USA patents 
issued annually, indicate the rate at which the patent files are 
growing. Pilch and Wratschko78 have indicated that, on average, every 
8 seconds of a working day a patent is issued from one of the 45 major 
patent issuing authorities in one of fourteen different languages. 
Returning to the USPTO files, Marmor states that after patent family 
duplication elimination and multiple filing because of classification 
cross-referencing, the USPTO search files contain more than 11.5 
million US patent documents and 9.5 million non-USA patent documents, 
together with approximately 1 million items of non-patent literature 
- 
a staggering 22 million documents growing at a rate of 650,000 items 
per year. By comparison, Chemical Abstracts provided almost 500,000 
abstracts in 197879. 
At the time this study was initiated, Derwent services covered the 
documents of 26 patent issuing authorities providing a weekly input of 
9,500 documents which, it was calculated, would have cost more than 
£5000 to purchase 
- 
and to this must be added the costs of screening 
their 150,000 multilingual pages for items of interest to any particu- 
lar user wishing to consult patent literature. 
From all this it follows that there are a number of reasons why one 
should consult patent specifications. These are summarised in the range 
of information which users of the patent system or patent literature 
usually call for as reported in a 1979 British Library Consultative 
Paper80 and are as follows: 
- 
(a) The latest patent on a topic or topics. In other words the user 
is concerned with current awareness searching and seeks informa- 
tion either on new developments or on research in progress, 
since patents often give an indication of this. 
(b) State of the art searches; clearance searches. These are jargon 
terms for extensive retrospective searching which may be con- 
cerned with finding out whether a new idea is really novel or 
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whether a new line of production, research or development is 
worth starting. 
(c) Retrospective searching is also undertaken when the requirement 
is simply to find one or more ways of solving a problem 
- 
in 
which case it may be sufficient to retrieve only one or two 
documents, adequate to generate ideas in the mind of the techno- 
logist or engineer. 
(d) Patents are used as a source of information about the level of 
R&D activity in a company. Much can be deduced in cerain cases 
by a study of the level of patenting activity in a company, or 
the changes in activity with time. In this situation the user 
would study both applications and granted patents. 
(e) The status of a patent. Has an application been granted and, if 
so, is the patent still in force or has it been allowed to 
lapse. 
(f) Another area of information which is continually sought is the 
identification of the number of countries in which protection 
for a particular invention has been obtained. Family informa- 
tion, as it is called, may also be sought for other purposes 
such as obtaining a translation of a foreign patent written in a 
language unfamiliar to the user. 
(g) Finally, in this list of types of information must come that of 
opportunities for licensing. This is related to the status of a 
patent but requires much more knowledge than that; in particu- 
lar, whether the invention in which the licensee is interested 
has been carried through to full scale production or whether it 
is still in the development stage. 
There are further interrelated and increasingly recognised uses to 
which patents information may be put. Firstly, there is the use of 
patent literature as a tool for industrial forecasting for marketing 
and research strategists 
81; 
secondly, the use of patents in bibliome- 
82 tric analyses to determine pseudoproprictary information '83 
, 
such as 
predicting the fate of products under development84'S5. [These aspects 
of the use of patents information are dealt with more fully below. ] It 
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may also be necessary to watch for patent applications which may 
infringe upon one's own proprietary rights. 
Patent information may also provide ideas for new products or new 
applications for existing products; it may suggest companies for 
acquisition or collaboration and it will help identify personnel with 
specialist expertise. 
PATENTS 
- 
AN UNDERUTILISED INFORMATION RESOURCE 
Despite the important, if not vital, reasons given above for using 
patents as a source of information on both past and recent developments 
in technology, it is generally recognised that they remain an under- 
utilised medium of information apart from their legal use. Furthermore, 
many information workers consider patents to be an information source 
of last resort. 
The field of information science abounds with user studies. The habits 
and preferences of users of all types of information products and 
services have been analysed and reported in countless studies. User 
studies on the use of patents literature are, however, very rare. 
In a 1962 NAS-NRC symposium on the role of patents in research, C. G. 
Suits, Director for Research of the General Electric Company, presented 
the results of a study öf technical papers submitted for publication by 
staff members of the General Electric Research Laboratory86. A sampling 
of papers submitted for publication approval yielded the following 
statistics: 
- 
57% 
- 
involved no subject matter on which it was desired to file 
patent applications 
35% 
- 
included important patentable subject matter, which, at the 
time of the request to publish had been adequately covered by 
patent applications already on file 
7% 
- 
included patentable subject matter on which new patent appli- 
cations had to be filed to permit publication approval; prompt 
filing and prompt approval usually followed 
1% 
- 
included proprietary information on which no patent applica- 
tion was filed. Questions of patentability may have been 
involved. There might have been an extensive delay in 
publication, or there might have been no publication. 
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This information was presented by Suits to indicate the extent to which 
patent filing provides the freedom to publish. The statistics shed some 
light on the relationship between patents and technical literature. 
The study findings indicated that of the papers submitted for formal 
publication by GE staff members, 142% included patentable subject matter 
on which a patent application had been, or would have been, filed. 
Presumably most of these applications ultimately matured into patents 
so that nearly 42% of the published literature written by the research- 
ers covered material that will also be found in the patent literature. 
Since the published literature is generally available more than a year 
before the issuance of the US patents (note that the same does not 
apply to other countries, but it is assumed the GE patents would be the 
subject of US applications; see also comments below), and since it is 
usually written in a style far more palatable to the engineer and 
scientist than the patent document, the formal technical literature may 
take the place of the patent document as a means to disseminate techni- 
cal information in nearly 42% of the published literature (assuming the 
GE laboratory output is typical of all journal literature). 
It should be noted that the 42% found in the GE study is the percentage 
of literature for which patent applications had been filed not the per- 
centage of patents with subject matter common to published literature. 
A second study was performed in 1966 by J. S. Gilmore of the Denver 
Research Institute under contract to NASA 
87. 
This study sought to 
identify the channels through which commercial firms acquire new 
technology. Patents were one of a number of channels studied. In 
this study technology acquisition "channels" were investigated in 
commercial firms and organisations in five industries. The industries 
surveyed were: batteries, medical electronics, industrial controls, 
printing machinery and vocational technical education. 
Through 217 interviews in 73 companies and 480 mail questionnaires, 
participants were asked to rank a number of alternative channels of 
information gathering for both "awareness" and "problem solving". 
Patents ranked very low behind such other channels as trade and profes- 
sional journals, meetings, supplier personnel, vendor catalogues and 
textbooks. 
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On a scale of 100, patents ranked 5 for both "awareness" and "problem 
solving", while trade and professional journals, meetings, supplier 
personnel and vendor catalogues ranked above 30 in nearly every inst- 
ance. Abstracting services ranked at about the same level as patents. 
The importance ranking was stratified by the orientation of the indivi- 
dual responding. Research-orientated personnel ranked patents at 9; 
product-orientated personnel ranked patents at 3; and respondents fron 
the management category ranked patents at 5. In spite of this low 
ranking, Gilmore reported: "Patent literature, although not widely 
used, was highly valued, both for the'specific and detailed technical 
information it contained and for that portion of a patent application 
which surveyed the state of the art". 
A further study dealing with the use of patent information was con- 
ducted by a committee of the American Chemical Society in 196988. The 
ACS surveyed 2,790 chemists with a mail questionnaire and received 
1,394 responses. Respondents were asked to indicate whether certain 
categories of information services were available to them and whether 
they were using the services that were available. Patents services 
were available to 84% of the respondents and were used for current 
awareness by 63% and for searching by 45%. A total of 68% of the 
respondents used the patents services either for current awareness or 
for searching. The other services considered in this study were: 
abstracting services (92% use), title services (62% use), Science 
Citation Index (24% use) and computerised information services (60% 
use). This is clearly a different set of alternative sources of 
information to the set used in the NASA study. Furthermore, the NASA 
study sought to rank a broader range of services in terms of importance 
for "awareness" and "problem solving". The ACS study was limited to 
"availability" and "use". Nevertheless, the differences in the quanti- 
tative results of the two studies are striking. 
An analysis of the characteristics of the respondents to the two 
studies clearly indicates the reasons for the different results. The 
respondents to the ACS study were predominantly PhDs heavily research- 
orientated, 
- 
working for large organisations. The majority of respon- 
dents to the Denver Research Institute study did not have graduate 
degrees, were product or development orientated and worked for relativ- 
ely small organisations. The comparison of the characteristics of the 
respondents to the two studies is summarised in Table 1. The results 
reported in the two studies on the relative use and Importance of 
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patents information provide some insight into the characteristics of 
different types of users. 
Research or Development or 
research product Size of 
Study PhDs orientated orientated Firm 
DRI 19% 15% 52% 61% had less than 
500 employees 
ACS 55% 67% 23% 73% had sales >$100 
million per year 
Table 1: Comparison of DRI and ACS Study Respondents 
Chasen89 has commented that librarians, especially those in corporate 
libraries, who are seldom the direct users of patents, should become 
knowledgeable in the rich resources of patents data. Chasen points out 
that technology transfer can be accomplished by the engineer and 
scientist having the complete picture which the librarian offers in 
response to a search request. 
Chasen surveyed (a) major library schools in the USA to ascertain 
whether courses on patents information were included in curricula for 
special librarians, and (b) a number of major industrial libraries in 
the USA on their patent handling and management. Chasen found that not 
one of the four Schools of Library Science he surveyed had a specific 
course in patent literature and that the professors responsible thought 
they had not made their students aware of the value of patents, 
- 
alth- 
ough each thought that a specific course would be desirable. 
Chasen's survey of industrial libraries (two public and eleven corpo- 
rate) is equally revealing. The questions asked and responses received 
are as follows: 
- 
(1) My library is the central point in my organisation to handle and 
order patents. Response: Yes 
-2 public libraries; Yes -4 special 
libraries; No 
-7 special libraries. 
(2) When performing a literature search, patent literature is included 
in the final results. Response: Yes 
-1 public library and 9 
special libraries; No 
-1 public library and 2 special libraries. 
(3) Are you, or is any member of your library staff, trained in patent 
searching? Response: Yes 
-2 public libraries and 5 special 
libraries; No 
-6 special libraries. 
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(4) Do you believe,, as a professional librarian, we have overlooked 
patents as aý valuable information resource? Response: Yes 
-2 
public libraries and 7 special libraries; No 
-4 special libraries. 
(5) Any comments of the value and pertinency of patent literature as an 
integral part of a literature search would be greatly appreciated. 
Responses: 
From public libraries: 
"A literature search would be of greater value if it included patent 
literature as well. " 
"The Brooklyn Public Library subscribes to The Official Gazette 
- 
for 
full patents we send patrons to the New York Public Library. " 
From special libraries: 
"Look upon patents as just another piece of published technical infor- 
mation. Wasn't this settled years ago? Why another study? It seems 
we keep re-inventing the wheel. " 
"I am sure all. major libraries in research orientated firms such as GE 
or Dupont [sic] include and pay close attention to patent literature, 
when performing technical literature searches. However, this is 
certainly not the case in many literature searches from other sources. " 
"One member of the library staff attended a half-day seminar on patent 
searching: thus, we have a cursory understanding of the process and its 
inherent problems. " 
"I think it is just now becoming important as a source of information 
since the advent of the online systems and the numerous databases. Our 
appreciation of this type of information will greatly increase in the 
next several years. " 
"My staff engages in a great deal of literature searching to provide 
evidence of patent infringement. " 
"We have a patent attorney at our company, and his office takes care of 
all patent matters. We do searches for our patent attorney. " 
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Starkloff, Hesse and Paul90 offer two possible explanations for the 
underutilisation of patents as an information source: (a) patent 
literature as an information source is considered not very useful 
(benefit/cost ratio too low), and (b) knowledge about patent literature 
and its benefits is not widely distributed (benefit/cost ratio is high, 
but unknown to potential users). 
These workers carried out an investigation in Germany, France and 
Ireland through mail questionnaires, interviews and expert panel 
discussions. They concluded that the use of patents is limited because 
both knowledge of the patents literature and experience in its use are 
not very widespread. In other words, the potential users who theoreti- 
cally could profit most from the application of information found in 
the patent literature: (a) are not aware of the possibilities of this 
source of information, (b) do not have enough specialised training and 
knowledge to work the patent literature, (c) find other ways of inform- 
ation gathering more efficient, or (d) live in a psychological environ- 
ment that does not encourage the use of patent literature. 
Bank91 has stated that the most important reasons for the low degree of 
exploitation of the patent literature seem to be: (a) lack of knowledge 
of its contents, its qualities or even its existence, (b) it is consid- 
ered too difficult to access, or potential users lack knowledge of 
access possibilities, and (c) the special language used in patent 
documents, derogatorily called "patentese". 
In a follow up study to those of Starkloff et al. and Bank, Thomsen92 
concluded that the most important problem areas in the matter of access 
to patent information and documentation in public patent libraries are: 
(a) identification of user's needs, (b) the extent of the documentation 
needed, (c) publicity programmes, (d) location of the patent informa- 
tion centres, and (e) organisation and staffing of the centres. 
Shuchman93 has reported on a survey of the patenting activities of 
1315 American "bench" engineers; in answer to a question which asked 
how useful they find a variety of sources of information this group 
replied that patents were among the least useful sources. Only 4.8% 
rated patents "very important"; another 15% rated them "moderately 
important". 
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Shuchman reports that the survey data also indicated that patents 
information use varied between industries, for example between the 
aerospace and metallurgical industries (although she gives no data on 
such differences), but that it is consistently low irrespective of 
differences based on educational degree or engineering discipline. The 
population of engineers surveyed communicates largely on an informal 
basis and mostly within the company. 
Shuchman states that "there is no printed alternative to reading 
patents" and, because of their reluctance to read such documents, 
engineers are unlikely to pick up information about new inventions from 
journal sources as such a large proportion of inventions are never 
ý, 95. 9! disclosed outside the patent literature 
Shuchman concludes that in all likelihood, informal communication and 
internal company reports provide engineers with their link to technolo- 
gical innovations, albeit that her survey results indicate that the 
link is weak. 
A study on the uniqueness of patents as a technological resource given 
in the Eighth Report (1977) of the Office of Technology and Assessment 
Forecast (OTAF) of the US Patent and Trademark Office94(8), 95 adds 
further possible factors in the matter of use of patent literature: (a) 
the information in a patent may be outdated as a result of the delay 
between the development of the invention and its acceptance and publi- 
cation as a patent, (b) the inefficiencies in such secondary patent 
literature as abridgments, and the structure of indices to patents, 
hinder certain types of searches, (c) the fact that non-domestic 
patents may be in an unknown language to the potential user, and (d) 
potential patent users have a belief that the information contained in 
patents will eventually come to their attention through other means 
such as scientific or technical journals. 
In discussing the OTAF programme and functions, Marmor et al. 
96 
postul- 
ated that there are four "myths" associated with patents which lead to 
their under-utilisation; these are: (a) patented technology is reported 
and adequately covered by the non-patent literature, (b) patents to a 
large extent do not disclose significant new technology, (c) by the 
time a patent is obtained everyone knows about the technology since 
patents are untimely, and (d) the validity of the disclosure may be 
suspect. 
_7$_ 
For (a) and (e), Marmor presents counter arguments similar to those 
given by other workers, and which are discussed below. With regard to 
(b) Marmor points out that over 80% of granted US patents are owned by 
organisations, mostly large corporations. He states that the top 343 
patenting organisations represent only 0.7% of the total number of 
patenting firms, but they receive 41% of the patents granted. Thus 
most patents are obtained by the serious inventor working for organisa- 
tions which invest considerable sums of money in obtaining patents 
(attorney's charges, searching costs, filing fees, etc., easily adding 
up to many thousands of dollars). The costs are such that the corpora- 
tions will be selective in their patenting activities and that what is 
patented or described in patents are technological developments that 
corporate developers consider promising and useful. 
In considering the validity of disclosures, Marmor points out that 
although a commonly held misconception is that patented technology is 
passed on reluctantly and with some of the important features missing, 
just the opposite is likely. Patent laws require inventors to disclose 
the best mode of their inventions; to do otherwise constitutes fraud 
which makes the patent unenforceable. Furthermore, patent disclosures 
are virtually always far more detailed and complete than non-patent 
literature since they often contain many detailed drawings and examples 
which publishers of books and periodicals are reluctant to publish. 
Oppenheim97 has also referred to the reluctance of publishers to print 
dozens of drawings 
- 
often with only minor differences between them 
- 
or to print scores of examples, and quotes as possible cases where 
publishers would have been hard to find, the many voluminous specifica- 
tions relating to computers, especially British Patent 749,836 which 
has 267 pages of specification with 780 drawings, and British Patent 
1,108,800 which had to be bound in four volumes. 
Marmor's "myths" type (a) and (c) are interrelated; indeed they can be 
considered as a single function since it is axiomatic that, if "every- 
one knows about the technology" prior to the issuance of a patent [myth 
(c)] then that knowledge could only be gleaned by disclosure elsewhere, 
almost invariably through the non-patent literature [myth (a)], al- 
though some information transfer will be by personal contact such as at 
conferences and symposia. 
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There have been several studies reported in the literature designed to 
quantify the extent to which technology described in patents has been 
published in the non-patent literature. 
In an article published by UNESCO, Vicer, asnij98 states, without apparent 
detailed statistical analysis, that only 5 to 10% of new technological 
solutions offered by patents is published elsewhere. 
In 1974 Liebesny, Hewitt, Hunter and Hannah" gave the following 
examples of important inventions which were first disclosed in the 
patent literature several years before their appearence in other forms 
of literature: 
- 
Date of first 
Date of disclosure in 
published other form of 
Invention Inventor patent literature 
Punch card Hollerith 1889 1914 
Television Baird 1923 1928 
Jet engine Whittle 1936 1946 
Ductile cast iron Morrough 1939 1947 
Liebesny and his co-workers studied the overlap of a random sample of 
1058 British patents with journal literature. The patent specifications 
were published in 1962,1965 and 1968. Name (author) searches were 
carried out in the names of the inventors through Chemical Abstracts, 
Engineering Index and Electrical and Electronic Abstracts. The main 
results obtained are given in Table 2 and demonstrate an overlap rate 
of 3 to 9% depending on subject matter. 
An analysis of time difference between date of publication in a journal 
article and date of publication of the patent or date of application 
for a patent showed a peak of journal publishing occured a year after 
application for the corresponding patent; this is illustrated in Figure 
3. 
Liebesny et al. also made an analysis of the number of multiple publi- 
cations from their sample of patents. They found that in six cases two 
journal articles appeared, in three cases three journal articles 
appeared and in one case four journal articles appeared. 
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1962 1965 1968 Total 
Chemical Patents 
Investigated 91 95 127 313 
Retrieved 9(10%) 10(11%) 8(6%) 27(8.6%) 
Electrical Patents 
Investigated 49 89 74 212 
Retrieved 5(10%) 4(4%) 7(9%) 16(7.5%) 
Mechanical Patents 
Investigated 143 181 209 533 
Retrieved 3(2%) 12(6%) 3(1.4%) 18(3.3%) 
Totals 283 365 410 1,058 
17(6.0%) 26(7.1%) 18(4.4%) 61(5.8%) 
Table 2: Numbers of specifications in respect of which subsequent 
99 
references were found in other forms of literature, by subject. 
10- 
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Figure 3: Publication of specifications in other forms 
of literature, chronological from date of application 
(C=Chemical; E=Electrical; H =Mechanical) 
99 
A further study of the patent/non-patent literature relationship was 
carried out in the OTAF study referred to earlier 
94(8 
, 
this study has 
also been described by Terapane. This investigation examined a 95 
random selection of 220 US patent specifications issued in 1967 and a 
sample of 215 patents issued in 1972. 
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Literature references were determined by author and subject in Science 
Citation Index, Chemical Abstracts, Electrical and Electronics Abstracts 
and Engineering Index. Furthermore, to check the effectiveness of 
these secondary reference sources in picking up all pertinent refer- 
ences, a telephone survey was undertaken with at least one of the 
inventors of each of the 45 patents of USA domestic origin in the 1972 
set of 220 specifications. 
The overall results of this investigation showed that 16.0% of patented 
technology was fully disclosed in other literature, 13.3% was partially 
disclosed and 70.7% was not disclosed. Differences were found in the 
different subject areas; an overlap between journal and patents litera- 
ture was found for 24.3% of the chemical, 5.0% of the electrical and 
5.0% of the mechanical cases. 
In a more recent study Allen and Oppenheim100 studied the overlap of 
Canadian and US patent literature with journal literature. A random 
sample of 300 US and 100 Canadian patents published in 1968 were 
examined. These workers searched the same journals (partly online) as 
the Liebesny team. The results obtained indicated that 6.0% of the US 
patents and 11.0% of the Canadian patents also appeared in the journal 
literature. As with the earlier studies differences were found in 
respect of the subject area: 6.1% of chemical patents, 6.0% of mechan- 
ical patents and 11.3% of electrical patents 'appeared in the journal 
literature. 
Allen and Oppenheim also studied the time lag between the priority date 
for a patent and subsequent publication in another form of literature 
as well as the time lag with publication of the patent. The results 
indicated that most items in other forms of literature appeared 1 to 4 
years after the priority date of the patent, a result in agreement with 
that of Liebesny et al. Most items in the Allen and Oppenheim study 
appeared in journal literature 1 to 3 years before the patent was 
published and 19% after the patent appeared. This is significant since 
both USA and Canada are so-called "slow publishing" countries for 
patents; indeed Allen and Oppenheim showed that for USA applications 
most patents appeared 3 to 4 years after priority date, and for Canada 
most appeared 4 to 5 years after priority date. 
Data for the appearence of journal articles in chronological relation- 
ship to patent specifications would probably have been quite different 
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if Liebesny et al. and Allen and Oppenheim had studied patents issuing 
form the "quick publishing" countries (i. e., publication 18 months from 
priority date) such as France or West Germany, or if consideration had 
been given to "foreign" counterparts, or equivalent patents, to the 
specifications used in their studies. 
Marcus10 hss observed that patents contain more experimental detail 
than most journal articles and gives this as an added reason for R&D 
workers to be aware of patents information. 
A series of papers100,102-109 emanating from the Centre for Information 
Science, The City University, has demonstrated the importance of 
patents as sources of information and the coverage of patents by 
abstracting services in a wide variety of subject areas. 
Schiffels110 has discussed the reasons for the dissemination needs of 
patent information, the types of information required and the charact- 
eristics of users and potential users. He has pointed out that there 
exists a need for patent information marketing and that official 
bodies, such as patent offices, should play a key role in making patent 
information available. 
A comprehensive bibliography of patents information has been given in a 
recent NATO/AGARD publication on patents as an information resource111. 
The implication of the various studies reviewed above is obvious: 
ignore the patents literature and there is a strong risk that you would 
miss the technology that is relevant to your work. If not being aware 
of such technology leads to less productive ß&D, or to a faulty busi- 
ness decision, then failing to adequately review the patent literature 
can be very costly. 
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7: PATENTS AS A MEDIUM FOR TECHNOLOGICAL FORECASTING 
According to Hausser112, an advantage of using patent information that 
has hitherto been neglected is its reliability as a pointer to techni- 
cal information regarding new developments long before their effects 
are felt in the market. 
Taking the transformation of the clock and watchmaking industry as an 
example, Hausser has endeavoured to evaluate the usefulness of such 
information, especially as this industry has undergone a remarkable 
transformation since 1975. Many undertakings which had formerly made 
mechanical clocks and watches, or their components, were taken by 
surprise by the advent of electronically controlled products. However, 
the early warning signs of these developments would have been clearly 
discernable in the patent documents. The first patent document pub- 
lished in West Germany in 1970 concerned the Hamilton Watch Company's 
"Pulsar" wristwatch, which appeared on the market soon afterwards but 
could still be considered, because of its "fancy" price, a technical 
toy. But from 1971 onwards, there appeared patent documents describing 
clocks with liquid crystal display and minimal power consumption which 
subsequently appeared on the market, from about 1976 onwards in very 
large numbers at very low prices. Hausser stresses that the 5 year 
period which saw such a striking increase iin the number of patent 
documents in this technology should have sufficed for the taking of 
appropriate measures and for the avoidance of heavy financial losses 
incurred by certain companies. 
Hausser also points out that a similar situation is arising in the 
technology of video and data recording. Although these technologies are 
also showing remarkable advances, evidence of activity in this area can 
be identified in the patent literature from as long ago as 1970. 
Kronz and Grevink76 have stated that the patent literature is perhaps 
the truest mirror of the state of advancement of technology and of the 
progress of R&D in all fields of human endeavour; they used the term 
"patent literature" to cover all the various ways in which an attempt 
is made to gain a monopoly in ideas, i. e., patent specifications, 
published patent applications, utility model (registered design) 
specifications and inventors' certificates. 
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The authors emphasised that trends in technology and invention can be 
followed over a number of years and that it was possible to identify 
trends in technology, e. g., fast growing fields, fields where the 
growth is slowing down, foreign dominated fields, national dominated 
fields, etc. For example, in the Netherlands the number of applications 
for cycloaliphatic compounds showed a continual rise, but this was due 
to foreign filings, whereas the "national/residential" filings decreas- 
ed in number. Similarly, a decrease of numbers of applications in 
France in the field of pig-iron processing was noted; for the same 
technology in West Germany the ratio of national to foreign applica- 
tions was seen to be falling steadily. 
The data was also used to collect together and group a number of IPC 
classes and sub-classes relating to one particular branch of industry 
or commerce. It was found that, from the point of view of "patent 
concern", the machine industry ranks before the electrical industry, 
and the electrical industry before the chemical industry; furthermore, 
the manufacture of metallic articles is as much concerned with inven- 
tions and applications as the rubber industry and the working of 
plastics. 
In an extension of their studies Kronz and Grevink113 carried out a 
statistical analysis of the published patent applications in six of the 
EEC Member States during the period 1969 to 1975. They followed the 
general trend of filing of patent applications in the EEC, in Japan and 
in the USA; the areas of major technological importance for the patent 
filing activities in the EEC, and the technological areas showing a 
steady rise or fall in annual number of applications filed in the EEC. 
They also attempted to link patents statistical data to the activity in 
some industrial fields. 
In this second study the authors arrived at similar conclusions to 
their previous work. However, they were much more specific in ident- 
ifying areas of technology where significant changes of patenting 
activity were taking place; again these areas were defined in terms of 
the IPC. Kronz" and Grevink pointed out that the objective of their 
study was to help prepare the basis in Europe for a wider and more 
reliable use of statistical data in investigations concerning problems 
such as policy in R&D, innovation and technology transfer. 
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Ivanov114, in discussing the use of patent information in technology 
forecasts, has stated that the extent and scope of contemporary progr- 
ess in science and technology and its impact on the economic, political 
and social life of the community requires the development of a techni- 
que for reliable scientific forecasting. He gives this as the reason 
for present worldwide interest in the forecasting of trends in science 
and technology; this forecasting technique is gradually becoming an 
independent applied discipline. Ivanov states that the use of patents 
as an important element of the general information base for forecasting 
is dicatated by the following reasons: 
(1) First of all, a survey of patent literature enables one to obtain a 
detailed and systematic idea of the world state of the art, and of 
the trends and prospects of a given branch of industry. The 
distinctive features of patent information compared with other 
kinds of technical information are that patents are the most 
up-to-date, the most reliable and the most complete source. 
Furthermore, in principle, a patent as a legal document is not 
supposed to contain unreliable data. Patents contain concrete 
solutions of technical problems, and special indexing systems 
facilitate their retrieval from the mass of information. Finally, 
their language is in theory more concise, informative and formal- 
ised; thus it is easier to use patents for abstracting and even for 
machine translation. These advantages are of particular signific- 
ance for the elaboration of mid-range forecasts for normative 
purposes, where an especially high level of confidence is required 
which cannot be reached by the average values of intuitive esti- 
mates in the interquartile range (as for example in "consensus" or 
"Delphi" techniques) but rather by careful consideration of factual 
information. 
(2) Secondly, patent literature provides one of the most representative 
mass-scale sources of information. The need for legal protection 
of industrial property rights for inventions as a basis for further 
exclusive rights for commercial exploitation impels all organisa- 
tions involved in R&D activities to patent their results as exten- 
sively as possible. 
(3)-Thirdly, patents contain, in addition to technical information, 
extremely important bibliographic data, which permits a superposi- 
tion of schemes representing general technological development and 
- 
86 
- 
industrial structure. By giving information on priority dates and 
the inventor's and patent owner's names and addresses they permit 
the linking of the "technical side" with the existing possibilities 
for the introduction of inventions into industry, which depend on 
the technological policy and the patent owner's resources, i. e., 
the forecasting of the level not only of developments, but also of 
industrially manufactured technology. 
According to Ivanov this makes patents applicable for use in most of 
the inernationally recognised forecasting techniques, especially the 
mid-range techniques, i. e., for 4 to 10 years, with the object of 
finding the next "stratum" of technology which will replace the exist- 
ing one. In particular, patent information may be used for the fore- 
casting techniques shown in Table 3. This set of forecasting techniques 
is cited according to Hayden115. In the table, the differences in 
significance relate to the use of patents in the elaboration of a 
forecast. For an extension of a forecaster's knowledge and experience, 
patents are important irrespective of the forecasting technique used. 
For long-range forecasting, i. e., for periods greater than 10 years, 
Ivanov states that account should be taken of the possibility of the 
appearence of technological solutions which are new in principle; 
whereas in short-range forecasting, i. e., less than 4 years, the 
current general economic situation can become the decisive factor for 
the utilisation of innovations. 
De Jonge116 has drawn attention to the fact that graphical representa- 
tion of the number of patent families in the year of first filing, or 
of the cumulative number of patent families since a certain point in 
time, gives useful information regarding the inventions made in a field 
of coherent subjects. He concludes that a statistical evaluation of 
the numbers of scientific and/or technical papers does not give as good 
a base for R&D policy decisions as a corresponding evaluation of 
patents literature. 
Perhaps the widest use of patents for technological forecasting has 
been by the US Patents and Trademark Offfice; this use has been descri- 
77 96 bed by Marmor and by Marmor, Lawson and Terapane. 
The USPTO has built up an enormous computerised database of patents 
information; the uses and benefits of the database are not limited to 
patent search file maintenance and improvement. The existence of the 
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Forecasting Technique Decisive Significant Small Optional 
1 Expert Forecasts 
1.1 Individual intuitive 
forecasting x 
1.2 "Consensus" x 
1.3 "Delphi" x 
2 Extrapolation Techniques 
2.1 Linear extrapolation x 
2.2 Development trends 
according to curves x 
2.3 Envelope curves x 
2.41 Correlation and 
regression analysis x 
2.5 Determination of 
"thresholds" of 
technology changes x 
2.6 "Substitution curves" x 
2.7 "Outstripping-delay" x 
2.8 Rate of "diffusion 
of technology" x 
3 Systems Analysis 
3.1 Examination of the 
state of the art x 
3.2 Examination of 
hypothetical futures x 
3.3 Study of the impact x 
u Analysis by Parameters 
4.1 Evaluation of theoretically 
possible limits x 
4.2 Estimation of "perfection 
contour" X 
4.3 Detection of unique 
properties x 
5 Mathematical Modelling 
5.1 Matrices "investment- 
output" x 
5.2 Historical and genetic 
models x 
5.3 Biological development 
analogy x 
6 Auxiliary Techniques 
6.1 Relevance tree x 
6.2 Morphological box x 
6.3 Flow-charts x 
6.4 "Life-cycle" curves x 
6.5 Estimations of demand 
expectations x 
6.6 Dynamic forecasting x 
6.7 Technological tracing x 
Table 3: Degree of Necessity of Use of Patents for the supply 
of Information for Forecasting Purposes (from Ivanov11 ) 
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base, augmented by a variety of other bibliographic data, has enabled 
the establishment of a programme specifically aimed at those in the 
non-patent community. 
This program, called "Technology Assessment and Forecast", began in 
1971. It sprang from the knowledge that within the patent file can be 
found almost all major technological advances that have occurred in the 
USA during the period since the first US patent was granted in 1790, 
and from the realisation that this file has significant potential as a 
resource for determining the history, development and current status of 
technology. 
Data utilised include information about all US patents, such as the 
technology to which each patent is directed, its title, the inventor's 
name and residence, ownership (both specifically and by type), filing 
and issue dates, IPC and domestic-patent classsifications as well as 
search and citation information. Also data about the patents of other 
countries and facts concerning the technological characterisation of 
pending patent applications has recently been added. More recently, 
relationships between the US patent classification system and the 
Standard Industrial Classification (SIC) have been added to the data- 
base. This latter addition permits, for the first time, broad scale 
use of patent data in economic studies. 
OTAF (Office of Technology and Assessment Forecast, the Department 
within USPTO responsible for the programme) uses the database in two 
principal ways. Firstly, it periodically issues general distribution 
publications; ten of these issued between 1973 and 198194 
. 
These 
publications have included reports on highly active technological 
areas; areas experiencing high levels of patenting by foreign (i. e., 
non-USA) residents; profiles of patenting patterns of the residents of 
selected foreign countries and US states; review of patenting activity 
of the most active patent assignees; and comparisons of patent activity 
in selected SIC categories. In addition, several of the publications 
have examined the patenting trends in high-interest energy technologies. 
The second principal use of the OTAF database is in the preparation of 
special reports, tailored to individual needs. These reports, which 
are provided on a cost reimbursable basis, have been utilised by many 
USA government agencies and a large number of private sector organisa- 
tions. 
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It is not possible in this thesis to describe in any detail all the 
OTAF publications. Each of the reports contains reviews and assessments 
of patenting activity in a dozen or more areas. However, as an example 
of these reviews, the reports on prostaglandin compounds may be consid- 
ered as typical of the reports of interest to one industry sector, 
i. e., the pharmaceutical industry. 
Prostaglandins are pharmacologically active lipids, widely distributed 
in animal and plant tissue, and are among the most potent pharmaceuti- 
cal agents known. They elicit multiple responses and have a broad 
spectrum of activity. In doses as small as 10 ng/kg these compounds 
can affect the reproductive, cardiovascular, respiratory, nervous, 
renal, gastrointestinal, endocrine and/or metabolic systems as well as 
the sensory organs and skin. Hence, prostaglandins are useful in 
treating a wide variety of diseases, including asthma, ulcers and 
hypertension. Additionally, they have uses as labour inducing, abortive 
and antifertility agents. 
Due to this potency and broad activity spectrum, the prostaglandins 
have experienced phenomenal patenting activity in recent years: since 
1971 patenting activity has been growing at an average annual rate of 
84% which, for the USA, is about 34 times the average for all technol- 
ogies. 
The first OTAF report on these compounds appeared in the Fifth Report 
published in August, 19759 4 5) 
. 
The report surveyed the patents by 
geographical location of the patentees and then gave a review of the 
main thrust of the technology in terms of isolation of the compounds 
from natural sources, semi-synthetic and synthetic derivatives and 
provided a patent bibliography. 
The report concluded by oberving that the (then) most recent effort in 
the technology involved development of compounds which alter more than 
a single site of the naturally occuring prostaglandins, especially 
alkylation at 15- and/or 16-positions. 
An update of the first report was given in the Seventh Report published 
in March, 1977 94(7). The-report was similar in conent and format to 
the previous one and reviewed the patent data available up until the 
end of 1976. At its conclusion the report comments on "Future Trends" 
and observes that patent activity appears to be directed to matching 
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specific compounds to a specific use with sufficient potency, duration 
and specificity to obtain useful drugs. 
Prostaglandins were also the subject of an OTAF Special Report117 which 
surveyed the patent activity in the period until the end of 1978. This 
Special Report takes the form of computer generated listings and 
analyses all USA patents in the technology. Analyses by types of 
ownership (corporate, foreign, etc. ), geographic location of owner, 
number of patents per year by corporate ownership are provided as well 
as detailed lists by corporation giving patent numbers and titles. 
A comparison of economic and patent data was presented. in the OTAF 
Sixth Report published in June, 19769 
« 6). In this report patent 
activity data, developed through the use of the USPTO Classification/ 
SIC concordance, were used for comparison, in six selected industries, 
with R&D expenditures and the number of R&D scientists and engineers 
employed in those industries. The object of the report was to inform 
workers in economics and related fields of the availability of useable 
patent data and, perhaps, to stimulate thinking as to how this data 
might be employed. 
The selected industries were: Food, Chemicals, Fabricated Metal Prod- 
ucts, Machinery, Electrical and Communications Equipment and Scientific 
Instruments (SICs 20,28,34,35,36 and 38 respectively). 
The patent data used included only those US patents which were assigned 
(owned) at the time of issue to USA organisations. Patents were not 
included which, at the time of issue, were: not assigned (i. e., owned 
by the inventor); assigned to foreign (i. e., non-USA) organisations; or 
assigned to individuals. This was done since the economic data used 
related only to the R&D expenditures and manpower of USA industry 
and/or Government. 
An important feature of the comparisons made was the use of patent data 
distributed on the basis of the dates on which the patent applications 
were filed, rather than on the dates on which the patents were granted 
(i. e., published). The application date distribution more accurately 
approximates the period when the patented technology was developed. 
In making the economic/patent data comparisons, the economic data was 
lagged by two years. The rationale for this was that R&D funds spent 
- 
91 
- 
in a given year, or R&D manpower used in a given year, is not likely to 
result in a patent application within the same year, given development 
time, time needed for patent application preparation, etc. 
The time lag chosen 
- 
two years 
- 
was an estimate of the time taken to 
develop a patentable invention and to'file an application for a patent 
for that invention. A year was allowed for R&D efforts to develop the 
invention and to draw up the patent application. Also, since an 
applicant has up to a year to file for an application, a second year 
was added to the lag time. 
The results of the review indicated that over the-time period (1965 to 
1973), in each industry covered, there had been a decrease in the 
number of patents obtained per $1M. of R&D invested and an increase in 
the professional man-years required for each patent obtained. In other 
words, more resources (money and man-power) are going in and fewer 
patents are coming out. 
In trying to. offer explanations for this observation the report poses 
three questions: 
- 
(1) Has the great increase in technological complexity brought about a 
corresponding increase in the amount of effort, i. e., resources, 
required to "invent" something patentably different? 
(2) Has the character of patents changed over time? Are they now 
generally more comprehensive, including bigger "chunks" of increas- 
ingly complex technology? 
(3) Is USA industry becoming less patent-minded? If so, why and what 
implications (technological and commercial) does this have in view 
of the dramatic increase in foreign patenting in the USA? 
The report did not try to answer these self-imposed questions, but 
offered them as stimulants to workers in economics and related fields. 
It is understood that OTAF had not done any further work in this area 
118 by the end of 1981. 
The Semiconductor Group of the Japanese Patent Office have used patent 
and assignment data for technology trend analysis in the field of 
semiconductors119. The philosophy behind their approach was that 
assignment data can be used to measure the number of firms obtaining 
patents in a given technology; this information is an indicator of the 
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interest in the technology. Hence, a profile of corporate patent 
activity indicates the trend of interest in a technology. 
When this trend is correlated with that of the patent activity, which 
is an indicator of technological activity, the "maturity" of a technol- 
ogycan be assessed. For example, a technology in which both patent 
activity and corporate activity are increasing shows increased technol- 
ogical activity and interest. Thus, the technology is probably in a 
development stage. 
Conversely, a technology having decreased patent and corporate activity 
(decreasing technological activity and interest) can be said to be in a 
fully mature or declining stage. The possible correlations between 
patent activity and company activity, and the appraisal of these 
correlations is given in Figure 4 and Table 4. 
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Figure 4: Vector Analysis of Patenting Activity 
Figure 4 illustrates, for a hypothetical technology, a graphical mode 
of depicting with vectors the trend of activity in that technology. 
Each year of technological activity is represented by a vector having 
scalar values which represent the change in the number of patented app- 
lications (X-axis) and the change in the number of different assignees 
(Y-axis) for that year from the previous year. The base of the vector 
for the first year of the analysis period is situated at the origin of 
the graph, which represents the initial year, while the terminating 
point of the vector is located at the patent and assigness data points 
for the following year. When the vectors pertaining to a particular 
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technology are placed end-to-end, as in Figure 4, the result is a 
dynamic vectoral pattern of the rate of change of that technology over 
the time period of interest. 
The quadrant of the graph towards which a particular vector is directed 
is indicative of the status of the technology as of the end of the year 
represented by that vector. Table 4 presents the technological trends 
and the concomitant appraisals indicated by each quadrant. 
Quadrant 
of Graph 
I 
II 
III 
IV 
Patent Company Appraisal 
Activity Activity 
Increasing Increasing Development stage 
Deceasing/ Increasing/ Research or perfection 
Stable Stable stage 
Decreasing/ Decreasing Fully mature or 
Stable declining stage 
Increasing Decreasing/ Research or perfection 
Stable stage (or a notable 
invention by a single 
firm) 
Table 4: Trends indicated by Vector Graphics 
To ascertain the trends indicated by the vector graphics, the relative 
magnitudes and directional changes of the vectors are compared to 
determine the degree to which a certain vector indicates a particular 
trend. Vectors with proportionately larger magnitudes provide a 
greater, and therefore more certain, indication of the direction of 
technological change than vectors of relatively small magnitude. 
Equally pertinent is the relative direction of the vector. The amount 
of angular deviation by the vector from the bisecting line of a quadr- 
ant is indicative of the degree to which that vector denotes a particu- 
lar trend. Thus, the closer a vector is to being parallel to a line 
bisecting a particular quadrant (i. e., being directed at n /4 degrees, 
n being an odd integer), the greater the accuracy of the trend apprai- 
sal derived from the quadrant towards which the vector is directed. 
Such vector analysis can be extended by considering the probability of 
the vectors crossing and forming a closed pattern. Figure 5 depicts 
- 
94 
- 
another hypothetical technological trend vector diagram with the vector 
for the last period of interest, year D, intersecting with the first 
vector, which represents the first year of the trend analysed. This 
closing of vectors represents the return of a technology to a state of 
activity it had previously occupied. 
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Figure 5: Closing Pattern of Vectors 
Such a reversion to a prior state of activity indicates the strong 
tendency of that technology towards stability or towards maturity. 
Where a technology is not reverting towards a previous activity state, 
as indicated by a vector pattern having little or no probabilty of 
closing (e. g., as in Figure 4), a strong tendency towards either 
development or decline is suggested 
- 
development by vectors directed 
towards Quadrant I and decline by vectors directed towards Quadrant 
III. 
Applying these techniques to semiconductor patents filed in Japan from 
1965 to 1969, the authors concluded that semiconductor technology, as a 
whole, was approaching a stage of maturity. On the other hand, there 
was observed a trend towards research and development on integrated 
circuits and their production and increases in output of silicon 
devices in Japan. 
A patent analysis on computer memory components using the same techni- 
que of vector analysis was published in the OTAF Seventh Report in 
March, 197794(7). The results obtained were compared with a forecast 
prepared by the MITRE Corporation in 1973 for the Canadian government, 
and which covered memory systems which were in existence or which were 
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predicted to be developed by 1985120. A comparison of the results 
obtained by both surveys is shown in Table 5. 
Phase 
Technology Patent Analysis Mitre Report 
Magnetic Core Mature and declining Declining 
Magneto optics Stable research or Research and development 
perfection 
Semiconductor Mature and declining Development; with increased 
use forecast 
Superconductor Research and development Laboratory curiosity; comm- 
ercial-production doubtful 
Ferroelectric Fully mature and 
slightly declining 
Cathode Ray Tube Declining 
Planar film Mature and declining 
Plated wire 
Magnetic bubble 
Domain tip 
propagation 
Mature and declining 
Research and development; 
no significant use expected 
Research or perfection 
Declining 
Declining 
Research and development Research and development 
(No assessment due to 
lack of adequate 
statiftics) 
Charge coupled 
devices 
Research and development 
Research and development Research and development 
Holographic Declining Research and development; 
many difficult problems to 
solve, limited probability 
will be in use in 1985 
Table 5: Comparison of Assessment Results for Computer Memory 
Technology obtained by OTAF Vector Patent Analysis and MITRE Report 
Marmor121, in describing the work of OTAF, has commented that patent 
document collections, chronologically arranged and technically categor- 
ised, represent unique records of technological change. Continuously 
generated and catalogued, patent literature can be drawn upon as 
valuable input to technology assessment processes, both from a current 
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and an historical perspective. Marmor observes that comprehensive 
patent information packages can be developed and tailored to benefit 
corporate strategists, policy analysts, educators, entrepreneurs, 
future innovators and the like. 
Mlodzik91, has used Section B (Farmdoc) of Derwent's Central Patents 
Index file as available online to assemble, analyse and make available 
meaningful information about the research and development activities 
and expenditures of companies active in the field of non-steroid 
anti-rheumatic drugs. She states that the publicly available data can 
furnish information of particular value to marketing managers and 
research strategists 
- 
information which is not normally extracted from 
patent literature. As an important feature of her studies an attempt 
was made to determine if the patent data might suggest changes in 
corporate interests and perhaps reveal proprietary-like information. 
Patent data was supplemented by market share information derived from 
marketing journals for the period 1972 to 1978. From this data trends 
in the patenting activities of several companies, both in terms of the 
number of CPI-defined basics and equivalents (see Chapter 10 below), 
were obtained. The results showed different patterns of activity by 
the companies investigated. However, the differences in numbers of 
patents by the companies could not be interpreted as indicators of 
whether they were a reflection of the patent policies of the companies 
or of R&D effort. 
Mlodzik points out that the important inventions are usually patented 
in several countries. It would be possible, therefore, by listing the 
chemical structures from these patents in a table, to review the new 
structures in the technology concerned. Among these structures one 
would find the new drugs of the future. Of course, as Mlodzik states, 
the ones of priority must be non-toxic and without side-effects, they 
must be stable, etc.; but one would probably find a few of them on the 
market in approximately ten years. 
Using the IFI Data Base of US Patents 
- 
1950 through 1976, maintained 
on magnetic tape by IFI/Plenum Data Company of Arlington, Va., Allcock 
and Lotz82,83, using conventional computer processing techniques, 
extracted data on the number of US patents issued in 1976 by various 
USPTO classifications. 
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The first observation that these workers were able to make from their 
results was that a relatively small number of corporations own a major 
proportion of all assigned patents. For their further studies they 
selected 125 companies each of which received 65 or more patents in 
1976. These 125 companies owned 24,210 patents; this amounted to 42% 
of all the assigned patents and averaged 194 patents per company. Of 
the 125 companies, 90 (72%) were USA based whilst the remaining 35 
(28%) were non-USA based. 
For five of the corporations, Allcock and Lotz compared the annual 
research budgets for 1972 with the number of patents obtained in 1976. 
They chose 1972 research budgets on the assumption that US patents 
issue about 4 years after the research work was carried out (cf. the 
OTAF studies referred to earlier in which a two year lag period from 
application date was used). They also assumed that one-half of an 
organisation's research budget was spent on projects unlikely to 
generate patentable inventions. A review of their results indicates 
that the costs of obtaining patents are extremely high. However, from 
the wide spread of the average costs per patent calculated ($120,000 
for Xerox Corporation to $475,000 for Westinghouse Corporation) no 
simple conclusions could be made. 
As a feature of their studies, Allcock and Lotz tried to determine if 
Publicly available data, i. e., patent information, might suggest 
changes in corporate in£erests and reveal proprietary-like information. 
For this they adopted two approaches. In the first they compared USPTO 
classifications for patents issued in 1976 with those issued in 1975 
for each of the 125 companies. In this way they were able to identify 
Potentially new technology. They point out that whilst the issuance of 
one or two patents in a new class may not represent a change of subst- 
ance, a new class producing multiple patents may well signal a signifi- 
cant change in research activity. As an example of their findings 21 
patents issued in USPTO Class 418 (Rotary Expansible Chamber Devices) 
for the Caterpillar Tractor Company in 1976, whereas this company had 
no patents assigned to Class 418 in 1975. The authors point out that 
changes in patent activity such as this should be of considerable help 
in evaluating future trends for the companies concerned. 
For their second approach, Allcock and Lotz compared the average number 
of patents issued in the previous five years in a company's major areas 
of interest with those issued in 1976. Ciba-Geigy, with 508 patents in 
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1976, was chosen for this analysis. The USPTO Classes in which this 
company was most active were: 8,71,260,424 and 428. By comparing 
the changes in the percentage of total issues in these classes, it was 
apparent that the greatest change occured in Class 428; the percentage 
of patents issued in this class increased by over 300% over the prev- 
ious five years. In looking at the Ciba-Geigy patents in Class 428 the 
investigators found that all related to textile treating and finishing; 
this indicated an apparently new emphasis that competitors might wish 
to follow. 
Allcock and Lotz also looked into the possibility of predicting corpor- 
ate mergers from patent information. They state that it should be 
possible to review a company's patent profile and compare this with 
other companies' profiles to locate candidates for possible acquisi- 
tion. Again using Ciba-Geigy as a model (the two Swiss firms of Ciba 
AG and Geigy AG merged in 1970), they studied the patents assigned, by 
USPTO class, in the ten year period from 1967 to 1976 for the original 
independent companies and for the merged corporation. A calculation of 
the total patent issues for each company showed that 94% of all Ciba's 
patents were in classes common to those of Geigy's patents and 98% of 
Geigy's patents were in classes common to Ciba's patents. They conclude 
that the patent histories of these two companies suggests the merger 
which came about. 
Windsor has used bibliometric analyses of patent and non-patent litera- 
ture to predict the clinical fates of developing drugs84'85. For his 
studies he recorded in chronological sequence of publication date all 
patents and journal articles (the former information being derived from 
Section B of Derwent's CPI service) relating to Minoxidil, an antihy- 
pertensive vasodilator drug marketed by Upjohn Company. Windsor then 
expressed this sequence of publications as a binary vector assigning 
"1" for a patent and "0" for a non-patent article. The decimal equiva- 
lents for standardised vector lengths were claimed to provide scalar 
values for comparing one drug with another. 
In order to incorporate equivalent patents into his calculations, 
Windsor used fuzzy subsets, with the number of attempts required to 
achieve transitive closure being the values for comparison. Windsor 
concludes that bibliometric studies of this nature can be used to 
predict the clinical fates of drugs, although he does state that the 
evidence he presents does not conclusively show this. 
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In commenting on Windsor's work Osinga122 points out that a statistical 
relationship between two sets of figures does not prove anything about 
the causal relat! on between the facts behind the sets of figures: one 
might cause the other, or the reverse may be true, or both may be 
caused by a third one. Osinga stresses that the fate of a drug may 
either be determined by the bibliometric traits, or the bibliometric 
traits are determined by the clinical fate of the drug, or both are 
determined by some other factor. It. is not possible to distinguish 
between the three possibilities on a statistical basis. In Osinga's 
opinion the bibliometric traits do not determine the fate of a drug, 
but that the reverse is true. In such a case the bibliometric traits 
will be apparent in the literature only after some time, and prediction 
on this basis is not possible. 
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8: BIBLIOMETRICS AND PATENTS 
Bibliometrics has been defined by Pritchard123 as "the application of 
mathematics and statistical methods to books and other media of comm- 
unication", and paraphrased by Fairthorne124 as "quantitative treatment 
of the properties of recorded discourse and behaviour appertaining to 
it". 
Information science literature abounds with bibiometric studies con- 
ducted on the characteristics of journal literature in certain disci- 
plines and subjects; much of this work has been reviewed by Narin and 
Moll125. A great number of these studies have employed Bradford's 
Law and the Bradford-Zipf Distribution to estimate efficiency values 
and completeness of journal collections. Some such studies have been 
concerned with primary journals and others with secondary, or abstract- 
ing and indexing, publications in both humanities and hard science 
subjects. 
Bibliographies of bibliometrics have been compiled by Pritchard 
126 
1 
Hjerppe 127 and Vlachy128; a recent issue of Library Trends129 was 
entirely devoted to papers on bibliometrics, several of the contribut- 
ions being reviews. 
Although Clark130 in 1976 advocated that patents deserve bibliometric 
study both for their own sake, and because their formality could be 
exploited, no reports on the application of bibliometrics relating to 
collections of patents data on specific technologies have been found in 
the literature. Clark studied the obsolescence of patent literature as 
indicated by the age distribution of patent-to-patent and periodicals- 
to-patent citations. 
Bibliometric Laws and Distributions 
Two basic laws of bibliometries have been developed: Bradford's Law and 
Lotka's Law. Bradford's Law is based on the distribution of publica- 
tions (usually journals) in a particular discipline or articles in a 
set of journals. Lotka's Law is based on the number of authors pub- 
lishing in a discipline or other defined field. 
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Lotka's Law 
Productivity in terms of scientific publication was described by Lotka 
13 in 19261. Lotka's Law of Scientific Productivity is an inverse 
square law claiming that the number of authors of n papers in a popula- 
tion is about 1/n2 of the number of authors of one paper, or: 
p(n)=K/n2 
where p is the number of authors producing n papers, and where K is a 
constant characteristic of a particular subject area. 
The factor for predicting the number of papers in a field like chemis- 
try was found to conform to 1/n2 of the number of authors writing only 
one paper. That is, if 100 authors wrote only one paper, only 25 would 
write two papers and only 11 would write three papers, etc. 
Table 6 on the next page summarises a number of studies which have been 
carried out to verify Lotka's Law; the table does not list all such 
studies 
- 
only a selection. 
Bradford's and Zipf's Laws 
Zipf, a linguist, was interested in the frequencies with which diffe- 
rent words are used 
143. He demonstrated that, if the words appearing 
in any reasonably long piece of text are counted and ranked in order of 
frequency of occurence, this frequency is proportional to the rank 
order. For example, a word ranked tenth in terms of frequency of usage 
is employed one tenth as often as the word ranked first. 
Zipf analysed the number of different words and the frequency with 
which each occured in different texts and plotted these on logarithmic 
paper. Figure 6, taken from Zipf's book, shows such a graph for the 
vocabularies in James Joyce's Ulysses and a combined sample of American 
newspapers; these had 29,899 and 6,002 different words out of totals of 
260,430 and 43,989 words respectively. 
According to Zipf this sort of rank-frequency relationship is obeyed by 
a wide range of social phenomena. He argues that it is a result of a 
natural tendency to use more frequently those intellectual tools with 
which one is beat acquainted and which are more flexible. The rank- 
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Author Reference Data Authors' comments 
Number 
Lotka 131 Chemical Abstracts Exponent = 1.888 
Lotka 131 Auerbach's Tables Exponent =2 
Stoddart 132 Royal Geographic Soc. Index Exponent is 
close to unity 
Schorr 133 Map Librarianship "Fits Lotka" 
Schorr 134 Legal Medicine "Does not fit 
Lotka" 
Schorr 135 Library sciences journals Postulates 
exponent =4 
Voos 136 Information science journals Postulates 
exponent = 3.5 
Murphy 137 History and technology journal "Fits Lotka" 
Frost 138 Geo Abstracts authors Exponents ranging 
from 1.23 to 2.35 
Rogge 139 Anthropology literature "Fits Lotka" 
Radhak- Computer science authors Postulates 
rishnan & exponent =3 
Kernizan 140 
Potter 141 University of Illinois Postulates 
library catalogue exponent = 2.09 
McCallum & Library of Congress MARC tapes Postulates 
Godwin 142 exponent = 2.343 
Table 6: Some Studies of Lotka's Law 
Figure 6: Rank-frequency distribution of words: 
(A) James Joyce's "Ulysses"; (B) American newspapers; 
(C) Ideal plot with slope of -1 
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order relationship therefore reflects the operation of some "principle 
of least effort"; in fact Zipf never demonstrated that this principle 
leads mathematically to his law. 
Zipf's Law may be expressed thus: if. words are ranked according to 
their frequency of occurence (f), the nth ranking word will appear 
approximately k/n times, where k is a constant, or: 
f(n)=k/n 
Bradford first published his observations of the increasing scatter of 
relevant journal articles on a given topic (the topic chosen was eng- 
ineering) in 1934144 and later in 1948 summarised these observations 145 
by relating the number of journals in the nuclear, or most productive, 
zone to the numbers of journals in sucessively less productive zones 
containing equal numbers of papers. He stated that if a core of n 
journals contains A articles relevant to a discipline, and if kn 
journals (k>1) are required for a second zone with an additional A 
articles, then k2n journals are required for the third zone with A 
articles, and, finally, km-ln journals for the mth zone with A arti- 
cles. Vickery 16 pointed out that in his graphical formulation of the 
data, Bradford placed the cumulative numbers of journals in the ratio 
1: k: k2...... rather than the zonal numbers in that ratio as his verbal 
formulation indicated. 
The theory and application of Bradford's Law have been extensively 
studied by 152,153 15 y Brookes 
, 
Leimkuhler and Aiyepelcu Wilkin- 
son155 has analysed the disparities Vickery pointed out and has con- 
eluded that, of the two Bradford Law formulations, the graphical one is 
in closer accord with existing data. Drott156 has reviewed the theory 
and empiricism of Bradford's Law whilst Wy11ys157 has published a 
similar review of Zipf's Law. 
Relationships between the Laws of Bibliometrics 
The Bradford distribution and the Zipf distribution have frequently 
been linked, first by the statistician Kendalll58. Indeed, Bradford's 
Law is often called the Bradford-Zipf Law. Kendall showed that the 
Bradford distribution falls into a general type called the Yule distri- 
bution by Simon159. 
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Coile160 briefly described the applications of Simon's Yule distribu- 
tion to scientific productivity, thus linking Bradford-Zipf to Lotka as 
well. 
Brookes has long worked with the Bradford distribution and interprets 
it strictly. Showing the close relationship between Bradford and Zipf, 
Brookes 147 implied that only his lack of complete data caused a devia- 
tion from a straight line and the resultant droop characteristic on the 
upper part of the S-curve observed in the graphical representation of 
Bradford (see Figures 15 to 18). 
In a later paper, Brookes1I9 explained the initial concave curve of the 
Bradford distribution as a representation of the higher density of the 
nuclear zone. He believed this higher density to be caused by the 
restrictive effect of competition for the limited space in the nuclear 
journals. Brookes affirmed that "whenever a droop has been observed, 
it has always been possible to indicate either some selectivity or some 
omissions". 
O'Neill161 disagreed with Brookes, contending that the extent of the 
characteristic droop is dependent on the sample size, with larger 
samples having a more prominent droop. 
In a key paper, Fairthorne124 described and interpreted a series of 
frequency distributions in terms of work published by Mandelbrot162. 
Some of the frequency distributions Fairthorne described are empirical, 
others are theoretical. While Fairthorne provided seven references to 
Mandelbrot's work, he never actually described the research. Although 
Fairthorne's paper is important for its collection and description of a 
wide variety of frequency distributions, it does not succeed in clari- 
fying, for the average reader, the differences and the similarities 
between these distributions. 
More recently, Bookstein1b3 has attempted to clarify and resolve the 
relationships between the Bradford, Zipf and Lotka distributions. 
Current mathematical research on bibliometric laws and frequency 
distributions has tried to define theoretical models of the mechanics 
responsible for the empirical laws and distributions. Naranan164 has 
attempted to arrive at a theoretical justification for the basic laws 
by deriving a power law relationship between the number of journals and 
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their articles on a particular subject. Naranan claims that a power 
law relationship also extends to the relationship between citations and 
articles and to the relationship between citations and journals. 
Price165 has attempted to show that all of these bibliometric distribu- 
tions are related to the concept of "cumulative advantage" processes in 
which success breeds success but failure is not penalised. Both 
Naranan's and Price's hypotheses seem logical. 
The relationship between Bradford's and Zipf's Laws can be seen if the 
latter is slightly rephrased. Instead of relating frequency of word 
usage to rank order, one asks the question: how many words (N) occur 
exactly f times " in a text? The answer follows from Zipf's Law: N= 
1/f2. But Bradford's Law can also be written in a power law form: the 
number of jcurnals J containing exactly p articles on a specified 
2 
subject is given by J= 1/p. Lotka's Law states that the number of 
scientists who produce x papers is proportional to 1/x2. This Law, 
too, can be assimilated to Zipf's Law, if one generalises the latter, 
and supposes that there is a general bibliometric distribution follow- 
ing an inverse power law (i. e., proportional to 1/xn). The value being 
attached to n will depend on the bibliographical property being mea- 
sured. The three laws all have n=2, in the form in which they have 
been defined. However, these are postulated average values; empiri- 
cally determined values may differ appreciably. Power law distribu- 
tions of this type all have the same general implication, which is that 
a small proportion of the items under consideration, e. g., journals, 
scientists, are responsible for a large proportion of the desired 
products, e. g., research papers, and vice versa most of the items 
considered make little contribution to the total products. 
The Bradford-Zipf Law is now well established in the field of bibliome- 
tries. It has been tested on a large number of bibliographies in many 
disciplines and has been shown to usually apply to the observed data. 
However, hitherto it has only been tested on journal literature or on 
samples containing primarily journal literature; it has not been tested 
against data sets containing only patent literature. 
Scientific Productivity and Frequency Distributions 
Whilst Lotka's Law has been widely used in investigations of scientific 
productivity in several disciplines, in recent years other researchers 
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have attempted to find other frequency distributions which fit the 
collections of empirical data gathered from the journal literature. 
For example Shockley 
166 
suggested a lognormal distribution; Williams 
167 
examined a geometric distribution and Fisher 
168 
a logarithmic series 
distribution in a study of the publication pattern of biologists. 
Hersh769 has used a power series to describe scientific productivity. 
Price 165 has proposed a cumulative advantage distribution related to a 
Beta function derived by Yule and which was described by Simon59. 
170 1 
Coile171 has shown how various frequency distributions may be derived 
from Pareto's Law and, furthermore, shown how they are interrelated. 
Coile tested seven theoretical distributions against twenty-six collec- 
tions of data on author productivity. 
Rao172 has tested eleven theoretical frequency distributions against 
five sets of scientific publishing data. The frequency distributions 
tested, as well as those used by Coile are shown in Table 7. 
Coile found that the Singh-Maddala and, especially, the Weibull theore- 
tical distributions most closely fitted the observed data where using 
the Kolmogorov-Smirnov Test173 for "goodness of fit". Whilst these two 
distributions had not previously been used in studies of scientific 
productivity, the principal reason for the ability of these functions 
to obtain a better fit than the other functions tested is that they 
contain, unlike the other distributions, three parameters. This is to 
be expected since the greater the number of variables taken into 
consideration, the greater the likelihood that the mathematical model 
will fit the observed data; thus the three parameter frequency distri- 
butions should, by definition, provide a better fit than those which 
consider only two parameters. 
The Weibull distribution has been used in research on reliability174, 
whilst the Singh-Maddala function was developed as an econometric model 
to describe the distribution of incomes in the USA175. Coile171 was 
not able to distinguish any particular values of the three parameters 
which might be associated with a discipline. 
Amongst the two-parameter distributions studied by Coile, the Simon- 
Yule function gave the best fit to observed data when tested by the 
Komogorov-Smirnov Test. 
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Theoretical Frequency Distribution Coile Rao 
Lotka Yes No 
Simon-Yule Yes No 
Price's Pareto-type Yes No 
William3' Geometric Yes Yes 
Fisher's Logarithmic Yes Yes 
Shockley's Lognormal Yes Yes 
Poisson Yes Yes 
Singh-Maddala Yes No 
Weibull Yes No 
Borel-Tanner No Yes 
Negative Binomial No Yes 
Cumulative No Yes 
Truncated Negative Binomial No Yes 
Truncated Poisson No Yes 
Zeta No Yes 
Sinh Transformation No Yes 
Table 7: Studies using Frequency Distributions by Coile17land Rao172 
Rao172 found that the Negative Binomial distribution fitted all his 
data sets when tested by the X2 "goodness-of-fit" test. and has shown 
that the Negative Binomial distribution describes a pattern of scien- 
tific productivity under the "success-breeds-success" phenomenon 
described by Price165. Rao found that the Borel-Tanner distribution176, 
derived as a model of queuing situations, was the only other function 
which fitted all five data sets; however the X2 values obtained for 
Borel-Tanner were not as low as those for the Negative Binomial. 
Whilst previous studies have shown that on the one hand frequency 
distributions may be applicable in bibliometric studies, they have 
indicated on the other hand that Lotka'a Law is not proven and that 
other distributions may provide better models for the observed data. 
The application of such distributions in bibliometrics have hitherto 
included studies of doubtful validity, and there is thus a need for 
further work in this area. 
None of the investigations of frequency distributions and scientific 
productivity identified in the literature of bibliometrics has been 
concerned with patents. It was thus considered appropriate to test 
sets of patents data in different technologies with various functions. 
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9: CITATION ANALYSIS AND PATENTS 
An essential part of research appears, particularly in the sciences, in 
the list of references pointing to prior publications. As Ziman 
observes, "a scientific paper does not stand alone; it is embedded in 
the 'literature' of the subject"177. A reference is the acknowledgement 
that one document gives to another; a citation is the acknowledgement 
178 
that one document receives from another. In general, a citation 
implies a relationship between a part or the whole of the cited docu- 
ment and a part or a whole of the citing document179. Citation analysis 
is that area of bibliometrics which deals with the study of these 
relationships. 
Although citation analysis techniques have not been used in this study, 
the techniques are becoming more popular and significant interest in 
their application to patents is growing. It is, therefore, thought 
appropriate to make mention of them here. The fundamental principles 
of citation analysis have been given by Narin178, whilst Smith180 has 
focussed on the development of citation analysis as a bibliometric 
research method, uses and abuses of the method and prospects for the 
future 
- 
although in her paper, she has not commented upon its applica- 
tion to patents. 
Traditionally, scientific papers contain references to the earlier 
literature. The reason such references are referred to are varied 
181; 
since they are dependant on an author's personal choice, they often 
contain errors and omissions182. Over the years, a large body of work 
on citation studies has appeared in the information science literature 
(see, for example, the bibliography on bibliometrics by Hjerppe127). 
Such studies have involved the analysis of citations made in scientific 
papers from a number of viewpoints. The number of such studies in- 
creased considerably following the start of publication of Science 
Citation Index (SCI) by the Institute for Scientific Information, in 
1963, and its subsequent computerisation. This service made the 
carrying out of citation studies far easier than previously183. 
In the scientific literature, citation analysis adds many dimensions to 
elementary paper counting. Counting scientific papers is an objective 
measure of research activity; it does not provide much information 
about impact of the work 
184. Citation frequency measures add a quality 
dimension to a publication count. Citation frequency is relatively 
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highly correlated with almost all peer based indicators of quality or 
impact-in science and, in fact, Jones has found that as an indicator of 
scientific quality, counting citations is a more effective and better 
indicator than counting papers. 
185 
Citations provide many other capabilities to science indicator data 
also. For example, they provide linkage measures, demonstrating in a 
quantitative way how different research institutions and countries 
depend upon each other. Using citation network techniques one can show 
whether a country's applied research heavily cites its own basic 
research or other countries' basic research, one can look at linkages 
between basic and applied research, and also look at information flow 
186 
among universities, industries and governmental laboratories. 
The nature of the citation distributions also have added valuable 
insight into perceptions of productivity and efficacy in the scientific 
process. Lotka131 and Shockley166 showed that scientific productivity 
is highly concentrated, with typically 50% of the research papers being 
produced by 20% of the researchers. When citations are added to this 
analysis, these distributions become even more highly non-linear and 
skewed. For example, in a very detailed study of one laboratory by 
Narin186, he found that 4% of the professional staff produced half of 
the papers, and that an even smaller 3% of these researchers received 
half of the citations. Thus, Narin concludes, bibliometrics adds a 
quantitative dimension"to the general observation that productivity is 
highly concentrated in a relatively small number of key people. 
One of the most interesting types of studies to be carried out using 
citation data is the study of citation networks. A citation network is 
built up by obtaining one or more relevant articles and noting and 
reading the references cited in these articles. Science Citation Index 
(or the equivalent publications covering the Social Sciences, or the 
Humanities) is then used to take a step forward in time by noting later 
items which cite earlier articles. A network is contructed after 
several such iterations, connections being shown by lines connecting 
published items. Having created such a citation network, key events are 
identified, together with their chronology, their interrelationships 
and their relative importance. It is thereby possible to observe 
historical and sociological processes at work and it is easy to ident- 
ify the work that has had the greatest impact on the subject. This 
technique is sometimes called the historiograph approach, and has 
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received some attention in the information science literature. It is 
generally agreed that although a chronological listing of articles can 
give some clues to the development of a subject, such historical 
citation networks or maps produce better results188'189. The maps are 
difficult to keep clear and aesthetically pleasing, and some work has 
0-192. 19 gone into algorithmic techniques for creating such displays 
A large number of citation networks have been created, predominately by 
Cawke11193-196, by Garfield187-188,190-192,197 or by the two working 
together19II. Bernal199, who was the first person to use this technique, 
used a small map in 1953 to trace the antecedants*and consequences of 
Pasteur's discovery of molecular asymmetry. The subjects covered by 
such historiographs vary widely, but mostly have been confined to 
science and technology. 
The validity of historiograph technique in the creation of an accurate 
historical description of a scientific field can be tested by construc- 
ting and then comparing two networks on the same subject. One network 
is prepared from a standard historical account and the other using 
citation relationships190. May200 argued that a historiograph will not 
give a faithful map of the history of a subject, so clearly the techni- 
que does need to be tested out in this way. Such a test has been 
carried out by Garfield and his co-workers 
201 
who compared citation 
data on DNA and the genetic code with a historiograph prepared from a 
book by Asimov. They found close parallels between the two maps; 
however, Oppenheim202 has pointed out that the two DNA historiographs 
were not created independantly. The papers representing the key events 
in the historical account by Asimov were identified, and these were the 
papers used to initiate the citation network. The results must there- 
fore be regarded as inconclusive. 
Until recently, very little work has been carried out using these 
techniques on patents, although a number of authors have hinted it 
might be a useful application. Cawke11195 has suggested that patent 
citations could be used to trace scientific developments as has been 
achieved with journal articles. Garfield203 considered United States 
patent references to be a valuable and relevant source of further info- 
rmation on a subject. Patent citations have been mentioned as a means 
of surveying technological innovations for forecasting future develop- 
ments as well as perceiving links between inventions203. This lack of 
study of patent citations can be attributed to three main factors. 
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Firstly, in sharp contrast to journals, relatively few countries' 
national patent specifications publish citations. Secondly, there is 
no convenient source of patent citation data analagous to ISI's journal 
citation data. (At one time, Science Citation Index included US 
patents as source documents 
204 but this practice was dropped many 
years ago). Thirdly, citations in patent specifications do not serve 
the same purpose as citations in journal articles. Patent citatior. s 
are made by the examiner to warn the applicant of related work which 
affects the novelty of his invention. Depending on the examiner, such 
citations can be very relevant or of peripheral interest only 
204 
Patent citations are not made for the various reasons18ýý205,206 that 
journal citations are made. 
Although the lack of a suitable data base has held back the field of 
patent citation analysis, the idea of studying the information in 
patent citations is not new, and was first published by Seidel in 
1949207 in respect of the US Patent Office. 
In an editorial, Seidel proposed that "the Patent Office adopt a system 
of citations to colligate issued patents with later patents". Sub- 
sequently, Hart endorsed the proposal mentioning that "such a system 
... 
would furnish a network of paths to dissipate the inevitably 
artificial boundaries of classification" 
2o8. 
A systematic attempt at bibligraphic tracing of patents was described 
209 by Reisner. She reported an experiment abstracting references from 
3,250 patents of interest to IBM attorneys. Tracing through the data 
base citation network, she recovered 43 of the 60 patents submitted for 
testing. In 1972, Gerson210 reported on a computer-aided classification 
and retrieval system for United States patents, based on a clustering 
of patents by similarities in citations received. This is one of the 
earliest papers to discuss patent citations from an analytic point of 
view. A 1974 study of the Franklin Pierce Law Center 
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examined the 
uses of patents as technology/science indicators. Linkages between 
important "basic" patents and the scientific literature were shown. 
Their study was based on a relatively small sample of patents. 
As indicated earlier one of the most important of the citation analysis 
techniques is the historiograph approach developed by Garfield 
187,190, 
193,97. In this approach, a graphic display of citation data that 
shows key scientific events in chronological order is prepared by 
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linking one paper to another that it cites with a straight line. 
Papers that have been highly cited by other papers and therefore 
presumably of importance, can easily be identified by this graphic 
technique. In addition to the DNA study referred to above190. The 
historiograph method has been more recently applied to the history of 
amorphous semiconductors194, and of bridge design195. These are 
technologial subjects, but journal articles only were considered. 
Ellis, Hepburn and Oppenheim212 have used the historiograph approach 
with patents as a means of mapping technological history and identi- 
fying major developments. These authors chose five subject areas for 
their study: electrophotography, semi-synthetic penicillins, tobacco 
substitutes, Ziegler-Matta catalysis and hovercrafts; US patents 
relating to these technologies were used. 
They found that in many cases the citation networks revealed key 
patents and the important clusters. Sometimes, due to either the 
diffuseness of the origins of a field, or apparent misreferencing, or 
technologies with a short patent history, the key clusters were not 
identified. 
Ellis et al. conclude that the technique of mapping historiographs of 
patent citation data could, if successful, have considerable potential 
in two main areas: 
1. They could identify key developments in the history of technolo- 
gical progress. Historians of science have a ready made tool in 
journal citation patterns for identifying key events in the deve- 
lopment of a scientific theory, but no analogous tool for techno- 
logy has been developed to date. 
2. If co-citation studies in the networks prove successful, such 
studies could be used to identify smaller subject areas of current 
interest within the main subject field. This could be valuable for 
future analysts and organisations involved in high-risk investments 
for identifying topics of high current importance. 
Oppenheim202 has reported the results of some studies designed to 
evaluate patent citation networks as a method of identifying key 
turning points in the development of a technological subject. Nine 
subject areas were chosen 
- 
cardiac pacemakers, quadraphonic systems, 
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fibre optics devices, ring pull cans, underwater holography, alkene and 
alkyne disproportionation, hovercraft, magnetic bubble memories and 
prostaglandins. Oppenheim found that although frequently the technique 
identified the key starting patent neatly and precisely, there were 
several instances'of failure. These can usually be attributed to one 
of several factors 
- 
the subject has no clear starting patent, or for 
some reason the patent history is confused, or because of bad cases of 
mis-citation by the U. S. patent examiners. Because of these difficult- 
ies, it is concluded that results from a patent citation network are 
not sufficiently reliable to be used alone for identifying key events 
in the development of a technology. 
Oppenheim also described the development of a program for inputting 
citation data (for both patents and journal articles) and for plotting 
them out. 
Nun and Oppenheim213 described work on a citation network starting from 
ten U. S. patents and comprising 1204 journal articles and 43 patents in 
the field of prostaglandins. A journal citation network was created 
independently from 85 recent articles on the subject. It was found 
that the two networks were virtually identical except that the former 
included patents and was therefore more complete. It was found that 
the most highly cited references were those widely regarded as being 
key turning points in the development of the subject. 
Their results demonstrated that in a subject field which incorporates 
patentable subject matter, a patent/journal citation network is fuller 
and more reliable than a patent citation network or a journal citation 
network on their own. 
Results obtained from the creation of a patent citation network on 
X-ray tomography have been described by Dunlop and Oppenheim21 
. 
Previously such networks had been created by noting the patents and 
journal articles cited in a given starting patent. In their work, 
Science Citation Index was used to 'recycle' the network by identifying 
further journal articles. This recycling technique added some new 
references to the network, but did not fundamentally alter the charact- 
eristics of the network. It was concluded that whilst a reliable 
patent citation network can be created by the simple techniques prev- 
iously used, use of Science Citation Index makes a more complete 
network. 
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A critical piece of information related to the use of patent citations 
was generated in a recent study by Carpenter, Narin and Woolf218, in 
which they tried directly to determine whether more citations were 
received by patents associated with important technological advances 
than by a set of randomly selected patents. That is, in essence a 
direct test of the hypothesis that technological importance would be 
associated with high citation rate. 
In their study the patents selected as important were patents assoc- 
iated with inventions which had received an Industrial Research and 
Development "IR-100" award. The IR 100 awards are given by the journal 
Industrial Research and Development and "honour the 100 most signifi- 
cant new technical products 
- 
and innovators responsible for them 
- 
developed during the year". Patents related to the 1969 and 1970 
awards were used for their product set patents, in order to ensure that 
there was sufficient time for the patents to be cited fully by subse- 
quent patents. The set of patents serving as controls were chosen so 
that the number of control patents issued in each year was the same as 
the number of product patents. This equalised the time distributions 
for the control and product patents. Within each cited year the 
control patents were chosen randomly. The number of citations to these 
product and control patents by examiners of subsequently issued patents 
was then determined. Table 8 shows these citation distributions. It 
is noted that the product set patents were more than twice as frequen- 
tly cited (significance4level of 0.0001) as the randomly selected set 
of 102 control patents. This finding provides strong evidence sup- 
porting the hypothesis that patent citation data can be used in tech- 
nological indicators development and in technological policy analysis, 
since it clearly implies that the location and analysis of groups of 
highly cited patents can provide a valid indicator of patent areas of 
technical importance. 
Using the references from US patents to scientific journal articles, 
Carpenter, Cooper and Narin216 have demonstrated that these citations 
provide a mechanism whereby the major parameters of a linkage model 
explore the utilisation of basic research in technological advances. 
The US patent files were selected as the appropriate vehicle for the 
analysis since the patent process met several critera. First, the 
patent files are external to science and thus cannot be said to be 
affected by the scientific community itself. Second, the patent files 
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Second, the patent files demonstrate active utilisation of science by 
current technology, and not archival usage. Third, the patent files 
can be searched without any a prior i selection of scientific topical 
areas. Thus the patent files provide a documented source of information 
on technological uitilisation of basic research. In the US patent 
system the applicant references imbedded in the text and examiner 
references on the front page of the specifications provide parallel and 
complementary views of the pertinent linkages to the research litera- 
ture. 
N= Number of Patents Receiving N Citations 
Number of Product set Control set 
Citations Patents Patents 
0 11 31 
1 12 23 
2 12 17 
3 15 12 
4 12 6 
5 3 5 
6 7 3 
7 5 1 
8 4 
9 2 
10 4 3 
11 1 
12 4 
13 4 
14 1 
15 1 
16 
17 1 
18 1 
19 1 
Total Patents 100 102 
Total Cites 494 208 
Cites/Patent 4.94 2.04 
Table 8: Citation Distribution for Product set and Control 
set of Patents from Carpenter, Narin and Woolf215 
Carpenter, Cooper and Narin216 investigated four aspects of the patent 
to science citation linkages: (1) the extent to which patent applicants 
and examiners utilised'research findings as evidenced by their citation 
of the science literature; (2) the nature of the cited research acti- 
vity: are the citations referring to basic research or applied work, to 
a wide or narrow swath of scientific investigation, or to old or 
recent papers; (3) the acknowledged source of financial support for 
the research cited by the applicant/examiner, and (4) the performers 
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of the cited research., Furthermore, these authors limited their work 
to two areas: gas lasers and prostaglandins. Nevertheless their 
results indicate an intimate relationship between current science and 
patents. 
More recently, Narin217 has reported on an extension of these studies 
using the same data sets of US patents plus data relating to chemical- 
analytical processes, electrical-field effect devices, electrical-light 
responsive semiconductors, mechanical semiconductor manufacturing and 
mechanical medicinal applicators. 
The results of this second study demonstrate extensive utilisation of 
fundamental scientific literature by patent applicants and examiners. 
More than half of the journal references in the selected patents are to 
the more basic scientific journals, as opposed to the engineering and 
technological literature. It was also found that the time between 
publication of a journal article and the patent application citing that 
article was relatively short, typically two to five years. This citing 
age is typical of the amount of time that elapses between the publica- 
tion of a scientific article and its citation by other scientific 
articles. 
In addition the scientific articles cited by patent applicants and 
examiners lie quite clearly within the central core of the scientific 
literature. 
Thus in many aspects the swath of the literature cited and the nature 
of the citing by patent applicants and examiners appears to be quite 
similar to the swath and nature of the article cited by scientists 
themselves when publishing in the open journal literature. This 
clearly indicates that 'the process of reduction to practice in the 
industrial community continues to require recent basic science, and 
that the support of such science is a necessary prerequisite for the 
continuing emergence of new technology. 
Studies at the Battelle Pacific Northwest laboratories on researches 
into technology indicators, using patents data derived from the US 
Patent Office OTAF database, have concentrated on relationships 
between numbers of patents and the age of the material they cite; these 
studies have been reported by Campbell 218 and Nieves and Campbell219. 
These workers studied the approximately 3000 citations (to science 
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literature and to patents) on some 800 US patents concerned with 
catalytic converters and obtained an indicator of technological progr- 
ess which they term "immediacy". 
US Patent Law requires that patents cite documents that have priority 
over them. "Immediacy" measures the age of the closest prior art in 
those documents, whether it is in technical and scientific papers or in 
patents. The Battelle studies conclude that if the closest prior art 
is very immediate, i. e., very recent, the implication is that the case 
in question is a rapidly growing technology. Conversely, if the 
patents cite only old material the area concerns minor variation on old 
technological themes. 
0 
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10: DERWENT PUBLICATIONS LIMITED AND ITS PATENTS INFORMATION SERVICES 
For many years, Derwent Publications Limited have been collecting, 
abstracting, coding, indexing and cross-referencing patent documents 
into a series of products which enable its clients to make maximum use 
of patents data. 
Derwent was established in the early 1950s. At that time there was a 
delay of about half a year between the publication of details about 
British patent specifications in the Official Journal (Patents) and the 
issue of the Abridgments compiled by the examiners and published by 
the Patent Offfice. Accordingly, in the belief that there would be a 
demand for rapidly published abstracts of Bristish patent specifica- 
tions, British Patents Report commenced publication in 1951. The 
company was set up at that time for the purpose of issuing these 
abstracts. The name of the company was then Derwent Information 
Services; the name was changed to the present one in 1963. 
Abstract journals of the patent specifications of various countries 
where then introduced progressively: German Patents Report in 1953, 
Belgian Patents Report and Commonwealth Patents Report (covering India, 
South Africa and Australia) in 
. 
1955, and French Patents Abstracts' in 
1961. Subsequently, due to an amendment of the Australia Patents Act, 
the Commonwealth patents lost some of their advantage of early availab- 
ility, and due to an amendment of the French patent laws the early 
availability of French documents was increased. Accordingly, when 
processing of French patents was commenced in 1961, publication of 
Commonwealth Patents Report was discontinued and Indian and South 
African patents were included in French Patents Abstracts (Indian 
patents are no longer abstracted by Derwent, but the South African 
documents continue to be covered in French Patents Abstracts). 
In its Patents Abstracts Publications, as this series of country 
coverage abstracting services is known, Derwent, from the beginning, 
consistently concentrated on early availability, easy readability 
(patents in all languages are published in the form of an English 
language abstract by Derwent), and low cost. Basically it dealt only 
with chemical subjects. However, of the national patents abstracts 
journals those for the United Kingdom, and subsequently (from 1961), 
West Germany and USSR covered all technical fields. 
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As far as Japanese patents are concerned, in 1961 a contract was 
entered into whereby Nippon Gijutsu Boeki Company Limited were made 
Derwent's general agents in Japan, and, on a proposal from Derwent, 
this company undertook the compilation of abstracts of Japanese patents 
in the chemical technologies resulting in the issue of Japanese Patents 
Report from 1962. 
At that time, apart from the Patents Abstracts Publications, Derwent 
issued a series of Derwent Patents Journals with titles: Fine Chemicals 
Plastics, Petrochemicals and Metallurgical; as well as Derwent Patents 
Bulletins with titles: Polychemicals, Pharmaceuticals, Paper, Photogra- 
phy and Graphic Arts, Metals, Nuclear Power, Chemical Processes and 
Organic Chemicals. These publications comprised abstracts collected 
for each technical field and sub-divided by country, the abstracts 
originating from the Patents Abstracts Publications series, i. e., 
abstracts originally issued by country were repackaged and issued by 
subject matter. 
The foregoing describes only the compilation of English language 
abstracts with the emphasis on rapid availability and easy readability 
together with a simple index. However, elaboration of the means of 
retrieval to achieve a real documentation service was first performed 
in the 1960s with Farmdoc. The motivating reasons behind the intiation 
of this service are interesting since they set the pattern through 
which other services were subsequently launched by Derwent. Derwent 
had, by 1962, progressively launched new publications dealing with the 
patent documents of a number of countries; by that time a publication 
dealing with Netherlands documents had been added to the series, and 
plans had been formulated to progressively add further country docum- 
ents to the portfolio. 
However, a group of leading European pharmaceutical companies approach- 
ed Derwent indicating that, whilst the then existing series of publica- 
tions was most useful to them, the products lacked certain features and 
they would have liked wider country coverage. The most important 
features of a desired service were stated to be: copies of patent 
specification claims to be supplied automatically, copies of' complete 
specifications, linking of. members of the same "family", indexes by 
subject matter and patentee and methods for chemical structure and 
pharmacological activity subject matter searching. Derwent set about 
formulating a pooled patents information service for the pharmaceutical 
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industry which would incorporate these features and held a meeting with 
potential subscribers to discuss its proposals in Milan early in 1963 
(hence the name Farmdoc for "farmaceutici" rather than "Pharmdoc" for 
"pharmaceutical"). 
The proposed service was found to be acceptable to the potential users 
and the service was initiated later that year; by the end of the first 
six months of operations there some thirty users in Europe, North 
America and Japan. The service was important from Derwent's point of 
view since it established the template upon which later introduced 
services were modelled. The service has changed little over the past 
nineteen years and now exists as part (Section B) of Derwent's Central 
Patents Index which is described more fully below. 
The success of Farmdoc led, in 1965, to the introduction of a companion 
service, called Agdoc (now Section C of Central Patents Index) which 
dealt with patents relating to agricultural chemicals in a similar 
fashion to the pharmaceutical coverage of Farmdoc. 
Both Farmdoc and Agdoc used a fragmentation code for the encoding and 
subsequent retrieval of structual and biological activity data for 
compounds. The code, based upon assigning to the 960 positions on a 
standard 80-column punch card a specific meaning such as benzene ring,, 
or thio acid group or anti-rheumatic activity, remained in use until 
1981 when, largely as a result of greatly increased use of online 
retrieval and the consequent fall in the demand for punch cards on the 
one hand, and the greater flexibility of the online system which was 
not limited to the number of possible available codes (960 per card) on 
the other hand, the code was revised. Because the former code often 
necessitated the punching of more than the usual maximum of three 
holes in any card column, the code was known as a "multipunch" code. 
Following the success of these documentation services, Derwent was 
approached by ICI Limited to see whether a similar service could be 
introduced for patents dealing with plastics, polymers and monomers. 
ICI offered Derwent a multipunch code which they had developed. As a 
result of this cooperation Derwent was able to launch Plasdoe (now 
Section A of Central Patents Index) in 1966. 
It was clear from the success of these systems that Derwent had the 
right formula for patents documentation services. Plans were laid to 
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launch a new service every eighteen months or so: Chemdoc (covering 
general chemicals), Dyedoc (dyestuffs), Textdoc (textiles), Metaldoc 
(metallurgy, etc. However, in 1968 Derwent was approached by H. I. Du 
Pont de Nemours & Company, who indicated that whilst they were well 
served by the then existing Derwent services they did not want to wait 
until well into the 1970s before all "chemical" patents were covered; 
furthermore, the technology was being fragmented amongst the different 
services offered by Derwent and they wanted an overall integrated 
patents information system. The Du Pont approach to Derwent was foi' 
the latter to introduce a specialised service just for Du Pont to 
replace that company's internal system which was called Central Patent 
Index. The significance of this is that when Derwent launched its 
service in 1970, it derived its name from the Du Pont system by adding 
an "s" to the word "patent". 
Derwent was not in favour of producing a service just for one client, 
but proposed a service which would (a) appeal to a number of clients, 
and (b) preserve the identity of the already existing documentation 
services whilst allowing for expansion of coverage and the ability for 
any particular client to subscribe to just that part of the overall 
service which met the particular client's patents information require- 
ment profile. 
The service, Central Patents Index (CPI), took some time to develop and 
was eventually launched at the beginning of 1970. By 1982 there were 
more than 750 clients from all over the world subscribing to CPI, 
ranging from those buying just a few of the products available for any 
one section of the service to those buying the complete service with 
all available product options. The service is described in more detail 
below. When CPI was introduced the publications in the Derwent Patents 
Journals and Derwent Patents Bulletins series were withdrawn. 
In the late 1960s and early 1970s BIRPI (the French language acronym 
for the United International Bureau for the Protection of Intellectual 
Property), now known as WIPO (World Intellectual Property Organisation) 
sought to introduce, with the cooperation of. industrial organisations 
such as Derwent, in a joint venture, a patents information and indexing 
service which would cover the entire output of the world's patent 
offices. 
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After many years of fruitless negotiations, Derwent decided to launch 
its own service, although this would not cover as many countries as the 
WIPO service intended, nor would it have the "authority" of a WIPO- 
sponsored service. Accordingly Derwent started publication of World 
Patents Index in 1971; this service covered all technologies for the 
patent documents of the countries covered (initially only 12 countries 
but later extended to 24 plus the PCT and EPO documents, and with the 
exception that for Japan only chemical cases were covered). Meanwhile, 
WIPO in conjunction with the Austrian government established INPADOC in 
Vienna 
- 
an organisation founded with the object of providing an 
"official" service in collaboration with the Patent Offices. 
Derwent's World Patents Index comprises lists, issued weekly and 
cumulatively, of the documents covered; the lists are arranged by 
patentee, subject matter [using the IPC (International Patent Classifi- 
cation)], patent number, Derwent accession (or patent family) number 
and priority data. No abstracts are provided. The launch of the 
service represented a major and significant step forward for Derwent 
inasmuch as this was the first of its products to be fully phototype- 
set, a process which simultaneously provided machine readable data to 
form the basis of a wholly computerised patents information service. 
Having broadened its subject coverage for a number of countries, the 
next logical step for Derwent was to to extend its abstracting activit- 
ies beyond the chemical' services and the non-chemical abstracts provid- 
ed for just UK, West Germany and USSR. Consequently, in 1975, a new 
series of subject-matter orientated publications providing abstracts 
for general, mechanical and electrical patents was commenced. The ser- 
ies of publications were collectively entitled World Patents Abstracts 
by Subject and, at the same time, the former series known as Patents 
Abstracts Publications were renamed World Patents Abstracts by Country. 
Derwent's next step forward came in 1976 with the launching of online 
access to the database it had compiled from Central Patents Index 
(together with its precursors Farmdoc, Agdoc and Plasdoc) and World 
Patents Index. Initially the company had entered into an agreement 
with Tymshare Inc. of the USA to place the files online; however, after 
partially loading the files, Tymshare revised its business plans and 
decided to withdraw from providing a host computer for online database 
"spinning". Subsequently Derwent allowed SDC Search Service, a division 
of System Development Corporation (SDC) of Santa Monica, California, 
- 
123 
- 
to load the files and make them available to registered users for 
online retrieval. In October 1979 the files were also loaded onto a 
computer in Tokyo to allow Japanese users to gain online access; the 
Tokyo computer is run by a Japanese subsidiary of SDC. Subsequently in 
July 1981, a partnership was formed (Derwent-SDC Search Service) to 
mount the files on a host computer in the United Kingdom; this service 
became operation early in 1982. By July 1982 the Derwent files, which 
also included those for the company's non-patents information services, 
were being used for more than 2,500 hours, with more than 150,000 
off-line printed citations and 450,000 online printed citations, per 
month. 
Derwent's next venture in patents information services was to launch a 
specialised documentation service for the electrical and electronics 
industries. This service, Electrical Patents Index, was also modelled 
on the successful already established formula, but was not as sophisti- 
cated as Central Patents Index inasmuch as some features, such as 
copies of complete specifications on microfilm, were not provided. The 
service commenced publication in May, 1980. 
An account of recent developments in Derwent's services, and some 
indications of future activities, have been given by this author and 
220 Oppenheim. 
Ownership of Derwent 
Derwent was founded by, and is very much the brainchild of, its Chair- 
man and Managing Director, Montagu Hyams. Until 1968, Mr Hyams and his 
wife owned the company, but in that year they sold 51% of the shares to 
Thomson Publications Limited, a subsidiary of The Thomson Organisation. 
Over the following years The Thomson Organisation purchased further 
shares in the company and, by 1980, owned 84%; the remaining 16% being 
held by the Hyams family. Following a reorganisation and restructuring 
of The Thomson Organisation in 1979, Derwent became a part of Thomson 
Data Limited; this company in turn is a part of Thomson. Information 
Services which is a division of International Thomson p. l. e. Montagu 
Hyams, in addition to being Chairman and Managing Director of Derwent, 
is also Chairman of Thomson Data Limited and serves on the board of 
Thomson Information Services. 
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In 1981 a subsidiary company (or rather a "cousin" company as it is 
part of Thomson's North American operations), Derwent Incorporated, was 
established in the USA. At the time of this study the main product of 
Derwent Inc. was an online service based upon magnetic tapes from the 
USPTO; the tapes contain full details of all US patents and the data- 
base created therefrom is loaded onto SDC's computers in the USA to 
provide online access. 
Range of Coverage of Derwent Patents Services 
At the time of this study Derwent services covered the documents issued 
by the following 24 national patent offices: 
- 
Austria, Belgium, Brazil, 
Canada, Czechoslovakia, Denmark, Finland, Prance, East Germany, West 
Germany, Hungary, Israel, Italy, Japan, Netherlands, Norway, Portugal, 
Romania, South Africa, Soviet Union, Sweden, Switzerland, United 
Kingdom and USA. The "international" PCT and European patents are also 
covered. The quasi-patent literature articles published in the journal 
Research Disclosure are also included. Commencing in 1983, Australian 
patents are to be covered in the Derwent system once again. 
For each document issuing authority, all the patent documents, irresp- 
ective of subject matter, were taken into the services. The sole 
exception was Japan where, for reasons of economy (abstracting of 
Japanese documents into English being excessively expensive) only 
chemical 
- 
and later electrical cases were covered. 
An indication has been given above as to when the various technologies 
were first covered by Derwent; just as these technologies were phased 
into the system over a number of years, so too were the different 
countries. This matter will be dealt with more fully in the description 
of Central Patents Index given below. 
From these sources Derwent, at the time this study was commenced, was 
taking into its services approximately 10,000 documents with 150,000 
multi-lingual pages, each week. 
The Major Derwent Services 
World Patents Index (WPI) 
- 
contains titles and bibliographic details, 
without abstracts, in the printed form as weekly gazettes which cover 
all countries and are iszued in four sections according to subject: 
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Chemical, Electrical, General and Mechanical. The coverage of each 
section is defined in terms of the International Patent Classification 
(IPC). 
World Patents Abstracts (WPA) 
- 
this service offers English language 
abstracts in individual weekly country reports under the following 
titles: Belgian Patents Report, British Patents Abstracts, French 
Patents Abstracts, German Patents Abstracts (covering examined docum- 
ents), German Patents Gazette (covering unexamined documents), Japanese 
Patents Report (covering examined documents), Japanese Patents Gazette 
(covering unexamined documents), Netherlands Patents Report 
, 
PCT 
Patents Report, European Patents Report, Soviet Inventions Illustrated 
and United States Patents Report. The French, Japanese and Netherlands 
publications cover only chemical cases. 
Additionally, WPA offers abstracts arranged by subject matter in a 
series of journals with the following titles: Human Necessities, 
Performing Operations, Transport, Construction, Mechanical Engineering, 
Instrumentation, Computing, Electronic Components, Circuitry and 
Communications, Power. 
Central Patents Index (CPI) 
- 
provides alerting, documentation and 
retrieval of chemical-related patents in a variety of subject defined 
Alerting Bulletins, Basic Abstracts Journals, Profile Booklets, coded 
cards, microfilm, microfiche and magnetic tapes. A fuller description 
is given on following pages. 
Electrical Patents Index (EPI) 
- 
provides, for the electrical and 
electronics industries, rapid current awareness with weekly abstracts 
bulletins and selective subject coverage by a range of profile bookl- 
ets. Retrospective searching is handled by a choice of coded abstracts, 
microfiche indexes and magnetic tapes. 
Online Search Service 
- 
The Derwent online database is in two parts: 
WPI which covers documents entered as basics prior to the end of 1980 
and subsequent equivalents to basics within that period, and WPIL for 
all basics and associated later equivalents processed since the begin- 
ning of 1981. The database (WPI and WPIL) includes the special coding 
features of CPI and EPI as well as abstracts for those basics included 
in WPIL. The database may be accessed from computers in California, 
Tokyo and Woking using the System Development Corporation ORBIT IV 
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software package. Searching is carried out interactively, i. e., in a 
conversational mode, with the computer and the searcher taking turns on 
the users remote access terminal. At the time of this study the files 
contained over two million patent families, representing some four 
million patent documents. 
Searching is straightforward and search statements may include any o%' 
the bibliographic features such as patent numbers, priority details, 
title terms, words in the abstracts, company names, IPCs, Derwent 
classification and special codes for CPI and EPI. Answers to searches 
are obtained as citations which may be printed in a variety of formats 
either online at the users terminal or offline at the host computer for 
onward mailing to the user. - The searches may incorporate all forms of 
Boolean logic ("and", "or" and "not") and may be conducted over subsets 
of the file selected by the searcher in terms of either subject matter 
or chronology. The computer files are updated with the latest informa- 
tion each week; during the updating procedure records of recently 
issued equivalents are added to the records of the corresponding 
basics. This need to update previously loaded records represents one 
of the major unique features of the WPI/WPIL files. Most bibliographic 
files enter a record and that record remains unaltered other than 
corrections of any errors; however, for the patent files additional 
information only new issued equivalents is continually added to earlier 
processed (basic) records. The ability to achieve these pseudo-correc- 
tions in large numbers required the development of special "mod" 
(modification) files and amendments to the ORBIT program suite. 
During the early part of 1981, at the time the file was divided into 
WPI and WPIL, the files were completely reloaded onto the host comput- 
ers so as to give greater flexibility of searching and additional 
alternative print-out formats. One feature of this is the ability to 
sort citations into desired sequences prior to offline printing, for 
example by patentee code or by priority date; this feature was not 
available at the time of the original online retrievals conducted for 
this study. Had it been available much of the keyboarding and computer 
listing of relevant data could have been avoided. (Indeed it was 
partly as a result of the work which this studied required that the 
offline sorting feature was recognised as a desirable system improve- 
ment. ) 
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In addition to the descriptive brochures which the company issues, 
descriptions of the Derwent services have been published by Hyams221- 
226 
, 
this author 
227-228 
, 
Pope 229, Mayer, Angus and Mariucci230, a 
Japanese study group231, Kaback232,233, Bankowski23', Oppenheim235 and 
Kimi236. Various aspects of the services have been described by a 
number of authors, mostly Derwent employees, in the proceedings of a 
237 
conference sponsored by Derwent and held in 1978. 
Other authors such as Saunderson238, HelliwellX39, Johns and Ryno240 
and Vincent 
241, have described how Derwent services are used in indus- 
trial information departments. Other articles, such as those by 
Kaback242, Carpenter, Jones and Oppenheim243 and Silk 
244, have describ- 
ed Derwent's classification and coding systems. 
The use of the online system has been described by Oppenheim245, 
Grant-Smith, Anderson and Jackson 
246, Bechtel 247, Kaback248, Walton 
249 
r 
and Herz250. Johns et al. ' have reported on Derwent's effectiveness 
in identifying patent families. Kaback252 has given a review of the 
various user aids issued by Derwent. 
Derwent's Non-Patents Information Services 
Following the success of the Farmdoc service, Derwent was approached in 
1964 by two groups of industrial organisations in an effort to get the 
company to produce a cothpanion service which would cover the pharmaceu- 
tical journal literature rather than patents. The first of 'these 
groups comprised Sandoz Limited and F. Hoffmann-La Roche & Company 
Limited, both of Basel, Switzerland. These companies had developed 
between them a system of keyword indexing of journal articles for 
retrieval; the system is known as "Codeless Scanning" and was offered 
to Derwent as an incentive to commence a service. The second group was 
the Pharmadokumentationsring e. V., a consortium 
- 
at that time 
- 
of 
some seven European and one USA pharmaceutical companies. This group 
had developed a fragmentation coding system, employing multi-punching 
of 80-column punch cards, known as the "Ring Code". The group had also 
developed an abstracting and exchange. system between themselves. 
The Pharmadokumentationsring code was also offered to Derwent. Using 
these systems, and adding Derwent's unique know-how and production 
techniques, a service was launched in mid 1964 which is known as 
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Ringdoc. This service selects, abstracts and codes articles from some 
750 technical journals which yield about 40,000 items per year. 
Once again, the success of one of its services led Derwent to introduce 
further publications. Fashioned in a. manner similar to Ringdoe, which. 
deals exclusively with articles of relevance to the pharmaceutical 
industry, Vetdoc and Pestdoc were initiated in 1966. Vetdoc covers the 
non-patent literature dealing with veterinary medicine, whilst Pestdoc 
covers the literature of agricultural chemicals such as pesticides and 
herbicides. 
In 1975 Derwent acquired the rights to publish Teilheimer's "Synthetic 
Methods of Organic Chemistry", input to an enlarged coverage being 
obtained by virtue of the company's extensive coverage of chemical 
journals for its other services as well as its unique coverage of 
patents. At the same time the Pharmadokumentationsring e. V. offered 
Derwent their coding system for chemical reactions and the company was 
able to commence its Chemical Reactions Documentation Service (CRDS) 
and Journal of Synthetic Methods as successor to Teilheimer's publica- 
tion. 
The Ringdoc, Pestdoc, Vetdoc and CRDS files are also mounted on the 
host computers used for online access to the patents files. 
In July 1982, Derwent added to its portfolio of information products an 
abstracting, and corresponding online service, entitled Biotechnology 
Abstracts. This service covers both patent and journal literature 
documents and was launched to meet the growing needs for information in 
the increasingly important biotechnology area. 
Central Patents Index (CPI) 
Main features of CPI 
CPI is a sophisticated abstracting and retrieval service dealing with 
chemical patents under twelve major subject matter categories. 
On a current basis, for each category, CPI takes the form of a booklet 
giving 100-120 word abstracts (see Figure 8) of all current inventions 
arranged in country of document sequence; a week later, the same abstr- 
acts, arranged by Derwent classification; and, the following week, a 
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booklet giving detailed, coded abstracts of all first disclosure or 
"basic" patents (see Figure 9). 
Retrieval is possible through the provision of cumulated indexes, 
manual code cards, magnetic tapes for in-house usage and online access. 
At the time this study was commenced punch coded cards were also 
available, but have since ceased to be produced. Abstracts and complete 
patent specifications are also available as microfilm records. 
Basics and Equivalents 
In the production of CPI, the filing details and classification are 
recorded on magnetic tape for each new document. The priority informa- 
tion is then matched by computer against a master file containing all 
previously processed document data; there are built-in checks to guard 
against input errors. In this way the documents are divided about 
equally into those which relate to entirely new inventions, or "basics" 
and those for which corresponding patents have already been published, 
or "equivalents". Meaningful, text-edited, are prepared and input for 
all basics. 
The whole of the computer input for any one week is blended with all 
the information ever included on the master file in a "merge and 
update" computer session. 
As a result, all the new basics are automatically assigned CPI acces- 
sion (or patent family) numbers, entered into the system and detailed 
abstracts prepared. For any new equivalent, the patent number and any 
new IPCs are posted against the CPI accession number of the family to 
which it belongs. At the same time, tapes are generated for the 
phototypeset production of the various indexes, abstract headings and 
abstracts. Subsequently, structure coding is carried out for basic 
patents disclosing chemical or polymer features, as well as deep 
classification, or "manual coding" for all basic documents. 
Country Coverage 
Because the laws under which patents are issued vary from country to 
country, applications made at the same time in different countries may 
be published (laid Open to Public Inspection, or OPI) at different 
times. Slow publishing documents have usually been through the process 
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of novelty searching and are published approximately 2 to 3 years after 
filing in the form of a printed specification as accepted after amend- 
ment where necessary. The specifications normally contain a small 
number of narrow, well defined, claims of proven novelty. 
Fast publishing documents are normally the so-called "new law" quick 
disclosures, published approximately six months after filing, or 18 
months from the earliest priority date, as typewritten documents in the 
same form as filed, without examination. Usually they contain a large 
number of broader-than-justified claims, often of doubtful novelty. 
The countries covered for CPI (and for WPI), the numbers issued, and 
the date of introduction into the service are as follows: 
- 
(a) "Major" countries 
(i) Fast Publishing 
Average total number Year first 
OPI per week (1982) included in CPI 
Belgium 100 1963 
European (unexamined) 500 1979 
PCT 75 1978 (Dec. ) 
France 500 1963 
Germany, W. (unexamined) 750 1968 
Japan (Kokai)* 2090 1972 
Netherlands (unexamined) 125 1963 
South Africa 125 1963 
Sweden** 135 1974 (Sept. ) 
UK (unexamined) 500 1978 
(ii)Slow Publishing 
Canada 430 1963 
European (examined) 120 1980 
Germany, E. 150 1963 
Germany, W. (examined) 460 1963 
Japan (Koho) 340 1963 
Netherlands (examined) 60 1963 
Soviet Union 1500 1963 
UK (examined) 500 1963 
USA 1300 1963 
(b) "Minor" countries 
(i) Fast Publishing 
Brazil 190 1976 (Jan. ) 
Denmark 110 1974 (Nov. ) 
Finland 60 1974 (Nov. ) 
Italy 100 1978 (Jan. ) 
Norway 80 1974 (Dec. ) 
Portugal 30 1974 (Nov. ) 
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(ii) Slow Publishing 
Austria 
Czechoslovakia 
Hungary 
Israel 
Romania 
80 1975 (Mar. ) 
175 1975 (Mar. ) 
85 1975 (May) 
40 1975 (Mar. ) 
60 1975 (Mar. ) 
Total number patents per week = 10,905 
*Only chemical patents from Japan were included prior to 1981 
"Prior to 1979 Sweden was treated as a "minor" country 
Since 1978, articles, about 15 each week, from the publication Research 
Disclosure have been included in the service. Additionally covered in 
the pre-CPI services, but discontinued at the start of CPI in 1970, 
were Australia (to. be included again from 1983), Eire and Italy (Ital- 
ian documents were only included in Plasdoc); subsequently Italy was 
re-introduced as a "minor" country in 1978 (January). 
Classification 
Patents included in CPI are assigned to one or more of the CPI sections 
A to M: 
- 
CPI Section Subject 
A (Plasdoc) Polymers 
B (Farmdoe) Pharmaceutical 
C (Agdoc) Agricultural, Veterinary 
D Food, Cosmetics, Detergents 
E (Chemdoc) General Chemical 
F Textiles, Paper, Cellulose 
G Printing, Coating, Photography 
H Petroleum, Fuels 
J Chemical Engineering 
K Nucleonics, Explosives 
L Refractories, Cement, Eleetro(in)organic 
M Metallurgy 
Basics in 1981 
39,000 
9,200 
5,300 
13,700 
18,900 
8,700 
9,600 
8,000 
15,200 
2,500 
22,100 
25,800 
On average each basic is assigned to 1.55 Sections. These twelve 
sections are broken down into 135 well-defined classes, which serve to 
divide the subject matter simply and unambiguously into a number of 
profiles for alerting, SDI and scanning purposes. Full details of the 
classification for Section B (Farmdoc) are as follows: 
- 
Scope: All specifications stated to be of pharmaceutical or veterinary 
interest., as well as those relating to compounds for use as intermed- 
iates in the manufacture of drugs or veterinary products. 
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All steroids, alkaloids, vitamins, vaccines and antibiotics 
are covered automatically. Also compositions used for diagnosis and 
analysis in the pharmaceutical and veterinary fields. 
Inventions dealing with bactericides and fungicides are 
included when these substances are for internal or topical application. 
However, when they are used for other purposes (such as in detergent 
compositions, disinfection of textiles, lubricating oil additives, 
etc. ) they are not covered in this section. 
Patents dealing with the production of tablets, pills, caps- 
ules, suppositories, etc., are included. Also, devices for specifically 
dispensing pharmaceuticals such as syringes, tamper-proof closures and 
calendar pill-boxes, aerosols, etc., are included. 
In the classification given below, the order of priority is B1 
before B2, B2 before B3, and so in in the same compound. 
Classes: B1 : Steroids 
B2 : Fused ring heterocycles 
B3 : Other heterocycles 
B4 : Natural products 
- 
peptides, analytical processes for 
body fluids 
B5 : Others organics 
- 
aromatics, aliphatics, organo-metallics, 
general compositions 
B6 : Inorganics 
B7 : General 
- 
tablets, dispensers 
CPI Products 
The abstracts, indexes, etc., which are available as part of CPI are 
shown in Figure 7 (note, however, that punch cards are no longer 
available). Further details are available from the relevant Derwent 
brochures. 
Manual Code Classification 
The manual code classification is far deeper than the arrangement 
according to CPI class, and is similar in structure to a national 
patent office classification, but is strengthened to take care of 
chemicals and polymers. 
The manual code classes may be likened to keywords, a hierarchical 
system being used. For example, adhesive tapes are broadly classified 
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Alertin Bulletin. (Country Order) g 
Bulletin. (Cl... tiled) 
ABSTRACTS Basic Abstracts Journal. 
Doeumentatlo. Profite Booklet. 
' k: lcrofllm 
PATENT B. Je Patente 
Printed 
CGPICS Microfilm 
Comp.. y Cod. Printed 
Ma al C d 
Printed 
CARDS nu o . Nie rofllm 
Punch Cod. 
Card. 
RIN Irrem 
. 
Patent.. 
Alerting Aceodon Number 
Bulletin. Patent Number 
" CPI class "" 
Patent.. 
Beal. Aec... fon Number 
INDEXES 
Abet 
.. eu Patent Number 
journJa Manaal Cod. 
Puten.. 
Quart l 
Acc"e. lon Numb., 
er y 
COM Patent Numb., 
Mlcrol: eb. Priority 
IPC 
Quarterly Accession Nun, ber 
Printed Patent Number 
Meekly bibliography Data 
ktAGNCTIC 
TAPi3 or Manual Cod.. 
Monthly MulupnMh Cod.. 
" Part ee"er. g. only 
"ý Alcrting 0-11-Un. (Country Order) only 
5%cdno", D. T and G cmnbiaed 
A B C O c F O H ] K L M 
A D C D C F O H 7 K L M 
A B C D L F G H J K L M 
A" H" C H" 
B C D E FG H )KL Ni A 
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A B C D E F 6 H J K L M 
A B C D E F C H 3 K L M 
A B C D E F 6 H J K L M 
A B C D E F 6 H J K L M 
H 10 
H+J+K 
[E=. Q 
Figure 7: Scheme to show which products (and for which Sections) 
are available for CPI 
YAMA * B02 307158/16 *J54032-694 
Cephem-4-carboxylic acid derivs. prodn. 
- 
by contacting D- 
aminoacid oxidase active mycelium with 7-beta. (5- 
aminovoleramide)-7-alpha-methoxy delta-cephem-4-carboxylic 
acid 
YAMANOUCHI PHARM KK 12.08.77-JA-096711 
C02 (10.03.79) C12d-09 C12d-13 
Prepn. of 7p-(4-carboxybutyramide)-7a-methoxy-03-ceph- 
em-4-carboxylic acid deriv. of the formula (I): (where 
-SR is OCHS nucleophilic 
HOOC-(CH2)3-CONH-}-_ S es. contact ngs- 
CH 
-SR mycelium Z possessing D- 
00011 (I) amino acid 
oxidase activ- 
ity or its extract with 73-(5-amino- 5-carboxyvaleramide)- 
7a-methoxy-As-cephem-4-carboxylic acid of formula (II) 
or its salt, in the presence of hydrogen peroxide. 
HOOCH OCHS 
CH-(CHZ)3-CONH , 
HZNý 
ON 
CHZ-SR 
COON (II) 
(II) is converted to (I) in high yield. 12.8.77 as 096711. (9pp68) 
Figure 8: Typical Alerting Abstract 
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Figure 9: Typical Basic, or Documentation Abstract 
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in group A12 under "applications"; generically in sub-group A12-A under 
"all adhesives and binders"; and specifically in code "A12-A1". 
On average an invention is assigned to three or four codes. In all, 
there are about 4,000 manual codes in 
-CPI, each one having an average 
of just under 60 documents assigned to it per year. 
The details of the Section B (Farmdoc) manual codes relating to Aroma- 
tics, Cycloaliphatics (mono- and bi-cyclic only) and Aliphatics are 
shown in Figure 10; the full description of the code is given in Der- 
went's Instruction Manual 3. 
Patentee Codes 
The patentees from all patents entered into the Derwent system are 
assigned a four or five character code related to the patentee name. 
These codes are then used in place of the patentee names for the 
generation of patentee indexes and may be used for retrospective 
retrieval using such indexes, the company code cards (unit abstract 
records) or the online files. 
Codes are applied to every company listed as a patentee, tip to a 
maximum of four patentees being coded for any one document. In cases 
where a company and an individual are joint patentees, only the company 
name and code are recorded; where several individuals are joint patent- 
ees, only the first name mentioned is used to generate a patentee 
code. 
From 1963 to 1969 all patentees, even individuals, were assigned 
distinct four-letter codes. Except for the codes assigned to individ- 
uals, these codes still apply. Since 1970, only the more prolific 
patentees newly encountered have been assigned unique "standard" codes, 
the remainder being treated as "non-standard" as described below. 
For larger companies, all recognisable subsidiaries are assigned the 
same code; for example, Chloride Group Limited, Chloride Batteries 
Limited, Chloride Lorival Limited and Chloride Batterijen BV are all 
assigned the code "CHLO". Subsidiaries with substantially different 
names may also be assigned the same code; for example, American Home 
Products Corporation, J. Wyeth & Brother Limited and Ayerst McKenna & 
Harrrison Limited are each assigned the code "AMHP". When a company 
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1310 AROMATICS AND CYCLO ALIPHATICS 
(MONO AND BICYCLIC ONLY); ALIPHATICS 
In B10 cpds are coded according to the type of lunchonal gp present (sl any). 
Order of p onues. whereby only one card is applied to a specific cpd 
. 
is 
A> B-- >J end) >2>3 etc. Thus B70-At rs highest. and 81042 lowest. 
priorntycode. 
Symboi'X' represents a halogen. 
B10-A Rarer chemical groups, general 
1 Sutphonium, iodonium, free radicals, carbonium, 
oxonium, etc. 
2 Halogen bonded to Hal, Nor 0h 
3 Nitrogen oxide, nitroso " 
4 Peroxide, polysulphide 
5 Nitrate, nitrite " 
6 Quinoneb 
7 Sugar+ba 
8 Amide of sulphur acid " 
9A Sulphuric(ous) acid a b" 
9B Sulphonic acid, general' b" 
9C Other S acids. ab" 
10 Sulphone, sulphoxide, ' 
II A Thiocarbonic acid b" 
11B Carbonic acid b" 
12A Dithiocarbamic acid b" 
12B Monothiocarbamic acid b" 
12C Carbamicacidb" 
13A (lso)thiourea" 
13B (Iso)urea, general! " 
13C 
-- 
Unsubstituted urea' 
13D 
-- 
Other (iso)urea cpds. ' 
14 (Iso)cyanate, thiocyanidea 
15 (Iso)cyanide 
16 Azide, azo, diazo(nium) 
17 Biguanide, guanidine. amidine 
18 Hydroxylamino 
19 Hydrazine 
20 Imine 
21 Quat. ammonium (bis or poly) c 
22 Quat. ammonium (mono) C 
23 Acetal, ketal+ 
24 Imide 
25 Acid anhydride, halide (carboxylic only) ah 
B10-B An-iines 
IA Polyamines, at least 1 amine aromatic- 
IS Polyamines with no amine aromatic- 
2A Amino-acid. 
- 
ester or- amide (amine aromatic)" 
2B Amino-acid. 
-ester or- amide (amine not aromatic). 
generals " 
2C 
-Mixtures contg. at least 3 naturally occurring 
amino acids' 
2D 
"- 
Sulphur-containing amino acids (incl. amides and 
esters of the acid group(s))' 
2E 
"- 
Ring-containing amino acid with free acid group or 
salt' 
2F 
-- 
Ring-containing amino amide' 
2G 
-- 
Ring-containing amino ester' 
2H 
-- 
Opt. esterified or etherified hydroxy amino acids 
(incl. amides and esters of the acid group(s))' 
2J 
"- 
Other amino acids (incl. amides and esters of the 
acid group(s))' 
3A Amino-phenol, 
-alcohol or-ether (amine 
aromatic) "" 
3B Amino-phenol, 
- 
alcohol or 
- 
ether (amine not 
aromatic) a '' 
4A Other aromatic amines" 
4B Other non-aromatic amines" 
B1 0-C Carboxylic acids (CA) 
1 Thio-CA 
2 Poly-CA 
3 CA with phenol or phenolic ester or ether gp(s). 
4 Other CA, general 
4A 
-" 
Cycloaliphetic CA' 
4B 
"- 
Hydroxy, aldehyde or ketonic CA (or ethers thereof) 
with an aromatic ring' 
4C 
-- 
Other CA with aromatic ring' 
4D 
"- 
Acyclic hydroxy, aldehyde or ketonic CA and 
acyclic ether thereof' 
4E 
"- 
Otheracyclicmono-CA' 
BiO-DAldelAldehydes bnd carboxylic amides 
I Aldehydes' 
2 Carboxylic amide, thio 
3 Carboxylic arnides 
B10-E Flydroxy compounds 
1 Thiophenols 
2 Phenols 
3 Thioalcohols 
4 Alcohols, general' 
4A 
-- 
Alcohols contg. 
- 
OH attached directly to alicyclic 
ring' 
4B 
-- 
Alcohols tonig. carbocyclic ring(s) 
4C 
-- 
Po! yaicohols and ethers and esters thereof' 
4D 
-- 
Other alcohols' 
B10-F Ketones a 
1 Thioketones 
2 Ketones 
B10-G Carboxylic esters and nitro' 
1 Thiocarboxylic esters 
2 Carboxylic esters 
3 Nitro 
B10-H Ethers and halogens " 
1 Ethers" 
2A F. linked to aromatic ring" 
2B F. not linked to aromatic ring" 
2C Or or I, linked to aromatic ring" 
2D Br or I, not linked to aromatic ring" 
2E Cl, linked to aromatic ring" 
2F Cl, not linked to aromatic ring" 
610-J Hydrocarbons 
I 
-C: C-. may form part of alicyclic ring- 2 Others" 
Notes 
I Oxygen atoms maybe replaced by S. 
b Includes all denn,.. except those with higher priority. 
C Where patent claims amines and their qual. amm. salts. only code of 
parent ammo given. Thus to obtain all relevant quit. emm. cpda., two 
ssuches must be made. 
d For iodic or basic ells see the parent cpde. (I a. amine,, acids, etc. ) 
I For all cyclic derive, of the pps. fisted above sea 01 to B7. 
I For lips. not listed above, the highest priority segment of the pp is used as 
Its coding feature. For example. somrcarbatones era coded Bi 0-At 30. and 
not also B10- A19 or B10-A20. 
p Sugars conto free kerornc or aldehyde function are coded in open chain 
( not cyclic) form. In example, glucose is 010-A7, but methyl glucosids is 
B7-A2, 
h Halides of acids other than cotbosyhc (B10-A25) or those contg N-%m 
O-X bond (810-A2) are assigned code of the parent acid For example 
sulphenyt halide is B10-A9C. a chlorotormare 010-A11 Band a carbamoyt 
hahde010-A12C. 
I These generic codes are only used for general disclosures which would 
otherwise require several specific codes. When a specific search is made. 
any corresponding'i'Bannics must also be so itched. 
Figure 10: Part of the CPI Manual Code for Section B 
- 
137 
- 
changes its name, the standard code is retained, so that Bayer AG, 
formerly Farbenfabriken Bayer AG, continues to be coded as "FARB". 
When two companies with standard codes merge, one code is retained and 
the other abandoned; e. g., Ciba-Geigy AG is coded "CIBA", and the code 
"GEIG" is no longer used, in this case having been converted on the 
files to "CIBA" during a major updating of codes in 1975 (at which time 
the company code was rationalised so that only one code was applied to 
any particular patentee). 
For each of the 13,500 standard codes, Derwent stores a standard name 
on a dictionary file. Where several subsidiaries, or associates, of a 
company exist, the standard name is usually the name most frequently 
met with on patent documents; it is not necessarily the name of the 
parent company. Part of the list of standard company names is given as 
Figure 11. 
For non-standard patentees, Derwent usually (at least for 95% of cases) 
takes the first four letters of the first significant word (ignoring 
such words as Societe, Firma, etc. ) of the name as the code. Such 
non-standard patentee codes terminate with a hyphen (-), except for 
individuals where an oblique (/) is used. For Soviet names a translat- 
ion is made of significant words and the codes terminated with an 
equals sign Full details of the code are in Instruction Manual 
2. 
Fragmentation, or Multipunch Code 
At the time that the retrievals were carried out for this study, a 
punch card code was used in CPI to deal with structural and special 
property concepts of chemicals. For the "chemical" sections of CPI 
(i. e., Sections B, C and E), details of the fragmentation code used 
were given in Instruction Manual 3, the Chemical Retrieval Manual. The 
code used for polymer concepts (in CPI Section A) is described in 
Instruction Manual 4 (Plasdoc Retrieval Manual). 
In an aneilliary service to the punch card codes, the RIN (Ring Index 
Numbers) system, unique registry numbers are assigned for any ring 
systems which were not completely coded by a single unambiguous punch 
card position in the chemical code. For those systems recorded in the 
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AACH AACHEN GERRESHEIMER GMBH ACTP ACTIPHARMA SOC CIV 
AACH 
-GEVETEX TEXTILGLAS ACTP -SOC CIV ACTIPHARMA 
AAGR AAGRUNOL NV ACTV ACTIVIT OCTROOIEN M NV 
AAIC AA1 CORP ACTV 
-OCTROOIEN ACTIVIT M 
AARB AARONSON BROS LTD' ADAI ADAM CO INC 
AARH AARHUS OLIEFABRIK A/S ADAL ADAMANT LAB 
AARI RICE AA INC ADAM ADAM CONSOL INO INC 
AARN AARON R ETAS ADAP ADAMS PAPER CONVERT CO 
AAMK ALWO ALTENBURGER VEB ADAS ADAMS CC CO LTD 
RANK 
-VEB ALWO ALTENBURGER ADAU ADAMSON UNITED CO 
ABBE ABBEY CHEMICALS ADCO a^AD CHEM CO -NOW ADCP 
ABBE 
-ABBEY SPORTS CO LTD ADCO ADCOTE CHEMICALS INC 
ABBM ABBOTT MACHINE CO ADCP 
- 
SEE AOCO 16) 
ABBO *ABBOTT LABORATORIES ADCP fAD CHEMICAL INC 
ABB0 ABBEY QUILTING LTD AUDI ADDI-COLOR AG 
ABBU "ARBUZOV ORG PHYS CHEM ADDR "ADORESSOGRAPH-MULTI CORP 
ABSU 
-INST ORG FIZ KHIM ARBUZO ADEC ADELAIDE CHEM C FER LTD 
ABBV ABBYVILLE CORP ADEK ADEKA-ARGUS IND KK 
ABCO ABCOR INC ADEK 
-ADEKA-ARGUS KOGYO KK 
ABCO 
-ABCOR WATER MANAGEM ; ADEL ADAMS ELECTRONICS INC 
ABEC AB ELECTRONIC COMP LTD ADEW ADELAIDE C WALLAROO 
ABEE 
-ABEL SOC ETAS ADHE ADHESIVE TAPES LTD 
ABEE SOC ETAS ABEL ARNE 
-INDUSTRIAL SEALANTS 
ABEK ABEKAWA KOGYO KK 'ADHK ADHEYA KAKO KK 
ABEN AB ENGINEERING CO ; ADHR ADHERE KAKO KK 
ABER "ABEX CORP LOIN ADHESIVES NUNEZ SL INO 
ABIC *ABIC LTD LOIN 
 NUNEZ ADHESIVES SL 
ABIC 
 ABIC CHEMICAL LAB ADIS ADIS CHEMICAL KK 
ABIS ABISAN CORP ADIS 
 ADIS KASEI KK 
ABIT ABITIBI PAPER CO LTD ARME ADMEL INTERNATIONAL 
ABIT 
-ABITIBI POWER C PAPER ADM5 ADAMS L LTD 
ABLO FABRICA PROD QUIMIC AOON ADONSELL LTD 
ABMA ABRASIVE METAL PROD INC AOOX ADOX FOTOWERKE 
ABMA 
-ABRASIVE PRODUCTS ADRE 
-ADREMA PITNEY-BONES 
ARME AB METAL PRODUCTS LTD ADRE ADREMA-WERKE GMBH 
ABPL AB PLASTICS LTD ADRS ANDERSON C SON 0 LTD 
ABRD ABRASIVE DEV LTD ADSC ADS CHEMICAL CO 
ABRI ABRIL IND WAXES LTD ROSE ATELIERS SECHERON SA 
ABRS ABRAHAMS C SONS PTY LTD ADVA ADVANCE GLOVE MFG CO 
ABUA ABU AB ADVA @ADVANCE GROWTH- NOW ADVC 
ACCE ACCELERATED IND INC ADVC 
- 
SEE ADVA (8) 
ACCF *-ACCUMULATEURS FIXES SOC ADVC fADVANCE GROWTH CAPI CORP 
ACCF 
-SAFT BATTERIES LTD ADVE ADVERTISING PUBLICI LTD 
ADVF ADVANCE FINISHING INC 
ACCF 
-SAFT SOC ACCUMUL FIXES AOVI ADVANCE INDUSTRIES INC 
ACCF *SOC ACCUMUL FIXES TRAC ADVP ADVANCE PROC SUPPLY CO 
ACCL ACCLES C POLLOCK LTD ADVR ADVANCE RESEARCH CO 
ACCM ACCMETA SA AEBW ALLGEMEINER ELEKTRO 
ACDE ATEL CONSTR D'EPLUCHES AECR AERO CHEM RES LAB INC 
Figure 11: Part of the WPI/CPI List of Standard Patentee Codes 
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American Chemical Society's Patterson Ring Index the number used in 
that publication was assigned, otherwise a Derwent-assigned number was 
used. 
The scheme for encoding fused ring heterocyclic compounds (card columns 
17 to 28) is shown in Figure 12. Details of the definitions of part of 
card column 26 and card column 28 are shown in Figure 13, and the 
complete coding of Cephalothin in Figure 14 in order to illustrate the 
code. 
In 1981,, after the retrievals for this study were conducted, a majcr 
revision of the chemical coding system took place and a new chemical 
code introduced. The principal feature of this revised code is that it 
is independent of the limitations of punch cards, i. e., to combinations 
of the 960 possible positions, an advance brought about by the flexibi- 
lity of the online system and the disappearence of the need to supply 
subscribers with punch coded cards per se. The removal of the punch 
card format limitations has led to the use of codes for increased 
numbers of features and thus an increase in the specificity of the 
code. During a major revision of the online files early in 1982, the 
former assigned codes were converted to the new codes. The RIN system, 
as mentioned above, continues to be assigned without any change. 
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Figure 12: Part of the Multipunch Code for Section B showing 
schematically the Meanings of each position in card columns 17 to 28 
SOLE HETEROS S&N 27 8. 
.. 
benzothiazepines (-ocines) 
With 2 rings -"' May be 
26 3 
.. 
unsatd. N OTNS 
0 May be 
4 
.. I' 
SI N 
unsaid. N 
N1.. others, 1-S & 1-N 
5\I SN \I NH 2 with 2-S&1-N 
3 6 .. CC S1Jx N4.. others, 1 -S Et 2-N 5 
.. 
others 
7A With 3 rings INS 
6 
8 
.. 
'ý% (MS 
a7.. 
with l-S & 1-N in same ring, 
excl. 27/6 
8 
.. 
with 1-S & 1-N not in same rind 
Figure 13: Detailed Explanation of the Multipunch Code for 
CPI Section B for part of Column 26 and for Column 27 
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S 
CH2CONH 
II 
0N CH2000C113 
COON 
Cephalothin 
Card 
Column Position Explanation 
13 Antibiotic 
- 
cephalosporin type 
27 0 Fused heterocyclic ring system, sole hetero 
atoms S and N, saturated or unsaturated: 
- 
30 0 Mononuclear heterocycle, sole heteroatom 
one S or N, furan or thiophene :- 
L) 
47 12 One carboxylic acid group (-COOH) linked 
through C-atom in heterocyclic group 
48 5 Carboxamide group (-CONH) linked through 
N to C-atom in heterocyclic ring 
50 12 One'oxo group (: 0) linked to C-atom in 
heterocyclic ring 
51 1 Ester group (-CH2OCO-) linked through 
C-atom to an aliphatic carbon (-C113 ) 
58 1 Antibacterial 
59 11 One fused ring heterocyclic system 
61 12 One monocyclic heterocycle 
62 11 No aromatic rings present 
62 0 No alicyclic rings present 
64 11 Natural product coded in Sections B and/or C 
68 12 Section B control punch 
71 3 "Basic Group" = heterocyclic fused ring 
Figure 14: Comp lete Multipunch Coding for Cephalothin 
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11: METHODOLOGY AND RESULTS 
Cephalosporins Data Analysis 
Two sets of Cephalosporins patents data. sets were retrieved as describ- 
ed in Appendix I. The original set was retrieved in October 1979; this 
was supplemented with a set of updating data two years later. 
The original data set was analysed through a series of computer gener- 
ated lists as described in Appendix I. The data obtained from these 
lists was subsequently amended with the information from the update 
retrieval. 
The computer generated lists and supplemental data were used to prepare 
a series of tables as follows: 
Table 9: Patentee Names and Countries for Proprietary Companies 
Table 10 : Patentees and Countries for Academic Institutes 
Table 11 : Patentees and Countries for Not-for-Profit Organisations 
Table 12 : Patentee Names for Private Inventors 
Table 13 : Patentees (excluding private inventors) Listed by Country 
of Domesticity 
Table 14 : Patentees Ranked by Earliest Priority Date 
Table 15 : Patentees Ranked by Earliest Publication Date 
Table 16 : Patentees Ranked by Number of Cephalosporin Patents 
Table 17 : Patentees (excluding private inventors) Ranked by Total 
Number of Patents in Database pre-1980 
Table 18 : Patentees (excluding private inventors) Ranked by Total 
Number of Patents in CPI Section B pre-1980 
Table 19 : Patentees (excluding private inventors) Ranked by Per- 
centage of Total pre-1980 Patents in CPI Section B 
Table 20 : Patentees (excluding private inventors) Ranked by Per- 
centage of Total CPI Section B Patents which are for 
Cephalosporins 
Table 21 : Classification of Cephalosporin Patents into Types of 
Invention 
Tables 17 
- 
21 inclusive contain data in respect of the original 
Cephalosporin data set only. 
- 
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PATENTEE NAME COUNTRY 
Abbott Laboratories Inc. USA 
Ajinomoto KK Japan 
Akzo NV Netherlands 
Albert Rolland SA France' 
Alfa Farmaceutici SpA Italy 
Alza Corporation USA 
American Cyanamid Company USA 
American Home Products Corp. USA 
Amstar Corporation USA 
Antibiotics SA Spain 
Aries Associates SA France 
Asahi Chemical Industries KK Japan 
Astra Pharmaceutica AB Sweden 
Ausonia Farmaceutici SRL Italy' 
Banyu Pharmaceutical Company Limited Japan 
Bayer AG Germany 
Beecham Group Limited UK 
Biochemie GmbH Austria 
Boehringer Mannheim GmbH Germany 
Boehringer Sohn GmbH, C. H. Germany 
Bristol Myers Company USA 
Bristol-Banyu KK Japan 
Carlo Erba SpA Italy 
Caw Industries Inc. USA 
Chemie Grunenthal GmbH Germany 
Chemische Fabriken von Heyden GmbH Germany 
Chugai Pharmaceuticals KK Japan 
Ciba-Geigy Limited Switzerland 
Clin-Midy SA, Laboratoires France 
Connlab Holdings Limited Canada 
Craf Sud SpA Italy 
Cusi SA, Laboratorios Spain 
Daiichi Seiyaku Company Limited Japan' 
Dainippon Pharmaceuticals KK Japan 
Dobfar SpA Italy 
Dow Chemical Company USA 
du Pont de Nemours & Company, E. I. USA 
Dynamit Nobel AG Germany 
Eiken Kagaku KK Japan 
Eisai Company Limited Japan* 
Eli Lilly & Company USA 
Ethicon Inc. USA 
Farmitalia SpA Italy 
Fermion Oy Finland 
Ferrer & Cia. SA, Laboratorios Spain 
Fisher Scientific Company USA 
Forest Laboratories Inc. USA 
Fujisawa Pharmaceutical Industries KK Japan 
Gallardo SA, A. Spain 
Gema SA Spain 
Gist-Brocades NV Netherlands 
Glaxo Group Limited UK 
Grelan Pharmaceutical Company Limited Japans 
Hodogaya Chemical Industries KK Japan 
Table 9: Patentee Names and Countries for 
Proprietary Companies 
(*From Cephalosporins update set only) 
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PATENTEE NAME COUNTRY 
Hoechst AG Germany 
Hoffmann-La Roche Company Limited, F. Switzerland 
ICI Limited UK 
ISF Italseber SpA Italy 
Instituto Luso-Farmaco SarL Portugal 
Instituto de Farmacologia Espanola SA Spain 
Intellectual Property Development Corp. USA 
Ist. Biochim. Ital. de Loredana 
Lorenzini SAS Italy 
KRKA-Farmacevtica Yugoslavia 
Kanebo Pharmaceuticals Limited Japan 
Key Pharmaceuticals Corporation USA* 
Kisses Pharmaceutical Company Limited Japan 
Kommanditbolaget Kockums Chemicals AB Sweden 
Kureha Chemical Industries KK Japan 
Kyoto Ceramic Company Limited Japan* 
Kyowa Hakko Kogyo KK Japan 
Lafarqium SA, Laboratorios Farmaceutico Quimico Spain 
Landerlan SA, Cia. Internationale Farmacia Spain 
Lark SpA Italy 
Leo Pharmaceutical Products AB Sweden 
Lepetit SpA Italy 
Liofilizaciones Esterilizaciones y Sinteses SA Spain* 
Lumac International NV Netherlands 
Antilles 
McDonnell Douglas Corporation USA 
Meiji Seika KK Japan 
Merck & Company Inc. USA 
Merck AG, E. Germany 
Merrell-Toraude SA, Laboratoires France 
Miles Laboratories Inc. USA 
Mitsubishi Chemical Industries KK Japan 
Mitsubishi Petroleum Company Limited Japan 
Mitsui Toatsu Chemicals Inc. Japan* 
Mundipharma AG Switzerland 
National Patent Development Corporation USA 
Nelson Research & Development Company USA 
Nikken Chemicals Company Limited Japan 
Nikko Chemicals Industries KK Japan 
Nippi Inc. Japan 
Nippon Chemifar Company Limited Japan 
Nippon Kagaku KK Japan 
Nippon Shinyaku KK Japan 
Nisshin Flour Milling Company Limited Japan 
Novo Industries A/S Denmark 
Ohta Seiyaku KK Japan 
Organon NV Netherlands 
Otsuka Pharmaceuticals KK Japan 
Parke Davis & Company USA 
Fencillin Assays Inc. USA* 
Pfizer Inc. USA 
Pharmacia AB Sweden 
Pharmaco Inc. USA 
Pierrel SpA Italy 
Table 9: Patentee Names and Countries for 
Proprietary Companies, continued (*From Cephalosporins update set only) 
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PATENTEE NAME COUNTRY 
Plantex Limited Israel* 
Procter & Gamble Company USA 
Proter SpA Italy 
Purdue Frederick Company USA 
R&L Molecular Research Canada 
Recherches et Industries Therapeutique SA Belgium 
Rhone-Poulenc SA France 
Richardson-Merrell USA 
Roussel-Uclaf SA France 
Sandoz Limited Switzerland 
Sankyo Company Limited Japan 
Sanraku-Ocean KK Japan 
Sawai Seiyaku KK Japan* 
Scherico Limited Switzerland 
Schering AG Germany* 
Seoul Pharmaceutical Industries KK S. Korea 
Shionogi Limited Japan 
Showa Denka KK Japan* 
Sigma-Tau SpA Italy 
Smith, Kline & French Laboratories Inc. USA 
Snam-Progetti SpA Italy 
Societe Chemie et Biologie France* 
Societe Omnium-Chimique SA Belgium 
Sparamediea AG Germany 
Squibb & Sons Inc., E. R. USA 
Stada Arzneimittel GmbH Germany 
Sumitomo Chemical Company Japan 
Sutures Inc. USA 
Syntex Corporation USA 
Takeda Chemical Industries Japan 
Tanabe Pharmaceutical Company Japan 
Teijin KK Japan 
Teikoku Chemical Industries Japan 
Teikoku Hormone Manufacturing Company Japan 
Thekan SA, Laboratoires France 
Thomae GmbH, Dr. Karl Germany* 
Tobishi Pharmaceutical Company Japan 
Toho Pharmaceutical Laboratories Company Japan 
Toho Yakuhin Kogyo KK Japan 
Tokyo Tanabe KK Japan 
Toray Industries Inc. Japan 
Toshin Chemical Industries KK Japan 
Toyama Chemical Industries KK Japan 
Toyo Jozo KK Japan 
Toyobo KK Japan 
Unilever BV Netherlands 
Union Carbide Corporation USA 
Upjohn Company USA 
Verronmay Limited UK* 
Viridis, Etablissements Leichtenstein 
Wakamoto Pharmaceutical Company Japan 
Warner-Lambert Company USA 
Wellcome Foundation Limited UK 
Yamanouchi Pharmaceutical Company Japan 
Yoshitomi Pharmaceutical Industries KK Japan 
Table 9: Patentee Names and Countries for 
Proprietary Companies, concluded 
(*From Cephalosporins update set only) 
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PATENTEE NAME COUNTRY 
Antibiotics Research Institute USSR 
Baylor College of Medicine USA 
Institute Recherche Scientifique France 
Instytut Przemyslu Farmaceutyczneco Poland 
Massachusetts Institute of Technology USA 
Osaka University Japan 
Politechnica Gdanska Poland 
Priorov Traumatolog USSR 
Purdue Research Foundation USA 
Purdue University USA 
Queens University Canada 
Regents of the University of California USA 
Woodward, R. B., Prof. USA 
Yeda Research & Development Israel 
Table 10: Patentee Names and Countries for 
Academic Institutes 
PATENTEE NAME COUNTRY 
Agence Nationale de Valorisation France 
Chinoin Gyogyszer Hungary 
NASA USA 
National Research & Development Corporation UK 
Research Corporation USA 
Sagami Chemical Research Centre Japan 
Sendai Institute of Heterocyclic Chemistry Japan' 
Zaidan Hojin Sangyo Kagaku KK Japan 
Zaidan Hojin Seikan-Kai Japan 
Table 11: Patentee Names and Countries for 
Not-for-Profit Organisations 
(*From Cephalosporins update set only) 
Ansberg, S. E. 
Banker, G. S. 
Bocher, D. 
Charm, S. E. 
Crast, L. B. 
Gregor, H. P. 
Higashikawa, T. 
Ito, S. 
Jackson, B. G. 
Keck, J. M. 
Levine, B. B. * 
MacLaren, S. A. 
Marx, R. 
Masuda, G. 
Metcalf, B. W. 
Miyauchi, Y. * 
Naito, T. 
Ogura, H. 
Panoz, D. E. * 
Pereira da Luz, A. 
Peters, H. V. * 
Petrzilka, T. 
Prugnard, R. L. 
Romano, A. * 
Sakakida, T. 
Seheieher, H. 
Stapley, E. 0. 
Takino, H. 
Treuner, V. D. 
Yamada, S. 
Table 12: Patentee Names for Private Inventors 
(*From Cephalosporins update set only) 
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COUNTRY PATENTEE NAME 
Austria Biochemie GmbH 
Belgium Recherches et Industries Therapeutique SA 
Societe Omnium-Chimique SA 
Canada Connlab Holdings Limited 
Queens University 
R&L Molecular Research 
Denmark Novo Industries A/S 
Finland Fermion Oy 
France' Agence Nationale de Valorisation 
Albert Rolland SA* 
Aries Associates SA 
Institute de Recherches Scientifiques 
Laboratoires Clin-Midy SA 
Laboratoires Merrell-Toraude SA 
Laboratoires Thekan SA 
Rhone-Poulenc SA 
Roussel-Uclaf SA 
Societe Chiinie et Biologie* 
Germany, W. Bayer AG 
Boehringer Mannheim GmbH 
C. H. Boehringer Sohn GmbH 
Chemie Grunenthal GmbH 
Chemische Fabriken von Heyden GmbH 
Dr. Karl Thomae GmbH* 
Dynamit Nobel AG 
E. Merck AG 
Hoechst AG 
Schering AG* 
Sparamedica AG 
Stada Arzneimittel GmbH 
Hungary Chinoin Gyogyszer es Vegyeszeti 
Termekek Gyara RT 
Israel Plantex Limited* 
Yeda Research & Development 
Italy Alfa Farmaceutici SpA 
Ausonia Farmaceutici SRL* 
Carlo Erba SpA 
Craf Sud SpA 
Dobfar SpA 
Farmitalia SpA 
ISF Italseber Spa 
Istituto Biochimico Italiano di 
Loredana Lorenzini SAS 
Lark SpA 
Lepetit SpA 
Pierrel SpA 
Proter SpA 
Sigma-Tau SpA 
Snam-Progetti SoA 
Japan Ajinomoto KK 
Asahi Chemical Industries KK 
Banyu Pharmaceutical Company Limited 
Bristol-Banyu KK 
Chugai Pharmaceuticals KK 
Table 13: Patentees (excluding private inventors) listed 
by Country of Domesticity (*From Cephalosporins update set only) 
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COUNTRY PATENTEE NAME 
Japan, Daiichi Seiyaku Company Limited* 
continued Dainippon Pharmaceuticals KK 
Eiken Kagaku KK 
Eisaa Company Limited* 
Fujisawa Pharmaceuticals Industries KK 
Grelan Pharmaceutical Company Limited' 
Hodogaya Chemical Industries KK 
Kanebo Pharmaceuticals Limited 
Kissei Pharmaceutical Company Limited 
Kureha Chemicals Industries KK 
Kyoto Ceramic Company Limited' 
Kyoto Yakuhin Kogyo* 
Kyowa Hakko Kogyo KK 
Meiji Seika KK 
Mitsubishi Chemical Industries KK 
Mitsubishi Petroleum Company Limited 
Mitsui Toatsu Chemicals Inc. * 
Nikken Chemicals Company Limited 
Nikko Chemical Industries KK 
Nippi Inc. 
Nippon Chemifar Company Limited 
Nippon Kagaku KK 
Nippon Shinyaku KK 
Nisshin Flour Milling Company Limited 
Ohta Seiyaku KK 
Ono Pharmaceuticals KK 
Osaka University 
Otsuka Pharmaceuticals KK 
Sagami Chemical Research Centre 
Sankyo Company Limited 
Sanraku-Ocean KK 
Sawai Seiyaku KK* 
Shionogi Limited 
Showa Denko KK* 
Sumitomo Chemical Company 
Takeda Chemical Industries 
Tanabe Pharmaceutical Company KK 
Teijin KK 
Teikoku Chemical Industries 
Teikoku Hormone Manufacturing Company 
Tobishi Pharmaceutical Company 
Toho Pharmaceutical Laboratories Company 
Toho Yakuhin Kogyo KK 
Tokyo Tanabe KK 
Toray Industries Inc. 
Toshin Chemical Industries 
Toyama Chemical Industries KK 
Toyobo KK 
Toyo Jozo KK 
Wakamoto Pharmaceutical Company KK 
Yamanouchi Pharmaceutical Company 
Yoshitomi Pharmaceutical Industries KK 
Zaidan Hojin Sangyo Kagaku KK 
Zaidan Hojin Seiken-Kai 
Table 13: Patentees (excluding private inventors) listed 
by Country of Domesticity, continued 
(*From Cephalosporins update set only) 
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COUNTRY PATENTEE NAME 
Korea Seoul Pharmaceutical Industries KK 
Liechtenstein Etablissement Viridis 
Netherlands Akzo NV 
Gist-Brocades NV 
Organon BV 
Unilever BV 
Netherlands 
Antilles Lumac International NV 
Poland Instytut Przemyslu Farmaceutyczneco 
Politechnika Gdanska 
Portugal Instituto Luso-Farmaaco SARL 
Spain A. Gallardo SA 
Antibioticos SA 
Cia. Internationale Farmacia Landerlan SA 
Gema SA 
Instituto do Farmacolgia Espanola SA 
Laboratorios Cusi SA 
Laboratorios Farmaceutico Quimico Lafarquim SA 
Laboratorios Ferrer & Cie SA 
Liofilizaciones Esterilizaciones y 
Sinteses SA* 
Sweden Astra Pharmaceutica AB 
Kommanditbolaget Kockums Chemical AB 
Leo Pharmaceutical Products AB 
Pharmacia AB 
Switzerland Ciba-Geigy Limited 
F. Hoffmann-La Roche Company Limited 
Mundipharma AG 
Sandoz Limited 
Scherico Limited 
UK Beecham Group Limited 
Glaxo Group Limited 
ICI Limited 
National Research & Development Corporation 
Verronmay Limited* 
Wellcome Foundation Limited 
USA Abbott Laboratories Inc. 
Alza Corporation 
American Cyanamid Company 
American Home Products Corporation 
Amstar Corporation 
Baylor College of Medicine 
Bristol Myers Company 
Caw Industries Inc. 
Dow Chemical Company 
E. I. du Pont de Nemours & Company 
E. R. Squibb & Sons Inc. 
Eli Lilly & Company 
Ethicon Corporation 
Fisher Scientific Company 
Forest Laboratories Inc. 
Intellectual Property Development Corporation 
Key Pharmaceuticals Inc. * 
Massachusetts Institute of Technology 
Table 13: Patentees (excluding private inventors) listed 
by Country of Domesticity, continued (*From Cephalosporins update set only) 
- 
150 
- 
COUNTRY PATENTEE NAME 
McDonnell Douglas Corporation 
Merck & Company Inc. 
Miles Laboratories Inc. 
NASA 
National Patent Development Corporation 
Nelson Research & Development Company 
Parke Davis & Comapay 
Penicillin Assays Inc. * 
Pfizer Inc. 
Pharmaco Inc. 
Procter & Gamble Company 
Purdue Frederick Company 
Purdue Research Foundation 
Purdue University 
Regents of the University of California 
Research Corporation 
Richardson-Merrell Inc. 
Smith, Kline & French Laboratories Inc. 
Sutures Inc 
Syntex Corporation 
Union Carbide Corporation 
Upjohn Company 
Warner-Lambert Company 
Woodward, R. B., Prof. 
USSR Antibiotics Research Institute 
Priorov Traumatolog 
Yugoslavia KRKA-Farmacevtica 
Table 13: Patentees (excluding private inventors) listed 
by Country of Domesticity, concluded 
(*From Cephalosporins update set only) 
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Earliest 
PATENTEE NAME Priority RANK 
Date 
National Research & Development Corp. 02.02.55 1 
Eli Lilly & Company 16.11.59 2 
Glaxo Group Ltd. 06.04.60 3 
Pfizer Inc. 28.06.60 4 
Merck & Company Inc. 11.07.60 5 
Smith, Kline & French Laboratories Inc. 15.08.60 6 
Ciba-Geigy Limited 25.07.61 7 
Bristol Myers Company 16.08.61 8 
Farmitalia SpA 25.07.62 9 
E. R. Squibb & Sons Inc. 29.10.62 10 
Astra Pharmaceuticals AB 14.12.62 11 
Bayer AG 27.02.63 12 
Fujisawa Pharmaceutical Industries KK 13.04.63 13 
Jackson, B. G. 05.03.65 14 
Aries Associates SA 21.06.65 15 
R&L Molecular Research 28.06.65 16 
Roussel-Uclaf SA 03.08.65 17 
Woodward, R. B., Prof. 10.09.65 18 
Organon NV 24.11.65 19 
Ajinomoto KK 16.09.66 20c 
Toyobo KK 16.09.66 20_ 
American Cyanamid Company 15.02.67 22 
Beecham Group Limited 07.03.67 23 
Leo Pharmaceutical Products AB 10.03.67 24 
Parke Davis & Company 11.05.67 25 
Research Corporation 22.06.67 26 
Societe Omnium-Chimique SA 28.07.67 27 
Institute de Recherches Scientifiques 01.08.67 28 
Gist-Brocades NV 07.08.67 29 
Bristol-Banyu KK 28.11.67 30 
National Patent Development Corp. 13.08.68 31 
Banker, G'. S. 03.09.68 32= 
Purdue University 03.09.68 32= 
American Home Products Corp. 16.09.68 34 
Osaka University 02.04.69 35 
Yamanouchi Pharmaceutical Company 22.09.69 36 
Sankyo Company Limited 19.11.69 37 
Syntex Corporation 19.01.70 38 
Takeda Chemical Industries 11.02.70 39 
Akzo NV 18.02.70 40 
Laboratoires Thekan SA 23.02.70 41 
Chemie Grunenthal GmbH 30.05.70 42 
Regents of the University of California 22.06.70 43 
Toyama Chemical Industries KK 17.10.70 44 
Kyowa Hakko Kogyo KK 11.12.70 45 
Toyo Jozo KK 19.12.70 46 
Hoechst AG 28.12.70 47 
Caw Industries Inc. 20.01.71 48 
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Chemische Fabriken von Heyden GmbH 22.02.71 49 
Union Carbide Corporation 08.03.71 50 
Teikoku Hormone Manufacturing Company 22.03.71 51 
Upjohn Company 12.04.71 52 
Snam-Progetti SpA 28.04.71 53 
Alfa Farmaceutici SpA 13.08.71 54 
F. Hoffmann-La Roche Company Limited 03.01.72 55 
Sakakida, T. 05.01.72 56 
Yeda Research & Development 18.01.72 57 
Crast, L. B. 31.01.72 58 
Takino, H. 14.02.72 59 
Queens University 10.04.72 60 
Sutures Inc. 12.04.72 61 
Meiji Seika KK 14.04.72 62 
Fermion Oy 12.05.72 63 
Sumitomo Chemical Company 31.05.72 64 
Treuner, V. D. 01.06.72 65 
Purdue Research Foundation 09.06.72 66 
Recherches et Industries Therapeutiques SA 22.06.72 67 
Shionogi Limited 29.06.72 68 
Laboratoires Clin-Midy SA 30.06.72 69 
Naito, T. 26.07.72 70 
Maclaren, S. A. 03.08.72 71 
Bocher, D. 18.08.72 72 
Biochemie GmbH 05.09.72 73 
Dainippbn Pharmaceuticals KK 06.09.72 74 
Ist. Biochim. Ital. di Loredana Lorenzini 02.11.72 75 
E. I. du Pont de Nemours & Company 11.11.72 76 
Masschusetts Institute of Technology 14.11.72 77 
Nikken Chemicals Company Limited 02.12.72 78 
Novo Industries A/S 27.12.72 79 
Yamada, S. 23.01.73 80 
Politechnica Gdanska 07.02.73 81 
Gema SA 21.02.73 82 
A. Gallardo SA 08.03.73 83 
Instituto Luso-Farmaco SARL 16.03.73 84 
Priorov Traumatolog 09.04.73 85 
E. Merck AG 21.04.73 86 
Stapley, E. O. 06.06.73 87 
Banyu Pharmaceutical Company Limited 11.06.73 88 
Kanebo Pharmaceutical Limited 18.06.73 89 
Pereira da Luz, A. 02.07.73 90 
Carlo Erba SpA 27.07.73 91 
Rhone-Poulenc SA 06.09.73 92 
Dynamit Nobel AG 28.09.73 93= 
Laboratorios Ferrer & Cia. SA 28.09.73 93= 
Richardson-Merrell Inc. 07.11.73 95 
Teijin KK 28.12.73 96 
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Lepetit SpA 03.01.74 97 
Toshin Chemical Industries KK 07.02.71 98 
Nikko Chemical Industries KK 08.02.74 99 
Ogura, H. 06.03.74 100 
ISF Italseber SpA 02.04.714 101 
Pharmacia AB 03.04.74 102 
Teikoku Chemical Industries 09.04.7+ 103 
Zaidan Hojin Sangyo Kagaku KK 28.05.74 104 
Zaidan Hojin Seikan-kai 03.06.74 105 
Sparamedica AG 21.06.74 106 
Amstar Corporation 03.07.74 107 
Asahi Chemical Industries KK. 09.07.74 108 
Chinoin Gyogyszer 30.07.74 109 
ICI Limited 08.08.74 110 
Keck, J. M. 21.09.74 111 
Nippon Kagaku KK 27.09.74 112 
Hodogaya Chemical Industries KK 09.11.714 113 
Instytut Przemyslu Farmaeeutyczneco 25.11.74 114 
McDonell Douglas Corporation 02.12.74 115 
Ethicon Inc. 11.12.74 116 
Nasshin Flour Milling Company Limited 28.12.74 117 
Ito, S. 07.01.75 118 
Kissel Pharmaceutical Company Limited 08.01.75 119 
Alza Corporation 28.01.75 120 
Otsuka Pharmaceuticals KK 21.02.75 121 
Laboratorios Cusi SA 03.03.75 122 
C. H. Boehringer Sohn GmbH 07.03.75 123 
Intellectual Property Development Corp. 12.03.75 124 
Sanraku-Ocean KK 18.03.75 125 
Antibiotics Research Institute 20.03.75 126 
Nelson Research & Development Company 11.04.75 127 
Lab. Farmaceutico Quimico Lafarquim SA 14.04.75 128 
Chugai Pharmaceuticals KK 24.04.75 129 
NASA 30.04.75 130 
Boehringer Mannheim GmbH 17.05.75 131= 
Instituto de Farmacologia Espanola SA 17.05.75 131= 
Proter SpA 27.05.75 133 
Wakamoto Pharmaceutical Company 17.06.75 134 
Connlab Holdings Limited 23.06.75 135 
Dobfar SpA 26.06.75 136 
Mitsubishi Chemical Industries KK 16.09.75 '137 
Pierrel SpA 01.10.75 138 
Gregor, H. P. 07.11.75 139 
Dow Chemical Company 21.11.75 140 
KRKA-Farmacevtica 05.12.75 141 
Abbott Laboratories Inc. 08.12.75 142= 
Procter & Gamble Company 08.12.75 142= 
Ansberg, S. E. 24.12.75 144 
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Mitusubishi Petroleum Company Limited 27.12.75 145 
Tokyo Tanabe KK 30.12.75 146 
Unilever BV 12.01.76 147 
Seoul Pharmaceutical Industries KK 19.01.76 148 
Antibioticos SA 20.01.76 149 
Fisher Scientific Company 19.02.76 150 
Pharmaco Inc. 02.03.76 151 
Sagami Chemical Research Centre 04.03.76 152 
Agence Nationale de Valorisation 26.03.76 153 
Forest Laboratories Inc. 05.05.76 154 
Yoshitomi Pharmaceutical Industries KK 06.05.76 155 
Cia. Internationale Farmacia Landerlan SA 08.05.76 156 
Nippi Inc. 20.05.76 157 
Ono Pharmaceuticals KK 27.05.76 158 
Eiken Yagaku KK 04.06.76 159 
Marx, R. 16.06.76 160 
Toko Yakuhin Kogyo KK 21.06.76 161 
Establissements Viridis 28.06.76 162 
Kommanditbolaget Kockums Chemical AB 29.06.76 163 
Lumac International NV 30.06.76 164 
Tobishi Pharmaceutical Company 26.07.76 165= 
Toho Pharmaceutical Laboratories Company 26.07.76 165= 
Nippon Chemifar Company Limited 30.07.76 167 
Mundipharma AG 25.08.76 168_ 
Purdue Frederick Company 25.08.76 168= 
Kyoto Yakuhin Kogyo* 26.08.76 170 
Nippon Shinyaku KK 19.10.76 171 
Masuda, G. 30.11.76 172 
Sherico Limited 17.12.76 173 
Toray Industries Inc. 07.02.77 174 
Higashikawa, T. 10.02.77 175 
Stada Arzneimittel GmbH 04.03.77 176 
Kureha Chemical Industries KK 13.04.77 177 
Miles Laboratories Inc. 20.04.77 178 
Warner-Lambert Company 03.06.77 179 
Craf Sud SpA 07.06.77 180 
Laboratoires Merrell-Touraude SA 01.07.77 181= 
Metcalf, B. W. 01.07.77 1810 
Petrzilka, T. 18.07.77 183 
Prugnaud, R. L. 25.07.77 184 
Sandoz Limited 27.07.77 185 
Lark SpA 05.08.77 186 
Ohta Seiyaku KK 12.08.77 187 
Wellcome Foundation Limited 16.08.77 188 
Tanabe Pharmaceutical Company 22.09.77 189 
Charm, S. E. 21.11.77 190_ 
Penicillin Assays Incorporated' 21.11.77 190= 
Baylor College of Medicine 02.12.77 192 
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Scheicher, H. 16.12.77 193 
Daiichi Seiyaku Company Limited' 28.12.77 194 
Verronmay Limited 23.01.78 195 
Sigma-Tau SpA 27.01.78 196 
Mitsui Toatsu Chemicals Incorporated' 21.03.78 197 
Miyauchi, Y. * 31.03.78 198 
Levine, B. B. * 20.04.78 199 
Peters, I. V. * 23.05.78 200 
Liofilizaciones Esterilizaciones y Sintesis* 08.06.78 201_ 
Albert Rolland SA* 08.06.78 201= 
Dr. Karl Thomae GmbH' 28.06.78 203 
Sawai Seiyaku KK* 26.08.78 204 
Ausonia Farmaceutici SRL* 20.10.78 205 
Plantex Limited 20.11.78 206 
Showa Derko KK' 06.12.78 207 
Panoz, D. E. # 22.12.78 208 
Societe Chimie et Biologie' 04.01.79 209 
Schering AG' 10.01.79 210 
Key Pharmaceuticals Incorporated' 11.01.79 211 
Kyoto Ceramic Company Limited' 13.02.79 212 
Eisas Company Limited' 09.04.79 213 
Sendai Institute of Heterocyclic Chemistry' 13.04.79 214 
Grelan Pharmaceutical Company Limited' 01.06.79 215 
Romano, A. * 31.10.79 216 
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National Research & Development Corp. 07.09.60 1 
Smith, Kline & French Laboratories Inc. 10.08.61 2 
Pfizer Inc. 06.09.61 3 
Glaxo Group Limited 12.02.62 4 
Eli Lilly & Company 11.02.63 5 
Bristol Myers Company 18.02.63 6 
Merck & Company Inc. 05.03.63 7 
Ciba-Geigy Limited 15.08.63 8 
Farmitalia SpA 12.02.64 9 
E. R. Squibb & Sons Inc. 30.06.64 10 
Bayer AG 28.08.64 11 
Aries Associates SA 13.05.66 12 
Astra Pharmaceuticals AB 30.06.66 13 
Fujisawa Pharmaceutical Industries KK 10.08.66 14 
R&L Molecular Research 23.08.66 15 
Roussel-Uclaf SA 17.02.67 16 
Woodward, R. B., Prof. 19.02.67 17 
Organon NV 25.05.67 18 
American Cyanamid Comapny 12.09.67 19 
Beecham Group Limited 20.09.67 20 
Societe Omnium-Chimique SA 02.01.68 21 
Toyobo KK 18.03.68 22 
Leo Pharmaceutical Products AB 12.07.68 23 
Research Corporation 31.10.68 24 
Institute de Recherches Scientifique 06.01.69 25 
Gist-Brocades NV 31.01.69 26 
Bristol-Banyu KK 19.05.69 27 
Parke Davis & Company 22.07.69 28 
National Patent Development Corporation 13.02.70 29 
American Home Products Corporation 16.03.70 30 
Ajinomoto KK 18.03.70 31 
Banker, G. S. 30.04.70 32 
Yamanouchi Pharmaceutical Company 01.04.71 33 
Jackson, B. G. 04.05.71 34 
Sankyo Company Limited 27.05.71 35 
Osaka University 15.07.71 36 
Laboratories Thekan SA 16.07.71 37 
Takeda Chemical Industries 10.08.71 38 
Akzo NV 17.08.71 39 
Purdue University 21.09.71 40 
Chemie Grunenthal GmbH 02.12.71 41 
Regents of the University of California 15.12.71 42 
Toyama Chemical Industries KK 20.04.72 43 
Hoechst AG 30.06.72 114 
Snam-Progetti SpA 16.08.72 45 
Syntex Corporation 22.08.72 46 
Chemische Fabriken von Heyden GmbH 21.09.72 47 
Teikoku Hormone Manufacturing Company 12.10.72 48 
Kyowa Hakko Kogyo KK 25.10.72 49 
Sutures Inc. 08.02.73 50 
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Alfa Farmaceutici SpA 22.02.73 51 
Yeda Research & Development 23.03.73 52 
Union Carbide Corporation 27.06.73 53 
F. Hoffmann-La Roche Company Limited 05.07.73 54 
Sakakida, T. 11.10.73 55 
Toyo Jozo ICK 23.10.73 56 
Meiji Seika KK 25.10.73 57 
Purdue Research Foundation 11.12.73 58 
Naito, T. 18.12.73 59 
Recherches et Industries Therapeutiques SA 27.12.73 60 
Laboratoires Clin-Midy SA 10.01.74 61= 
Shionogi Limited 10.01.74 61= 
Sumitomo Chemical Company 22.01.74 63= 
Queens University 22.01.74 63= 
Ist. Biochim. Ital. di Lorendana Lorenzini 15.02.74 65 
Bocher, D. 18.02.74 66 
Fermion Oy 05.03.74 67 
Biochemie GmbH 07.03.74 68 
Novo Industries A/S 16.04.74 69 
Dainippon Pharmaceuticals KK 27.04.74 70 
Crast, L. B. 28.05.74 71 
Nikken Chemicals Company Limited 11.06.74 72 
Gema SA 17.06.74 73 
Massachusetts Institute of Technology 26.07.74 74 
Politechnica Gdanska 14.08.74 75 
Yamada, S. 09.09.74 76 
A. Gallardo SA 12.09.74 77 
Pereira da Luz, A. 16.09.74 78 
Instituto Luso-Farmaco SARL 26.09.74 79 
MacLaren, S. A. 08.10.74 80 
E. Merck AG 21.10.74 81 
Carlo Erba SpA 18.11.74 82 
Dynamit Nobel AG 16.01.75 83 
Stapley, E. 0. 28.01.75 84= 
Treuner, V. D. 28.01.75 84= 
Banyu Pharmaceutical Company Limited 13.02.75 86 
Kanebo Pharmaceuticals Limited 15.02.75 87 
Richardson-Merrell Inc. 03.03.75 88 
Rhone-Poulenc SA 05.03.75 89 
Laboratorios Ferrer & Cia SA 02.04.75 90 
Lepetit SpA 10.07.75 91 
Teijin KK 31.07.75 92 
Nikko Chemical Industries KK 26.08.75 93- 
Toshin Chemical Industries KK 26.08.65 93= 
Ogura, H. 02.10.75 95= 
Upjohn Company 02.10.75 95= 
ISF Italseber SpA 09.10.75 97 
Pharmacia AB 16.10.75 98 
Teikoku Chemical Industries 18.10.75 99 
E. I. du Pont de Nemours & Company 21.10.75 100 
Table 15: Patentees Ranked by Earliest Publication Date 
Continued 
- 
158 
- 
Earliest 
PATENTEE NAME Publicat- RANK 
ion Date 
Chinoin Gyogyszer 17.11.75 101= 
Laboratorios Cusi SA 17.11.75 101= 
Zaidan Hojin Sangyo Kagaku KK 02.12.75 103 
Zaidan Hojin Seikan-kai 12.12.75 104 
Sparamedica AG 22.12.75 105 
Lab. Farmaceutico Quimico Lafarquim SA 26.12.75 106 
Asahi Chemical Industries KK 20.01.76 107 
Ito, S. 30.01.76 108 
ICI Limited 26.02.76 109 
Keck, J. M. 02.04.76 110 
Nippon Kagaku KK 03.04.76 111 
Hodogaya Chemical Industries KK 18.05.76 112= 
Intellectual Property Development Corp. 18.05.76 112= 
McDonnell Douglas Corporation 18.05.76 112= 
Priorov Traumatolog 20.05.76 115 
Instytut Przemyslu Farmaceutyczneco 16.06.76 116 
Nisshin Flour Milling Company Limited 12.07.76 117 
Kissei Pharmaceutical Company Limited 15.07.76 118 
Ethicon Inc. 13.08.76 119 
Otsuka Pharmaceuticals KK 30.08.76 120 
Boehringer Mannheim GmbH 01.09.76 121: 
Instituto de Farmacologia Espanola SA 01.09.76 121= 
C. H. Boehringer Sohn GmbH 16.09.76 123 
Alza Corporation 28.09.76 124 
Sanraku-Ocean KK 29.09.76 125 
Caw Industries Inc. 05.10.76 126 
Connlab Holdings Limited 18.10.76 127= 
Nelson Research & Development Corporation 18.10.76 127= 
Chugai Pharmaceuticals KK 02.12.76 129 
Wakamoto Pharmaceutical Company 22.12.76 130 
Proter SpA 31.12.76 131 
Dobfar SpA 11.01.77 132 
Pierrel SpA 17.01.77 133 
Amstar Corporation 18.01.77 134 
Antibiotics Research Institute 24.02.77 135 
Kommanditbolaget Kockums Chemical AB 16.03.77 136 
Mitsubishi Chemical Industries KK 22.03.77 137 
NASA 29.03.77 138 
Gregor, H. P. 18.05.77 139 
Dow Chemical Company 26.05.77 140 
KRKA-Farmacevtica 08.06.77 141 
Procter & Gamble Company 21.06.77 142 
Abbott Laboratories Inc. 23.06.77 143 
Unilever BV 11.07.77 144 
Mitsubishi Petroleum Company LImited 12.07.77 145= 
Tokyo Tanabe KK 12.07.77 145= 
Antibioticos SA 21.07.77 147 
Seoul Pharmaceutical Industries KK 27.07.77 148 
Sagami Chemical Research Centre 05.09.77 149 
Pharmaco Inc. 06.09.77 150 
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Mundipharma AG 03.10.77 151_ 
Purdue Frederick Company 03.10.77 151= 
Fisher Scientific Corporation 05.10.77 153 
Cia. Internationale Farmacia Landerlan SA 14.11.77 154= 
Yoshitomi Pharmaceutical Industries KK 14.11.77 154= 
Forest Laboratories Inc. 17.11.77 156 
Agence Nationale de Valorisation 25.11.77 157 
Ono Pharmaceuticals KK 02.12.77 158 
Nippi Inc. 08.12.77 159 
Eiken Kagaku KK 10.12.77 160 
Ansberg, S. E. 12.12.77 161 
Toko Yakuhin Kogyo KK 19.12.77 162 
Mark, R. 29.12.77 163 
Lumac International NV 02.02.78 164 
Tobishi Pharmaceutical Company 13.02.78 165= 
Toho Pharmaceutical Laboratories Company 13.02.78 165= 
Nippon Chemifar Company Limited 20.02.78 167 
Etablissements Viridis 03.03.78 168 
Miles Laboratories Inc. 07.03.78 169 
Nippon Shinyaku KK 08.05.78 170 
Scherico Limited 15.06.78 171 
Laboratoires Merrell-Toraude SA 11.07.78 172= 
Metcalf, B. W. 11.07.78 172= 
Warner-Lambert Company 18.07.78 174 
Toray Industries Inc. 29.08.78 175 
Takino, H. 04.09.78 176 
Stada Arzneimittel GmbH 07.09.78 177 
Kureha Chemical Industries KK 17.10.78 178 
Higashikawa, T. 28.11.78 179 
Craf Sud SpA 04.01.79 180 
Lark SpA 14.02.79 181 
Sandoz Limited 19.02.79 182 
Wellcome Foundation Limited 21.02.79 183 
Ohta Seiyaku KK 10.03.79 184 
Charm, S. E. 16.03.79 185 
Baylor College of Medicine 20.03.79 186 
Masuda, G. 27.03.79 187 
Prugnard, R. L. 30.03.79 188 
Petrzilka, T. 10.04.79 189 
Tanabe Pharmaceutical Company 17.04.79 190 
Sigma-Tau SpA 16.05.79 191 
Scheicher, H. 21.06.79 192 
Daiichi Seiyaku Company Limited 23.07.79 193 
Verronmay Limited 08.08.79 194 
Liofilizacions Esterilizaciones y Sintesis 01.10.79 195 
Miyauchi, Y. 06.10.79 196 
Albert Rolland SA 13.12.79 197 
Peters, H. V. 20.12.79 198 
Dr. Karl Thomae GmbH 09.01.80 199 
Ausonia Farmaceutici SRL 15.02.80 200= 
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Romano, A. 15.02.80 200= 
Kyoto Yakuhin Kogyo 16.04.80 202= 
Sawai Seiyaku KK 16.04.80 202= 
Plantex Limited 28.05.80 204 
Mitsui Toatsu Chemicals Inc. 04.06.80 205 
Panoz, D. E. 17.06.80 206 
Showa Denka KK 19.06.80 207 
Schering AG 23.07.80 
. 
208= 
Key Pharmaceuticals Inc. 23.07.80 208_ 
Kyoto Ceramic Company Limited 21.08.80 210 
Societe Chemie et Biologie 05.09.80 211 
Eisai Company Limited 08.10.80 212 
Sendai Institute of Heterocyclic Chemistry 31.10.80 213 
Grelan Pharmaceutical Company Limited 12.12.80 214 
Penicillin Assays Inc. 15.12.80 215 
Levine, B. B. 24.02.81 216 
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Fujisawa Pharmaceutical Industries KK 316 1 
Eli Lilly & Company 273 2 
Takeda Chemical industries 153 3 
E. R. Squibb & Sons Inc. 140 44 
Glaxo Group Limited 134 5 
Ciba-Geigy Limited 114 6 
Bristol Myers Company 109 7 
Merck & Co. Inc. 103 8 
Smith, Kline & French Laboratories Inc. 88 9 
Sankyo Company Limited 87 10 
Yamanouchi Pharmaceutical Company 82 11 
Beecham Group Limited 65 12 
Toyama Chemical Industries KK 59 13 
Meiji Seika KK 50 14 
Shionogi Limited 47 15 
Roussel-Uclaf SA 46 16 
American Home Products Corporation 45 17= 
Asahi Chemical Industries KK 45 17= 
Teijin KK 42 19 
Sumitomo Chemical Company 41 20 
Hoechst AG 37 21 
Bayer AG 36 22 
Toyo Jozo KK 32 23 
Aries Associates SA 31 24= 
Chemische Fabriken von Heyden GmbH 31 24: 
Banyu Pharmaceutical Company Limited 29 26 
Zaidan Hojin Sangyo Kagaku KK 26 27 
Pfizer Inc. 24 28= 
Yeda Research & Development 24 28= 
Gist-Brocades NV 22 30 
Nippon Kagaku KK 20 31 
Farmitalia SpA 18 32= 
Laboratoires Merrell-Toraude SA 18 32= 
Rhone-Poulenc SA 18 32= 
National Research & Development Corporation 17 35 
Toyobo KK 16 36 
Hoffmann-La Roche Company Limited 15 37= 
Kanebo Pharmaceuticals Limited 15 37= 
Kyowa Hakko Kogyo KK 14 39 
E. Merck AG 13 40= 
Woodward, R. B., Prof. 13 40= 
Leo Pharmaceutical Products AB 12 42 
Dainippon Pharmaceuticals KK 11 43 
American Cyanamid Company 10 44= 
Novo Industries A/S 10 44= 
Richardson-Merrell Inc. 10 44= 
Ajinomoto KK 9 47= 
Astra Pharmaceuticals AB 9 47= 
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Hodogaya Chemical Industries Kk 8 149= 
Massachussets Institute of Technology 8 49= 
Nikken Chemicals Company Limited 8 149= 
Parke Davis & Company 8 49= 
Nippon Chemifar Company Limited 7 53= 
R&L Molecular Research 7, 53= 
Biochemie GmbH 6 55= 
Bristol-Banyu KK 6 55= 
Carlo Erba SpA 6 55= 
Proter SpA 6 55= 
Recherches et Industries Therapeutique SA 6 55= 
Syntex Corporation 6 55= 
Alfa Farmaceutici SpA 5 61= 
Chugai Pharmaceuticals KK 5 61= 
Gema SA 5 61= 
Osaka University 5 61= 
Queens University 5 61= 
Teikoku Chemical Industries 5 61= 
Antibioticos SA 4 67= 
Chemie Grunenthal GmbH 4+ 67= 
Connlab Holdings Limited )} 67= 
Daiichi Seiyaku Company Limited* 4 67= 
E. I. Du Pont de Nemours & Company 4 6? = 
Politechnica Gdanska 4 67= 
Kissel Pharmaceutical Company Limited 4 67= 
Otsuka Pharmaceuticals KK 4 67= 
Dr. Karl Thomae GmbH* 4 67= 
Toshin Chemical Industries KK 4 67= 
Boehringer Mannheim GmbH 3 77= 
Caw Industries Inc. 3 77= 
Laboratorios Cusi SA 3 77= 
Dobfar SpA 3 77= 
Dow Chemical Company 3 77= 
Fermion Oy 3 77= 
A. Gallardo SA 3 77= 
Ist. Biochim. Ital. di Loredana Lorenzini SAS 3 77= 
Kyoto Yakuhin Kogyo* 3 77= 
Mitsui Toatsu Chemicals Incorporated* 3 77= 
Mitsubishi Chemical Industries KK 3 77= 
Nelson Research & Development Company 3 77= 
Pierrel SpA 3 77= 
Sagami Chemical Research Center 3 77= 
Sakakida, T. 3 77= 
Sandoz Limited 3 77= 
Snam-Progetti SpA 3 77= 
Sutures Inc. 3 77= 
Tanabe Pharmaceutical Company 3 77= 
Tobishi Pharmaceutical Company 3 77= 
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Upjohn Company 3 77= 
Warner-Lambert Company 3 77= 
Abbott Laboratories 2 99= 
Alza Corporation 2 99= 
Ausonia Farmaceutici SRL* 2 99= 
Banker, G. S. 2 99= 
Chinoin Gyogyszer 2 99= 
Laboratoires Clin-Midy SA 2 99= 
Eisai Company Limited* 
. 
2 99= 
Fisher Scientific Company 2 99= 
Forest Laboratories Inc. 2 99= 
Grelan Pharmaceutical Company Limited* 2 99= 
ISF Italseber SpA 2 99= 
Lab. Farmaceutico Quimico Lafarquim SA 2 99= 
Lepetit SpA 2 99= 
Liofilizaciones Esterilizaciones y Sintesis S. A. * 2 99= 
Instituto Luso-Farmaco SarL 2 99= 
McDonnell Douglas Corp. 2 99= 
Mitsubishi Petroleum Company 2 99= 
Ohta Seiyaku KK 2 99= 
Ono Pharmaceuticals KK 2 99= 
Procter & Gamble Company 2 99= 
Purdue Research Foundation 2 99= 
Regents of the University of California 2 99: 
Research Corporation 2 99= 
Scherico Limited 2 99= 
Schering AG* 2 99= 
Sigma-Tau SpA 2 99= 
Toray Industries Inc. 2 99= 
Etablissements Viridis 2 99= 
Yamada, S. 2 99 
Akzo NV 1 128= 
Amstar Corporation 1 128= 
Ansberg, S. B. 1 128= 
Antibiotics Research Institute 1 128= 
Agence Nationale de Valorisation 1 128= 
Baylor College of Medicine 1 128= 
Bocher, D. 1 128= 
C. H. Boehringer Sohn GmbH 1 128= 
Charm, S. E. 1 128= 
Societe Chimie et Biologie* 1 1280 
Cia. Internationale Farmacia Landerlan SA 1 128= 
Craf Sud SpA 1 128= 
Crast, L. B. 1 128= 
Pereira da Luz, A. 1 128= 
Dynamit Nobel AG 1 128= 
Eiken Kagaku KK 1 128= 
Ethicon Inc. 1 128= 
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Instytut Przemyslu Farmaceutyczneco 1 128= 
Instituto de Farmacologia Espanola SA 1 128= 
Gregor, H. P. 1 128- 
Higashikawa, T. 1 128= 
ICI Limited 1 128= 
Institute de Recherches Scientifique 1 128= 
Intellectual Property Development Corporation 1 128= 
Ito, S. 1 128= 
Jackson, B. G. 1 128= 
Keck, J. M. 1 128= 
Key Pharmaceuticals Incorporated* 1 128= 
Kommanditbolaget Kockums Chemical AB 1 128= 
KRKA-Farmacevtica 1 128= 
Kureha Chemical Industries KK 1 128= 
Kyoto Ceramic Company Limited* 1 128_ 
Lark SpA 1 128= 
Levine B. B. * 1 128= 
Laboratorios Ferrer & Cia SA 1 128= 
Albert Rolland SA* 1 128= 
Lumac International NV 1 128= 
Marx, R. 1 128= 
Masuda, G. " 1 128= 
Maclaren, S. A. 1 128= 
Metcalf, B. W. 1 128= 
Miles Laboratories Inc. 1 128= 
Miyauchi Y. * 1 128= 
Mundipharma AG 1 128= 
Naito, T. 1 128= 
Nippi Inc. 1 128= 
Nisshin Flour Milling Company Limited 1 128= 
Nikko Chemical Industries KK 1 125= 
Nippon Shinyaku KK 1 128= 
National Patent Development Corp. 1 128= 
Ogura, H. 1 128= 
Organon NV 1 128= 
Panoz, D. E. * 1 128= 
Penicillin Assays Incorporated* 1 128= 
Peters, H. V. * 1 128= 
Petrzilka, T. 1 128: 
Pharmacia AB 1 128= 
Pharmaco Inc. 1 128= 
Plantex Limited* 1 128= 
Priorov Traumatolog 1 128= 
Prugnaud, R. L. 1 128= 
Purdue University 1 128= 
Purdue Frederick Company 1 128= 
Romano, A. * 1 128= 
Sanraku-Ocean KK 1 128: 
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Sawai Seiyaku KK* 1 128= 
Scheicher, H. 1 128= 
Zaidan Hojin Seikan-Kai 1 128= 
Sendai Institute of Heterocyclic Chemistry* 1 128= 
Showa Denko KK* 1 128= 
Societe Omnium-Chimique SA 1 128= 
Seoul Pharmaceutical Industries KK 1 128_ 
Sparamedica AG 1 128= 
Stada Arzneimittel GmbH 1 128= 
Stapley, E. 0. 1 128= 
Takino, H. 1 128= 
Tokyo Tanabe KK 1 128= 
Teikoku Hormone Manufacturing Company 1 128= 
Laboratoires Thekan SA 1 128= 
Toho Pharmaceutical Laboratories Company 1 128= 
Toko Yakuhin Kogyo KK 1 128= 
Treuner, V. D. 1 128= 
Union Carbide Corporation 1 128: 
Unilever BV 1 128= 
NASA 1 128= 
Verronmay Limited* 1 128= 
Wakamoto Pharmaceutical Company 1 128= 
Wellcome Foundation Limited 1 128= 
Yoshitomi Pharmaceutical Industries KK 1 128= 
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Bayer AG 10,330 1 
Asahi Chemical Industries KK 8,910 2 
E. I. du Pont de Nemours & Company 8,836 3 
Ciba-Geigy Limited 8,492 4 
Sumitomo Chemical Company 8,157 5 
ICI Limited 8,154 6 
Teijin KK 7,888 7 
Toray Industries 7,416 8 
Hoechst AG 7,109 9 
Toyobo KK 5,674 10 
Union Carbide Corporation 4,481 11 
American Cyanamid Company 3,819 12 
Merck & Company Inc. 3,401 13 
Takeda Chemical Industries 3,355 14 
Sandoz Limited 3,332 15 
Mitsubishi Chemical Industries KK 2,988 16 
Upjohn Company 2,892 17 
F. Hoffmann-La Roche Company Limited 2,627 18 
Kanebo Pharmaceuticals Limited 2,625 19 
Sankyo Company Limited 2,367 20 
E. R. Squibb & Sons Inc. 2,303 21 
Rhone-Poulenc SA 2,292 22 
Ajinomoto KK 2,089 23 
American Home Products Corporation 1,991 24 
Tanabe Pharmaceutical Industries KK 1,951 25 
Kyowa Hakko Kogyo KK 1,894 26 
Dyanamit Nobel AG 1,836 27 
Shionogi Limited 1,7511 28 
Fujisawa Pharmaceutical Industries KK 1,738 29 
Unilever BV 1,709 30 
Rousell-Uclaf SA 1.676 31 
Procter & Gamble Company 1,602 32 
Kureha Chemical Industries KK 1,598 33 
Pfizer Inc. 1,485 34 
National Research & Development Corporation 1,482 35 
Eli Lilly & Company 1,472 36 
Syntex Corporation 1,275 37 
Yoshitomi Pharmaceutical Industries KK 1,272 38 
NASA 1,268 39 
Dow Chemical Company 1,249 40 
Smith, Kline & French Laboratories Inc. 1,136 41 
Nippon Kagaku KK 1,134 42 
Agence Nationale de Valorisation 1,122 43 
Dainippon Pharmaceuticals KK 888 44 
Abbott Laboratories Inc. 883 45 
Akzo NV 872 46 
Warner-Lambert Company 832 47 
Beecham Group Limited 829 48 
Yamanouchi Pharmaceutical Company 823 49 
Bristol Myers Company 810 50 
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Mitsubishi Petroleum Company Limited 790 51 
Boehringer Mannheim GmbH 783 52 
C. H. Boehringer Sohn GmbH 710 53 
E. Merck AG 697 54 
Aries Associates SA 675 55 
Nisshin Flour Milling Company Limited 639 56 
Meiji Seika KK 636 57 
Hodogaya Chemical Industries KK 630 58 
Sagami Chemical Research Centre 628 59 
Parke Davis & Company 603 60 
Snam-Progetti SpA 595 61 
Wellcome Foundation Limited 556 62 
Miles Laboratories Inc. 541 63 
Toyama Chemical Industries KK 530 64 
Otsuka Pharmaceuticals KK 485 65 
McDonnell Douglas Corporation 421 66 
Glaxo Group Limited 391 67 
Chugai Pharmaceuticals KK 388 68 
Richardson-Merrell Inc. 364 69 
Chinoin Gyogyszer 359 70 
Zaidan Hojin Seikan-kai 345 71 
Ono Pharmaceuticals KK 343 72 
Färmitalia SpA 340 73 
Teikoku Hormone Manufacturing Company 329 74 
Nippon Shinyaku KK 304 75 
Lepetit SpA 300 76 
Research Corporation 298 77 
Massachusetts Institute of Technology 263 78 
Astra Pharmaceticals AB 248 79 
Banyu Pharmaceuticals Company Limited 247 80 
Scherico Limited 238 81 
Organon NV 219 82 
Toyo Jozo KK 210 83 
Leo Pharmaceutical Products AB 188 84 
Gist-Brocades NV 186 85 
Ethicon Inc. 181 86 
Nippon Chemifar Company Limited 177 87 
Regents of the University of California 175 88 
Nikken Chemicals Company Limited 147 89 
Pharmacia AB 139 90 
Yeda Research & Development 133 91 
Alza Corporation 120 92 
Chemische Fabriken von Heyden GmbH 117 93 
Novo Industries A/S 116 94 
National Patent Development Corporation 108 95 
Purdue Research Foundation 105 96 
Carlo Erba SpA 104 97 
Societe Omnium-Chimique SA 91 98 
Mundipharma AG 83 99 
Laboratoires Clin-Midy SA 81 100 
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Teikoku Chemical Industries 79 101 
Wakamoto Pharmaceutical Company 78 102 
Sparamedica AG 71 103 
Recherches et Industries Therapeutique SA 70 104= 
Chemie Grunenthal GmbH 
- 
70 104= 
Kommandibolaget Kockums Chemical AB 68 106 
Antibiotics Research Institute 67 107 
Osaka University 66 108 
Bristol-Banyu KK 61 109 
Tokyo Tanabe KK 52 110 
Institute de Recherches Scientifique 51 111 
Laboratoires Merrell-Toraude SA 50 112 
Eiken Kagaku KK 48 113 
Nelson Research & Development Company 45 114 
Zaidan Hojin Sangyo Kagaku KK 44 115 
Sigma-Tau SpA 40 116 
Pierrel SpA 36 117 
Sutures Inc. 33 118 
Sanraku-Ocean KK 30 119 
A. Gallardo SA 28 120= 
Gema SA 28 120= 
R&L Molecular Research 28 120= 
NIkko Chemical Industries KK 27 123 
Alfa Farmaceutici SpA 24 124 
Ohta Seiyaku KK 20 125 
Toshin Chemical Industries KK 19 126 
Caw Industries Inc. 18 127= 
Ist. Biochim. Ital. di Loredana Lorenzini 18 127= 
Kisses Pharmaceutical Company Limited 18 127= 
Labostorios Ferrer & Cia SA 18 127= 
Instituto Luso-Farmaco SARL 18 127= 
ISF Italseber SpA 17 132= 
Nippi Inc. 17 132= 
Queens University 15 134 
Tobishi Pharmaceutical Company 13 135= 
Woodward, R. B., Prof. 13 135= 
Purdue Frederick Company 12 137 
Fisher Scientific Company 11 138= 
Intellectual Property Development Corp. 11 138= 
Baylor College of Medicine 10 140_ 
Connlab Holdings Limited 10 140 
Proter SpA 10 140= 
Lark SpA 9 143 
Cia. International Farmacia Landerlan SA 8 144= 
Instytut Przemyslu Faramaceutyczneco 8 144= 
Toko Yakuhin Kogypo KK 8 144= 
Amstar Corporation 7 147= 
Fermion Oy 7 147= 
Politechica Gdanska 7 147= 
Priorov Traumatolog 7 147= 
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Forest Laboratories Inc. 6 151= 
Pharmaco Inc. 6 151= 
Laboratorios Cusi SA 5 153= 
Lab. Farmacutico Quimico Lafarquim SA 5 153= 
Dobfar SpA 4 155= 
Etablissements Viridis 4 155= 
Antibioticos SA 3 157= 
Biochemie GmbH 3 157= 
Instituto de Farmacologica Espanola SA 3 157= 
Craf-Sud SpA 2 160= 
KRKA-Frmacevtica 2 160= 
Lumac International NV 2 160= 
Seoul Pharmaceutical Industries KK 2 160= 
Toho Pharmaceuticals Laboratories Company 2 1604 
Purdue University 1 165= 
Stada Arzneimittel GmbH 1 165= 
Laboratoires Thekan SA 1 165- 
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Merck & Company Inc. 1,648 1 
Takeda Chemical Industries 1,422 2 
Sandoz Limted 1,397 3 
Ciba-Geigy Limited 1,382 4 
F. Hoffmann-La Roche Company Ltd. 1,378 5 
Upjohn Company 1,257 6 
American Home Products Corporation 1,242 7 
Sumitomo Chemical Company 1,217 8 
Tanabe Pharmaceutical Company 1,192 9 
E. R. Squibb & Sons Inc. 966 10 
Hoechst AG 924 11 
Eli Lilly & Company 921 12 
Fujisawa Pharmaceutical Industries KK 896 13 
Ajinomoto KK 860 14 
Kyowa Hakko Kogyo KK 848 15 
American Cyanamid Comapny 809 16 
Sankyo Company Limited 785 17 
Yoshitomi Pharmaceutical Industries KK 775 18 
Bayer AG 771 19 
Pfizer Inc. 754 20 
Shionogi Limited 682 21 
Yamanouchi Pharmaceutical Company 630 22 
Smith, Kline & French Laboratories Inc. 621 23 
Roussell-Uclaf SA 552 240 
Teijin KK 552 24= 
Beecham Group Limited 520 26 
Syntex Corp. 502 27. 
Ashahi Chemical Industries KK 498 28 
Warner-Lambert Company 494 29 
Boehringer Mannheim GmbH 470 30 
Bristol Myers Company 453 31 
Abbott Laboratories Inc. 446 32 
ICI Limited 440 33 
Mitsubishi Chemical Industries KK 434 34 
Aries Associates SA 387 35 
C. H. Boehringer Sohn GmbH 341 36 
Dainippon"Pharmaceuticals KK 335 37 
Meiji Seika KK 328 38 
Otsuka Pharmaceuticals KK 312 39 
Ono Pharmaceuticals KK 295 40 
E. Merck AG 282 41 
Kanebo Pharmaceuticals Limited 275 42 
Chugai Pharmacueticals KK 273 43 
Sagami Chemical Research Centre 271 44 
Rhone-Poulenc SA 267 45 
Toyama Chemical Industries KK 261 46 
Wellcome Foundation Limited 254 47 
Richardson-Merrell Inc. 252 48 
E. I. du Pont de Nemours & Company 240 49 
Parke Davis & Company 235 50 
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Glaxo Group Limited 233 51 
Chinoin Gyogyszer 220 52 
Toyobo KK 211 53 
Miles Laboratores Inc. 210 54= 
Nippon Shinyaku KK 210 54= 
Banyu Pharmaceutical Company Limited 202 56 
Agence Nationale de Valorisation 191 57 
Teikoku Hormone Manufacturing Company 190 58 
Farmitalia SpA 174 59= 
Kureha Chemical Industries KK 174 59= 
Nippon Chemifar Company Limited 166 61 
Lepetit SpA 165 62 
Toyo Jozo KK 162 63 
Procter & Gamble Company 160 64 
Research Corporation 157 65 
Nippoon Kagaku KK 150 66 
Scherico Limited 129 67 
Astra Pharmaceutica AB 126 68 
Nisshin Flour Milling Company Limited 116 69 
Akzo NV 107 70 
Alza Corporation 105 71= 
Gist-Brocades BV 105 71= 
Leo Pharmceutical Products AB 95 73 
Dynamit Nobel AG 88 74 
Chemische Fabriken von Heyden GmbH 85 75 
National Research & Development Corporation 81 76 
Toray Industries Inc. 80 77 
Unilever BV 79 78 
Carlo Erba SpA 73 79. 
Societe Omnium-Chimique SA 70 80 
Pharmacia AB 69 81 
Sparamedica AG 62 82 
Organon NV 60 83 
Nikken Chemicals Company Limited 59 84= 
Union Carbide Corporation 59 84= 
Wakamoto Pharmaceuticals Company 58 86 
Yeda Research & Development 52 87 
Chemie Grunenthal GmbH 51 88 
Antibiotics Research Institute 49 89= 
Mundipharma AG 49 89= 
Regents of the University of California 49 89 
Snam-Progetti SpA 49 89= 
Mitsubishi Petroleum Company Limited 48 93= 
Teikoku Chemical Industries 48 93= 
Tokyo Tanabe KK 44 95 
Novo Industries AS 43 96 
Massachusetts Institute of Technology 42 97= 
Nelson Research & Development Company 42 97= 
Laboratoires Merrell-Toraude SA 39 99= 
Zaidan Hojin Sangyo Kagaku KK 39 99= 
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Recherches et Industries Therapeutiques SA 38 101 
Dow Chemical Company 37 102= 
Eiken Kagaku KK 37 102: 
Bristol-Banyu KK 35 104= 
Laboratoires Clin-Midy SA 35 104= 
National Patent Development Corp. 32 106= 
Zaidan Hojin Sangyo Kagaku KK 32 106= 
Sigma-Tau SpA 30 108 
Osaka University 29 109= 
Hodogaya Chemical Industries KK 24 110= 
Sanraku-Ocean KK 24 110= 
Purdue Research Foundation 23 112= 
R&L Molecular Research 23 112= 
NASA 22 114 
Institute de Recherches Scientifique 21 115 
Alfa Farmaceutici SpA 20 116= 
Pierrel SpA 20 116: 
A. Gallardo SA 18 118= 
Laboratorios Ferrer & Cia. SA 18 118= 
Instituto Luso-Farmaco SARL 18 118= 
Ohta Seiyaku KK 18 118= 
Ist. Biochim. Ital. di Loredana Lorenzini SAS 17 122= 
ISF Italseber SpA 17 122: 
McDonnell Douglas Corporation 17 122= 
Kissei Pharmaceutical Company Limited 16 125 
Ethicon Inc. 13 126= 
Woodward, R. B., Prof. 13 126: 
Tobishi Pharmaceutical Company 12 128 
Intellectual Property Development Corporation 11 129 
Connlab Holdings Limited 10 130: 
Proter SpA 10 130: 
Purdue Frederick Company 10 130= 
Lark SpA 9 133= 
Queens University 9 133: 
Toshin Chemical Industries KK 9 133= 
Cia. International Farmacia Landerlan SA 8 136= 
Instytut Przemyslu Farmaceutyczneco 8 136= 
Nippi Inc. 8 136= 
Toko Yakuhin Kogyo KK 8 136: 
Fermion Oy 7 140= 
Sutures Inc. 7 140= 
Fisher Scientific Company 6 142 
Caw Industries Inc. 5 143: 
Laboratorios Cusi SA 5 143: 
Forest Laboratories Inc. 5 143= 
Gema SA 5 143= 
Nikko Chemical Industries 5 143: 
Pharmaco Inc. 5 143= 
Dobfar SpA 4 149: 
Politechnica Gdanska 4 149= 
Table 18: Patentees (excluding private inventors) Ranked by 
Total Number of Patents in CPI Section B pre-1980 (continued) 
- 
173 
- 
NUMBER 
PATENTEE NAME OF RANK 
PATENTS 
Lab. Farmaceutico Quimico Lafarqium SA 4 149= 
Etablissements Viridis 4 149 
Antibioticos SA 3 153= 
Biochemie GmbH 3 153= 
Instituto de Farmacologia Espanola SA 3 153= 
Craf Sud SpA 2 156= 
KRKA-Farmacevtica 2 156= 
Seoul Pharmaceutical Industries KK 2 156= 
Toho Pharmaceutical Laboratories Company 2 156= 
Amstar Corporation 1 160= 
Baylor College of Medicine 1 160= 
Kommanditbolaget Kockums Chemical AB 1 160= 
Lumac International NV 1 160= 
Priorov Traumatolog 1 160= 
Purdue University 1 160= 
Stada Arzneimittel GmbH 1 160= 
Laboratoires Thekan SA 1 160= 
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Antibioticos SA 100.00 1= 
Biochemie GmbH 100.00 1= 
Cia. Internationale Farmacia Landerlan SA 100.00 1= 
Connlab Holdings Limited 100.00 1= 
Craf Sud SpA 100.00 1= 
Laboratorios Cusi SA 100.00 1= 
Dobfar SpA 100.00 1= 
Instytut Przemyslu Farmaceutyczneco 100.00 1= 
Instituto de Farmacologia Espanola SA 100.00 1= 
Fermion Oy 100.00 1= 
Intellectual Property Development Corporation 100.00 1. 
ISF Italseber SpA 100.00 1= 
KRKA-Farmacevtica 100.00 1= 
Lark SpA 100.00 1; 
Laboratorios Ferrer SA 100.00 1= 
Instituto Luso-Farmaco SARL 100.00 1_ 
Proter SpA 100.00 1= 
Purdue University 100.00 1= 
Seoul Pharmaceutical Industries KK 100.00 1= 
Stada Arzneimittel GmbH 100.00 1= 
Laboratoircs Thekan SA 100.00 1= 
Toho Pharmaceutical Laboratories Company 100.00 1: 
Toko Yakuhin Kogyo KK 100.00 1= 
Etablissements Viridis 100.00 1: 
Woodward, R. B., Prof. 100.00 1= 
Ist. Biochim. Ital di Loredana Lorenzini SAS 94.44 26 
Nippon Chemifar Company Limited 93.79 27 
Nelson Research & Development Company 93.33 28 
Tobishi Pharmaceutical Company 92.31 29 
Ohta Seiyaku KK 90.00 30 
Kissel Pharmaceutical Company Limited 88.89 31 
Alza Corporatipon 87.50 32 
Sparamedica AG 87.32 33 
Ono Pharmaceuticals KK 86.01 34 
Tokyo Tanabe KK 84.62 35 
Alfa Farmaceutici SpA 83.33 36= 
Forest Laboratories Inc. 83.33 36= 
Pharmaco Inc. 83.33 36_ 
Purdue Frederick Company 83.33 36= 
R&L Molecular Research 82.14 40 
Banyu Pharmaceutical Company Limited 81.78 41 
Lab. Farmaceutico Quimico Lafarquim SA 80.00 42= 
Sanraku-Ocean KK 80.00 42= 
Laboratoires Merrell-Toraude SA 78.00 44 
Toyo Jozo KK 77.14 45 
Eiken Kagaku KK 77.08 46 
Societe Omnium-Chimique SA 76.92 47 
Yamanouchi Pharmaceutical Company 76.55 48 
Sigma-Tau SpA 75.00 49 
Wakamoto Pharmaceutical Company 74.36 50 
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Antibiotics Research Institute 73.13 51 
Chemie Grunenthal GmbH 72.86 52 
Zaidan Hojin Sangyo Kagaku KK 72.73 53 
Chemische Fabriken von Heyden GmbH 72.65 54 
Chugai Pharmaceuticals KK 70.36 55 
Carlo Erba SpA 70.19 56 
Richardson-Merrell Inc. 69.23 57 
Nippon Shinyaku KK 69.08 58 
Otsuka Pharmaceutical KK 64.33 59 
A. Gallardo SA 64.29 60 
Beecham Group Limited 62 73 61 
Eli Lilly & Company 62.57 62 
American Home Products Corporation 62.38 63 
Chinoin Gyogyzer 61.28 64 
Tanabe Pharmaceutical Company 61.10 65 
Yoshitomi Pharmaceutical Industries KK 60.93 66 
Teikoku Chemical Industries 60.76 67 
Boehringer Mannheim GmbH 60.03 68 
Queens university 60.00 69 
Glaxo Group Limited 59.59 70 
Warner-Lambert Company 59.37 71 
Mundipharma AG 58.33 72 
Teikoku Hormone Manufacturing Company 57.75 73 
Bristo-Banyu KK 57.38 74 
Aries Associates SA 57.33 75 
Politechnica Gdanska 57.14 76 
Gist-Brocades NV 56.45 77 
Bristol Myers Company 55.93 78 
Pierrel SpA 55.56 79 
Lepetit SpA 55.00 80 
Smith, Kline & French Laboratories Inc. 54.67 81 
Fisher Scientific Company 54.55 82 
83cherches et Industries Therapeutique SA 54 29 83 
Scherico Limited 54.20 84 
Research Corporation 52.68 85 
F. Hoffmann-La Roche Limited 52.46 86 
Meiji Seika KK 51.57 87 
Fujisawa Pharmaceutical Industries KK 51.55 88 
Farmitalia SpA 51.18 89 
Astra Pharmaceutical AB 50.81 90 
Pfizer Inc. 50.77 91 
Leo Pharmaceutical Products AB 50.53 92 
Abbott Laboratories Inc. 50.51 93 
Lumac International NV 50.00 94 
Pharmacia AB 49.64 ' 95 
Toyama Chemical Industreis KK 49.25 96 
Merck & Company Inc. 48.46 97 
C. H. Boehringer Sohn GmbH 48.03 98 
Toshin Chemical Industries KK 47.37 99 
Nippi Inc. 47.06 100 
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Wellcome Foundation Limited 45.68 101 
Kyowa Hakko Kogyo KK 44.77 102 
Osaka University 43.94 103 
Upjohn Company 43.46 104 
Laboratoires Clin-Midy SA 43.21 105 
Sagami Chemical Research Centre 43.15 106 
Takeda Chemical Industries 42.38 107 
E. R. Squibb & Sons Inc. 41.95 108 
Sandoz Limited 41.93 109 
Institute de Recherche Scientifiques 41.18 110 
Ajinomoto KK 41.17 111 
E. Merck AG 40.46 112 
Nikken Chemicals Company Limited 40.14 113 
Syntex Corporation 39.37 114 
Yeda Research & Development 39.10 115 
Shionogi Limited 38.88 116 
Miles Laboratories Inc,. 38.82 117 
Parke Davis & Company 38.79 118 
Dainippon Pharmaceuticals KK 37.73 119 
Novo Industries A/S 37.07 120 
Sankyo Company Limited 33.16 121 
Roussel-Uclaf SA 32.94 122 
National Patent Development Corporation 29.63 123 
Regents of the University of California 28.00 124 
Caw Industries Inc. 27.78 125 
Organon NV 27.40 126 
Purdue Research Foundation 21.90 127 
Sutures Inc. 21.21 128 
American Cyanamid Company 21.18 129 
Nikkon Chemical Industries KK 18.52 130 
Nisshin Flour Milling Company Limited 18.15 131 
Gema SA 17.86 132 
Agence Nationale de Valorisation 17.02 133 
Ciba-Geigy Limited 16.27 134 
Massachusetts Institute of Technology 15.97 135 
Sumitomo Chemical Company 14.92 136 
Mitsubishi Chemical Industries KK 14.52' 137 
Amstar Corporation 14.29 138= 
Priorov Traumatolog 14.29 138= 
Nippoon Kagaku KK 13.23 140 
Hoechst AG 13.00 141 
Akzo NV 12.27 142 
Rhone-Poulenc SA 11.65 143 
Zaidan Hojin Seikan-Kai 11.30 144 
Kureha Chemical Industries KK 10.89 145 
Kanebo Pharmaceuticals Limited 10.48 146 
Baylor College of Medicine 10.00 147 
Procter & Gamble Cpmpany 9.99 148 
Snatn-Progetti SpA 8.24 149 
Bayer AG 7.46 150 
Table 19: Patentees (excluding private inventors) Ranked by 
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Ethicon Inc. 7.18 151 
Teijin KK 7.00 152 
Mitsubishi Petroleum Company Limited 6.08 153 
Asahi Chemical Industries KK 5.59 154 
National Research & Development Corporation 5.47 155 
ICI Limited 5.40 156 
Dynamit Nobel AG 4.79 157 
Unilever BV 4.62 158 
McDonnell Douglas Corporation 4.04 159 
Hodogaya Chemical Industries KK 3.81 160 
Toyobo KK 3.72 161 
Dow Chemical Comapny 2.96 162 
E. I. du Pont de Nemours & Company 2.72 163 
NASA 1.74 164 
Kommanditbolaget Kockums Chemical AB 1.47 165 
Union Carbide Corporation 1.32 166 
Toray Industries Inc. 1.08 167 
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Amstar Corporation 100.00 1_ 
Baylor College of Medicine 100.00 1= 
Politechnica Gdanska 100.00 1= 
Gema SA 100.00 1= 
Kommanditbolaget Kockums Chemical AB 100.00 1= 
Lumac International NV 100.00 1= 
Priorov Traumatolog 100.00 1= 
Purdue University 100.00 1= 
Stada Arzneimittel GmbH 100.00 1= 
Laboratoires Thekan SA 100.00 1= 
Woodward, R. B., Prof. 100.00 1_ 
Zaidan Hojin Sangyo Kagaku KK 78.13 12 
Dobfar SpA 75.00 13 
Antibioticos SA 66.67 14 
Caw Industries Inc 60.00 15= 
Laboratorios Cusi SA 60.00 15= 
Queens University 55.56 17 
Glaxo Group Limited 50.21 18 
Craf Sud SpA 50.00 19= 
KRKA-Farmacevtica 50.00 19= 
Lab. Farmaceutico Quimico Lafarquim SA 50.00 19= 
Seoul Pharmaceutical Industries KK 50.00 19_ 
Toho Pharmaceutical Laboratories Company 50.00 19= 
Etablissements Viridis 50.00 19= 
Toshin Chemical Industries KK 44.44 25 
Laboratoires Merrell-Toraude SA 43.59 26 
Fermion Oy 42.86 27= 
Sutures Inc. 42.86 27= 
Proter SpA 40.00 29 
Chemische Fabriken von Heyden GmbH 35.29 30 
Biochemie GmbH 33.33 31: 
Instituto de Farmacologia Espanola SA 33.33 31= 
Fisher Scientific Company 33.33 31= 
Hodogaya Chemical Industries KK 33.33 31= 
Yeda Research & Development 32.69 35 
Fujisawa Pharmaceutical Industries KK 32.25 36 
R&L Molecular Research 30.43 37 
Connlab Holdings Limited 30.00 38 
Eli Lilly & Company 27.80 39 
Alfa Farmaceutici SpA 25.00 40= 
Kissei Pharmaceutical Company Limited 25.00 40= 
Bristol Myers Company 22.30 42 
National Research & Development Corporation 20.99 43 
Forest Laboratories Inc. 20.00 44= 
Gist-Brocades NV 20.00 44= 
Nikko Chemical Industries KK 20.00 44= 
Pharmaco Inc. 20.00 411= 
Novo Industries A/S 18.60 48 
Ist. Biochim. Ital. di Lorendana Lorenzini SAS 17.65 49 
Toyama Chemical Industries KK 17.62 50 
Table 20: Patentees (excluding private inventors) Ranked by 
Percentage of Total CPI Section B Patents which are for 
Cephalosporins 
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PATENTEE NAME % RANK 
Toyo Jozo KK 17.28 51 
Osaka University 17.24 52 
Bristol-Banyu KK 17.14 53 
A. Gallardo SA 16.67 54= 
Tobishi Pharmaceutical Company 16.67 54= 
Recherchee et Industries Therapeutiques SA 15.79 56 
Pierrel SpA 15.00 57 
Massachusetts Institute of Technology 14.29 58 
Meiji Seika KK 14.02 59 
Smith, Kline & French Laboratories Inc. 13.85 60 
E. R. Squibb & Sons Inc. 13.56 61 
Cia Internationale Farmacia Landerlan SA 12.50 62= 
Instytut Przemyslu Farmaceutyczneco 12.50 62- 
Nippi Inc. 12.50 62= 
Toko Yakuhin Kogyo KK 12.50 62_ 
Banyu Pharmaceutical Company Limited 12.38 66 
ISF Italseber SpA 11.76 67= 
McDonnell Douglas Corporation 11.76 67= 
Leo Pharmaceutical Products AB 11.58 69 
Yamanouchi Pharmaceutical Company 11.27 70 
Beecham Group Limited 11.15 71 
Lark SpA 11.11 72= 
Instituto Luso-Farmaco SARL 11.11 72= 
Takeda Chemical Industries 10.06 74 
Purdue Frederick Company 10.00 75 
Intellectual Property Development Corporation 9.09 76 
Purdue Research Foundation 8.70 77 
Nippon Kagaku KK 8.67 78 
Sankyo Company Limited 8.66 79 
Nikken Chemicals Company Limited 8.47 80 
Teikoku Chemical Industries 8.33 81 
Carlo Erba SpA 8.22 82 
Dow Chemical Company 8.11 83 
Farmitalia SpA 8.05 84 
Aries Associates SA 8.01 85 
Chemie Grunenthal GmbH 7.84 86 
Asahi Chemical Industries KK 7.83 87 
Ethicon Inc. 7.69 88 
Teijin KK 7.61 89 
Toyobo KK 7.58 90 
Ciba-Geigy Limited 7.53 91 
Astra Pharmaceutica AB 7.14 92_ 
Nelson Research & Development Company 7.14 92= 
Snam-Progetti SpA 6.12 94 
Shionogi Limited 6.01 95 
Laboratoires Clin-Midy SA 5.71 96 
Merck & Company Inc. 5.611 97 
Laboratorios Ferrer & Cia SA 5.56 98= 
Ohta Seiyaku KK 5.56 98= 
Kanebo Pharmaceutical Limited 5.45 100 
Table 20: Patentees (excluding private inventors) Ranked by 
Percentage of Total CPI Section B Patents which are for 
Cephalosporins, continued 
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PATENTEE NAME % RANK 
Rhone-Poulenc SA 5.24 101 
Institute de Recherches Scientifique 4.76 102 
NASA 4.55 103 
E. Merck AG 4.26 104 
Mitsubishi Petroleum Company Limited 4.17 105= 
Sanraku-Ocean LKK 4.17 105= 
Regents of the University of California 4.08 107 
Bayer AG 3.89 108 
American Home Products Corporation 3.62 109 
Parke Davis & Company 3.40 110 
Sigma-Tau SpA 3.33 111 
Hoechst AG 3.25 112 
National Patent Development Corp. 3.13 113 
Pfizer Inc. 2.79 114 
Richardson-Merrell Inc. 2.78 115 
Eiken Kagaku KK 2.70 116 
Zaidan Hojin Seikan-Kai 2.56 117 
Toray Industries Inc, 2.50 118 
Dainippon Pharmaceuticals KK 2.39 119 
Sumitomo Chemical Company 2.30 120 
Tokyo Tanabe KK 2.27 121 
Antibiotics Research Institute 2.04 122_ 
Mundipharma AG 2.04 122= 
Nippon Chemifar Company Limited 1.81 124 
Wakamoto Pharmaceutical Company 1.72 125 
Union Carbide Corp. 1.69 126 
E. I. du Pont de Nemours & Company 1.67 127= 
Organon NV 1.67 127= 
Sparamedica AG 1.61 129 
Chugai Pharmaceuticals KK 1.47 130 
Pharmacia AB 1.45 131 
Societe Omnium-Chimique SA 1.43 132 
Research Corporation 1.27 133= 
Unilever NV 1.27 133= 
Procter & Gamble Company 1.25 135 
American Cyanamid Company 1.24 136 
Lepetit SpA 1.21 137 
Syntex Corporation 1.20 138 
Dynamit Nobel AG 1.14 139 
Alza Corporation 0.95 140 
F. Hoffmann-La Roche Company Limited 0.94 141= 
Kyowa Hakko Kogyo KK 0.94 141= 
Akzo NV 0.93 143 
Nisshin Flour Milling Company Limited 0.86 144 
Scherico Limited 0.78 145 
Sagami Chemical Research Centre 0.74 146 
Ajinomoto KK 0.70 147 
Mitusbishi Chemical Industries KK 0.69 148 
Ono Pharmaceuticals 0.68 149 
Kureha Chemical Industries KK 0.57 150 
Table 20: Patentees (excluding private inventors) Ranked by 
Percentage of Total CPI Section B Patents which are for 
Cephalosporins, continued 
- 
181 
- 
PATENTEE NAME % RANK 
Teikoku Hormone Manufacturing Company 0.53 151 
Agence Nationale de Valorisation 0.52 152 
Miles Laboratories Inc. 0.48 153= 
Nippon Shinyaku KK 0.48 153= 
Abbott Laboratories Inc. 0.45 155= 
Chinoin Gyogyszer 0.45 155= 
Boehringer Mannheim GmbH 0.43 157 
Wellcome Foundation Limited 0.39 153 
Otsuka Pharmaceuticals KK 0.32 159 
C. H. Boehringer Sohn GmbH 0.29 160 
Tanabe Pharmaceutical Company 0.25 161 
ICI Limited 0.23 162 
Warner-Lambert Company 0.20 163 
Upjohn Company 0.16 164 
Sandoz Limited 0.14 165 
Yoshitomi Pharmaceutical Industries KK 0.13 166 
(excluding private inventors) Ranked 
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RETRIEVAL OF ADDITIONAL DATA SETS 
For the further studies, described below, an additional nine sets of 
patents data for different technologies were retrieved from the WPI 
online database. In each case, the retrieved citations were printed 
offline sorted by (a) patentee, and (b) priority. These additional 
data sets, and the strategies used to retreive them, are described in 
Appendices II to X. Table 22 gives details of all the data sets used 
in the subsequent studies. 
Total No. Total No. 
Data Set Patents Patentees 
Cephalosporins 
- 
original data set 2599 192 
Cephalosporins 
- 
updated data set 2944 216 
Air cushion vehicles 160 233 
Cyclopropane derivative insecticides 1106 168 
Videodiscs 548 162 
Genetic engineering 1308 665 
Pressure sensitive adhesives 1126 427 
Production of terephthalic acid 722 159 
Pharmacologically active pyrazolones 243 130 
Olivanic acid 118 13 
Clavulanic acid 133 16 
Table 22: Patents Data Sets used in Bibliometric Studies 
BRADFORD-ZIPF LAW BIBLIOGRAPIIS 
Bradford's Law offers the possibility of estimating the number of 
sources and the number of items that one can expect to find for any 
bibliographic data set. This estimate is based only on knowledge of a 
small but sufficient number of the most productive sources. Unfortu- 
nately, Bradford formulated his "law of scatter" in two versions which 
Wilkinson155 has shown to be formally different although closely 
similar and concluded that, of the two Bradford formulations, the 
graphical one is in closer accord with existing data. Both formula- 
tions lend themselves to methods of estimating the size of a comprehen- 
sive bibliography if the subject and the range in time are first 
well-defined. 
In its original form Bradford's Law said nothing about comprehensive- 
ness. But a bibliography must be finite and the number of items 
produced by the least productive sources cannot be less than one. When 
this consideration is expressed in one of the two formulations of 
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Bradford's Law, a simple graphical technique for estimating the size of 
the complete bibliography can be devised149. It requires the drawing 
of the "bibliograph". 
The "bibliograph", Figure 15, is a plot of the cumulative number of 
articles (vertical axis) versus the logarithm of the cumulative number 
of journals in which the articles appear (horizontal axis). The plot 
has an S-shape with a central straight section following Bradford's 
log-linear law. The upward curving bottom of the curve represents the 
small nuclear zone of the most relevant journals. The upper end of the 
curve, usually termed the Groos Droop, represents the peripheral zone 
where relevant references are widely scattered amongst a great number 
of journals. 
In constructing the bibliograph, the most productive sources are first 
ranked in decreasing order of productivity. The cumulative sums, of 
items found are then plotted on a graph as shown in Figure 16. The 
most convenient graph paper for this purpose is semi-logarithmic; the 
linear scale is applied to the cumulative sums and the logarithmic 
scale is used to indicate the ranks of the sources. So, on the graph 
(Figure xx) point A indicates the number of items yielded by the most 
productive source, point B indicates the number of items yielded by the 
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OF JOURNALS 
teure 15: The Bibliograph 
two most productve sources together, etc., etc. The first few points 
are found to lie on a rising curve which, sooner or later, should run 
into a straight line. As soon as the straight line is definite enough, 
an estimate of the end point of the line can be made. 
R(N; 
R(p) 
E 
u 
ö 
R(n1 
6 
O 
Figure 16: Plotting and Interpreting the Bibliograph 
When the technique is applied to manually produced bibliographies the 
real and estimated end-points can differ appreciably. A common occu- 
rence is illustrated in Figure 17. Here, if the plotting of the graph 
is continued beyond the points required to determine the straight line, 
the plotted points may fail to maintain the linear climb and fall away 
in a droop to end at some point such as G. In such cases it is plaus- 
ible to argue that the bibliography is not complete in the sense in 
which the technique requires. For example, the bibliographer may quite 
reasonably state that he has been selective. He may say that he has 
noted only those references which are "of professional interest" or 
that he has omitted exact translations of some items 'in to other 
languages. According to Brookes 149, whenever a droop has been observed, 
it has always been possible to indicate either some selectivity or some 
omissions. 
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Figure 17: The "Droop": an indication of Incompleteness 
4 
It has been noted, however, that the point E as calculated slightly 
overestimates the total number of items, though not the total number of 
sources. This fault arises because, as the graph nears the end-point, 
the sources end with a number which provides three items, a larger 
number which provides two items and a still larger number of sources 
which provide only one item each. When the corresponding cumulative 
sums are plotted on a logarithmic scale they do not lie exactly on a 
straight line, but form a series of lengthening arcs which intersect on 
the straight line (Figure 18). The last one, however, is open at the 
end-point. When the complete data are carefully plotted, the graph 
ends in an open hook which ends just below the estimated end-point E. 
The "hook", however, is clearly distinguishable from the "droop": the 
hook is concave upwards whereas the drop is concave downwards. 
- 
192 
- 
1 log n ^i N 
R(N) 
R(N') 
E 
Y 
Ö 
E 
Y 
O 
7 
E 
U 
Figure 18: The Arcs near the end of the Bibliograph 
The straight line is extended to meet the axis of log n (at S in Figure 
18) and some convenient point P is marked on the straight line. Brooks 
showed149 that the total number of sources, N, expected to contribute 
to the bibliography is given by: 
- 
N_ R(p). OT 
3SM 
where R(p) is the number of items corresponding to the point P and 
where the lengths OT and SM are measured as accurately as possible in 
millimetres. 
Brookes does not explain in his paper that T is the point where N=20. 
Furthermore, the "3" in the denominator of the equation for calculating 
N should really be In 20 which is 2.9957. Thus, 
3T is simply a 
factor for the scale of the graph paper used in constructing the 
bibliograph, whilst BSM is a measure of the slope of the straight 
line portion. 
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Having calculated N, it is then possible to estimate the total number 
of items to be expected. It may be possible to mark the point N on the 
graph and so to mark the corresponding point E on the continuation of 
straight line SP. The required value of R(N) can then be read from the 
scale of R(n) on the left hand side. Alternatively, and more precisely, 
R(N) can be calculated from the formula: 
R(N) =N In (NIS) 
where S is the number corresponding to S on the log n scale. 
It is not possible to prove that E must be the end point of the line 
because there is no logical reason why a comprehensive bibliography 
should conform so precisely to a mathematical law. However, the 
technique has now been tested many times, especially against computer- 
produced bibliographies derived from retrospective searches of large 
databases and seems to be realistic. The advantage of using computer- 
produced bibliographs is that the items found must all conform to the 
search question as formulated for the computer search program. The 
relevance to the subject specified by the question is therefore uni- 
formly controlled and it does not matter (for the purpose of testing 
the technique) whether the search question is correctly formulated or 
not. 
Using the technique described above, bibliographs have been drawn for 
eight of the eleven patents data sets; these are shown in Figures 19 to 
26. Using these graphs, calculations for total numbers of patentees 
and patents, i. e., N and R(N), have been calculated and are given in 
Table 23. 
Vector Graph Analysis 
The Vector Analysis technique described in Chapter 7, as used by the 
Japanese Patent Office and OTAF, was considered to be a possible 
suitable method of technology assessment; therefore, such Vector 
Analysis Graphs were constructed for each of the patents data sets. 
Data for plotting the graphs was taken from the online print outs 
sorted by priority, except for the cephalosporins where the data was 
taken from the computer generated lists, supplemented by the updating 
data, as described in Appendix I. The Vector Analysis Graphs obtained 
are shown in Figures 27 to 37. 
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Figure 20: Bradford-Zipf Plot for Air Cushion Vehicles Patents 
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Figure 21: Bradford-Zipf Plot for Cyclopropane Derivative 
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Figure 25: Bradford-Zipf Plot for Pressure Sensitive 
Adhesive Patents 
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FREQUENCY DISTRIBUTIONS AND PATENTS DATA SETS 
None of the investigations of frequency distributions and scientific 
productivity identified in the literature of bibliometrics has been 
concerned with patents. It was thus considered appropriate to test 
sets of patents data in different technologies with various functions. 
The distributions chosen for investigation, and those which have been 
tested in bibliometric studies by Coile171 and Rao172 are shown in 
Table 24. 
Present 
Theoretical Frequency Distribution Coile Rao Study 
Lotka Yes No Yes 
Simon-Yule Yes No Yes 
Price's Pareto-type Yes No Yes 
Williams' Geometric Yes Yes Yes 
Fisher's Logarithmic Yes Yes Yes 
Shockley's Lognormal Yes Yes Yes 
Poisson Yes Yes No 
Singh-Maddala Yes No No 
Weibull Yes No No 
Borel-Tanner No Yes Yes 
Negative Binomial No Yes Yes 
Cumulative No Yes No 
Truncated Negative Binomial No Yes No 
Truncated Poisson No Yes No 
Zeta No Yes No 
Sinh Transformation No Yes No 
Table 24: Theoretical Frequency Distributions used by Coile136, Rao137 
and in the present study 
Of the frequency distributions tested against patents data, and which 
are listed in Table 24, the Simon-Yule function was selected following 
Coile's171 demonstration of its applicability whilst the Negative 
Binomial and Borel-Tanner were selected because of Rao's successes with 
them172. These, together with the other seven functions, and the 
method of determining the theoretical distributions, are described in 
Appendices XI to XVIII. 
"Goodness-of-fit" was ascertained by using the Kolmogorov-Smirnov 
one-sample test. This was used in preference to the X2 test and, as 
discussed by Coi1e171, is based on observed and theoretical cumulative 
distributions; the Kolmogorov-Smirnov test is distribution free, and 
its use requires data at least in an ordinal scale and assumes that the 
data are continuously distributed. Robertson253 has expressed the 
opinion that in testing for goodness-of-fit with frequency distribution 
- 
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functions the Kolmogorov-Srirnov test is more suitable than the X2 
test. The Kolmogorov-Smirnov test is discussed in Appendix XIX. 
An Eaca EG3003 (Video Genie) microcomputer was used to carry out the 
calculations for determining theoretical distributions and applying 
Kolmogorov-Smirnov tests. This machine uses BASIC programming language. 
The EG3003 has 16K of random access memory, and 3.5K of read only 
memory. The particular machine available was not equipped with a 
printer, but with only a video display unit; for this reason the 
programs written for this study, and those adapted from other sources, 
e. g., Coile, were mostly written to display output such that manual 
recording of results could be achieved before the next output data item 
was displayed. Generally, for clarity, double width characters were 
displayed. Program listings and sample runs on hard copy were, however, 
obtained using a machine equipped with a printer. The programs and 
sample runs are given in the appropriate Appendices. Programs developed 
for this study were checked for validity by running them with data for 
which the theoretical distributions were known from either Coile or 
Pao. 
In the program listings exponentiation is shown by the symbol [ (left 
hand square parenthesis), the character used on the EG3003, rather 
than the more usual +(upwards arrow). 
The observed and theoretical frequency distributions for each of the 
patents data sets are given in Tables 25 to 35; Table 36 summarises the 
results of the Kolmogorov-Smirnov Tests for each data set. Addition- 
ally, Lotka's Law plots were constructed for the patents data set; 
these are given in Figures 38 to 47. 
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Figure 38: Lotka's Law Graph for Original Cephalosporins 
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Figure 39: Lotka's Law Graph for Air Cushion Vehicles Patents 
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Figure 40: Lotka's Law Graph for Cyclopropane Derivative 
Insecticide Patents [Exponent 
= 
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Figure 41: Lotka's Law Graph for Videodisc Patents 
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Figure 42: Lotka's Law Graph for Genetic Engineering Patents 
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Figure 43: Lotka's Law Graph for Terephthalic Acid 
Production Patents [Exponent 
= 
0.967] 
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Figure 44: Lotka's Law Graph for Pressure Sensitive 
Adhesives Patents [Exponent = 1.169] 
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Figure 45: Lotka's Law Graph for Pharmacologically Active 
yrazolone Patents [Exponent 
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Figure 46: Lotka's Law Graph for Olivanic Acid Patents 
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Figure 47: Lotka's Law Graph for Clavulanic Acid Patents 
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FREQUENCY DISTRIBUTIONS AND PATENT CITATIONS 
The patent citation studies of Oppenheim202, Carpenter, Narin and 
Woolf 215, and Ellis Hepburn and Oppenheim212, discussed in Chapter 9, 
give data for the number of citations received per patent for several 
patents data sets. Following the observations of applying frequency 
distributions to patents described above, it was thought appropriate to 
see whether the theoretical distributions which most closely fitted the 
observed results, i. e., the Simon-Yule, Borel-Tanner and Negative 
Binomial, would also fit the citation data reported in the three 
studies referred to. This was accomplished by using the same computer 
programs as used previously; the results are given in Tables 37 to 47 
for eleven sets of citation data taken. Goodness-of-fit between 
observed and theoretical distribtion was again tested using the Kolmo- 
gorov-Smirnov Test; a summary of the results obtained is given in Table 
48. 
Citations Observed Expected Frequencies 
Per Patent Frequency Simon-Yule Borel-Tanner Negative Binomial 
1 23 42.8058 36.7459 23.7444 
2 17 12.1668 12.5261 16.1506 
3 12 5.3856 6.4049 10.7214 
4 6 2.9279 3.8815 7.0589 
5 5 1.7967 2.5843 4.6283 
6 3 1.1949 1.8267 3.0271 
7 1 0.8417 1.3459 1.9765 
8 0 0.6190 1.0223 1.2890 
9 0 0.4708 0.7948 0.8399 
10 3 0.3679 0.6294 0.5469 
11 1 0.2939 0.5059 0.3559 
>'12 0 2.1290 2.7323 0.6611 
Table 37: Observed and Theoretical Frequency Distributions for 
Number of Citations per Patent for "Industrial Research IR100 Award" 
Patents from Carpenter, Narin and Woolf215 
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Citations Observed Expected Frequencies 
Per Patent Frequency Simon-Yule Borel-Tanner Negative Binomial 
1 96 105.5290 96.6982 94.6041 
2 29 25.7961 28.6667 28.5793 
3 12 10.1342 12.7476 13.8972 
4 6 4.9915 6.7184 7.6109 
5 4 2.8157 3.8900 4.4018 
6 4 1.7400 2.3913 2.6269 
7 2 1.1484 1.5322 1.5999 
8 2 0.7967 1.0121 0.9885 
9 0 0.5746 0.6843 0.6172 
10 0 0.4277 0.4713 0.3885 
11 1 0.3267 0.3294 0.2462 
X12 0 1.7194 0.8585 0.4395 
Table 38: Observed and Theoretical Frequency Distributions for 
Number of Citations per Patent for Hovercraft Patents fron 
Oppenheim202 
Citations Observed Expected Frequencies 
Per Patent Frequency Simon-Yule Borel-Tanner egative iromia 
1 25 22.9189 21.5313 25.3899 
2 4 5.0663 5.7403 2.7078 
3 0 1.8343 2.2956 1.2783 
4 2 0.8435 1.0880 0.7591 
5 0 0.4485 0.5665 0.4971 
6 0 0.2631 0.3132 0.3436 
7 0 0.1657 0.1805 0.2459 
8 0 0.1102 0.1072 0.1803 
9 0 0.0765 0.0652 0.1345 
10 0 0.0550 0.0404 0.1017 
11 0 0.0407 0.0254 0.0778 
12 1 0.0308 0.0162 0.0600 
>'13 0 0.1465 0.0302 0.2240 
Table 39: Observed and Theoretical Frequency Distributions for 
Number of Citations per Patent for Magnetic Bubble Memory from 
202 Oppenheim 
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Citations Observed Expected Frequencies 
Per Patent Frequency Simon-Yule Borel-Tanner Negative Binomial 
1 19 19.0256 17.4704 20.8609 
2 6 4.6179 5.1417 2.7282 
3 0 1.8039 2.2699 1.3427 
4 2 0.8842 1.1877 0.8225 
5 0 0.4968 0.6827 0.5534 
6 0 0.3059 0.4166 0.3924 
7 0 0.2012 0.2650 0.2876 
8 0 0.1392 0.1738 0.2158 
9 0 0.1001 0.1167 0.1647 
10 0 0.07411 0.0798 0.1274 
11 0 0.0567 0.0554 0.0995 
12 0 0.0442 0.0389 0.0784 
13 0 0.0350 0.0276 0.0622 
14 1 0.0283 0.0198 0.0496 
)15 0 0.1866 0.0540 0.2147 
Table 40: Observed and Theoretical Frequency Distributions for 
Number of Citations per Patent for Magnetic Bubble Memory 
Patents from Dansey as quoted by Oppenheim202 
Citations Observed Expected Frequencies 
Per Patent Frequency Simon-Yule Borel-Tanner Negative Binomial 
1 65 67.1910 65.7919 69.5854 
2 20 17.5645 19.0580 14.8018 
3 7 7.2800 8.2808 7.1114 
4 6 3.7491 4.2644 4.0514 
5 2 2.1971 2.4126 2.4888 
6 1 1.4039 1.4492 1.5956 
7 0 0.9544 0.9073 1.0514 
8 0 0.6800 0.5456 0.7062 
9 1 0.5025 0.3869 0.4811 
10 0 0.3824 0.2603 0.3314 
11 0 0.2892 0.1778 0.2302 
12 0 0.2372 0.1230 0.1610 
13 0 0.1920 0.0859 0.1133 
14 0 0.1877 0.0606 0.0801 
15 1 0.1313 0.0430 0.0569 
>16 1 1.0787 0.1127 1.1440 
Table 41: Observed and Theoretical Frequency Distributions for 
Number of Citations per Patent for Fibre Optic Devices for 
Visible Light Patents from Oppenheim202 
- 
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Citations Observed Expected Frequencies 
Per Patent Frequency Simon-Yule Borel-Tanner Negative Binomial 
1 33 41.0870 36.9587 31.1826 
2 14 10.6031 11.5636 14.4383 
3 4 4.3500 5.4270 7.6370 
4 5 2.2313 3.0186 4.2073 
5 4 1.2924 1.8447 2.3641 
6 0 0.8206 1.1968 1.3439 
7 2 0.5547 0.8093 0.7699 
8 1 0.3932 0.5643 0.4435 
9 0 1.6777 1.6171 0.6134 
Table 42: Observed and Theoretical Frequency Distributions for 
Number of Citations per Patent for Cardiac Pacemakers 
and Defribillator Patents from Oppenheim202 
Citations Observed Expected Frequencies 
Per Patent Frequency Simon-Yule Borel-Tanner Negative Binomial 
1 9 11.7111 10.8222 10.9780 
2 7 2.7789 3.1114 2.8462 
3 0 1.0659 1.3418 1.3440 
4 0 0.5146 0.6858 0.7301 
5 0 0.2853 0.3851 0.4225 
6 0 0.1737 0.2296 0.2535 
7 0 0.1131 0.1427 0.1557 
8 1 0.0775 0.0914 0.0972 
>i 9 0 0.2799 0.1900 0.1728 
Table 43 Observed and Theoretical Frequency Distributions for 
Number of Citations per Patent for Underwater Holography 
Patents from Oppenheim202 
Citations Observed Expected Frequencies 
Per Patent Frequency Simon-Yule Borel-Tanner Negative Binomial 
1 41 44.6420 41.4818 38.6674 
2 10 10.3671 11.6588 13.4962 
3 6 3.9076 4.9152 6.0271 
4 3 1.8590 2.4559 2.8875 
5 3 1.0179 1.3481 1.4308 
6 0 0.6127 0.7857 0.7225 
7 1 0.3950 0.4773 0.3696 
>, 8 0 1.1988 0.8772 0.3994 
Table 44: Observed and Theoretical Frequency Distributions for 
Number of Citations per Patent for Ring Pull Cans 
from Oppenheim202 
- 
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Citations Observed Expected Frequencies 
Per Patent Frequency Simon-Yule Borel-Tanner Negative Binomial 
1 13 14.1842 12.6800 10.9185 
2 3 3.7182 4.0270 4.7691 
3 1 1.5445 1.9184 2.5774 
4 1 0.7968 1.0831 1.4820 
5 2 0.4677 0.6718 0.8777 
6 1 0.2992 0.4424 0.5290 
7 2 0.2037 0.3037 0.3224 
8 0 0.7857 0.8736 0.5239 
Table 45: Observed and Theoretical Frequency Distributions for 
Number of Citations per Patent for Four Channel (Quadraphonic) 
Systems Patents from Oppenheim202 
Citations Observed Expected Frequencies 
Per Patent Frequency Simon-Yule Borel-Tanner Negative B nomial 
1 23 23.4000 24.7424 23.3873 
2 8 6.0667 6.3769 6.6369 
3 2 2.4980 2.4653 2.6906 
4 0 1.2795 1.1296 1.1999 
5 1 0.7464 0.5686 0.5594 
6 1 0.4750 0.3039 0.2676 
7 0 0.3217 0.1693 0.1302 
8 1 1.2127 0.2440 1.1280 
Table 46: Observed and Theoretical Frequency Distributions for 
Number of Citations per Patent for Alkene and Alkyne 
Disproportionation Patents from Oppenheim202 
Citations Observed Expected Frequencies 
Per Patent Frequency Simon-Yule Borel-Tanner Negative Binomial 
1 97 90.9689 95.6390 90.0757 
2 15 17.3430 16.7981 12.6112 
3 3 5.5539 4.4256 4.2171 
4 2 2.2997 1.3819 1.6995 
5 0 1.1156 0.4741 0.7432 
6 0 0.6034 0.1727 0.3403 
7 1 0.3533 0.0655 0.1605 
8 0 0.2200 0.0257 0.0773 
>i 9 1 0.5422 0.0174 1.0753 
Table 47: Observed and Theoretical Frequency Distributions for 
Number of Citations per Patent for Semisynthetic Penicillins 
Patents from Ellis, Hepburn and Oppenheim212 
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FINANCIAL DATA 
To obtain a parameter with which to measure the relative sizes of the 
proprietary organisations retrieved as patentees in the cephalosporin 
searches, it was decied to ascertain their sales volumes. This was 
chosen as suitably indicative of size since it is the method adopted by 
the internationally recognised "Fortune 500" lists of the largest 
companies within and outside of the USA. 
For the majority of patentees, the principal sources of sales figures 
were: 
(a) CA 200, Chemical Age, 31 July, 1981 
(b) Fortune 500, Fortune, 4 May, 1981 
(c) Fortune Second 500, Fortune, 15 June, 1981 
(d) Fortune Foreign 500, Fortune, 10 August 1981 
(e) Diamond's Japan Business Directory, 1981 (Diamond Head Co., 
Tokyo) 
(f) Million Dollar Directory, 1981 (Dunn and Bradstreet) 
Sales figures for Research Corporation, Forest Laboratories and Ethicon 
Inc. were obtained from Standard and Poor's register of companies; 
however, in the case of Ethicon Inc. 
-a wholly owned subsidiary of 
Johnson and Johnson Inc. 
- 
the figure used is that for the parent 
company as no separate sales figure could be found for the subsidiary. 
Sales for Nelson Research & Development Company were taken from Middle 
Market Directory, 1978 also published by Dunn and Bradstreet. 
Figures for Alfa Farmaceutici SpA, Sigma-Tau SpA, Scherico Limited, 
Mundipharma AG, Antibioticos SA, Cia. Internationale Farmaeia Landerlan 
SA, Laboratorios Farmaceutico Quimico Lafarquim SA, Laboratorios Cusi 
SA, Stada Arzneimittel GmbH, Purdue Frederick Company and Pharmacia AB 
were provided through the generosity of Ciba-Geigy Limited, Basel, 
using their in-house maintained files. 
Sales figures for Glaxo Holdings Limited and Wellcome Foundation 
Limited were ascertained from company annual reports. 
Sales figures for Bristol-Banyu KK, Eiken Kagaku KK, Meiji Seika KK, 
Nippon Chemifar Company Limited, Ohta Seiyaku KK and Toshin Chemical 
Industries KK were obtained from Teikoko Ginko Kaisha Yoroku, published 
- 
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by Teikoku Kohinsho Limited, Tokyo (1980), and for Seoul Pharmaceutical 
Industries KK from Kankoku Kigyo Chosa Coroku, published by Kankokui 
Seisansei Honbu, Seoul (1978) through the kindness of Nippon Gijutsu 
Boeki Company Limited, Tokyo. 
The sales figure for Lepetit SpA was obtained from data cards of the 
European Services issued by McCarthy Information Limited, London. The 
sales figure for Societe Omnium-Chimique SA is that of the parent 
company (owning 100%), PRB Chemicals SA. 
Organen NV is a wholly owned subsidiary of Akzo NV; no separate sales 
figure per se could be found for Organon. However, in the entry for 
Akzo NV in International Business Year Book 1977/78, published by The 
Financial Times Limited, London (1977), it is stated that 30% of the 
revenue of Akzo NV is derived from pharmaceuticals. Accordingly, the 
sales figure used in the tables for Akzo NV is only 70% of that taken 
from Chemical Age 200, the remaining 30% has been taken as the sales 
figure for Organon NV. 
Although several sources were used for gathering this financial data, 
where possible sales figures reported for either 1978 or 1979 were used 
since the majority of figures taken from the Dunn and Bradstreet 
publications would appear to cover those years. However, it was not 
possible to check the exact period covered; Dunn and Bradstreet merely 
state that the figures used in the publications are the latest avail- 
able at the time of going to press. No cognisance is paid to the 
differences in financial accounting periods, e. g., January through 
December or April through March. Neither is there any clear editorial 
policy on how sales figures are derived for trans-national corporations 
- 
such as whether or not figures for overseas subsidiaries have been 
consolidated; for example it is not known whether the sales figures for 
ICI Limited include figures for African Explosives SA (South Africa) or 
ICI (America) Inc. 
Sales figures could not be found for the following patentees: 
Aries Associates SA, France 
Dobfar SpA, Italy 
Caw Industries Inc., USA 
Connlab Holdings Limited, Canada 
Craf Sud SpA, Italy 
- 
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Instituto de Farmacologica Espanola SA, Spain 
Gema SA, Spain 
Intellectual Property Development Corporation, USA 
Istituto Biochimico Italiani di Loredana Lorenzini SAS, Italy 
Lumac International NV, Netherlands Antilles 
Pharmaco, Inc., USA 
R&L. Molecular Research, Canada 
Sutures Inc., USA 
Leboratoires Thekan SA, France 
Etablissements Viridis, Liechtenstein 
Additionally, no sales figure could be ascertained for the one Eastern 
Bloc company, KRKA-Farmacevtica of Yugoslavia. 
In order to get some uniformity in converting sales figures reported in 
local currencies into USA $, exchange rates as at 31 December, 1980, 
supplied through the courtesy of National Westminster Bank Limited, 
were used. After conversion to US $, companies were listed in order of 
sales volume as shown in Table 49, which also shows the rank of each 
patentee by number of cephalosporin patents within the list of patent- 
ees in Table 16. 
To ascertain whether there was a correlation betwen sales volume and 
the number of Cephalosporin patents per patentee, the Spearman Coeffi- 
cient of Rank Correlation was determined for the two rankings shown in 
Table 49. The Spearman Coefficient, r, was determined to be 0.3369; 
with 1412 patentees (as per Table 49) the significance limits for r at 
the 0.10,0.05 and 0.01 levels are 0.1385,0.1651 and 0.2.169 respect- 
ively. The result thus indicates a high correlation between sales and 
Cephalosporin patenting activity. 
It was also thought appropriate to ascertain whether a close relation- 
ship exists between sales and patenting activity in a more diffuse set 
of patentees, and whether any differences could be noted between 
industries. Accordingly it was decided to examine the patenting 
activities of the 1981 Fortune 500 as compiled by Worthy 
254. For each 
of the companies listed in the Fortune 500, US patenting activity was 
determined from lists published by 0TAF255 of industrial patenting 
activity in the USA for 1969-80. These lists include only companies 
with three or more patents in the time period covered; thus companies 
in the Fortune 500 not in the OTAF list were given an equal rank, 
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although some of these companies may have had one or two patents 
between 1969 and 1980. The companies were then ranked according to 
total number of patents (including those of subsidiary companies where 
these could be identified); the companies with their Fortune 500 and 
patenting activities, together with two-digit Standard Industrial 
Classification Codes, are given in Table 50. 
The Spearman Rank Coefficient, r, was calculated for these two rankings 
and found to be 0.0518. The companies were then sorted in to industrial 
groups and ranked by sales and patenting activity within industrial 
group. Spearman Rank Coefficients were calculated for each group, other 
than those with 11 or fewer companies [Industry Codes: 21 (Tobacco); 25 
(Furnitiure); 31 (Leather) and 46 (Jewellery, Silverware)]. The 
Spearman Rank Coeffients determined and corresponding significance 
limits are given in Table 51. 
0 
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Sales in Rank Rank by no. 
PATENTEE NAME US $ by of Cephalo- 
Million Sales sporins 
Patents 
Hoechst AG 14809.4 1 21 
Bayer AG 14269.8 2 22 
E. I. du Pont de Nemours & Company 13652.0 3 57= 
ICI Limited 13258.8 4 102= 
Dow Chemical Company 10626.0 5 65= 
Union Carbide Corporation 9994.0 6 102: 
Procter & Gamble Company 8687.0 7 81= 
Ciba-Geigy Limited 6510.4 8 6 
Rhone-Poulenc SA 6470.0 9 29= 
McDonnell Douglas Corporation 6066.3 10 81= 
Ethicon Inc. 4212.0 11 102= 
Akzo NV 3980.4 12 102= 
Warner-Lambert Company 3479.2 13 65= 
American Cyanamid Company 3453.9 14 39= 
Asahi Chemical Industries KK 3385.8 15 17= 
Hoffmann-La Roche Company Limited 3202.5 16 33= 
Bristol-Myers Company 3158.3 17 7 
Mitsubishi Chemical Industries KK 3140.2 18 65= 
Pfizer Inc. 3029.3 19 26 
Merck & Co. Inc. 2734.0 20 8 
Sandoz Limited 2677.6 21 65= 
Sumitomo Chemical Company 2624.5 22 20 
Eli Lilly & Company 2558.6 23 2 
Beecham Group Limited 2385.9 24 12 
Parke Davis & Co. 2340.0 25 44= 
Toray Industries Inc. 2293.1 26 81= 
Showa-Denko KK* 2107.3 27 102= 
Takeda Chemical Industries 2090.0 28 3 
Abbott Laboratories 2038.2 29 81= 
Mitsui Toatsu Chemicals Inc. * 1935.0 30 65= 
Teijin KK 1915.0 31 19 
Upjohn Company 1760.6 32 65= 
Smith Kline & French Laboratories Inc. 1771.9 33 9 
Ajinomoto KK 1734.2 34 42= 
Organon NV 1705.9 35 102= 
Mitsubishi Petroleum Company 1678.9 36 81= 
E. R. Squibb & Sons Inc. 1675.8 37 4 
American Home Products Corporation 1651.0 38 17= 
Schering AG* 1595.8 39 81= 
Unilever BV 1496.4 40 102= 
Glaxo Group Limited 1434.1 41 5 
Toyobo KK 1217.5 42 32 
Kanebo Pharmaceuticals Limited 1185.9 43 33= 
Nisshin Flour Milling Company Limited 1179.3 44 102= 
Richardson-Merrell Inc. 1090.0 45 39= 
Wellcome Foundation Limited 1026.4 116 102= 
Kyowa Hakko Kogyo KK 977.4 47 35 
Table 49: Cephalosporin Patentees Ranked by Sales showing Rank by 
Numbers of Cephalosporin Patents (excluding academia, private 
inventors not-for-profit organisations) 
*From Ceahalosnorins update set only) 
- 
249 
- 
Sales in Rank Rank by no. 
PATENTEE NAME US $ by of Cephalo- 
Million Sales sporins 
Patents 
E. Merck AG 977.3 48 36 
Amstar Corporation 965.0 49 102= 
C. H. Boehringer Sohn GmbH 862.9 50 102= 
Meiji Seika KK 814.9 51 14 
Dynamit Nobel AG 812.2 52 102= 
Sparamedica AG 790.3 53 102= 
Sankyo Company Limited 762.3 54 10 
Fujisawa Pharmaceutical Industries KK 6G3.5 55 1 
Shionogi Limited 632.3 56 15 
Miles Laboratories Inc. 595.0 57 102= 
Boehringer Mannheim GmbH 531.8 58 65= 
Scherico Limited 489.3 59 81= 
Tanabe Pharmaceutical Company 481.8 60 65= 
Kureha Chemical Industries KK 452.2 61 102= 
Astra Pharmaceutica AB 444.8 62 42= 
Eisai Company Limited*' 438.7 63 81= 
Gist-Brocades NV 436.6 64 27 
Lepetit SpA 411.1 65 81= 
Kyoto Ceramic Company Limited 402.8 66 102= 
Nippon Kagaku KK 391.7 67 28 
Yamanouchi Pharmaceutical Company 364.7 68 11 
Fisher Scientific Company 350.0 69 81= 
Chugai Pharmaceuticals KK 338.5 70 54= 
Daiichi Seiyaku Company Limited* 317.6 71 57= 
Societe Omnium Chimique SA 279.0 72 102= 
Syntex Corporation 277.4 73 48= 
Banyu Pharmaceutical Company Ltd. 266.4 74 25 
Novo Industri A/S 262.4 75 39= 
Toyo Jozo KK 235.9 76 23 
Dainippon Pharmaceuticals KK 227.9 77 38 
Otsuka Pharmaceuticals KK 221.7 78 57= 
Dr. Karl Thomae GmbH* 212.5 79 57= 
Sanraku-Ocean KK 207.6 80 102= 
Yoshitomi Pharmaceutical Industries KK 202.7 81 102= 
Roussel-Uelaf SA 180.4 82 16 
Hodogaya Chemical Industries KK 160.8 83 44= 
Nippon Shinyaku KK 160.7 84 102= 
Toyama Chemical Industries KK 137.9 85 13 
Albert Rolland SAS 132.2 86 102= 
Farmitalia SpA 118.8 87 29= 
Fermion Oy 117.0 88 65= 
Pierrel SpA 115.0 89 65= 
Tokyo Tanabe KK 108.7 90 102= 
Carlo Erba SpA 104.2 91 48= 
Ono Pharmaceuticals KK 101.6 92 81= 
Chemische Fabriken von Heyden GmbH 93.8 93 24 
Bristol-Banyu KK 86.6 94 48= 
Nikken Chemicals Company Limited 82.5 95 44= 
Table 49: Cephalosporin Patentees Ranked by Sales showing Rank by 
Numbers of Cephalosporin Patents (excluding academia, private 
inventors, not-for-profit organisations), c ontinued 
(*From Cephalosporins update_set only) 
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Sales in Rank Rank by no. 
PATENTEE NAME US $ by of Cephalo- 
Million Sales sporins 
Patents 
Nippi Inc. 81.1 96 102= 
Chemie Grunenthal GmbH 76.1 97 . 57= 
Alza Corporation 72.0 98 81= 
Nippon Chemifar Company Limited 611.1 99 47 
National Patent Development Corporation 60.0 100 102= 
Teikoku Hormone Manufacturing Company 54.4 101 102= 
ISF Italseber SpA 52.2 102 81= 
Sigma-Tau SpA 48.0 103 81= 
Tobishi Pharmaceuticals Company 41.9 104 65= 
Purdue Frederick Company 40.0 105 102= 
Recherche et Industries Therapeutique SA 38.1 106 48= 
Toko Yakukin Kogyo KK 37.2 107 102= 
Leo Pharmaceutical Products AB 36.6 108 37 
Kissel Pharmaceutical Company Limited 33.0 109 57 
Laboratoires Merrell-Touraude SA 30.4 110 29= 
Biochemie GmbH 28.8 111 48= 
Grelan Pharmaceutical Company Limited* 25.9 112 81= 
Lark SpA 25.8 113= 102= 
Nikko Chemical Industries KK 25.8 113= 102= 
Antibioticos SA 25.5 115 57= 
Eiken Kagaku KK 25.3 116 102= 
A. Gallardo SA 24.4 117 65= 
Wakamoto Pharmaceutical Company 23.8 118 102= 
Sawai Seiyaku KK* 23.2. 119 102= 
Laboratories Clin Midy SA 22.5 120 81= 
Ohta Seiyaku ECK 20.1 121 81= 
Pharmacia AB 19.8 122 102= 
Alfa Farmaceutici SpA 19.2 123 54= 
Laboratoires Ferrer & Cia SA 16.2 124 102= 
Teikoku Chemical Industries 14.5 125 54= 
Forest Laboratories Inc. 14.0 126 81= 
Seoul Pharmaceutical Industries KK 13.4 127 102= 
Proter SpA 10.5 128 48 
Kyoto Yakuhin Kogyo* 8.5 129 65= 
Toshin Chemical Industries KK 8.4 130 57= 
Snam-Progetti SpA 7.2 131= 65= 
Lab. Farmaceutico Quimico Lafarquim SA 7.2 131= 81= 
Key Pharmaceuticals Inc. * 7.0 133 102= 
Laboratorios Cusi SA 6.6 134 65= 
Stada Arzneimittel GmbH 6.3 135 102= 
Instituto Luso-Farmaco SarL 4.7 136 81: 
Toho Pharmaceutical Laboratories Company 4.2 137 102= 
Cia. Internationale Farmacia Landerlan SA 3.0 138 102= 
Research Corporation 2.0 139 81= 
Nelson Research & Development Company 1.5 140 65= 
Kommanditbolaget Kockums Chemical AB 0.6 141 102= 
Mundipharma AG 0.3 142 102= 
Table 49: Cephalosporin Patentees Ranked by Sales showing Rank 
Numbers of Cephalosporin Patents (excluding academia, private 
inventors, not-Vor-profit organisations) 
(*From Cephalosporins update set only) 
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C014PANY 
INDUSTRY NO. OF RANK BY FORTUNE 
CODE PATENTS PATENTS 500 RANK 
Exxon 29 3257 12 1 
Mobil 29 2119 24 2 
General Motors 40 5425 5 3 
Texaco 29 2415 17 4 
Standard Oil of California 29 932 59 5 
Ford Motor 40 1949 29 6 
Gulf Oil 29 1240 45 7 
IBM 44 6467 2 8 
Standard Oil (Indiana) 29 383 141 9 
General Electric 36 11021 1 10 
Atlantic Richfield 29 945 57 11 
Shell Oil 29 2506 16 12 
ITT 36 1962 28 13 
Conoco 29 893 63 14 
Du Pont 28 5916 4 15 
Phillips Petroleum 29 4057 9 16 
Tenneco 29 412 131 17 
Sun 29 641 811 18 
US Steel 33 1179 48 19 
Occidental Petroleum 10 117 236= 20 
United Technologies 41 2058 26 21 
Western Electric 36 1196 47 22 
Standard Oil (Ohio) 29 95 248= 23 
Procter & Gamble 43 1271 43 24 
Dow Chemical 28 4361 8 25 
Getty Oil 10 16 360= 26 
Union Carbide 28 2779 13 27 
Union Oil of California 29 602 92 28 
Eastman Kodak 38 4536 6 29 
Boeing 41 816 71 30 
Dart & Kraft 20 490 107 31 
Chrysler 40 415 129 32 
Caterpillar Tractor 45 2629 15 33 
Westinghouse Electric 36 6203 3 34 
R. J. Reynolds Industries 21 156 209 35 
Goodyear Tire & Rubber 30 1576 36 36 
Beatrice Foods 20 213 190 37 
Xerox 38 3996 10 38 
Marathon Oil 29 398 136 39 
Ashland Oil 29 326 154 40 
RCA 36 4534 7 41 
LTV 33 74 269 42 
Amerada Hess 29 
- 
432= 43 
Cities Service 29 454 115= 44 
Philip Morris 21 221 187 45 
Rockwell International 41 2306 19 46 
Bethelehem Steel 33 468 111_ 47 
Monsanto 28 3683 11 48 
International Harvester 45 911 62 49 
Esmark 20 
- 
432= 50 
Table 50: 1981 Fortune 500 Largest US Industrial Corporations Ranked 
by Sales and showing Rank by US Patents 1969-1980 
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INDUSTRY NO. OF RANK BY FORTUNE 
COMPANY CODE PATENTS PATENTS 500 RANK 
W. R. Grace 28 1276 42 51 
3M 38 2231 21 52 
McDonnell Douglas 41 667 81 53 
Pepsi Co 49 26 338= 54 
General Foods 20 502 105 55 
Coca-Cola 49 50 298= 56 
Gulf & Western Industries 34 338 149= 57 
Armco 33 285 168 58 
Allied Chemical 10 1902 30 59 
Deere 45 833 69 60 
Lockheed 41 483 109 61 
Consolidated Food 20 65 278 62 
Aluminum Company of America 33 584 94 63 
Colgate-Palmolive 43 940 58 64 
Continental Group 34 148 215 65 
Coastal 29 
- 
432= 66 
International Paper 26 316 156 67 
Georgia-Pacific 26 141 221= 68 
Raytheon 36 858 65 69 
TRW 40 1487 37 70 
Honeywell 44 2322 18 71 
Ralston Purina 20 153 211= 72 
Firestone Tire & Rubber Co. 30 510 102 73 
Johnson & Johnson 42 592 93 74 
Union Pacific 29 
- 
432= 75 
American Can 34 488 108 76 
Sperry 44 2080 25 77 
Greyhound 20 
- 
432= 78 
General Dynamics 41 508 103 79 
Farmland Industries 29 6 401= 80 
Iowa Beef Processors 20 13 373= 81 
Borden 20 205 194 82 
Weyerhauser 26 199 196 83 
Charter 29 4 414= 84 
Signal Companies 40 5 1106= 85 
American Brands 21 16 360= 86 
Bendix 40 2204 22 87 
Litton Industries 36 635 86_ 88 
General Mills 20 394 137= 89 
IC Industries 20 
- 
432= 90 
CPC International 20 264 171: 91 
Texas Instruments 36 2248 20 92 
Dresser Industries 45 844 68 93 
CBS 48 230 179 94 
Owens Illinois 32 1704 34 95 
American Home Products 42 1161 49 96 
United Brands 20 9 387= 97 
Republic Steel 33 162 206 98 
Champion International 26 387 140 99 
National Steel 33 160 207 100 
Table 50: 1981 Fortune 500 Largest US Industrial Corporations Ranked 
by Sales and showing Rank by US Patents 1969-1980 (continued) 
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COMPANY 
INDUSTRY NO. OF RANK BY FORTUNE 
CODE PATENTS PATENTS 500 RANK 
Reynolds Metals 33 458 113 101 
Textron 34 759 74 102 
FMC 45 1820 32 103 
Warner-Lambert 42 614 89 104 
Kerr-McGee 29 95 248= 105 
American Cyanamid 28 2666 14 106 
Celanese 28 979 53= 107 
NCR 44 861 64 108 
Land 0' Laker 20 11 379= 109 
Anheuser-Busch 49 82 259= 110 
McDermott 34 17 356= 111 
Inland Steel 33 132 228 112 
Carnation 20 17 356= 113 
Kaiser Aluminum & Chemical 33 297 164= 114 
Eaton 40 998 52 115 
PPG Industries 28 1862 31 116 
Bristol-Myers 42 384 137= 117 
Combustion Engineering 45 656 82 118 
Diamond Shamrock 29 428 125 119 
Hewlett Packard 38 688 79 120 
Motorola 36 2197 23 121 
BF Goodrich 30 856 66 122 
Crown Zellerbach 26 131 229 123 
Emerson Electric 36 421 128 124 
Pillsbury 20 174 201 125 
Pfizer 42 912 61 126 
Boise Cascade 26 58 286= 127 
Standard Brands 20 94 250_ 128 
Ingersoll-Rand 45 306 160 129 
Norton-Simon 20 
- 
432= 130 
AMAX 33 149 213= 131 
Teledyne 45 429 124 132 
H. J. Heinz 20 16 360= 133 
Burlington Industries 22 222 185= 134 
Time Inc. 27 18 353= 135 
Northwest Industries 33 
- 
432= 136 
Burroughs 44 1408 40 137 
Levi Strauss 23 27 336= 138 
Archer-Daniels-Midland 20 14 367= 139 
Singer 36 1479 38 140 
Control Data 44 226 180= 141 
Merck 42 1667 35 142 
St. Regis Paper 26 48 301= 143 
Mead 26 401 135 144 
American Standard 37 313 159 145 
Borg-Warner 40 979 53= 146 
Agway 29 9 387= 147 
North American Philips 36 235 178 148 
Martin Marietta 41 297 164: 149 
Kimberly-Clark 26 432 122 150 
Table 50: 1981 Fortune 500 Largest US Industrial Corporations Ranked 
by Sales and showing Rank by US Patents 1969-1980 (continued) 
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COMPANY 
INDUSTRY NO. OF RANK BY FORTUNE 
CODE PATENTS PATENTS 500 RANK 
Avon 43 42 309 151 
Nabisco 20 78 266 152 
Campbell Soup 20 58 286= 153 
Eli Lilly 42 1087 51 154 
American Motors 40 27 336= 155 
Kidde 45 144 217= 156 
Dana 40 167 204= 157 
Hercules 28 827 70 158 
Pennzoil 29 20 347= 159 
Quaker Oats 20 223 182= 160 
Tosco 29 5 406= 161 
Digital Equipment 44 85 257= 162 
Gillette 34" 348 146 163 
Uniroyal 30 713 78 164 
Owens-Corning Fiberglass 32 920 60 165 
Johns-Manville 32 4117 117 166 
McGraw-Edison 36 423 126 167 
American Broadcasting 48 
- 
432= 168 
Kennecott 33 223 182= 169 
Whirlpool 36 571 95 170 
General Tire & Rubber 30 482 110 171 
Revlon 43 34 323= 172 
Gould 36 278 169 173 
Ogden 37 8 390= 174 
Colt Industries 33 133 226= 175 
Kellogg 20 18 353= 176 
NL Industries 28 330 153 177 
American Petrofina 29 
- 
432= 178 
Scott Paper 26 271 170 179 
Fruehauf 40 90 254 180 
Williams Companies 28 
- 
432= 181 
Allis-Chalmers 45 957 56 182 
Warner Communications 36 
- 
432= 183 
White Consolidated Ind. 36 40 310= 184 
Abbott Laboratories 42 637 85 185 
INTERCO 23 
- 
432= 186 
Penn Central 29 
- 
432= 187 
Murphy Oil 29 
- 
432= 188 
Jim Walter 26 4 414= 189 
Koppers 28 530 98 190 
J. P. Stevens 22 186 198 191 
SCM 28 539 96 192 
Gold Kist 20 7 396= 193 
Times Mirror 27 4 1114= 194 
Olin 28 1233 46 195 
Squibb 42 1159 50 196 
Cooper Industries 45 47 303= 197 
Marmon Group Inc. 33 11 379= 198 
Asarco 33 30 329= 199 
Emhart 45 226 180= 200 
Table 50: 1981 Fortune 500 Largest US Industrial Corporations Ranked 
by Sales and showing Rank by US Patents 1969-1980 (continued) 
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COMPANY 
INDUSTRY NO. OF RANK BY FORTUNE 
CODE PATENTS PATENTS 500 RANK 
International Minerals & Chemicals 
Oscar Mayer 
SmithKline 
MAPCO 
National Distillers & Chemical 
Upjohn 
Central-Soya 
Ethyl 
Schering-Plough 
Castle & Cooke 
Grumman 
Rohm & Haas 
Anderson Clayton 
Sterling Drug 
Stauffer Chemical 
Paccar 
Cummins Engine 
A. E. Staley Manufacturing 
Northrop 
Joseph E. Seagram & Sons 
Clark Oil & Refining 
Union Camp 
National Can 
Baker International 
AMF 
Clark Equipment 
Corning Glass Works 
Crane 
Allegheny Ludlum Industries 
General Signal 
Chromalloy American 
Cabot 
Superior Oil 
U. S. Gypsum 
Crown, Cork & Seal 
Polaroid 
Phelps Dodge 
Black & Decker Manufacturing 
Heublein 
Evans Products 
Lear Siegler 
Air Products & Chemicals 
Westvaco 
Sunbeam 
Blue Bell 
Whittaker 
Chesebrough-Pond's 
Baxter Travenol Laboratories 
Great Northern Nekoosa 
Timken 
28 108 242 201 
20 73 270 202 
42 739 76 203 
10 4 414= 204 
28 314 158 205 
42 1996 27 206 
20 23 342= 207 
28 966 55 208 
42 301 162 209 
20 17 356= 210 
41 116 238= 211 
28 790 73 212 
20 17 356= 213 
42 623 88 214 
28 1264 44 215 
40 36 319= 216 
40 67 275= 217 
20 149 213= 218 
41 218 189 219 
49 
- 
432= 220 
29 
- 
432= 221 
26 77 267 222 
34 87 256 223 
45 137 224 224 
47 514 100 225 
45 406 134 226 
32 1278 41 227 
33 63 279= 228 
33 264 171= 229 
38 414 130 230 
34 107 243 231 
33 141 221= 232 
10 15 364= 233 
32 31 327= 234 
34 56 292= 235 
38 1721 33 236 
33 52 296= 237 
45 240 176 238 
49 
- 
432= 239 
37 80 263= 240 
40 360 144 241 
28 407 133 242 
26 351 145 243 
36 147 216 244 
23 11 379= 245 
37 144 217= 246 
43 11 379= 247 
42 524 99 248 
26 4 414_ 249 
45 8 390= 250 
Table 50: 1981 Fortune 500 Largest US Industrial Corporations Ranked 
by Sales and showing Bank by US Patents 1969-1980 (continued) 
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COMPANY 
INDUSTRY NO. OF RANK BY FORTUNE 
CODE PATENTS PATENTS 500 RANK 
Hershey Foods 20 3 424= 251 
Armstrong World Industries 22 430 123 252 
Geo. A. Gormel 20 24 341 253 
Harris 36 468 111= 254 
Wheelabrator-Frye 45 71 273 255 
MCA 48 38 315 256 
Amstar 20 14 367= 257 
Commonwealth Oil Refining 29 4 414= 258 
Diamond International 26 129 231 259 
Norton 32 286 167 260 
St. Joe Minerals 10 30 329= 261 
Crown Central Petroleum 29 
- 
432= 262 
Avnet 36 19 351= 263 
Sherwin-Williams 28 189 197 264 
Pitney Bowes 44 422 127 265 
West Point-Pepperell 22 29 331= 266 
CF Industries 28 4 414= 267 
GAF 28 852 67 268 
Brown Group 31 31 327= 269 
Gannett 27 
- 
432= 270 
Richardson-Merrell 42 254 174 271 
Hughes Tool 45 82 259= 272 
Brunswick 47 1433 121 273 
Louisiana Pacific 26 
- 
432= 274 
GK Technologies 33 
- 
432= 275 
Pennwalt 28 635 86= 276 
Zenith Radio 36 725 77 277 
Hammermill Paper 26 46 305 278 
Witco Chemical 29 105 244 279 
Libbey-Owens-Ford 32 223 182= 280 
AMP 36 1439 39 281 
US Industries 45 130 230 282 
Campbell Taggert 20 6 401: 283 
R. R. Donnelley & Sons 27 26 338= 284 
Knight-Ridder Newspapers 27 
- 
432= 285 
Texasgulf 10 18 353= 286 
Wheeling-Pittsburgh Steel 33 15 364= 287 
Rexnord 45 236 177 288 
G. D. Searle 42 513 101 289 
International Multifoods 20 8 390= 290 
Harsco 34 72 271= 291 
Interlake 33 109 241 292 
Akzona 28 444 119 293 
ACF Industries 37 446 118 294 
Lever Brothers 43 687 80 295 
Parker-Hannifin 34 317 155 296 
Ex-Cell-0 445 141 221= 297 
Louisiana Land & Exploration 10 
- 
432= 298 
Airco 28 456 114 299 
McGraw-Hill 27 4 414= 300 
Table 50: 1981 Fortune 500 Largest US Industrial Corporations Ranked 
by Sales and showing Rank by US Patents 1969-1980 (continued) 
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INDUSTRY NO. OF RANK BY FORTUNE 
CODE PATENTS PATENTS 500 RANK 
Cessna Aircraft 41 58 286= 301 
Square D 36 341 148 302 
Perkin-Elmer 38 302 161 303 
GATX 37 
- 
432: 304 
Universal Leaf Tobacco 21 
- 
432= 305 
Johnson Controls 36 181 199 306 
National Semiconductor 36 219 188 307 
National Gypsum 32 85 257= 308 
Cyclops 33 16 360= 309 
Federal Co. 20 
- 
432= 310 
Tektronix 38 344 147 311 
Alumax 33 5 406= 312 
Becton Dickinson 38 331 152 313 
Willamette Industries 26 8 390= 314 
Stanley Works 34 200 195 315 
Springs Mills 22 11 379= 316 
Joy Maufacturing 45 72 271= 317 
Consolidated Aluminium 33 
- 
432= 318 
Sundstrand 41 168 203 319 
Kaiser Steel 33 33 325= 320 
Amsted Industries 33 206 193 321 
AM International 414 499 106 322 
Lone Star Industries 32 3 424= 323 
Midland Ross 45 334 151 324 
Fairchild Industries 41 88 255 325 
Lubrizol 28 298 163 326 
Scovill 36 170 202 327 
Jos. Schlitz Brewing 49 43 308 328 
Adolf Coors 49 14 367= 329 
NVF 33 3 424= 330 
Feichhold Chemicals 28 92 252= 331 
Newmont Mining 33 8 390= 332 
Certain Teed 32 56 292= 333 
U. S. Filter 45 14 367= 334 
Anchor Hocking 32 155 210 335 
Intel 36 96 246_ 336 
Twentieth Century Fox Films 48 3 424= 337 
Morton-Norwich Products 28 262 172 338 
Genesco 23 12 375= 339 
ConAgra 20 
- 
432= 340 
Pacific Resources 29 
- 
432= 341 
Dover 34 112 240 342 
Cincinnati Milacron 45 411 132 343 
General Host 20 
- 
432= 344 
Quaker State Oil Refining 29 
- 
432= 345 
Hoover 36 67 275= 346 
Belco Petroleum 29 
- 
432= 347 
Potlatch 26 39 313= 348 
Mattel 47 440 120 349 
White Motor 40 37 316= 350 
Table 50: 1981 Fortune 500 Largest US Industrial Corporations Ranked 
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INDUSTRY NO. OF RANK BY FORTUNE 
CODE PATENTS PATENTS 500 RANK 
Champion Spark Plug 36 69 274 351 
Thomas J. Lipton 20 40 310= 352 
National Service Industries 36 12 375= 353 
Sybron 38 338 149= 354 
Trane 45 126 232 355 
Smith International 45 167 204= 356 
Sperry & Hutchinson 22 
- 
1132= 357 
Memorex 44 63 279= 358 
Masco 34 40 310= 359 
Handy & Harman 33 6 401= 360 
A-T-O 45 210 191 361 
General Cinema 49 
- 
432= 362 
Bangor Punta 41 47 303= 363 
Arcata 27 7 396= 364 
Monfort of Colorado 20 - 432= 265 
Vulcan Materials 10 26 338= 366 
Crouse Hinds 36 20 347= 367 
Tecumseh Products 45 79 265 368 
Revere Copper & Brass 33 12 375= 369 
Cluett Peabody 23 61 283 370 
Mohasco 25 29 331= 371 
Southwest Forest Industries 26 
- 
432= 372 
Peavey 20 7 396= 373 
New York Times 27 
- 
432= 374 
Cone Mills 22 3 424= 375 
G. Heileman Brewing 49 432= 376 
Federal Mogul 40 133 226= 377 
Pabst Brewing 49 14 367= 378 
General Instrument 36 159 208 379 
Dayco 30 243 175 380 
Saxon Industries 26 5 406= 381 
Briggs & Stratton 45 94 250= 382 
Ball 34 117 236= 383 
Brockway Glass 32 29 331= 384 
Cameron Iron Works 45 97 245 385 
Ferro 28 121 235 386 
Signode 34 116 238= 387 
A. 0. Smith 40 134 225 388 
Columbia Motion Pictures 48 7 396= 389 
Outboard Marine 47 393 139 390 
Miles Laboratories 42 365 142 391 
Peabody International 45 28 335 392 
Hyster 45 35 321= 393 
Purex Industries 43 80 263= 394 
CBI Industries 44 
- 
432= 395 
Dow Corning 28 646 83 396 
Bemis 26 45 306= 397 
Bally Manufacturing 47 36 319= 398 
Thiokol 28 454 115= 399 
Hart Schaffner & Marx 23 5 406= 400 
Table 50: 1981 Fortune 500 Largest US Industrial Corporations Ranked 
by Sales and showing Rank by US Patents 1969-1980 (continued) 
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COMPANY 
Nashua 
Hobart 
Freeport Minerals 
United Refining 
Canon Mills 
Washington Post 
Big Three Industries 
H. K. Porter 
Data General 
Insilco 
Moore McCormack Resources 
Bell & Howell 
Gulf Resource & Chemical 
Clorox 
Magic Chef 
Harnischfeger 
VF 
Scott & Fetzer 
Envirotech 
DPF 
Kane-Miller 
INDUSTRY NO. OF RANK BY FORTUNE 
CODE PATENTS PATENTS 500 RANK 
United Merchants & Manufacturers 
Varian Associates 
M. Lowenstein 
Avery International 
Nalco Chemical 
McLouth Steel 
EG &G 
Dean Foods 
Dorchester Gas 
Dan River 
Idle Wild Foods 
Storage Technology 
Gerber Products 
Collins & Aikman 
Norris Industries 
Bausch & Lomb 
Maryland Corporation 
Hoover Universival 
Wallace Murray 
H. H. Robertson 
Marley 
MacMillan 
Tyler 
Gifford-Hill 
Carpenter Technology 
Wm. Wrigley Jr. 
Kellwood 
National Starch & Chemical 
Wyman-Gordon 
26 33 325= 401 
45 142 219= 402 
10 50 298= 403 
29 
- 
432= 404 
22 7 396= 405 
27 
- 
432= 406 
28 10 385= 407 
33 39 313= 408 
44 67 275 = 1109 
28 
- 
432= 410 
10 
- 
432= 411 
38 791 72 412 
33 5 406= 413 
28 20 347 = 414 
36 8 390= 415 
45 96 246= 416 
23 
- 
432 
= 
417 
45 23 342= 418 
45 142 219= 419 
20 
- 
432= 420 
20 
- 
432= 421 
22 57 291 422 
36 748 75 423 
22 9 387= 424 
26 56 292= 425 
28 533 97 426 
33 
- 
432= 427 
38 58 286= 428 
20 
- 
432= 429 
29 
- 
432= 430 
22 12 375= 431 
20 
- 
432= 432 
44 34 323= 433 
20 62 282 434 
22 21 346 435 
34 75 268 436 
38 294 166 437 
26 52 296= 438 
34 19 351= 439 
34 92 252= 440 
34 125 233 441 
45 22 344= 442 
27 
- 
432= 443 
33 11 379= 444 
32 6 401= 445 
33 45 306= 446 
20 13 373= 447 
23 29 331= 448 
28 222 185= 449 
34 10 385= 450 
_Table 
50: 1981 Fortune 500 Largest US Industrial Corporations Ranked 
by Sales and showing Rank by US Patents 1969-1980 (continued) 
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Spearman 
Industry Definition Coefficient 
Code R 
44 Office equipment (includes computers) 0.940 
47 Musical instruments, toys, sporting goods 0.900 
32 Glass, concrete, abrasives, gypsum 0.838 
41 Aerospace 0.829 
30 Rubber, plastic products 0.829 
29 Petroleum refining 0.824 
38 Measuring, scientific, photographic equip. 0.746 
33 Metal manufacturing 0.711 
45 Industrial and farm equipment 0.673 
37 Shipbuilding, railroad and transportation equip. 0.673 
40 Motor vehicles 0.665 
28 Chemicals 0.663 
49 Beverages 0.646 
20 Food 0.639 
36 Electronic appliances 0.614 
10 Mining, crude oil production 0.587 
34 Metal products 0.572 
27 Publishing, printing 0.539 
48 Broadcasting, motion picture production 0.500 
26 Paper, fibre and wood products 0.446 
42 Pharmaceuticals 0.439 
22 Textiles, vinyl flooring 0.363 
43 Soaps, cosmetics 0.357 
23 Apparel 
-0.138 
Table 52: Industries represented by the 1981 Fortune 500 Largest 
US Industrial Corporations ranked by Spearman Rank Coefficients 
determined for Sales and Patenting Activities 
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12: DISCUSSION 
The objectives of the studies undertaken for this work were as follows: 
firstly, to look in detail at a particular technology, the Cephalospo- 
rins, to ascertain what types of pseudo-proprietary information could 
be gleaned from a study of the patenting activity in the technology 
concerned and, by an examination of the patent applications themselves 
(as abstracts in Derwent's Central Patents Index), to review the 
scientific/chemical developments taking place in this particular field 
of pharmaceuticals. 
Secondly, having supplemented the patents data on Cephalosporins with 
data on other technologies, to see whether some bibliometric measure- 
ments which have previously been applied to patents data, and others 
which have not hitherto been applied to such data, are applicable to 
patents information retrievable from a large publicly accessible online 
database. 
THE CEPHALOSPORINS 
The Importance of Cephalosporins 
A review of world antibiotic sales, as shown in Figure 48 indicates 
that Cephalosporins occupy an important place in the total antibiotic 
market256. Before the appearence of the latest generation of compounds, 
the two principal advantages which allowed cephalosporins to occupy a 
favourable position in the market place in competition with penicillins 
were (a) a lesser degree of sensitivity to beta-lactamases, and (b) the 
less frequent occurrence of allergies. 
On the other hand, the relative daily costs of treating most infections 
with. cephalosporins are four to five times the costs for penicillins 
- 
a consequence of the more laborious and costly isolation procedures for 
cephalosporins. 
A senior executive of Roussel-Uclaf stated257, in June 1980, that the 
world market for cephalosporins, including the hospital sector, is 
$1.5 billion, nearly 33% of the total antibiotic market. Furthermore, 
growth rate is 12-15% per year 
- 
higher than any other antibiotic. 
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Figure 48: World Antibiotics Sales 
The Cephalosporins patents data retrieved from the WPI online database 
as described in Appendix I, and analysed as shown in Chapter 11, has 
permitted the preparation of the following observations. 
Who is working on Cephalosporins? 
A complete list of the applicants is given in Table 16. In this table 
the applicants have been ranked according to the number of Cephalospo- 
rin applications assigned to. each. 
The top ranked twenty applicants have assigned to them 2,039 basic 
patents, representing 69.3% of the total of 2,944; Figure 49 illust- 
rates the share of the applications each of these applicants has made. 
On the other hand 89 patentees had each only one patent and 29 had only 
two; the distribution of patents per patentee is shown in Figure 50. 
Types of Applicant 
An analysis of the types of patentee (Tables 9-12) showed that 75.5% 
were industrial proprietary organisations, a surprising 13.9% are 
independent inventors, 6.9% are working in academic institutes and 3.7% 
are not-for-profit organisations such as NRDC -in the UK and Agence 
Nationale de Valorisation in France; Eastern Bloc pseudo-proprietary 
organisations have been included in the not-for-profit sector. This 
distribution is illustrated in Figure 51. 
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Figure 49: The Top Twenty Cephalosporin Patentees and their Shares 
of the 2039 Patents, Representing 69% of the Total, which they own 
Figure 50: Distribution of Cephalosporin Patents amongst Patentees 
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Unlike other fields of technology, such as the mechanical disciplines, 
it is extremely difficult for independent inventors to sustain the 
financial involvement and risks associated with pharmaceutical R&D. 
Further examination of the 30 private inventors showed that for 11 
of them their patents concerned compositions and for four of them the 
subject matter concerned the use of cephalosporins in biological 
culture and assay media. Three private inventors have patents concern- 
ing isolation/purification and one biosynthesis of cephalosporins; the 
remainder hold patents involving chemical synthesis of cephalosporins. 
It is thought that this latter group are not truly "private" inventors 
but industrial workers who have been rewarded with their names on 
patents which, at the time of this study, remained unassigned to a 
corporate entity. 
P,, ate Inventors 
P'01), 
-etar 
Organisations 
145 
Figure 51: Types of Cephalosporin Patentee 
Where is the work being conducted? 
Two techniques have been used in the attempt to ascertain where the 
work on cephalosporins is being carried out. In the first method an 
analysis was made of the countries of domesticity of the patentees, 
other than those classed as private inventors (Table 13). For the 
trans-national corporations the country of domesticity was considered 
to be that of the parent company; for example, in the case of American 
Home Products Corporation some of their patents (total of 45) have 
originated from their wholly owned subsidiary company Ayerst Laborator- 
ies located in Canada 
- 
all these patents have been listed as if owned 
by AHP. This is illustrated in Figure 52. 
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From this analysis there is a clear indication that the greatest 
concentrations of workers in the field of cephalosporins are to be 
found in Japan and the USA. 
It is reasonable to assume that the priority country claimed in the 
earliest priority for any applications is likely to be the country in 
which the work has been carried out (although this is not necessarily 
so as some companies, such as some based in Switzerland and Japan, 
will file first overseas 
- 
notably in the UK 
- 
to take advantage of a 
feature of UK patent law known as 'provisional then complete'). A 
study was made of the priority countries claimed on the basic patents. 
This, too showed that the majority of patents originated from Japan 
and the USA, with the UK in third position. As mentioned before, the 
figure for the UK is probably inflated, i. e. not truly representative 
of the work being carried out in the UK, since, for example, many of 
the Japanese companies tend to claim UK priorities on their applicat- 
ions. For example, 49 of the Fujisawa basics claim a UK priority. 
Figure 52: Countries of Domesticity of Cephalosporin Patentees 
(Excluding Private Inventors) 
*Others: Austria 1 Hungary 1 Poland 2 
Belgium 2 Israel 2 Portugal 1 
Canada 3 Korea 1 USSR 2 
Denmark 1 Liechtenstein 1 Yugoslavia 1 
Finland 1 Dutch Antilles 1 
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The ratios of priority countries have changed over the years as addi- 
tional organisations have moved in, and some companies have moved out, 
of cephalosporin technology and/or as R&D work has been less fruitful 
in patentable innovation; the changes in priorities claimed are shown 
schematically in Figure 53. 
Whilst the foregoing may be true of other countries, and in part to 
Japan, it should be noted that one other factor greatly influenced 
patent filing activities in Japan in the mid-1970s. Japanese patent 
law was revised on January 1,1976, whereby, for the first time, 
chemical substances (rather than processes for their manufacture), 
foodstuffs and drugs per se became patentable. Pending this revision 
in the law patentees withheld filing applications during 1975 and filed 
them only in a surge after the effective date of the revised law. As 
shown in Figure 54, this resulted in a dramatic drop in the number of 
pharmaceutical applications claiming Japanese priorities in 1975 
-a 
fact which significantly influences any statistical and numeric analy- 
ses of patent activity covering this time period. 
Subject Coverage of Applications 
Each of the abstracts relating to the retrieved data was examined to 
asertain the type of invention for which protection was being request- 
ed. The data was classified into the main groups shown in Table 21 and 
illustrated in Figure 55. 
In many cases where a single compound, or a group of compounds, had 
been synthesised it was not always possible to determine from the 
abstract (and, in many cases where more detailed study was found 
necessary, from the patent specification) whether the subject compounds 
were for use as intermediates in the synthesis of pharmacologically 
active drugs, or were drugs per se. Such cases have been classified 
under "synthesis"; only in those cases where it was specifically stated 
that the subject compounds were intermediates have the patents been 
classified accordingly. 
Whilst the results obtained from classification of the retrieved data 
from the entire file indicate that the overwhelming number of applica- 
tions have been for the synthesis of endproducts or intermediates, this 
pattern has not always been true. 
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Intermediates: only when specifically stated 
* Other: such as use in assay/culture media 
Since the early clays there has been a marked tendency away from the 
isolation and purification of natural cephalosporins through the 
semi-synthetic compounds to the totally synthetic cephalosporius. 
Similarly there has been a small but sustained increase in the number 
of applications for compositions over the period concerned. 
When did the Applicants First. Enter the Field? 
To try and ascertain when patent applicants first entered cephalosporin 
technology the applicants have been listed in Table 14 in the order of 
the earliest priority date claimed on any of their applications. 
All of the major companies involved with early developments in Cephalo- 
sporn technology as described in Appendix I are to be found in the top 
13 companies when ranked by priority data. 
It is generally considered that the lead time between initiating a 
pharmaceutical research project and having sufficient successful re- 
sults to apply for a patent is around two years. This is borne out by 
the interval exhibited between the date: upon which agreese nt. s/licenses 
were entered into and the earliest priority loci for the companion, 
coneernýd. 
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Amongst the major companies to have moved into the field more recently 
are Miles Laboratories and Warner Lambert in the USA, Kureha and Tanabe 
in Japan, Sandoz in Switzerland, Sigma-Tau in Italy and Wellcome in the 
UK. 
A Closer Look at the Top Twenty 
With the exception of Asahi and Teijin, each of the leading companies 
in the field is well known for their pharmaceutical products. However, 
in terms of their total corporate activities, their individual commit- 
ment to pharmaceuticals varies. This variance is given in Tables 17 
and 18 and is illustrated in Table 53, where the numbers of total 
patent applications, pharmaceutical applications and cephalosporin 
applications for each company are given. 
Commitment to pharmaceuticals varies from as low as 6.8% of total 
applications for Asahi to 97.4% for Squibb. As most of these companies 
are usually considered to be pharmaceutical it is of interest to note 
some of their other activities. For example, Glaxo is involved with 
baby and health foods, surgical instruments and hospital equipment. 
Ciba-Geigy is involved in agrochemicals, adhesives and dyestuffs. 
Beecham's main non-pharmaceutical activities are in the area of toilet- 
ries, cosmetics, food and drinks. 
This pattern of involvement in other technologies is typical of the 
companies. Naturally related areas to pharmaceuticals, such as veteri- 
nary medicine, cosmetics and agrochemicals, are commonly pursued by the 
pharmaceutical houses. 
Two of the Japanese companies (Asahi and Teijin) are more well known 
for products other than 
. 
pharmaceuticals. Asahi is Japan's largest 
producer of synthetic fibres and additionally has interests in plas- 
tics, construction materials and printing systems; involvement in 
pharmaceuticals is a relatively new, but rapidly growing, area of 
interest for this company which has a declared policy of diversifica- 
tion 
- 
especially as the synthetic fibre demand decreases with the 
world recession. 
Teijin too is heavily involved with manufacturing, processing and 
selling man-made fibres; other major interests are petrochemicals, 
foodstuffs and materials (mostly plastics) for civil engineering. Like 
- 
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Asahi, Teijin is trying to diversify and as part of this policy has 
moved into pharmaceuticals in recent years. 
Table 53 also indicates, within the broad category of pharmaceuticals, 
the individual company's involvement with cephalosporins. The most 
heavily committed company is Glaxo. Amongst the other comanies heavily 
committed to cephalosporins are Bristol-Myers, Eli Lilly, Fujisawa, 
Toyama and Meiji. 
Not all the Top Twenty have been in Cephalosporin technology since the 
late 1950s when the NRDC was negotiating licence agreements with the 
companies mentioned earlier. Indeed eight of the Japanese companies 
only entered the field in the late '60s/early '70s. This is shown in 
the time-scale diagram given as Figure 56 based on Table 14. 
A second time-scale diagram, Figure 57, based on Table 15, indicates 
when each of these companies first made known publically their cephalo- 
sporin interests through the medium of having the first of their patent 
applications published. The pattern closely follows that of the filing 
of applications, but is additionally important as it provides an 
indication of when other companies, perhaps not amongst the leaders, 
may have gleaned information to enable them to embark on parallel R&D 
effort 
- 
possibly involving "molecular roulette" techniques of chemical 
structure manipulation. 
Figures 58 to 61 indicate how each of the Top Twenty has built up its 
bank of Cephalosporin patent applications. 
Amongst those ranked 1 to 5 Fujisawa, Eli Lilly, Squibb and Glaxo show 
a sustained and continued involvement in Cephalosporins since the early 
1960s. Takeda has only been in the field since the late 1960s (assuming 
again, that a patent application is filed only some two years after 
initiation of R&D programmes); in this time, however, the company has 
built up a commanding position and has evidentally diverted a great 
deal of effort into cephalosporin technology. 
Of those companies ranked 6 to 10, Sankyo has, like Takeda, embarked on 
Cephalosporin work relatively late. The other four companies show 
continuing and steady involvement. 
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Amongst the companies ranked 11 to 20 only Beecham and Roussel-WV 
have sustained research effort in this area since the early day: - 
Clustered in this group are a number of Japanese companies whose 
research efforts commenced around 1968 to 1970, soon after the first 
applications of the early workers (Glaxo, Squibb, Fujisawa, etc. ) had 
been publinhed. 
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Figure 58: Cumulative Numbers of Basic Patents by Priority Year 
for Companies Ranked 1 to 5 
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Figure 59: Cumulative Numbers of Basic Patents by Priority Year 
for Companies Ranked 6 to 10 
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Figure 59: Cumulative Numbers of Basic 
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for Companies Ranked 16 to 20 
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A Growing. Steady or Declining Technology? 
The number of priorities claimed each year on basic applications as 
shown in Figure 62, indicates significant increase between 1966 and 
1974. This would appear to reflect major research effort from the 
mid-1960s to early 1970s. In 1975 there was a significant fall in the 
number of priorities claimed, but this is explained by the effects of 
changes in Japanese patent law referred to earlier. The number of 
priorities claimed did not quite recover to its former level in 1976, 
but since then has shown a significant decline. 
Figure 62: The Growth and Decline of Cephalosporin 
Priority Applications 
- 
279 
- 
The decline in patenting activity since 1976 can be attributed to (a) a 
decline in R&D effort, (b) the fact that the field of cephalosporins is 
becoming exhausted, with fewer patentable discoveries to be made, and 
(c) the fact that more recent applications have not yet been published 
and so have not yet entered the database. Probably all three factors 
are at work. 
Whilst patent application counting as a measure of R&D effort effect- 
iveness has received recognition as a suitable index, the technique has 
some drawbacks and is purely empirical. 
Development in Cephalosporin Technology 
A review of recent developments in Cephalosporin technology and an 
assessment of the thrust of the technology is given in Appendix I. 
Whereas the foregoing indicates a decline in corporate research acti- 
vity in this field, there is nevertheless a continuing steady flow of 
patent applications. Many of these, superficially at least, seem to be 
indicative of the pharmaceutical industry's propensity for "molecular 
roulette", i. e., company B, having noted a development by company A as 
disclosed in a patent application, attempts to develop further active 
compounds which are derivatives of company A's disclosed compounds but 
which, by modifying positional substitution, functional groups, etc., 
lie beyond the scope of the earlier application. Such "molecular 
roulette" is an example of the technology building on technology 
phenomenon. 
Relationship Between Sales and Patenting Activity 
As discussed in Chapter 4, several economists have stated that for a 
company to sustain effective R&D effort and thereby introduce innova- 
tive products in to the marketplace, there is a need for that company 
to have a sufficiently high sales volume to support the R&D effort. 
According to Fortune magazine 
258 there exists, for those engaged in R&D 
work in the USA pharmaceutical industry, a problem invariably described 
as that of "critical mass". The term is borrowed from the world of 
nuclear physics and refers to the amount of fissionable material 
necessary to create a chain reaction. In an atomic bomb, for example, 
fissionable material the size of a golf ball would be too small - 
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"subcritical14. But if the mass is of baseball size, a self-sustaining 
reaction becomes possible. 
In the pharmaceutical business today, the equivalent of that baseball 
is widely perceived to be an annual-research budget of about $75 
million. At that level and up, the proposition goes, a company can 
fund research on a broad spectrum of products, allow for the inevitabl? 
disappointments and, over time, very likely develop enough new products 
to support a sizeable marketing operation. Each of these products, the 
conventional wisdom continues, will have taken years to get to market, 
at a cost of perhaps $50 million 
- 
the price imposed by tough laws 
concerning safety and efficacy. 
Another piece of conventional wisdom in the industry is that a company 
cannot rationally spend much more than 10% of its sales on research, a 
proposition suggesting that a $75-million research budget can be 
supported only by a company with at least $750 million in sales. 
If these suppositions are correct and can be applied worldwide one 
could conclude that many of those companies with sales less than about 
£300 Millions may not be engaged in basic research. However, it is 
probable that the figure of $750 Millions for sales required to sustain 
research is too high since leading companies - well known to be com- 
mitted to research 
- 
have sales below this figure, e. g., SmithKline, 
Fujisawa, Miles Laboratories and Sankyo. 
Nevertheless, the studies reported herein for that sector of the 
international pharmaceutical industry concerned with Cephalosporin 
technology, indicate a positive correlation between sales and Cephalo- 
sporin patents. The Spearman Rank Correlation Coefficient, for 142 
patentees ranked by numbers of patents and by sales, was found to be 
0.3369 which is significant at the 0.10 level. This would confirm, at 
least for the particualr technological field, that the companies which 
are the most successful at inovating are those with the higher sales 
volumes. 
Nolan, Oppenheim and Withers? found that overall, patenting in the 
pharmaceutical industry is positively correlated with profits and with 
sales, but for certain companies there was a significant negative 
correlation, whilst for others there was no significant correlation 
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either way. These authors also found that turnover was significantly 
correlated with both R&D and patenting. 
In an earlier study, Reekie25 examined the pharmaceutical industry's 
R&D activity at the national (UK), international and individual firm 
levels. In the national study the very smallest firms were found to 
perform proportionately less R&D than the medium to large sized compan- 
ies. In the same study increasing returns to scale were discovered for 
R&D effort. Reekie concluded that the hypothesis that very small firms 
are optimal for introducing technology changes was unsupported. 
Individual company case studies cofirmed this and indicated that firms 
had to be at least large enough to cover the entire British market 
before they could support the expense required to participate in some 
minimum level of innovating activity. 
In Reekie's international study, however, the contending hypothesis 
that the largest concerns were optimal also received little support. 
The firms of greatest R&D intensity were found to be those of around 
the size grouping of the existing largest UK domestic concerns, al- 
though a second but lower optimum was also observed at a size level 
considerably larger than this but still short of that of the industry 
"giants". On the other hand, economies of scale in R&D appeared to be 
unexhausted even at the level of the largest R&D efforts. However, 
although the giant firms conducted more R&D than any other size of 
firm, and although they appeared to be enjoying unexhausted scale 
economies, because of their lower R&D intensity levels, giant firms did 
not produce per unit of sales as much output of R&D as did each of two 
smaller size groupings of firms. 
Schwartzman31, in discussing the R&D efforts of the USA pharmaceutical 
industry, demonstrates that the largest companies discover relatively 
more new drugs than do smaller firms, regardless of the measure of the 
number of discoveries. Schwartzman's measures included number of new 
chemical entities (NCEs) placed on the market, NCE data weighted by 
sales, by novelty, medical importance, number of prescriptions and 
corporate output measured by number of patents. Schwartzman found that 
sales-size was less closely correlated with the number of patents than 
with the other measures of research output, but that the elasticity of 
research output does increase with firm size. 
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No cause-effect relationship can be drawn from this study or the 
previous ones. It is not clear if high patenting causes high sales, 
high sales cause high patenting or whether they are, in fact, both 
controlled by other external variables. 
In considering which other factors may have an effect on the sales-R&D 
effort relationship, it is to be borne in mind that the pharmaceutical 
manufacturers compete for sales chiefly by seeking to discover and 
develop new drugs 
To discover new 'drugs, laboratories must synthesize thousands of new 
compounds and test them in animals. Few compounds survive these tests 
and go on to clinical (human) tests, and only a tiny fraction become 
medically successful marketed drugs. Few prospective drugs satisfy 
the demands for proof of efficacy in the treatment of disease and of 
safety against serious side effects. Adding to the uncertainty, very 
few of the marketed drugs win large sales. Manufacturers cannot 
predict the sales of new drugs before doctors have had time to learn 
about their properties, and very few drugs become popular and financ- 
ially successful. It is difficult to predict the winners of this game. 
A few popular drugs have earned large profits, but these are the 
exceptional successes which have provided the resources for financing 
the major companies' activities and the incentive for the continued 
search for new drugs. What is forgotten frequently is that most drugs 
have small sales. The return from the large investment in research and 
development is highly uncertain. 
Thus, factors which may influence the relationship may include the 
unpredictable occurence of undesirable side-effects and failure of 
pharmacologically active compounds to meet stringent legislation 
concerning safety. Having met with such requirements, effective 
advertising/marketing campaigns muust be undertaken to bring this new 
product to the notice of the medical profession and, perhaps more 
importantly, persuade them to prescribe the new drug at the expense of 
other drugs available for the treatment of the same ailment which are 
proven and firmly established in the market place. Furthermore, in 
those countries such as the UK with a public health care programmes, 
physicians, especially those in state run hospitals, may not be totally 
free to prescribe whatever they like, and so the relations with the 
state may have a bearing on sales. 
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The study of the broader span of technologies represented by the 
Fortune 500 companies indictates that there are considerable differe- 
nces between different industries in the relationship between patenting 
activity and sales. The Spearman Rank Coefficients found for all 
industries (r= 0.518,0.10 Level of Significance = 0.074) indicates a 
strong relationship between sales and patenting activity. 
However, as shown in Table 51, r varies from 
-0.138 for the Apparel 
industry to 0.940 for the Office Equipment (including computers) 
industry. Table 52 shows these industries ranked according to the 
determined values of r. In this set of data, those classed as Pharma- 
ceutical (17 companies) gave r=0.439 (0.05 Significance Level 
0.490), i. e., a rather weaker relationship than exhibited by the 
Cephalosporin patentees. 
As with the Cephalosporin data, it is not possible to establish causal- 
effect relationships with this broader set of patenting-sales data. 
Furthermore, although one might expect a higher correlation between 
sales and patenting for the high-technology industries and a lower 
correlation for services (such as broadcasting and motion picture 
production) or with traditional industries e. g. industrial and farm 
equipment, Table 52 does not reveal such a trend; musical instruments, 
toys and sporting goods exhibit a Spearman Rank Coefficient of 0.900 
yet electronics and appliances have one of only 0.614. 
Just as the comments on the pharmaceutical industry given above indi- 
cate an array of other possible influencing factors, so too there 
are such factors applicable to each of the industries in this study. 
It may also be possible that, just as Schwar'tzman31 showed that a lower 
correlation exists between sales and R&D effort measured by patenting 
activity, other measures of R&D might be more appropriate, e. g., new 
products launched. Similarly, the measures of firm size by sales 
volume may not be the best parameter and firm sizes as indicated by 
profit, percentage of sales devoted to R&D, manpower or capital may be 
more appropriate. Further work in this area is recommended. 
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BIBLIOMETRIC STUDIES 
Bradford-Zfpf "Law" 
The Bradford-Zipf bibliographs given in Figures 19 to 26 for eight of 
the patents data sets studied, indicate that generally patents data 
fits into the pattern obtained with journal literature studies inasmuch 
as each data set bibliograph exhibits a clear nuclear zone, a log- 
linear zone and a subsequent deviation from a log-linear relationship 
which, in the case of Cephalosporins, Cyclopropane Derivative Insecti- 
cides, Videodiscs and Terephthalic Acid Production data sets give a 
characteristic Groos Droop with the same indication of arcing. Arcs 
are noticeable in the other four bibliographs, i. e., Air Cushion 
Vehicles, Genetic Enginering, Pressure Sensitive Adhesives and Pharmac- 
ologically Active Pyrazolones; however, in these four cases the arcs 
lie above the extrapolated log-linear line. 
Calculations for N and R(N), representing total patentees and total 
basic patents respectively, as given in Table 23, show considerable 
deviation from the observed values. For Cephalosporins, Cyelopropane 
Derivative Insecticides and Terephthalic Acid Production observed N and 
R(N) were lower than the calculated values; for Videodiscs observed N 
and R(N) were higher and lower respectively than calculated values. It 
is noted that these four data sets are those which exhibit the Groos 
Droop, whilst for the other four data sets observed values of N and 
R(N) were all higher than the corresponding calculated values. 
It is of interest to note that three of the technologies (Cephalospo- 
rins, Cyclopropane Derivative Insecticides and Terephthalic Acid 
Production) exhibiting the Groos Drooop, are each "chemical" technolo- 
gies which have been covered by Derwent since 1963,1965 and 1966 
respectively, whereas with the exception of Pharmacologically Active 
Pyrazolones and Genetic Engineering, the other technologies have only 
been covered by Dewent since 1974. 
In those cases, where calculated values of N and ß(N) are higher than 
observed values, the indication of "missing" patentees and "missing" 
basic patents is explained by the limited country coverage of WPI. 
This limitation originated in two ways: firstly, only 26 patent issuing 
authorities are coverd, and secondly, a number of those countries which 
are covered have only been included in the service since 1974 or later. 
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This latter point is most significant in the case of Cephalosporins 
since the data here presented clearly shows a most rapid growth in. 
patenting activity in the period from 1968 to 1974 
- 
after which a 
marked decline has been observed. 
The "missing" patents may be assumed, therefore, to have been filed in 
Australasia, Latin American and Third World Countries generally 
- 
none 
of which are included in the WPI service. Doubtless a number of these 
applications will have originated from the most active patentees 
identified in this study. The "missing" patentees 
- 
probably each with 
only one or two patents 
- 
will tend to be smaller pharmaceutical houses 
and independent inventors. 
Similar explanations may be given for the other data sets, although for 
those technologies covered in the database only since the mid-1970s it 
is probable that the retrievable data just does not extend back enough 
to enable the construction of conventional bibliographs, albeit that 
interpretation of the bibliographs for patents shows considerable 
differences between observed and calculated values for total numbers of 
patentees and patents. 
This study represents the first time that the Bradford-Zipf Law has 
been applied to patents data. This novel application of the bibliograph 
technique shows that patents data seems to conform to the same patterns 
as those observed with journal literature. 
However, there can only be a partial analogy between the clustering of 
articles in a particular journal and the clustering of patents by 
particular patentees; nevertheless, the analogy that certain patentees 
can be expected to receive more than their "fair share" of patents on a 
given technology is present. Clearly, as indicated earlier, the 
motivations for an author to publish a paper in a learned journal and 
the propensity for an inventor to apply for a patent are different, 
irrespective of whether the author or inventor are academic, corporate 
or government employees, or even totally independent. 
Numerous uses have been made of the bibliograph: items borrowed from a 
library, users ranked by number of items they borrow, number of items 
cited and the index terms assigned to documents. These uses of the 
Bradford-Zipf distribution have value for library decision-making, 
since the distribution allows for the prediction of regularity in a 
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variety of events. Broadly speaking, this regularity is characterised 
by both concentration and dispersion of specific items of information 
over different sources of information. Thus for a search on some 
specific topic, a large number of relevant articles will be concent- 
rated in a small number of journals; the remaining articles will be 
dispersed over a large number of titles. Knowledge of sources and 
their items permits prediction of core collections, core users and core 
index terms. 
Since the Bradford-Zipf Law appears from this study to be applicable to 
patents information, it could be used on a similar way as librarians 
apply it to decision-making. In an analogous way patents information 
users could use Bradford-Zapf to identify the major patentees, those 
patentees chose applications are not worth bothering with, and those 
patentees whose applications should be searched for in a patents 
database. 
One application to which Bradford-Zipf is applied is in the evaluation 
of the quality of abstracting services, i. e., the comprehensiveness of 
the service in covering all relevant literature. This achieved by 
determining, from the bibliograph derived data, the percentage of the 
total theoretical papers which it covers. Whilst Table 23 indicates 
considerable differences between observed and theoretical numbers of 
patents and patentees, it is to be noted that these differences, at 
least in part, must be attributed to (a) the changes in subject cover- 
age, (b) the changes in country coverage, and (c) the partial coverage 
of the total number of patents worldwide by the WPI/WPIL database. 
Sviridov259 has stated that globally there are about 1 million patent 
documents per year; at a weekly input level of 10,000 documents per 
week in 1982, WPI/WPIL is only covering 50 to 55% if the total 
'docu- 
ments. One aspect of this which it is considered worthy of further 
study is that the bibliographs used in this study were constructed 
using figures of basic patents per patentee, whereas using total patent 
families per patentee may give a different set of results. 
Vector Analysis Graphs 
Figures 27 to 37 give vector analysis graphs for each of the eleven 
patents data sets studied; in each case, with the exception of the 
Cephalosporins data sets, the final data point represents the patenting 
activity as recorded in the data base for 1978. As the retrievals were 
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conducted in mid-1981 these data points may be misleading as the 
database would have contained all those applications filed up until t)e 
end of 1978 which appeared from those countries publishing patents 
without examination under the so-called "18-months" system; but the 
applications from countries such as the USA, publishing only after 
examination, several years after the filing of an application, would 
not yet have been included. For the original Cephalosporins data se. 
a similar situation prevailed, with dates two years earlier; for the 
updated data set, the 1978 data point has been used as the retrieval 
was conducted 32 months after the end of 1978. Thus, in the discussion 
which follows, the location of the penultimate data point and the 
characteristics of the penultimate vectors are considered. 
(a) Cephalosporins 
For the original data set, the 1976 data point is located in Quadrant 
I, indicating that the technology gras in the Development Stage. The 
relative length of the 1975/1976 vector with the other vectors, the 
former being relatively large, indicates that this state is relatively 
certain, whilst the fact that the 1975/1976 vector is only moderately 
parallel to the bisecting line of the quadrant indicates that the trend 
appraisal is only moderately certain. 
For the updated Cephalosporins data set, the 1978 data point lies in 
Quadrant II, indicating that the technology is in the Research or 
Perfection stage; that is to say that in the time interval between the 
two data sets, the technology had progressed from Development and that, 
in all probability, whilst manufacturing processes may have been 
initiated, and indeed more Cephalosporin containing medicaments have 
become available on the market, R&D activities had slackened off and 
research was being concentrated elsewhere, for example, in the new 
Olivanic and Clavulanic Acids classes of antibiotics. The 1977/1978 
vector lies quite parallel to the vector bisect, but is only relatively 
short in length thus indicating that the trend appraisal is quite 
accurate, but because of this relative shortness it is probably trans- 
ient and a further shift should be expected. 
(b) Air Cushion Vehicles 
The 1977 data point lies in Quadrant III indicating a Fully Mature or 
Declining Stage. Both the direction and length of the 1976/1977 vector 
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indicates that the interpretation is reasonably accurate. Whilst the 
graph exhibits a certain amount of closing, the general appcarence is 
that research activity has been polarised between Quadrants I and III; 
this would indicate that there is a continuation of research in-this 
technology, but that such improvements that are made are quickly 
implemented and that a step-wise development occurs rather than a 
steady flow of improvements exhibited by the Cephalosporins. 
(e) Cyclopropane Derivative Insecticides 
The 1977 data point lies in Quadrant I indicating the technology is in 
a Development Stage. Both the length and direction of the 1976/1977 
vector indicate a high degree of certainty for this interpretation. 
The overall appearance of the graph indicated a bias towards Quadrant 
II (Research or Perfection) and some polarisation with Quadrant IV 
(also indicative of Research or Perfection). The more recent shift to 
Quadrant I would thus be indicative of a previously unknown group of 
derivatives with insecticidal activities. 
(d) Videodiscs 
In this case also the 1977 data point lies in Quadrant It again indica- 
tive of a Development Stage. Whilst the relative length of the 1976/ 
1977 vector would indicate a reasonable accuracy in this interpreta- 
tion, its direction indicates the opposite as it is almost parallel to 
the y-axis rather than to the vector bisect. On the other hand, the 
overall appearance of the graph shows a concentration of data points in 
Quadrant I which is in keeping with the fact that this is indeed a 
developing technology. 
(e) Genetic Engineering 
Once again the 1977 data point lies in Quadrant I, however, both the 
length and direction of the 1976/1977 vector indicate that the accuracy 
of the interpretation that the technology is in the Development Stage 
is not too strong. However, the overall appearance of the graph shows 
that with the exception of the 1974 data point, all others lie in Quad- 
rant I, confirming the known fact that this. is a developing technology. 
0 
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(f) Terephthalic Acid Production 
The 1977 data point lies in Quadrant II, indicative of the technology 
being in a Research or Perfection stage; this interpretation is confir- 
med by both the direction and relative length of the 1976/1977 vector. 
Whilst the graph exhibits a certain amount of closure of vectors, the 
overall appearance is that there is a polarisation of data points 
between Quadrants II and IV, both quadrants indicating the same stage. 
In all probability, as this is a technology which has been in existance 
for many years, the state of the art is one of Perfection rather than 
of Research and that recent applications are for process patents which 
involve minor modifications to marginally improve yields rather than 
significant new synthetic techniques. 
(g) Pressure Sensitive Adhesives 
In this case the 1977 data point lies in Quadrant III, i. e., Fully 
Mature or Declining Stage. Whilst the direction of the 1976/1977 
vector indicates that this interpretation is reasonably accurate, the 
length of the vector does not offer the same degree of confirmation. 
Again the overall appearance of the graph indicates a polarisation 
between Quadrants I and III with a concentration of data points in the 
former. ' The 1975/1976 and 1976/1977 (and also 1977/1978) vectors are 
however each directed towards Quadrant III indicating the interpretat- 
ion that this is a mature/declining technology is correct. 
(h) Pharmacologically Active Pyrazolones 
The overall appearance of the graph is that of polarisation of data 
points between Quadrants I and II, although the 1977 data point lies in 
Quadrant I indicating a Development Stage. Both the direction and 
length of the 1976/1977 vector indicate that the interpretation is 
reasonably accurate. The movement of vectors between Quadrants I and 
IV may be interpreted as indicative of a series of research efforts 
resulting in new pyrazolone derivatives which require little further 
research to bring them into the market place; having produced such a 
product, research continues until such time as another efficacious 
compound is identified and marketed, and so on and so forth. In this 
technology, however, it is possibletthat more recent developments could 
be in formulation rather than new effective compounds. 
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(i) Olivanic and Clavulanic Acid 
It is known that these two technologies represent some of the latest 
developments in the technology of antibiotics. It is not surprising, 
therefore, that in both cases the 1977 data point lies in Quadrant I 
and that the lengths of the 1976/1977 vector indicate a high degree of 
accuracy in this interpretation. For Olivanic Acid the direction of' 
the 1976/1977 vector further confirms this, although the direction of 
the 1976/1977 vector for Clavulanic Acid indicates a weaker confirma- 
tion. In both cases, the concentration of data points lies in Quadrant 
I. 
The Vector Analysis technique is a relatively new, and virtually 
untried, method for technology asessment. Other than the original work 
of the Japanese Patent Office, and the use of the technique by OTAF, 
vector analysis has not hitherto been used and certainly not in such a 
wide variety of technologies as in this study. 
This study represents a major confirmation of the value of Vector 
Analysis in providing a good indication of the state-of-the-art in any 
technology and thus can be used with a reasonable amount of confidence 
in technology forecasting. It is strongly recommended that it be more 
widely used in the future; it would be most desirable if future analy- 
ses of technologies include a patent vector diagram to support any 
assertions made. 
RELATIONSHIP BETWEEN BRADFORD-ZIPF AND VECTOR ANALYSIS GRAPHS 
Vector Analysis graphs are relatively complicated to construct, and 
require far more effort than the relatively simple Bradford-Zipf 
graphs. Bearing in mind that the degree deviation from the log-linear 
relationship exhibited by Bradford-Zipf plots is considered to be an 
indication of incompleteness, an attempt has been made to see if a 
measure of this incompleteness can be correlated with the technology 
assessment derived from the Vector Analyses. To do this measurements 
have been made of the relative length of the portion of the Bradford- 
Zipf graph which shows deviation to the nuclear and log-linear zones; 
referring to Figure 63, a factor of BC/AB has been calculated for the 
Bradford-Zipf plots given in Figures 19 to 26. 
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Figure 62: The Bibliograph Segments 
Comparing this factor with the Vector Analyses interpretations indic- 
ates that values of BC/AB less than 0.55 correspond to an assessment in 
Quadrant III, values of 0.55 to 0.80 to Quadrant II and values greater 
than 0.80 to Quadrant I. However, the values of BC/AB for Genetic 
Engineerng and Pharmacological Pyrazolones, both of which gave 1977 
data points in Quadrant I of the Vector Analysis graphs, were 0.13 and 
0.36 which correspond more Quadrant III; as far as the Genetic Engine- 
ering data is concerned the data points are however clustered in 
Quadrant I, but such clustering is not so obvious in the case of the 
pyrazolones. 
If in fact deviation from the log-linear relationship is an indication 
of completeness of the data set, then there is no reason to expect that 
the more mature a technology is, then the lesser the amount of deviat- 
ion; yet this is precisely the result that has been obtained. It may 
well be, therefore, that a scale of values for BC/AB can be established 
which will give a quick empirical indication of the state of a particu- 
lar technology by interpretation of Bradford-Zipf plots. 
The indication of a possible relationship between Bradford-Zipf biblio- 
graphs and Vector Analysis diagrams is intriguing. Had time permitted, 
this study would have been extended to elaborate on this aspect of 
patents statistics; this area is one for which further research is 
certainly desirable. 
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FREQUENCY DISTRIBUTIONS FOR PATENTS PER PATENTEE 
Figures 38 to 47 give Lotka's Law graphs for the patents data sets 
examined. These are based on calculated values for Lotka's exponent 
ranging from 0.24 (Clavulanic Acid) to 1.91 (Pyrazolones). Beacuse of 
these results it is clear that Lotka's empirical inverse square law 
does not hold for collections of patents data. In fact, this is not 
very surprising since, as shown in Table 6, relatively few studies have 
in fact confirmed Lotka's "Law" although a few have given values for 
the exponent which are close to 2. 
This observation, obtained from a comprehensive survey of the litera- 
ture, is surprising in the sense that hitherto Lotka's "Law" has 
generally beeen considered as proven and is widely used in bibliomet- 
rics. A first consideration of the results obtained in this study 
would indicate that patents data does not fit Lotka's "Law"; further 
consideration leads to the question: Is Lotka's "Law" widely applic- 
able? If it is not, as previous studies would seem to indicate, then 
the non-conformity of patent data to Lotka would appear to fit the rule 
rather than be the exception. 
At the expense of being repetitive it must by stated again that the 
motivations for publishing an article in a learned journal differs in 
several respects from those which lead to a patent application. For 
example, commercial considerations are of prime importance in deciding 
whether to seek a patent application whereas the decision of whether to 
publish a journal article by, for example, academic workers may well be 
influenced by a desire to maintain, or even advance, personal status 
within the academic community. Furthermore, since there is evidence 
that the major portion of technological progress which is published in 
patents is never published elsewhere, it is likely that had Lotka, and 
subsequent workers, studied patents literature or the total collection 
of patents plus journal literature for a given technology, Lotka's 
inverse square "Law" may never have been postulated. 
The "failure" of fitting patents data to Lotka's "Law" led, in this 
study to a consideration of the possible applicability of other fre- 
quency distribution models to the observed data. Some of these distri- 
butions have only been used once or twice before in bibliometric 
studies; certainlly they have not received the attention that Bradford- 
Zipf and Lotka distributions have. To achieve this and to bring 'the 
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applications of some of the little-known distributions into the domain 
of any information worker with access to a microcomputer, a series of 
programs written in easy-to-use BASIC language were developed 
- 
al- 
though some were based on earlier studies by other research workers. 
The same programs, without modification, were usable with both patents 
per patentee and citations per patent data sets; they are applicable to 
any data sets which need frequency distribution analysis, such as in 
econometrics. 
From Table 36 it is seen that when testing a selection of theoretical 
frequency distributions to the patents data sets studied, only the 
Negative Binomial distribution was found to fit all the observed 
distributions at the 0.01 Level of Significance for values of the 
Kolmogorov-Smironov Dmax parameter. The Borel-Tanner and Simon-Yule 
distributions were found to closely fit observed values in all cases 
other than the Cephalosporins data sets but generally values of D 
max 
for these distributions were higher than those for the Negative Bino- 
mial Distribution. 
These results are similar to those observed by Rao, who found that the 
Negative Binomial gave a theoretical distribution which closely fitted 
journal literature data when tested with the X2 test, and the observa- 
tions of Coile in respect of the Simon-Yule distribution when tested by 
the Kolmogorov-Smirnov Test. 
These results indicate that bibliometricians, who hitherto have gener- 
ally restricted their studies to the well-known frequency distributions 
such as Lotka's "Law", should broaden their investigations to include a 
wider selection of distributions such as the Negative Binomial, Simon- 
Yule and Borel-Tanner distributions. As a possible topic for further 
study, it is suggested that some of these lesser known distributions 
are applied to data sets published by various authors which have tested 
their data against Lotka's "Law" to see if better fits between observed 
and theoretical observations can be obtained; not least of all, their 
applicability to Lotka's original data used in his 1926 studies should 
be tested. 
FREQUENCY DISTRIBUTIONS FOR PATENTS CITATIONS 
As shown in Table 48, the Negative Binomial distribution was found to 
provide theoretical distributions which fitted all the observed data 
- 
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sets. Both the Borel-Tanner and Simon-Yule distributions gave frequen- 
cies of citations per patent which fitted all but one set of observed 
data but in nearly all cases values of Kolmogorov-Smirnov Dmax were 
lower for the Negative Binomial than the other two frequency distribu- 
tions. 
IMPLICATIONS OF THE APPLICABILITY OF THE NEGATIVE BINOMIAL DISTRIBUTION 
Rao has shown that the Negative Binomial distribution described the 
patterns of scientific productivity under the success-breeds-success 
condition, when using this distribution in reference to journal arti- 
cles, in a wide variety of social circumstances. The results obtained 
in this study show that this distribution is equally applicable to 
scientific productivity as indicated by the patent literature, although 
as indicated above, the motivations to apply for a patent may differ 
from those leading to publications of a journal article. 
If patenting activity does follow the success-breeds-success phenome- 
nom, then by analogy to the activities of journal article authors, 
i. e., that the probability that an author who has already published n 
articles in a given time interval will publish a further article 
increases as n increases, it may be concluded that successful patentees 
are more likely to apply for further patents. Furthermore, if, as 
indicated in the studies of sales vs. patenting activity, the latter is 
correlated with sales volumes, it is axiomatic that firms which are 
successful innovators are most likely to be those already established 
with a good market share for their product. 
APPLICATIONS OF THE RESEARCH REPORTED HEREIN 
It is clear from this study that, whether for. technological forecasting 
or for pseudo-proprietary information, statistical measurements of 
patenting activity are necessary to provide a most complete picture. 
Because of the author's management role in Derwent Publications Limited 
he has been able to influence that company's development plans such 
that it is proposed early 1983 to instal a suite of statistical manipu- 
lation computer programs in the same host computers as the WPIA? PIL 
databases so that the many users of the patents database will be able 
to quickly and easily derive meaningful patents statistics to assist 
them in their research and policy making decisions. 
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RECOMMENDATIONS FOR FURTHER RESEARCH 
There are several areas where further study is warranted. Firstly, 
with regard to the Cephalosporins, a more detailed look into the re- 
lationship between types of novel compound and priority and publication 
dates for the applications by patentees within the compound type might 
well shed some light on how extensive, or otherwise, is "molecular 
roulette". 
Secondly, in regard to patenting vs. sales data, further studies are 
recommended using different measures of firm sizes, for example, 
profit, percentage revenues and profit devoted to R&D, number of new 
entities placed on the market, capital investment and manpower. 
Thirdly, in respect of the Bradford-Zipf bibliographs, similar graphs 
should be constructed and extrapolated using the total number of 
patents, i. e., basics plus all family members, per patentee rather than 
just the numbers of basic patents. In such a study, consideration of 
problems associated with the patent procedure protocols of cognating, 
dividing-out and continuations-in-part is essential. Furthermore, in 
counting family members, allowance must be made for the issue of an 
initial unexamined document, followed by an examined document and then, 
for some countries, the granted document. 
There is a requirement for a simple method for technological assess- 
ment. Some thoughts on how this may be acheieved using Bradford-Zipf 
plots have been given; further study in this area is considered to be 
appropriate. The relationship between Bradford-Zipf bibliographs and 
Vector Analysis diagrams need further study. 
Similarly, it is thought that the closeness of fit between observed and 
calculated frequency distribution may provide an indicator of the state 
of the art: the closer the observed data is to the theoretical data (as 
calculated from the Negative Binomial distribution) then the greater 
the likelihood that development in the technology has attained a 
steady data. This possibility is also considered to be suitable for 
further study. 
This work clearly shows that some lesser-known frequency distributions 
are more applicable in bibliometrie studies than more widely accepted 
ones. It is suggested that these frequency distributions are tried 
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against other data sets to ascertain their possible wider applicability 
than has so far been demonstrated. In particular, it is recommended 
that they be applied to Lotka's data upon which he formulated his 
"Law" 
Finally, but not exhausting the possibilities, it is considered appro- 
priate to see whether similar observations on patenting activity would 
be obtained if a distinction was made, especially, for chemical techno- 
logies, between process patents and non-process patents. Process 
patents for large and successful companies can bring about economies of 
scale not achieveable by smaller organisations; it would be of interest 
to see whether such patents enhance the ability of larger corporations 
to forge ahead of their smaller competitors. 
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APPENDIX I: THE CEPHALOSPORINS 
Abraham and Loder260 have given an account of the early developments in 
the technology of the Cephalosporins; their work has been used as the 
basis for the historical description given here. 
The old medical literature contains many references to the use of soil 
and certain plants in the treatment of local infections. They might 
well have been sources of antibiotic forming micro-organisms. In 187; 
Pasteur and Joubert reported that anthrax bacilli did not grow in urine 
if it was infected by aerobic bacteria. A similar effect was observed 
when anthrax bacilli were administered together with other bacteria to 
animals. 
In 1928 Fleming noted that one of his bacterial cultures was markedly 
inhabited by a contaminating mould of the genus Penicillium. Later, in 
1939-41, penicillin (as the agent was named by Fleming) was isolated in 
pure form and its production started. This was the dawn of the age of 
antibiotics. 
The demonstration that penicillin, produced by Penicillium notatum 
during fermentation, possessed both therapeutic effectiveness. and a low 
order of toxicity in humans prompted enormous efforts by many workers 
to isolate, identify, characterise and synthesise analogous therapeuti- 
cally efficacious substances. 
One such worker was Guiseppe Brotzu of Sardinia. Brotzu began his work 
in 1945 by examining the microbial flora of seawater near a sewage 
outlet at Cagliari, supposing that the process of self-purification of 
the water might, in part, be due to bacterial antagonism. From a 
location, which is now reclaimed land, he isolated a fungus which he 
concluded was similar to Cephalosporium acremonium. When cultivated on 
agar this wild strain of Cephalosporium secreted material which inhib- 
ited the growth of a variety of gram-positive and gram-negative bacter- 
ia. Selection of colonies from many serial cultures led to the isolat- 
ion of a strain which produced significant amounts of antibacterial 
material when cultivated in glucose-starch broth. From the filtrates 
of such cultures a crude active concentrate was obtained after precipi- 
tation of inactive products with ethanol. 
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Both culture filtrates and crude active concentrates were tested clin- 
ically in Sardinia with encouraging results. However, Brotzu was unable 
to interest anyone in Italy in his discovery and wrote with details of 
his work and findings to Dr. Blyth Brooke in London. Brooke wrote, in 
19118, to Sir Howard Florey who arranged for investigations to be con- 
tinued at the Dunn Schol of Pathology at Oxford; Brotzu sent a culture 
of his organism to Oxford in September 1948 for work to commence. 
Initial work at Oxford by Heatley showed that the culture fluids 
contained an acidic antibiotic which was readiliy extractable into 
organic solvents. After July 1949, culture fluid production was 
carried out at the MRC's research establishment at Cleverdon, Somerset. 
Burton and Abraham, at Oxford, commenced studies on the active mater- 
ial; in particular they worked on the antibiotic extractable into 
organic solvents, but it soon became clear that this material 
- 
named 
cephalosporin P since it showed activity only against certain gram- 
positive bacteria 
- 
was not the antibiotic described by Brotzu. 
Iu August 1949 a second antibiotic was found to be present in the 
culture fluid of the Cephalosporium species by workers at Oxford. This 
substance remained in the aqueous phase after the extraction of cephal- 
osporin P, and was discovered independantly by workers at Cleverdon in 
the following October. It was active against gram-negative as well as 
gram-positive bacteria and was named cephalosporin N. Cephalosporin N 
was shown to be responsible for the antibacterial activity first 
observed in Sardinia four years previously. 
Abraham and Newton showed in 1953 that cephalosporin N was a new type 
of penicillin yielding the characteristic aminoacid penicillamine on 
acid hydrolysis. In 1954 these workers proved conclusively that it had 
the following structure: 
H3N S 
H(CH2)3CONH 
02C N C0,0 
0 \OH 
Cephalosporin N was then renamed penicillin N. 
In September 1953, Newton and Abraham discovered a second hydrophilic 
antibiotic amongst the metabolic products of the Sardinian Cephalospor- 
ium strain. This substance, cephalosporin C, was first encountered 
during the chemical studies of penicillin N and was obtained by chroma- 
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tographic separation from penicillin N on an Amberlite IR4B column. 
Because priority had been given to chemical studies in penicillin N, no 
further work was carried out on cephalosporin C until 1954. The new 
antibiotic was found to inhibit growth of Staplylococcus aureus, 
Salmonella typhi and Escherichia coli although its potency was only 
about one tenth of that of penicillin N. However, despite its low 
activity, the compound immediately aroused interest since, although it 
resembled pencillin N it differed from the latter in not yielding 
penicillai1ne on hydrolysis and being much more stable in dilute acid. 
Of even more significance was the fact that it was resistant to hydrol- 
ysis by penicillinase from B. subtilis. This suggested the possibility 
that cephalosporin C contained a modification of the penicillin ring 
system with potentially valuable properties. 
Biological and chemical studies were then embarked upon; the former 
showed that cephalosporin C was effective against a number of penicil- 
lin-resistant strains of Staphylococcus aureus, it was innocuous to 
mice when given intravenously in high doses, and would protect mice 
from infection with penicillin-resistant staphylococci when given 
subcutaneously. Chemical studies at Cleverdon and Oxford enabled the 
following structure to be proposed in April 1959: 
+HH 
H3N S 
CH(CH2)3CONH 
02Ci EN 
0 CH2O00CH9 
COOH 
This structure was later confirmed by X-ray crystallographic analysis. 
Attention was then given to the synthesis of the cephalosporin ring 
system and of cephalosporin C. As it seemed possible that one or more 
of the antibiotic substances obtained from the Sardinian Cephalosporium 
species might be of medical interest, and in accordance with MRC 
policy, applications for patents were made from time to time by workers 
at Oxford and the Antibiotics Research Station at Cleverdon. Such 
applications were assigned to the National Research and Development 
Corporation (NRDC) which had been set up in the UK in 1949 under an Act 
of Parliament (the Development of Inventions Act, 1948) with the 
function of protecting, developing and exploiting inventions in the 
public interest. 
Several pharmaceutical companies expressed interest in the cephalospor- 
ins at an early stage. The Distillers Company (Biochemicals) Ltd. made 
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contact with the Oxford workers in 1954 and considered the possibility 
of providing a supply of penicillin N. 
In 1955 Imperial. Chemical (Pharmaceuticals) Ltd. initiated connection 
with Abraham with the object of being made aware of current research on 
penicillin N and cephalosporin C. An informed suggestion was made to 
the Oxford group in 1955 by Eli Lilly & Company that a liaison be 
established for the purpose of producing cephalosporin C. However, 
when NRDC asked all UK pharmaceutical companies with fermentation 
facilities to assist in the production of cephalosporin C, only Glaxo 
showed interest. 
Meetings between Glaxo Ltd. staff and the Oxford and Cleverdon groups 
were initiated in 1956 under the aegis of the NRDC. The limiting 
factor in research work at that time was the difficulty of obtaining 
cephalosporin C jr. substantial quantities from the low yielding Cephal- 
osporium species. However, in 1957, a higher yielding mutant (No. 
8650) allowed 100gm. of cephalosporin C to become available to Glaxo; 
some of this was used in experiments to confirm the chemical structure. 
In the following year, the director of the Eli Lilly patent division, 
A. M. van Arendork, approached NRDC and discussed a proposal for a 
programme aimed at the fermentation production of substances structur- 
ally related to cephalosporin C, including the molecule nucleus, an 
idea stemming from work in progress on the isolation of the penicillin 
nucleus, 6-aminopenicillanic acid, by E. H. Flynn et al. NRDC and Eli 
Lilly signed an agreement in January 1959; the project was not success- 
ful, but they entered into a general option agreement early in 1960 
under which Eli Lilly received Cephalosporium sp. mutant 8650 and 
access to technical information; this enabled the company to make 
significant contributions to cephalosporin technology. 
Additional pharmaceutical companies were, by that time, showing inter- 
est in the cephalosporins. E. R. Squibb & Co. obtained a general option 
for a license from NRDC in 1959. In 1960 more USA firms, Merck and 
Company, Chas. Pfizer and Company and Smith, 
"Kline and French Laborato- 
ries entered into option agreements. CIBA in Switzerland and Farmitalia 
in Italy also entered into option agreements in 1960. In 1961 a 
similar agreement was made with Fujisawa Pharmaceuticals Company of 
Japan. 
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Up until this time it had been hoped that cephalosporin C would itself 
be a useful therapeutic agent in the treatment of penicillin-resistant 
staphylococcal infections, even though its low potency would mean 
administration by intravenous infusion. The preparation of methicillin 
(2,6-dimethoxyphenylpenicillin) from 6-APA, and the demonstration of 
its antibacterial properties, made this unlikely. Thus a great deal of 
effort went into the search for a method of preparing 7-aminocephalos- 
poranic ac. d on a large scale. 
Most of these searches concentrated on an enzymatic method of splitting 
the D-a-aminoadipyl side chain from cephalosporin C; but in 1960 Lilly 
Research Laboratories discovered a chemical method of doing this 
enabling 7-amino cephalosporanic acid to be obtained in higher yields; 
details of this work were reportred to NRDC. Meanwhile work at Glaxo 
and Eli Lilly had led to the fermentation production of cephalosporin C 
in quite large quantities and intensive studies of the properties of 
derivatives of this compound soon led to the introduction of two 
semisynthetic cephalosporins, Cephalothin and Cephaloridine, into 
medicine. Other derivatives soon followed in this increasingly popular 
group of antibiotics. As with the penicillins, the acylamido residue 
was modified as well as the new substituent, the acetoxymethyl group. 
The bacterial cell wall is the target for the selective action of the 
O 
-lactam antibiotics. An inhibition of synthesising as well as hydro- 
lysing enzymes results in a destruction of the peptidoglycan network of 
the cell wall. The main target seems to be a transpeptidase which 
catalyses cross-linking of peptide chains. 
The table which follows gives details of the main cephalosporin deriva- 
tives commercially available in late 1979; most of the proprietary 
preparations listed were marketed in the United Kingdom. 
Only the following preparations were listed in the Monthly Index of 
Medical Specialities (MIMS) for November, 1979. The launch dates for 
these products have been supplied through the courtesy of Glaxo Hold- 
ings Limited; the gaps in the dates and brand names are attributed to 
the complicated cross-licensing arangement which exists between Glaxo, 
Lilly and the NRDC. 
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Date of Introduction into 
UK USA 
Keflin (Cephalothin) 
Ceporin (cephaloridine) 
Kefzol (cefazolin) 
Ceporex (cefalexin) 
Keflex (cefalexin) 
Velosef (cephadrine) 
Mefoxin (cephoxitin) 
Distaclor (cefaclor) 
Kefadol (cefamandole) 
Zinacef (cefuroxime) 
Lilly 
- 
Glaxo November 1964 
Lilly June 1974 
Glaxo December 1969 
Lilly November 1969 
Squibb October 1972 
Merck October 1978 
Dista February 1979 
Lilly April 1978 
Glaxo April 1978 
May 1975 
March 1968* 
November 1973 
* as Loridine 
December 1970 
August 1974 
November 1978 
August 1979** 
October 1978*** 
** as Celcor *** as Mandol 
Table 55: Cephalosporins Listed in MIMS, November 1979 
Developments in Cephalosporin Technology 
In collaboration with Michael Gray, Patents Liaison Officer of Glaxo 
Holdings Limited, whose assistance is gratefully acknowledged, patents 
published from December 1977 to February 1981 have been examined in 
greater detail using CPI abstracts in order to identify recent develop- 
ments in the field and the direction of research. The subject matter 
of the 703 basic patents relating to cephalosporins published during 
the period has been classified. In particular, a distinction has been 
drawn between patents relating to novel final products and those 
describing chemical processes for the preparation of known compounds. 
There is no separate classification for purification/isolation. During 
this period there were, as would be expected, very few patents describ- 
ing the isolation of compounds from biological sources and these have 
been grouped with the 'Biological Synthesis' patents. Patents describ- 
ing procedures for the purification of known compounds are included in 
the Chemical Process classification. There are separate classifications 
for intermediates and compositions. 
As would be expected, the majority of applications have been for novel 
final products, and the classification encompasses compounds with a 
vast array of structural variations. However, a number of trends can 
be identified and the patents have been further classified according to 
the structures of the compounds covered. 
Before describing the structural classifications in detail, it is first 
necessary to explain something of the chemical structure of cephalospo- 
rins and the biological objectives of much of the research represented 
by the patents published during this period. 
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There are two principal positions on the cephalosporin nucleus, the S- 
and 7-positions, at which different groups can be introduced in an 
attempt to improve the biological properties. Much of the research 
effort has been directed to 
s 
0N/ -' 
COON. 
cephalosporin nucleus 
modifications at the 7-position since this generally has the more 
profound effect upon activity. The 7ß-substituents in just about all 
the active cephalosporins are substituted acetamido groups: 
9' 
7a 
k7 S R'-CHCON 
R' Ne R4 I 
----------- -J 
ý 
0 COON 
substituted acetamido group 
at 70-position 
{ 
In the early cephalosporins R1 was often a phenyl ring which itself 
could carry substitutes, or a heterocyclic ring such as furyl or 
thienyl. 
The group R 2, known as the a 
-substituent, could be a hydrogen atom, or 
a substituent such as an amino group (-NH2). The first cephalosporins 
to be marketed, cephalothin and cephaloridine, both have the same 7ß 
-substituent in which R1 is a thienyl ring and R2 is a hydrogen atom. 
In ce halexin R1 is a rin and R2 an amino p phenyl g group. The structures 
of all named compounds referred to in this section are given in Table 
56. 
The principal objectives of cephalosporin research from the start have 
been twofold, namely to increase the level of antibacterial activity 
and to broaden the spectrum of activity, i. e. increase the number of 
bacterial species against which the compounds are active. The period 
under consideration here has seen the arrival of the so-called 'third 
generation' cephalosporins, which generally have very high levels of 
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activity and an extremely broad spectrum, the activity extending to 
bacteria, such as the Pseudomonas species, not previously susceptible 
to cephalosporins. 
In order to achieve this broad spectrum of activity, it is necessary 
for the compounds to have at least some measure of stability to 
ß-lactamase enzymes produced by bacteria that can inactivate cephalosp- 
orins (and penicilins and other ß 
-lactam antibiotics). Increased 
stability to B-lactamases can generally be achieved either by introduc- 
ing certain groups at then-position of the 7ß-substituent or by introd- 
ucing a substituent as the 7a-position of the cephalosporin nucleus 
(see diagram above). The group at the a-position of the 70-substituent 
can be an oxime group, as found in the 'second generation' compound 
cefuroxime, or a substituted amino group: 
H 
RCON 
'N' 
OR1: 
L 
. -----j' Aoxime group 
H 
RCHCONigms-V 
NHR1 
substituted amino 
group 
The 7a 
-substituted compounds generally have a methoxy group at that 
position 
OCHS 
H 
R'CH2CONEM" 
The 7a-methoxy substituted cephalosporins are also known as cephmycins. 
Many of the new cephalosporins patented during the period under consid- 
eration can, therefore, be represented by the following structure: 
1H 
R9 S 
R CHC0N I 
RN R4 
0 
COON 
and this is used as the basis for the classification according to 
structure used in this section. 
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The major class of compounds are those in which R1 is an aminothiazolyl 
group: 
SN 
NH3 
In this class the grouping 
-CH-usually represents an oxime group 
R2 
-C- and R3 is generally a hydrogen atom. 
N 
\OR 
Other significant classes are those in which the a -substituent R2 is an 
acylamino group 
-NHCOR or a ureido group -NHCONRR1 and these have been 
termed 'a-Acylamino' and 'a-Ureido' respectively. The 7 a-methoxy 
cephalosporins, i. e. R3 is 
-OCH3, are classified separately. 
The group at the 3-position, R4, is usually a substituted methyl group 
-CH2R. However, a number of compounds have been prepared in which a 
halogen atom, hydroxyl group, alkoxy group, alkylthio group or similar 
such substituent is bonded directly to the cephalosporin nucleus. 
These are classified as '3-Halogen etc'. 
In an attempt to improve activity, researchers have prepared, usually 
by total synthesis, a variety of ring systems analogous to the cephalo- 
sporin nucleus. The most frequent modification is to replace the 
sulphur atom in the six-membered dihydrothiazine ring by an oxygen atom 
and these compounds are classified separately as 'Oxycephalosporins'. 
Other compounds with a modified ring structure are classified under 
'Total Synthesis' 
Compounds not falling within any of the above classifications and in 
which R1 is a heterocyclic ring other than aminothiazolyl have been 
classified under 'Non-Aminothiazolyl Heterocycles'. There is a large 
diverse group of compounds which cannot be accommodated in any of the 
above classifications and these are classified as 'Other Novel Compounds'. 
In quite a number of instances patents fell within more than one 
classification and when this situation arose the patent was classified 
according to what was considered to be the main point of novelty in the 
compounds. 
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The distribution of the patents into these various classifications is 
shown in Figure 64. In order to identify whether the classifications 
are expanding or contracting the period has been examined in two 
halves, each of 83 weeks. The results for the two halves and the total 
period are given in Table 57 and this facet will be discussed in more 
detail later. 
Aminothiazolyl 
- 
This has clearly been the single most active area of research and in 
order to fully understand the reasons for this it is necessary to go 
back beyond the period under consideration. 
Takeda's Belgian Patent No. 823861 was published in 1975 and was the 
first disclosure of cephalopsporins having an aminothiazolyl group in 
the 7ß-substituent. One of these compounds has been marketed by Takeda 
as cefotiam, which has a high level of antibacterial activity. However, 
it has no substituent at the a-position of the 7ß-group and is somewhat 
susceptible to ß 
-lactamase degradation. 
Since then cefotaxime (Roussel-Uclaf; British Patent No. 1580621) and 
cefmenoxime (Takeda; British Patent No. 1536281) have been the subject 
of patent applications. Both have oxime substituents at the a 
-position 
of the 7ß 
-group and have similar high levels and broad spectra of 
activity. Cefotaxime has been marketed by Hoechst/Roussel and cefinen- 
oxime is believed to be undergoing clinical trial. 
Four compounds, which have been the subject of patents published during 
the period under examination, are believed currently to be undergoing 
clinical trial and these are ceftizoxime (Fujisawa; German Patent 
Application 2810922), ceftazidime (Glaxo; UK Patent Application 2025398) 
cefatriaxon (Hoffmann-La Roche; UK Patent Application 2022090) and 
cefodizime (Hoechst; German Patent Application 2714880). Cefotaxime, 
cefmenoxine, ceftizoxime, cefatriaxon and cefodizime all have the same 
7ß- substituent and differ only in their 3-substituent. Ceftizoxime is 
notable in that it simply has a hydrogen atom at the 3-position. 
All the compounds have very high activity, but ceftazidime is reported 
to have the broadest spectrum of activity, including activity against. 
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Pseudomonas organisms, and the greatest stability to ß 
-lactamases of 
the new cephalosporins. 
In all during the period there were 93 basic patents, that is 13.20P of 
the total cephalosporin patents, published relating to aminothiazolyl 
cephalosporins. 
The majority of these described modifications of either the oxime 
substituent or the 3-substituent. 
a-Acylamino 
7.4% of the total cephalosporin patents published during the period 
related to cephalosporins having an a-acylamino group in the 7ß-substi- 
tuent. Many of the compounds described can be represented by the 
structure: 
H 
R1 S 
/ 
CHCON 
ýH N 
? 
--- 
co 0 I 
Rs 
COON R 
in which Rl is a hydrogen atom or a substituent such as hydroxyl, R2 is 
usually a nitrogen-containing heterocyclic ring which may itself carry 
substituents and the 3-substituent R3 can be any conventional 3-substi- 
tuent. It will be noted that the 7-substituent is derived from that 
found in cephalexin. 
An a 
-acylamino compound having the code number SM1652 (Japanese Patent 
Application 54030197) is being jointly developed by Yamanouchi and 
Sumitomo and is currently undergoing clinical trial. Three other 
similar compounds CN 92,982 (Warner Lambert; European Patent Applica- 
tion 15771), CN 106,947 (Warner Lambert) and AC 13709 (Ajinomoto; 
Japanese Patent Application 55076887) are currently believed to be 
undergoing pre-clinical development. The structures of AM 1652, 
CN98,982 and AC 1370 are given in Table 56. 
The structure for CN 106,947 is not known at this time, but it is 
believed to be an a-acylamino compound. 
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a-Ureids 
These compounds are a particular form of a-acylamino compounds, but in 
view of their numbers (7.4% of the total cephalosporin patents) have 
been classified separately. In order to appreciate developments in 
this area it is also necessary to go back before the period under 
consideration. This work appears to have been inspired by developments 
in the penicillin field, a number of penicillns, such as azlocillin, 
mezlocilin and piperacillin, having analogous structures. 
Toyama describe cefoperazone, which is analogous to the semi-synthetic 
penicilin piperacillin, in British Patent No. 1508071. Cefoperazone, 
which is licensed to Pfizer, was launched in Germany during early 1981, 
and has a 'very broad spectrum of antibacterial activity, including 
activity against Pseudomonas species. However, it does have some 
susceptibility to ß-lactamase degradation, as this is reflected by some 
of the more recent patent applications. 
Thus, Pfizer (French Patent 2442053) describe compositions of cefopera- 
zone with their ß-lactamase inhibitor, penicillanic acid 1,1-dioxide 
(sulbactam). Toyama (UK Patent Application 2017493) also describe 
compositions of cefoperazone with a ß-lactamase inhibitor such as 
clavulanic acid. These two patents are included in the 'compositions' 
classification. 
Toyama in Japanese Patent Applications 54022388,54022389,54022391 and 
54103888 and UK Patent Aplication 2009161 describe 7a-methoxy derivat- 
ives of cefoperazone and it analogues. The 7 a-methoxy substituent 
improves the ß-lactamase stablity of the compounds. 
Toyama (UK Patent Application 2005676) describe the dimethylacetamide 
adduct of cefoperazone, which is used to purify the compound. 
Boehringer Ingelheim's subsidiary Dr. Karl Thomae have described an 
a-ureido cephalosporin derivative (Code No. VX-VD-2; European Patent 
Application 21176 or 22494) whose exact structure is not yet known. 
The compound is reported to be considerably more active than cefopera- 
zone. 
Many of the compounds described in the patents published can be repres- 
ented by the structure: 
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HS 
R1- 
-CHCO 
NII 
1 
11 Ra co 0 COOIi 
/Ný 
in which R1 is a hydrogen atom or substituent such as hydroxyl and the 
group 
-N' Iý represents a5 or 6-membered ring which carries additional 
substituents and may contain additional hcteroatoms. R2 may be a 
variety of conventional 3-substituents. 
7a-Methoxy 
Cefoxitin (Herck; British Patent 1348984) and cefmetazole (Sankyo; 
British Patent 144920) are 7a 
-methoxy cephalosporins (cephamycins) 
published during the mid 1970's. As indicated above, the 7a-methoxy 
group confers B-lactamase stability to the compounds. 
Sankyo have described analogues of cefinetazole (Japanese Patent Applic- 
ations 52144690 and 52136194) and processes for its preparation (Japan- 
ese Patent Applications 54092985,5410887 and 54135791). 
Two new cephamycins, MT-141 (Meiji Seika; UK Patent Application 2040926) 
and cefotetan (Yamanouchi; Japanese Patent Application 54157591), are 
believed currently to be undergoing clinical trial. MT-141 is said to 
be between 3 and 300 times more potent than cefinetaxole and cefoxitin 
in treating gram negative and anaerobic infections in experimental 
animals. Cefotetan is very stable to ß-laetamases and has a broad 
spectrum of activity. However, it. does not have significant activity 
against Pseudomonas organisms. 
Oxacephalosporins 
Moxalactam (Shionogi; British Patent 1547351) was published just before 
the period under examination. It has activity similar to other 'third 
generation' cephalosporins and is licensed to Eli Lilly, who have 
recently launched it in West Germany. During the period Eli Lilly have 
described a sodium salt (Belgian Patent 882489) and the diammonium salt 
(US Patent 4252953) of moxalactam. 
q 
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Shionogi have patented various analogues of moxalactam, including the 
3-thiadiazolylthiomethyl analogue (German Patent Application 2837264), 
analogues having a halogen substituent on the phenyl ring in the 7 
a 
-group (German Patent Application 2818985), a -ureido analogues (German 
Patent Application 2739448) and analogues having a hydrogen or halogen 
atom or an alkoxy group at the 3-position (German Patent Application 
2735854). 
Fujisawa have patented the oxacephalosporin analogue of ceftizoxime (UK 
Patent Application 2014562) and Meiji Seika the corresponding analogue 
of MT-141 (Belgian Patent No. 885999). 
Total Synthesis 
A number of different ring systems have been synthesised as alternat- 
ives to the cephalosporin nucleus, and the principal ones are summar- 
ised below: 
Ring System Patentee Patent No. 
S 
Smith Kline US 4072674 
0 US 4103086 
Smith Kline Belgian 858356 
`/0 US 4122262 0 71 
US 4187375 
0 
(CH, )n 
N` NUJ Smith Kline US 409337 
0Y 
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Kyowa Hakko Belgian 875053 
Kogyo Belgian 875054 
German 2952413 
3-N 
G European 14475 
European 14476 
N- N 
N Beecham European 4134 
N 
0 
S `
., 
: 
N,, 
rN,,.. Fujisawa European 17138 0 
None of these ring systems would appear to have better properties than 
the natural cephalosporin nucleus. 
3-Halogen etc 
A variety of different groups have been attached directly to the 
cephalosporin nucleus. Thus, Ciba-Geigy describe (US Patent 4147864) a 
number of 3-hydroxy and alkoxy compounds which are analogous to the 
3-methoxy cephalosporin cephrozadine. 
3-Alkylthio compounds, i. e. compounds in which a sulphur atom is bonded 
directly to the cephalopsorin nucleus, are described by Merck (US 
Patent 4150156 and South African Patent 76/6941) and 3-halogen derivat- 
ives are described by Eli Lilly (US Patents 41088515 and 4252950), 
which are analogous to their marketed compound cefachlor. 
The interest in this group of compounds lies in the fact that many of 
them, including ceproxadine and cefachlor, are active when administered 
orally, whereas the majority of cephalosporins are inactive orally and 
only active when given by injection. 
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Non-Aminothiazolyl Heterocycles 
Before the discovery of the aminothiazolyl cephalosporins, heteorcyclic 
rings (when present) in the 76-substituent were typically thienyl (as 
in cephaloridine) and furyl (as in cefuroxime). Bristol Myers (Belgian 
Patents 856785 and 858112 and US Patent 4180685) and Smith Kline 
(Belgian Patents 856636 and 856637) describe analogues of cefuroxime 
having different, substituents at the 3-position. 
In the hope of emulating the activity found in aminothiazolyl cephalo- 
sporins, a number of heterocyclic rings have been introduced into the 7 
ß-substituent, i. e. 
Heterocyclic Ring 
"-- 
CH-COHN 
Some of these are listed below: 
Ring System Patentee Patent No. 
N=N 
Fujisawa German 2814641 
S !1 Belgian 859384 
S 
I 
Fujisawa 
S 
I 
German 2758159 
0 
Japanese 54128594 
Japanese 54155310 
S 
Fujisawa 
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SN Hoechst German 2822860 
European 17238 
NH2 
f Ciba Geigy European 22245 
There is no evidence to suggest that introduction of any of these rings 
has led to improved activity. 
Other Novel Compounds 
This is an extremely heterogenous group and there are no obvious trends 
within it. 
Chemical Processes 
The patents in this classification are predominantly concerned with 
processes for the preparation of established compounds. A few examples 
can be quoted to illustrate this. 
Toyama describe a number of processes for preparing cefoperazone 
(Japanese Patent Applications 52151187,53025589,53031688,53044584 
and 54022391). Eli Lilly describe a process for the preparation of 
cefotaxime (US Patent 425295) and Bristol Myers describe a process for 
the preparation of ceforanide (US Patent 11118563). 
Biological Synthesis 
The patents in this area of biotechnology fall into a number of groups 
such as the products of cephalosporin C or cephamycin C by fermentation 
or their isolation from fermentation broths 
- 
see, for example, Japan- 
ese Patent Application 50155696 (Meiji), German Patent Application 
2908848 (Shionogi), European Patent Application 9363 (Takeda) and 
Japanese Patent Application 55003750. 
Other developments include the removal of acyl groups from the 7-subst- 
ituent using an enzyme to yield a 7ß-amino compound, i. e. 
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r 
H 
RCO N H2N OEM. 
Acyl group 7ß 
-Amino compound 
- 
see for example Japanese Patent Application 53139791 and 53059045 
(Asahi) 
- 
and the reverse process, i. e. the introduction of an acyl 
group in to a 70-amino compound, using an enzyme 
- 
see for example 
Japanese Patent Application 54110395 (Banyu). 
No developments of particular note were found in the 'Compositions' and 
'Intermediates' classification. 
Research Trends 
The most marked trend shown by comparing patent publications in the 
first half of the period (December 1977 
- 
July 1979) with those in the 
second half (August 1979 
- 
February 1981) is the significant increase 
(7.9% to 19.9%) in the patenting of aminothiazolyl cephalosporins. The 
interest in this highly active group of compounds is reflected by the 
fact that one such compound is now marketed (Cefotaxime) and five 
others are in various stages of clinical trial. 
Other areas have generally been stable or have shown small decreases in 
patenting, as in the a 
-acylamino and a -ureido areas. There were, 
however, marked decreases in the 'Other Novel Compounds' (23.0% to. 
14.4%) and 'Chemical*Processes' (25.8% to 17.0%) classifications and a 
significant increase in the 'Compositions' (4.3% to 9.0%) classifica- 
tion, and no explanation can be given for these changes. 
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R' 
RiCO. HN 
R' 
coos 
Compounds R3 Rs Rs 
Cephaloridine 
03-cHa- 
H 'CH. 
ý 
\ 
Cephalothiu 
S 
E 
-Cii, 000H3 
Cephalexin ýH- 
Cý 
-CHs 
NHa 
Cefuroxime 
1\ 
/ 
C- R 
-CH2O00N'H, 
N 
BOCH 
3 
NH2 
Cefotiam k2 
CH, 
- -CEIs-S N/-r 
CH, CH, N(CH')a 
a 
SN 
Cefotaxime 
H 
-CH OCOCH C- a , 
N ý OCH3 
Table 56: Structures of Named Cephalosporins 
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Compound R' R' R' 
NHa 
N /` Cefmenoxime 
-H 
-CII=-S 
-4 
NIP lllýýýý11... i\ 
OCHS 
CHs 
NH, ý/\ 
Ceftazidime SN \' 
`' ü- H 
-CH, 
ý 
N CH0 
'-O-C-CO=H 
1 
CH, 
NH2 
Ceftizoxime +ý }3 HH 
U 
N 
OCHS 
NH, 
CUs ONa 
Cefatriaxon S 
-INN 
H 
-CHa-S-ý 1N 
ý10 
N 
OCHS 
NH2 
CEi3 COOEi 
Cefodizime H 
-CH-S II 
i- 
N CHs 
N 
OCHS 
N-N % 
SM 1652 HO CH- H 
-CH3-S--7 
ý 
'A 
NH 
Co CIR3 
HO 
CH3 
Table 56: Structures of Named Cephalosporins (Continued) 
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Compound R' Y. ' R' 
CN 92982 CH- / 
II 
-CY., -S 
N 
NH I 
CU' 
0 
Nß 
NH 
Co 
1 
CH, CONH-CH-(CH, )aCO\'H, 
AC 1370 ()>__ 1 H a_ N/ CH, CH, S O, Na 
NH 
Co 
Na000 / h"H 
/\ 
Cefoperazone 110 CH- /iV N 
- 
NH 
CH3 
Co 
0 
N0 
C2H3 
Table 56: Structures of Named Cephalosporins (Continued) 
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Compound PI Its RS 
VX-VD-2 A- CH a -CS, Y 
NII 
CO The grou ps represented by 
A, X and Y are unknown 
OR 
K*. 
__K 
N 
Cefoxitia 
E)_CR2... 
-OCRs -CH: OCONH3 
Cefmetazole NCCH2SCHa- -OCR, -Ciia-S 
xf 
CH3 
HT-141 EOOC-CH-CH, S-CH1- 
-OCHS CH, -S-ý 
NH2 
N 
CH, 
Nx ý 
Hoxalactam* HO CH- 
-OCHS -CH=-S - y 
COON NI 
CH, 
OO C 
-OCH -S -CH N Cefotetan Na C- S 2 ý S N 
CONHa 
3 
* The sulphur atom in the 6-membered ring of the cephalosporin 
nucleus is replaced by an oxygen atom. 
Table 56: Structures of Named Cephalosporins (Continued) 
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Compound Rs R° R' 
Cefachlor I 
Ct 
II 
_Cl : 
Cefroxadine CH_ 
Cý 
H 
-OCH3 
IIHS 
Ceforanide CH2- ß 
N 
-CH, -S-4 N 
C3 Ng Ca, 000ii 2 2 
Table 56: Structures of Named Cephalosporins (Concluded) 
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Retrieval of Cephalosporin Patents 
The Derwent WPI Files, of which the CPI file is a subset, are loaded 
for remote online interactive access on System Development Corporation 
(SDC) computers located in Santa Monica, California, USA, and in Tokyo, 
Japan. 
The Farindoc (CPI Section B) punch card code in use prior to 1981 was 
comprised of five subcodes defined within the online database by 
subheadings as follows: 
Subheading Code Starting Date 
B1 Natural Products 1970 
B2 General Chemical 1970 
B5 Steroid 1963 
B Galenical 1976 
B Non-steroid 1963-1969 
Searches were, therfore, carried out in subcodes B, B1 and B2. 
Position 3 in column 1 (searched as 013) of the Natural Products code 
(B1) is specifically for cephalosporins, whilst position 0 in column 27 
(searched as 270) in the General Chemical (B2) and 1963-1969 Non- 
steroid (B) subcodes is specific for the fused ring heterocyclic 
nucleus of the cephalosporin structures (I) whether or not it is 
present unsaturated. 
M 
When searching for positions 013 and/or 270 these needed to be qualif- 
ied within the search statements with the relevant subheadings to avoid 
retrieval of irrelevant data, including not only data in other Farmdoe 
codes but also data coded, for example, in the Plasdoc (polymer) code 
where the same punch positions have entirely different meanings. 
Additionally, as can be seen from the list above, subheading B was used 
for the Galenical code from 1976. Items coded in the Galenical code 
were eliminated by negation of the control punch for this code (posit- 
ion 11, represented by a hyphen, in column 66). 
_327_ 
The searches were carried out in two stages using the following search 
logic: 
SEARCH STATEMENT 1: 013/B1, B2 OR 270/B1, B2 
SEARCH STATEMENT 2: 1 LINK NOT 66- 
Search Schedule 
An initial search, using the logic given in the preceding section, 
showed that the logic used would retrieve more than 2,500 citations 
from the database as it was loaded in October, 1979. For budgetary 
reasons and to some extent for ease of handling the offline citation 
printouts to be obtained, it was decided to run five identical searches 
at different dates, printing offline different non-overlapping segments 
of the total of retrieved citations of each occasion. 
Searches were therefore conducted on 17 October, 30 October, 7 Novem- 
ber, 21 November and 30 November, 1979; the citations retrieved and 
printed offline in "segments" were entitled "Cephalosporins 1", "Ceph- 
alosporins 2", etc. 
Interim File Updates 
It was expected that over the period during which the leaches were 
carried out there would be at least one file update; in the event there 
were two, occuring in the intervals between Cephalosporins 1 and 2 and 
between Cephalosporins 2 and 3 (file updates 7908 and 7909 respect- 
ively). File updates for the search file, i. e., the multipunch data, 
comprise only the addition of newly coded most recent basics. For this 
reason the oldest data was printed offline for Cephalosporins 1, and 
the most recent data for Cephalosporins 5. The results of searches and 
the ranges of citations printed offline are shown schematically in Fig- 
ure 65; search logic and print commands are shown in Figures 66 to 70. 
Cephalosporins 1 retrieved 2,535 citations; update 7908 added 32 
citations and update 7909 a further 22 citations. A total of 2,589 
citations were thus retrieved. For ease of handling, the citations 
were filmed cnto microfiche, a (partially filled) fichc'being created 
for each of the five searches. 
Print file (bibliographic data) updates contain not only data for the 
most recently added basic patents, but also data concerning specifica-" 
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FROG: 
YOU ARE NOW CONNECTED TO THE ORBIT DATABASE. 
FOR A TUTORIAL, ENTER A QUESTION MARK. OTHERWISE ENTER A COMMAND. 
USER: 
FILE WPI 
PROG: 
ELAPSED TIME ON ORBIT: 0.01 HRS. 
YOU ARE NOW CONNECTED TO THE WFI DATABASE. 
COVERS 1963 THRU B31 (7907) FOR BASICS; EQUIVS THRU 031; MC THRU B29; 
MP SECTIONS B, C, E THRU B17; MP SECTION A THRU 018 
PLASDOC KEYTERMS ARE AVAILABLE FOR WEEKS THRU B10. 
***ENTER EXPLAIN LINK BEFORE SEARCHING THIS DATABASE*** 
SS 1/C? 
USER: 
013/B, B1 OR 270/81,82 
PROG: 
SS 1 PSTG (2537) 
SS 2/C? 
1 LINK NOT 66- 
PROG: 
SS 2 PSTG (2535) 
SS 3/C? 
PRT FU OFF-LINE 535 SKIP 2000 
PROG: 
NAME? 
USER: 
MD DIXON 
PROG: 
ADDRESS? 
USER: 
DERWENT PUBLICATIONS LTD, ROCHDALE HOUSE, 128 THEOBALDS ROAD 
PROG: 
(CITY, STATE, ZIP- 
FUSER: 
LONDON WC1X 8RP, ENGLAND 
FROG: 
TITLE? 
USER: 
CEPHALOSPORINS I 
Figure 66: Online Search and Print Commands for Offline 
Citations for Cephalosporins 1 
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PROG: 
YOU ARE NOW CONNECTED TO THE ORBIT DATABASE. 
FOR A TUTORIAL, ENTER A QUESTION MARK. OTHERWISE ENTER A COMMAND. 
USER: 
FILE WPI 
PROG: 
ELAPSED TIME ON ORBIT: 0.01 HRS. 
YOU ARE NOW CONNECTED TO THE WPI DATABASE. 
COVERS 1963 THRU B35 (7908) FOR BASICS; EQUIVS THRU 835; MC THRU 833; 
MP SECTIONS B, C, E THRU B26; MP SECTION A THRU B22 
PLASDOC KEYTERMS ARE AVAILABLE FOR WEEKS THRU 310. 
***ENTER EXPLAIN LINK BEFORE SEARCHING THIS DATABASE*** 
SS 1/C? 
USER: 
013/13,81 OR 270/81,82 
PROG: 
SS 1 PSTG (2569) 
SS 2/C? 
1 LINK NOT 66- 
PROG: 
SS 2 PSTG (2567) 
SS 3/C? 
PRT FU OFF-LINE 500 SKIP 1532 
PROG: 
NAME? 
USER: 
MD DIXON 
PROG: 
ADDRESS? 
USER: 
DERWENT PUBLICATIONS LTD, ROCHDALE HOUSE, 128 THEOBALDS ROAD 
PROG: 
CITY, STATE, ZIP- 
USER: 
LONDON WCIX ERP, ENGLAND 
PROG: 
TITLE? 
USER: 
CEPHALOSPORINS 2 
Figure 67: Online Search and Print Commands for Offline 
Citations for Cephalosporins 2 
- 
331 
- 
PROG: 
YOU ARE NOW CONNECTED TO THE ORBIT DATABASE. 
FOR A TUTORIAL, ENTER A QUESTION MARK. OTHERWISE kNTER A COMMAND. 
USER: 
FILE WPI 
PROG: 
ELAPSED TIME ON ORBIT: 0.01 HRS. 
YOU ARE NOW CONNECTED TO THE WPI DATABASE. 
COVERS 1963 THRU 839 (7909) FOR BASICS; EQUIVS THRU B39; MC THRU 033; 
MP SECTIONS B, C, E THRU B31; MP SECTION A THRU B22 
PLASDOC KEYTERMS ARE AVAILABLE FOR WEEKS THRU 810. 
***ENTER EXPLAIN LINK BEFORE SEARCHING THIS DATABASE*** 
SS 1/C? 
USER: 
013/8,81 OR 270/61,82 
PROG: 
SS 1 PSTG (2591) 
SS 2/C? 
1 LINK NOT 66- 
PROG: 
SS 2 PSTG (2589) 
SS 3/C? 
PRT FU OFF-LINE 500 SKIP 1054 
PROG: 
NAME? 
USER: 
MD DIXON 
PROG: 
ADDRESS? 
USER: 
DERWENT PUBLICATIONS LTD, ROCHDALE HOUSE, 128 THEOBALDS ROAD 
PROG: 
CITY, STATE, ZIP- 
USER: 
LONDON WC1X 8RP, ENGLAND 
PROG: 
TITLE? 
USER: 
CEPHALOSPORINS 3 
Figure 6C: Online Search and Print Commands for Offline 
Citations for Cephalosporins 3 
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PROG: 
YOU APE NOW CONNECTED TO THE ORBIT DATABASE. 
FOR A TUTORIAL, ENTER A QUESTION MARK. OTHERWISE ENTER A COMMAND. 
USER: 
FILE WPI 
PROG: 
ELAPSED TIME ON ORBIT: 0.01 HRS. 
YOU ARE NOW CONNECTED TO THE WPI DATABASE. 
COVERS 1963 THRU B39 (7909) FOR BASICS; EQUIVS THRU B39; MC THRU 837; 
MP SECTIONS B, C, E THRU B31; MP SECTION A THRU B26 
PLASDOC KEYTERMS ARE AVAILABLE FOR WEEKS THRU B10. 
***ENTER EXPLAIN LINK BEFORE SEARCHING THIS DATABASE*** 
SS 1/C? 
USER: 
013/6,81 OR 270/B1, B2 
PROG: 
SS 1 PSTG (2591) 
SS 2/C? 
1 LINK NOT 66- 
PROG: 
SS 2 PSTG (2589) 
SS 3/C? 
PRT FU OFF-LINE 500 SKIP 554 
PROG: 
NAME? 
USER: 
MD DIXON 
PROG: 
ADDRESS? 
USER: 
DERWENT PUBLICATIONS LTD, ROCHDALE HOUSE, 128 THEOBALDS ROAD 
FROG: 
CITY, STATE, ZIP- 
USER: 
LONDON WC1X 8RP, ENGLAND 
PROG: 
TITLE? 
USER: 
CEPHALOSPORINS 4 
Figure 69: Online Search and Print Commands for Offline 
Citations for Cephalosporins 4 
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PROG: 
YOU ARE NOW CONNECTED TO THE ORBIT DATABASE. 
FOR A TUTORIAL, ENTER A QUESTION MARK. OTHERWISE ENTER A COMMAND. 
USER: 
FILE WPI 
PROG: 
ELAPSED TIME ON ORBIT: 0.01 HRS. 
YOU ARE NOW CONNECTED TO THE WPI DATABASE. 
COVERS 1963 THRU B39 (7909) FOR BASICS; EQUIVS THRU 839; MC THRU 037; 
MP SECTIONS B, C, E THRU 031; MP SECTION A THRU B26 
PLASDOC KEYTERMS ARE AVAILABLE FOR WEEKS THRU B10. 
***ENTER EXPLAIN LINK BEFORE SEARCHING THIS DATABASE*** 
SS 1/C? 
USER: 
013/6,81 OR 270/B1,82 
PROG: 
SS 1 PSTG (2591) 
SS 2/C? 
1 LINK NOT 66- 
PROG: 
SS 2 PSTG (2589) 
5S 3/C? 
PRT FU OFF-LINE 554 
PROG: 
OFF-LINE PRINT TRUNCATED AT 551 CITATIONS 
NAME? 
USER: 
MD DIXON 
PROG: 
ADDRESS? 
USER: 
DERWENT PUBLICATIONS LTD, ROCHDALE HOUSE, 128 THEOBALDS ROAD 
PROG: 
CITY, STATE, ZIP- 
USER: 
LONDON WC1X 8RP, ENGLAND 
PROG: 
TITLE? 
USER: 
CEPHALOSPORINS 5 
SS 3/C? 
PP. T FU 3 SKIP 551 
PROG: 
-552- 
Figure 70: Online Search and Print Commands for Offline 
Citations for Cephalosporins 5 
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tions issued in the period since the previous update which are equival- 
ents to earlier processed basic documents. It was therefore necessary 
to search through the printed (Country Order Alerting Bulletins) 
abstracts for Section B of CPI to retrieve any added data on equival- 
ents contained in updates 7908 and 7909 for references retrieved in 
Cephalosporins 1, and in update 7909 for references retrieved in 
Cephalosporins 2 which had issued in the periods Weeks B32 to B39 and 
B36 to B39 respectively; this is shown schematically in Figure 71. 
Offline Prints of Citations 
From the online service several different printout formats are avail- 
able. The alternatives range from merely printing accession numbers to 
having the full citation printed out. For the Cephalosporins searched 
the entire citations were printed; these gave the format illustrated in 
the typical example shown in Figure 72. 
-294- 
AN 
- 
38455A/22 
CC 
- 
ELI LILLY & CO (ELIL ) B02 
IN 
- 
CISE MD. ROY ML 
TI 
- 
Stable. crystalline sodium cephalothin preps. 
- 
by freeze-drying 
aq. alkanol or aq. acetone solns.; used for parenteral injection. 
after reconstitution BE-861135 
PI 
- 
24.05.78 24.11.77-6E-861135 A61K 801J C07D A61K-31/54 
C07D-501/60 A61K-09 
EP 
- 
21.11.77-NL-012822 24.11.77-DT-752442 24.11.77-JA-141436 
24. I1.77-DK-005217 24.11.77-S4i-013318 24.11.77-SF-003564 
FM 
- 
BE-361135-A22 NL7712822-823 DT2752442-823 J54073115-829 
DK7705217-823 SW7713318-628 SF7703564-B35 
Figure 72: Typical Offline Citation 
The explanation of each of the print parameters shown at the left-hand 
margin (AN, CC, etc. ) in Figure 72 is as follows: 
AN 
- 
The*WPI accession and week numbers. For the CPI subset of WFI 
these accession numbers have- the format of five digits followed by 
a letter indicating the year (R=1970, S=1971, etc. ); all pre-CPI 
Farmdoc accession numbers terminate with the letter F. The 
accession number is followed by an oblique stroke and a two-digit 
number to indicate the week, within the year, of the WPI/CPI issue 
in which the basic was first reported. Thus, in the chosen 
example, the basic patent was first reported in Week 22 of 1974 
(year A) and was the 38155th CPI basic patent in that year. 
Non-CPI, or non-chemical patents have accession numbers with the 
format A1234B/16. 
_336.. 
CC 
- 
This line carries three units of information: (a) the name of the 
patentee limited to 24 characters, in this case Eli Lilly & Co., 
whether the name arises from the basic or from a subsequently 
issuing equivalent (as was found to be the case in some examples 
of "joint patentees"); (b) the patentee code in parentheses 
(ELIL); and (c) the assigned Derwent CPI classification (B02 
- 
corresponding to Section B (Farmdoc), fused ring heterocyclic 
compounds). For joint patentees all names and relevant codes are 
given; similarly all Derwent assigned classes were recorded. 
Prior to 1970 
- 
Derwent Week R01 
- 
no company names were recorded, 
only the patentee codes are given. 
IN 
- 
Since CPI Week A04 (early in 1978) up to three' inventors' names 
are recorded in the format of surname (up to ten characters) 
followed by up to three forename initials. 
TI 
- 
The title assigned to the basic specification by Derwent; not the 
title on the specification per se as such titles are often found 
to be inadequate. The title is followed by the country code and 
number of the basic specification. In some cases where the first 
issued document has been delayed and incorporated into WPI/CPI and 
another member of the family has been artificially made basic, the 
country code of the first published document and the OPI date are 
recorded in parentheses between the title and the patent/country 
number. 
PI 
- 
The priority line. Contains three data elements: (a) the publica- 
tion or OPI (Open for Public Inspection) date of the basic patent 
(24.05.78 in the example); (b) the latest priority, given as date, 
two-letter country code and number; and (c) IPCs (International 
Patent Classifications) assigned to the basic document by the 
issuing Patent Offices together with any additional IPCs assigned 
to equivalents; the latter are preceded by a "+" sign. ' 
EP 
- 
Additional, or, multiple, priorities in the same format as in the 
PI line. These may be multiple priorities given on the basic 
document, or introduced to the family through the issuance of an 
equivalent. 
FM 
- 
The patent family. A list showing the basic patent (country code, 
number and week number) followed by all documents found to be 
equivalent to the basic patent. 
- 
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Medium for Data Analysis 
Since it was considered. necessary to organise the retrieved data in 
several different ways, e. g., by patentee, publication date, priority 
date, etc., it was thought most appropriate to extract the relevant data 
from the offline printed citations and transfer this to 80-column punch 
cards which could be sorted and tabulated according to the desired 
sequence. Such data as was extracted from the offline prints was 
supplemented by information obtained by examination of each basic 
abstract in its printed (Basic Abstracts Journal) form. All data was 
recorded onto standard IBM keypunching instruction forms. The layout 
of the cards produced is given schematically on a keypunching instruc- 
tion form in Figure 73 and is as follows: 
Card Data Description 
Column Source 
1-5 Print-out Patentee code. A four or five character 
mnemonic code used by Derwent for 
encoding patentee data uniformly. The 
codes, some of which appear on the 
microfiche given at the end of this 
study, are fully explained in the 
Derwent Instruction Manual No. 1. 
7 Print-out and Multiple patentee indicator. In a 
abstract number of cases citations carried more 
than one patentee code; basic patents 
were examined to see whether such cases 
were truly joint applications or whether 
additional patentees had originated from 
equivalents. True multiple patentees 
were indicated with an ampersand (&), 
other cases with an asterisk M. 
. 
9 Abstract Patent type. Citations were coded for 
technical content: Synthesis: S; Isola- 
tion and/or Purification: P; Intermedia- 
tes: I; Biological Process: B; Composit- 
ions: C; Other Cephalosporin references 
(e. g. their use in culture media, assay, 
- 
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etc. ): X. This information was taken 
from the abstracts as the citation 
titles were often insufficiently detailed. 
11-18 Print-out and Publication date of the basic, recorded 
abstract as day. monLh. year. No publication dates 
given in online database for basic 
abstracts prior to January 1974; these 
dates were obtained from the abstracts. 
20 Print-out and Priority origin indicator. Priorities 
abstract not given on the basic abstracts but 
given in the citation, were taken as 
having been introduced through an 
equivalent. Such cases were ascertained 
from the basic abstract and marked with 
a "+11 sign in this column. 
21-38 Printout Priorities. Given as date-country-number 
Date was given as day. month. year in cols 
21-28; priority countries were recorded 
as ICIREPAT two-character country codes 
(as modified by Derwent) in cols 30-31; 
priority (application) numbers were 
recorded in cols 33-38. 
40 Printout Multiple priority indicator. A card was 
created for each priority given in the 
citation. Where only a single priority 
was given a letter ''S" was recorded in 
this column; where more than one prior- 
ity was given these were numbered 
sequentially. 
42-50 Printout Basic patent number. Two character 
ICIREPAT country code (as modified by 
Derwent) followed by patent number. 
52-57 Printout Derwent Accession number. Five digits 
followed by letter to indicate year. 
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59-62 Printout Citation Number. The offline citation 
number, 001,002,003 
.. 
etc., preceded 
by "1", "2", etc., for each of the five 
cephalosporin searches. 
64-65 Printout Cross referenced equivalents. The 
accession numbers, preceded by an 
equals symbol (_), of equivalents listed 
as basics in error within the database 
but at some time identified by Derwent 
as being equivalent subsequent to being 
assigned different accession numbers. 
75-79 Printout Cross referenced citations. The citation 
number, preceded by an equals symbol 
of equivalents given in cols 
67-73. 
Whilst examining the basic abstracts for data needed for card columns 
7,9 and 20, the opportunity was taken to cross check informatiom, such 
as priority dates, numbers, etc., given in the offline citation print- 
out. An example of a completed keypunching instruction form is given 
as Figure 74. 
Keypunching 
Punch cards were created using an IBM 029/Print Key Punch by an exper- 
ienced operator. This machine has the advantage of interpreting the 
keyboarded data at the same tine as perforation. The cards so produced 
were visually checked for accuracy against the Punching Instructions 
sheets. Corrections were carried out by rekeyboarding entire cards; 
corrected cards were again checked for accuracy. The entire data set 
gave rise to approximately 4200 punch cards; a typical card is illustr- 
ated in Figure 75. 
Sorting and Printing of Data 
The entire set of punched cards were used to generate six lists: 
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(a) Priority date/country/number with patentee List 1 
(b) Publication date within patentee List 2 
(c) Patentee within publication date List 3 
(d) Priority date/country/number within publication 
date List 4 
(e) Priority country/date/number overall List 5 
(f) Priority date/country/number overall List 6 
To achieve this the cards were processed, through the courtesy of 
Control Data Corporation, on an IBM 3031 main frame computer to which 
was coupled an IBM 3211 line printer. A utility program (PROC SORT) 
was suitably modified to sort the data according to the scheme shown 
below, whilst a second modified utility program (IEBPTPCH) was used to 
print the required lists; for each list the entire data contained in 
each card was printed. 
In order to minimise costs, and to avoid excessive manipulation of the 
programs, the data was not "rotated" prior to printing, such that the 
parameter arranged in sequence, e. g., the publication date in List 2, 
was given as the first data on each line. The data was merely printed 
out in the same order as it appeared in the input punched cards, i. e., 
so called "80/80" listings were produced. 
Data Sorting Sequences 
For List 1 
Card columns 59-62 
- 
Citation number 
within card columns 33-38 
- 
Priority number 
within card columns 30-31 
- 
Priority country 
within card columns 21-22 
- 
Priority date day 
within card columns 24-25 
- 
Priority date month 
within card columns 27-28 
- 
Priority date year 
within card columns 1-5 
- 
Patentee code 
For List 2 
Card columns 59-62 
- 
Citation number 
within card columns 11-12 
- 
Publication date day 
within card columns 14-15 
- 
Publication date month 
within card columns 17-18 
- 
Publication date year 
within card columns 1-5 
- 
Patentee code 
Data 
illustrated 
in Fig. 7 
5457 
045170 
JA 
19 
04 
76 
TOXN15 (16 = blank) 
5457 
27 
10 
77 
TOM 
- 
344 
- 
For List 3 
Card columns 59-62 
- 
Citation number 5457 
within card columns 1-5 
- 
Patentee code TOXNh 
within card columns 11-12 
- 
Publication date day 27 
within card columns 14-15 
- 
Publication date month 10 
within card columns 17-18 
- 
Publication date year 77 
For List 4 
Card columns 59-62 
- 
Citation number 5457 
within card columns 33-38 
- 
Priority number 045170 
within card columns 30-31 
- 
Priority country JA 
within card columns 21-22 
- 
Priority date day 19 
within card columns 24-25 
- 
Priority date month 04 
within card columns 27-28 
- 
Priority date year 76 
within card columns 11-12 
- 
Publication date month 10 
within card columns 17-18 
- 
Publication date year 77 
For List 5 
Card columns 59-62 - Citation number 5457 
within card columns 33-38 
- 
Priority number 045170 
within card columns 21-22 - Priority date day 19 
within card columns 24-25 
- 
Priority date month 04 
within card columns 27-28 
- 
Priority date year 76 
within card columns 30-31 
- 
Priority date country JA 
For List 6 
Card columns 59-62 
- 
Citation number 5457 
within card columns 33-38 
- 
Priority number 045170 
within card columns 30-31 
- 
Priority country JA 
within card columns 21-22 
- 
Priority date day 19 
within card columns 24-25 
- 
Priority date month 04 
within card columns 27-28 
- 
Priority date year 76 
Sample pages of Lists 1 to 6 are shown as Figures 76 to 81 respectively; 
the pages illustrated show the entries for the card which is the 
subject of Figure 75. In each case the lists comprised 70 pages each 
of 60 lines, plus a final page of 26 lines, representing the 11226 cards 
used as input. The lists are presented in microfiche format at the end 
of this thesis. 
- 
345 
- 
TOOH S 22.01.74 10.04.72-05-242842 1 049007263 23851V 2173 04 
T00ä I 07.04.76 10.04.72-05-242842 2 053946927 30000X 3045 01 
TOOH S 11.04.75 09.10.73-N1-013896 S ML7313896 28433A 3366 02 
TOOH S 15.05.75 14.11.73-DT-356862 S DT2ý56E62 34499V 3365 01 
TOOH S 01.12.75 06.08.74-GB-034614 1 bB-832174 00109X 3174 13 =23513Y =4206 
TOOH S 22.03.77 06.08.74-GB-034614 S US4013653 235131 4206 13 
-00109X =3174 
TOOH S 22.01.74 +12.08.74-DS-496620 2 349007263 23851V 2173 04 
TCOH I 07.04.76 12.08.74-US-496620 1 US3948927 300001 3045 01 
TOOH S 01.12.75 +04.10.77-GB-041215 2 5E-832174 00109! 3174 13 =235131 =4206 
TORA S 29.08.76 07.02.77-JA-011628 S 053098986 71444A 5209 01 
TCRA S 17.05.79 18.10.77-JA-125001 S 054061191 476265 5023 01 
TOSB/ S 11.10.77 07.04.76-11-039549 2 NL7703864 770737 5496 09 
TOSH/ *S 11.10.77 15.09.76-JA-111125 1 NL7703864 77073Y 5496 09 
TOS! S 26.08.75 07.02.74-31-014895 S J50108202 04663X 3147 01 
TOSZ 5 25.04.77 23.10.75-31-127666 5 352051388 40495Y 4142 01 
TOS! S 21.02.78.02.08.76-JA-092170 S J53018718 26122A 5322 01 
TOS! S 29.05.78 09.11.76-31-134452 S 353059689 46660A 5267 01 
TORN S 17.08.77 19.12.70-31-114804 S 377031878 64320Y 4010 01 
TOIN S 23.10.73 20.04.72-31-040136 S NL7305374 681453 2282 10 =726490 -2273 
TOXN P 05.02.74 01.06.72-3A-054983 S 349013195 21698V 2180 01 
TOX2: C 09.05.75 01.08.73-JA-086965 S J50052219 02547X 3159 01 
TORN B 15.05.75 23.01.74-JA-010471 2 LE-624681 39285W 3345 12 
TORN B 23.08.75 07.02.74-JA-016547 S 350137166 06282X 3143 01 
TORN B 12.09.75 25.02.74-JA-022579.5 J50116686 84040W 3195 01 
TO/. N B 12.09.75 25.02.74-31-022580 $ 350116667 84041W 3194 01 
TORN S 19.12.75' 07.06.74-JA-065227 S J50157389 23826A 5335 01 
TORN B 19.12.75 12.06.74-JA-066665 S 350157591 23858A 5332 01 
TORN B 17.04.76 14.10.74-31-117205 S 351044695 41066X 4497 01 
TORN B 15.05.75 12.12.74-JA-142761 1 BE-624681 39285V 3345 12 
TORN 5 03.08.76 03.02.75-JA-014550 S J51086694 71195X 4380 01. 
TOXX P 02.05.77 26.10.75-JA-130150 S 052054017 42261! 4134 01 
TORN C 27.05.77 18.11.75-GB-047562 S 352064432 48083Y 4104 02 
TOIL P 30.05.77 20.11.75-JA-139438 S 352065289 49344T 4101 01 
TORN ES 12.07.77 
. 
27.12.75-JA-156573 S 052063391 602931 4055 01 
TOX' B 11.07.77 27.12.75-JA-159808 S 352082791 60158T 4056 01 
TORN I 06.09.77 03.03.76-JA-023653 S NL7702304 67184Y 5544 06 
TORN 1. S 05.09.77 04.03.76-31-023522 5 LE-852031 63054Y 4019 09 
TOXN LS 21.10.79 09.04.76-31-040588 S 352125696 85730Y 5461 01 
TOIN &8 27.10.77 19.04.76-JA-045170 5 052126295 87402Y 5457 01 f 
Tbi NI 11.01.78 26.06.76-11-075001 S 053002491 14867A 5364 01 
TOIi7 B 08.04.78 18.09.76-31-112079 5 . 153036692 35986A 5302 01 
TOIN B 08.04.73 18.09.76-JA-112060 S J53038693 35987A 5301 01 
TORN B 08.04.78 18.09.76.3A-112081 S 053036694 35986A 5300 01 
TCXN dB 27.05.78 05.11.76-JA-132318 S 353059095 49601A 5268 01 
TORN B 17.10.78 28.03.77-JA-034205 S 053118591 84589A 5157 01 
TOXN X 13.03.79 23.08.77-JA-lo0162 S 354034293 321238 5059 01 
TOYA 5 22.09.76 17.10.70-JA-090972 S 076033918 78719X 4349 01 
TOYA *S 20.04.72 17.10.70-JA-090973 S DT2151530 27933T 1013 11 
TOTA S 14.11.72 31.03.71-JA-018603 S JA4731993 492000 2318 01 
TOYA S 01.12.72 15.04.71-JA-024139 2 Fä2133761 102330 2399 01 
TOYA *S 26.10.72 15.04.71-JA-024140 2 0T2218209 71522T 2447 13 
TOYA *S 26.10.72 15. ()4.71-JA-024141 1 DT2216209 715227 2447 13 
TOYA S 22.03.73 29.07.71-JA-056411 S JA4822491 512060 2312 01 
TOYA S 26.06.73 14.10.71-JA-061136 S JA4644296 553363 2307 01 
TOYA S 01.12.72 01.11.71-31-066943 1 FE2133761 102330 2399 01 
TOYA S 22.06.73 +08.12.71-65-057046 3 UL7137455 389970 2342 06 
TOYA 5 22.06". 73 +14.12.71-CA-130125 2 NL7117455 389970 2342 06 
TOTA S 22.06.73 20.12.71-NL-o17455 1 NL7117455 369970 2342 06 
TOYA S 18.09.73 23.12.71-31-104936 S 014868590 765240 2264 01 
TOYA *5 22.06.73 28.12.71-JA-002201 2 BE-793191 39684U 2338 06 
Figure 76: Part of Cephalosporins Patents Data Computer 
Generated List 1 
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TLGh S 22.01.74 IC. t4.72-US-242tti2 1 J. 9CCL. b3 2Db51V 2173 G4 
IC'_h S 22.01.74 +1: C"8.74-US-4Y6c"1G 2 J49GL7. 
_o3 234.5aV 2173 
C4 
TCCh S i1. C4.75 CV. 1L. 73-. NL-«13tSb S AL7313f. 
-V6 L843bd 3: ib (12 
Tf- h S 1?. C5.75 14.11.13-üT-ý. uyo2 S GTi35oooi 3ti499W 33u5 G1 
iEt; Fs S C"1-iß. 75 Co. Co. 74-Lb-: ý4u14 1 5E-b 2174 0'-1.9X 3174 15 cl. 3513Y =4ZGb 
TLi.. h S t«"1t. i5 +U4.1ý. 77-Ctf-"ac15 1 bc-&4114 LCICYX X174 la =s. 35adY t-42 %; b 
TCi H I G7.04.76 1G. 
, 
U. 74-US-y `JS 
.C 1 uS3's4iy27 3G) GI. X 3045 ui 
76,. H I Ci. C'4. to 1L. C4.72-1. S-24-b4t 2 63p3y461.0 Z7 3L, CCX 5.. 45 i: l 
: LLh S Z--1.77 34t, 1  US4.13c, 3 23513Y 42. o 13 =CC1L9X =3174 
TLA; A 1, 1b. CU. i8 U7. Ci. 77-JA-ilib2b S J, 3.9u'bc 71444A 5iU9 vl 
YL-PA S i1. C5.79 lb. AL. 77-JA-1e.. ß: 1 S J54. c, 1141 47,: 26b `. L. a c, & 
Tear/ * S Ii. aL. 77 15. Lv. 7o-Ja-I111Z5 a NL71C3 b4 77u1., Y 549o 09 
TUfh/ * S, i1.1C. 77 C7. C4.7c. 
-JA-v39549 2 NL7%3o64 77C7. iY 54y6 G9 
TCP. X S 26. Cä. 75 C7. C2.74-JA-C14L"`,, S JS:. "l. bc82 :. 4ob3X 3147 O1 
ILSA S 25.04.71 Z3. iC. 75-JA-l&: 7bto s J5: C5az 6b 4C4SSY 4142 Gi 
TCSX $ 21.02.16 Ci2. Cb. 1b-JA-C1200 S J53: 1o7i8 Zo122A 5s22 01 
TCSX S 2S. C5.76 09.11.7c-JA-1344 - S J53C59bb9 nboL:. A 5cb7 Li 
TCAN S 23.1 
. 
73 ZL. G4.72-.: A-;, 4Ll3b S t. L7305.74 bt; I45U : 2b2 il. =72L-49U r-2273 
IOXN P GS. 64.74 U1. Cu. 72-JA-C54963 S J49i. L 19> 21oYoV [1b Cs UI 
TUXN C 09.: 
">. 75 C1. C8.73-JA-C6b`f65 S JSCL52219 a.. 547X 3159 G1 TUXN'- 6 1`. 45.75 Ii. 1t. 74-JA-14.7f. ä 1 bi-at4obl 
. 
-9265W . 345 1[ 
TCXN b 15. 23.21.74-JA-i:. t"471 Z uc-b 46b1 392b>4 1345 12 
TCXA b 23.0o. 75 C7. C2.74-JA-016547 S J5uit11rb Cttö2X 3143 C" 
TUXN 6 12. t9.75 25. Cc. 74-., A-L125i(. S J5Ct16ub7 i; 4C41W 20494 01 
TUXN L. 1.. Ccj. 75 ZS. C2.74-JA-Ct2579 S J5z; lls. 6bb 944,4Gw 311> Cl 
T[jAN b 15.12.75 1t. Go. 74-JA-5 
.. 
ot> S J: C157>yI 4: 854A 5334 C. 1 
TJXP. S 1%. 1 
.l o7. Co. 14-JA-C"u. >127 S J5. A573b9 Z1, S1oM 
5: ): S5 Ci 
LCXN b i7. C4.76 14.14.74-JA-1172t5 S J5lt. o95 41%; ooX 4497 C1 
TUX:. b C. s. Lu. 7b G3. G2.75-JA-C1y>54 S J>: Ctbc94 741S: -X 4söi. C1 
TORN P Gý. t 5.77 7r. 1G. 75-JA-1sG15ý S J i.. 4E"17 4:: Z81Y 4134 GI 
TCXt. C 27. C5.77 111.11.75-{. U-&47562 S J5.4 4432 4bCo3Y 41C4 GZ 
TGXU P 5C. C5.77 2C. a1.75-J.. -1B943is S J>2Co!;;. b9 49344Y 4151 01 
TLArr U 11. C7. T7 27.12.7>-Ja-1.9, C. o S J5i: Co279i uL1SJY 4CSb v: 
kLA t. L S 12. L7.77 Z7.1!. 75-J*-156>7- S J. 339L 6C" . 9. ýY 4i55 :; 1 
TCXI S 17.58.77 19.12.7v-JA-1140t4 Sc, Jliu31. b7b t4J[CY 4Llü C1 
TOXN F. S Cß. (9.71 U4.1r3.7b-JA-Lc35&Z S uE-E.: 2Ci1 bJ,. i4Y 4C IV GY 
7O: x14 I Go. u9.77 03. C"3.1 
. -JA-C23o53 S : ýL77S[354 b7lb4Y »44 Co 
TLx1.4 F. n it 7. IC. 77 1S. C4.7o-JA-L4517. m S J5ýi2L195 4;, 74GZY 5457 c3 -<( 
: GY. N I 11.01.76 26. C6.7o-JA-.. 75(51 5. 153*.. 2,91 Irab? A : 304 L1 
TCX"; E. 5& 
. 
C4.7& L--JA-1Iz% i"1 S J53: sLcS4 : ): yubA 1; C1 
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SANY 1 24.01.73 C7. C7.76-JA-'"8! 656 S JD3CC769a 18400A 5353 Cl 
YAMA S 21.12.77 07.07.76-JA-060659 2 I+E-b55949 00'C77A 5440 07 
TEIJ 124.01.78 C9.07.76-JA-CECC25 S J53CG769o 1b4C1A 5352 Cl 
YAMA S 26.01.78 1b. C7.76-JA-Ci+4614 S J53CC"9787 161468 5351 01 
TFIJ 1 04.02.76 21.07.76-JA-0t5929 S J53012880 2C7'3A 5349 01 
TCYA S 13.02.78 24. C7.76-JA-; 67744 S J53C1539ti 24: 17A 5331 01 
YAMA 6 15.04.77 2t,. 07.76-JA-Cbt"770 1 rE-X49763 29215Y 4174 11 
1061- AS 13. C2.76 2o. C7.76-JA-030933 S J530540 24C23A 5329 01 
TCHP LS 11.0Z. 70 2o. C7.76-JA-Cb8933 S J53G15407 24023A 5329 01 
SANY S 20. C2.78 2b. 07.76-JA-089932 S J53018553 2hC45A 5325 01 
TAKE S 13.02.78 29. C7.76-JA-C9C942 S J53C)5? 95 24("188 5330 01 
NISO- S 20.02.78 30.07.76-JA-090141 S J5301b594 26046A 532'. 01 
TCYA S 20.02.78 02.08.76-JA-05128b S J53018595 260478 5323 Cl 
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YAMA S 29.09.77 26.03.76-JA-033328 S J52116490 80381Y 5489 01 
FARD S 29.09.77 27.03.7b-DT-613172 S NL77'rJ2Ob 7too3Y 5519 Ob 
IAKE S 14.07.77 29.03.76-. 1A-034971 1 G127if. 27t 54712Y 4096 OS 
MEAI S 04.07.78 30.03.76-US-871764 S US4L99G(. 0 65237A 5212 ul 
! 'SERI S 14.03.78 30.03.76-US-6717.5 S US47C9179 2671*4 5315 0a 
GHEÖ *S 13.16.77 30.03.76-US-871788 S U12114214 74413Y 55äb 64 
S. u1 *5 13.14.77 3G. C3.76-uS-6717äb S LTd714214 74413Y 5508 04 
ASAH S (14.10.77 31.03.76-JA-034379 S Jtitllä4bb 419o3Y 54u5 Ol 
FUJI 1 14.10.71 (k. C4.76-JA-136997 S J52). 223bb o3u96Y 5474 01 
SANY S £4.10.77 GZ. C4.76-JA"-Gisb9T1 S J52A22-'b7 8: )695Y 5475 O1 
114. E S 30. (. 9.77 02. Cf4.76-JA-037374 S LE-. 53("73 7C716Y 5525 13 
ELIL I 28.03.78 02.04.76-US-03G17 1 US4Gbl44G 36474A 5299 ul 
ELIL 123. ß. t. 76 +02.64.76-US-673036 3 LE-ci37L41 54069X 4451 14 
tL1L 104.10.77 02.04.76-US-673636 I US4(. SLsbT 74034Y 5511 01 
SANY 107.10.77 65.04.70-JA-631956 S HL77: s745 75ý11Y 5504 08 
SUI S 28. v6.76 05.04.76-US-o732ä2 S 04097¬70 o3382A 5237 01 
PkOT- S GL. 11.7d 06.04.7b-GB-013946 S Gä1531284 6L565A 5173 01 
ckBA S 16. (18.76 07. ä4.7b-1T-022016 1 BE-840i50 bb777X 4389 12 
SANG *5 11.10.77 07.04.76-JA-039549 2 1L7703bb4 77(73Y 5496 09 
705W *S 11.10.77 07.04.76-JA-0`39549 2 NL77C3884 71673Y 5496 09 
AMGY *X 05.10.77 07.64.76 u$-b7,. 473 5 bt-d53253 72453Y 5526 13 
F1Sk- sX 05.10.77 07.1,4.76--üS-b74473 S äc-L`rs 53 7.: 453Y 5520 13 
DA1N 1 20.10.77 08.04.74-JA-04:. 091 S J52125165 85561Y 5405 01 
1OXN bS 21.10.79 09.04.76-JA-04J58b U J52125o96 8573LY 5461 01 
ASAH dS 21.10.77 G9. C4.7b-JA-C4G55b S J521256So b573GY 5461 01 
SC"u1 S 30.05.78 09. C4.7o-US-675355 S'l, 54u9Z475 53361A 5256 0]. 
1!. AN S 20.1£:. 77 10. i. 4.76-JA-L4ä513 S J52125166 95: ob2Y 5464 01 
SANY S 20.10.77 1G. G4.7e. 
-JA-., 4ä53ü S J52125147 d5563Y 5463 ül 
FUJI S 14.69.77 12.04.76-Gb-014916 2 BL-6524Z7 6*L53Y 5551 040 
ELUL S 16.08.77 11.04.76-US-074183 S US4042472 bG9dlY 4637 02 
BtEC 5 24.05.77 13.04.76-68-014952 1 6E-b44111 38084Y 4149 10 
TAKE S 13.10.77 14.6ä. 76-JA-i. 42885 2 BL-b53545 74147Y 5, W9 12 
MERI 1 10.08.76 +14. C4.76-US-678771 2 uS3974151 64699X 4410 OL 
MERZ 1 20.12.77 14.64.76-05--676771 I 1. S46b4344 61S64A 5428 01 
8Ai'Y b 27.10.77 19.04.76-JA-643057 S . 752128293 b7400Y 5459 01 
TuXN dB 27.10.77 19.64.7u-JA-045170 S J52128295 8746 Y 5457 01 
-19 
ASAH bG 27.10.77 19.04.76-JA-045170 S J5212b295 67401Y 5457 01 
SGU1 S 20.09.77 19. C4.7b-6S-b7ä1:: £ S Vs4C49o51 70539Y 5527 Cl 
L-LIL S 28.07.77 19.04.76-US-676086 S 1. S4038275 55701Y 4074 06 
FUJI P 1: 7.10.77 20.04.76-JA--045131 S J5212bZ94 67461Y 5458 03, 
MEUJ S 04.11.77 24.04.7*-JA-040790 S j52131595 d917i. Y 5452 01 
BRIM S 26.10.77 21.04.76-Gc-:. 17096 I bL-Q53974 77)i9Y 5494 12 
Sn1U 1 31.16.77 27.04.7b-JA'ti 49274 S NL7164034 823EbY 5464 05 
GLAX 5 27.10.77 26.04.76-GB-017307 S bt-t54b12 77534Y 549a %07 
FA48 S 10.11.77 33.04.76-uT-619247 S DT2619t47 8i39JY 5487 G7 
5:; 10 S 25.03.76 3C. 04.7*-Ja-05CVS5 1 6L-85:. 912 66670Y 5537 15 
ShiK S 05.47.77 03.05.76-US-48t94d 1 UN40B4i, 92 5132. Y 4100 01 
bErC C 21.11.77 GS. GS. 7btid-L 183.4 i J5213S731 Gý94GA 5418 02 
FGhE *C 17.11.77 05.05.76-o 
-083410 S D12718266 632371 5481 05 
LCWE/ *C1.7.1... 77 65. C5.7*-US-683410 S DT271b. G0 03237Y 5481 G5 
TP. KE 5 14.11.77 46.05.76-JA-051b9 S J52136191 00718A 5433 01 
YUSH P 14.11.77 06.05.76-JA-05189b S J52136190 LG717A 5434 .1 
ELIL S 20.03.79 06.05.7o-US-683904 4 US414551U 27b01b 5669 01 
6EcL. C 07.04.77 08.05.7b-6b-UI9000 1 bk-141C45 Y5480Y 419.19 
(. 011- S 14.11.77 0b. J5.76-JA-C717a1 S J521o6192 4.719A 5432 U1 
MERE S 24.11.77 1ý. 05.7o-L'T-61£111 1 D12b21U11 b4927Y 5476 04 
SAVVY S 14.11.77 12.05.76-JA-0539bo S J52136194 C6723A 5433.01 
5.410 C 01.09.77 13. C5.7b-JA-C54s25 S bE-b54643 o5673Y 4665 13 
1IAUY P 19.11.77 13.45.70-JA-056118 S . 752139090 8.752A 5419 01 
NEIJ S 08.12.77 19.65.76-JA-C56645 S 012721731 865C. 4Y 5453 03 
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Problem of Computer Listing Errors 
The computer was utilised to produce only List 1 on the first run in 
order that the list could be checked for errors before generating the 
Lists in their entirety. This was done and, as far as could be ascert- 
ained the list was found to be correct. 
Instructions were therefore given for Lists 2 to 6 to be produced, 
although the computer bureau was only able to produce Lists 2 to 4 and 
6 at the next available session. Examination of List 2 showed that 
there were 4226 entries (i. e. lines of printout), but that the single 
entry for ICI Limited (citation number 3108) had the patentee code 
altered from ICIL to &C&L and had thus printed as the first line since 
numerals and special characters 
- 
such as ampersand 
- 
are listed before 
alphabetic characters. 
Examination of List 3 showed that the entry for citation number 3108 
had this time listed under &CIL and that only 4225 entries had printed 
out. It was not possible, without crosschecking every entry either 
against the Punching Instruction Forms, or the cards generated thereon, 
to ascertain which entry had been lost. 
List 4 had only 4224 entries and, therefore, two entries had been lost; 
one of these was for the ICIL entry (citation number 3108). List 6 had 
only 4223 entries; again the ICIL entry was found to be one of those 
missing. 
The lists were therefore produced a second time, together with List 5. 
This time all lists were found to be correct. No explanation could be 
given by the computer bureau personnel as to how th errors could have 
originated. The alteration of the ICIL patentee code, and the loss of 
entries, was considered to be a mystifying problem since the computer 
had obviously read all the input cards correctly and the sort and 
output systems appeared to be working satisfactorily to produce List 1 
on the earlier occasion. The data had been stored on discs between the 
session when Lists 2,3,4 and 6 were produced, i. e., the cards had 
been used as input only once. It was suspected, but not confirmed, 
that the errors originated during the program phase following sorting 
of data and listing the data in the desired sequence prior to printing. 
'. 
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Supplemental Data Retrieved from the Database 
(a) Total number of pre-1980 patent for each patentee 
The online system was used to search for each patentee, other than 
inventors who were listed as joint patentees with an organisation or as 
independant inventors. The searches were restricted to pre-1980 data 
since they were carried out in July, 1980, whilst the main patent 
bibliography had been produced in late 1979. This was achieved for 
companies with standard patentee codes by using the search strategy: 
XXXX/PC AND NOT 80/AY 
where: XXXX 
_ 
four character patentee code 
/PC = patentee code qualifier 
80 
= accession year 1980 
/AY = accession year qualifier 
For non-standard company codes a similar strategy was employed: 
XXXX-/PC AND NOT 80/AY 
where: XXXX- = non-standardised company code 
which may have been applied 
to more than one organisation 
The answers so retrieved were stringsearched (see note below) In the 
line containing the patentee code for the most significant word in the 
patentee name. Thus, for example, references to Lumac International NV 
were retrieved as follows: 
Step 1: LUMA-/PC AND NOT 80/AY 
Step 2: STRS /CC : LUMAC: 
In Step 2: STRS command for stringsearching 
/CC 
= command for the line (company code) to be 
so searched 
: LUMAC: = term to be stringsearched allowing either 
for left or right hand truncation (indicated 
by colons, :) in case the word had been 
coupled with another term such as by hyphenation. 
In several instances the total number of citations retrieved using 
patentee codes of either the type XXXX or XXXX- were relatively low; in 
such cases where there were less than 25 citations an abbreviated 
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citation, comprising accession number, classification and title (i. e., 
AN, CC and TI lines), were printed online since this data was also 
required for determining the number of patents classified into Central 
Patents Index Section B (Farmdoc). 
Note on Stringsearching 
The STRINGSCARCH command, or its abbreviation STRS, is used to perforn 
a text search online on the unit records retrieved by a search state- 
ment. It is used to narrow search results by searching for terms in 
context not possible through direct searching of the inverted files of 
search fields. The entry format for the STRINGSEARCH command is: 
STRS n/field(s) : character string: 
where n is the number of the search statement to be searched 
If the search statement number is not specified the search is done on 
the last entered search statement. If the fields are not designated, 
the search is on the title (/TI) field. The character string is 
normally enclosed in colons. 
(b) Total number of pre-1980 patents in CPI Section B for each patentee 
For the majority of searches carried out in (a) above the answers 
retrieved were searched to see if they had been classified in CPI 
Section B by stringsearching the CC line (containing patentee code, 
name and Derwent CPI classification) using the strategy: 
STRS /CC : B##: 
where: SIRS = stringsearch command 
/CC 
= qualifier for the CC line of citations 
B= classification for CPI Section B 
#_ "dummy" character permitting retrieval 
of any character from 0-9 and A-Z 
= left and right hand truncation so that B 
could be retrieved from amongst a series 
classification, e. g., from A13 A61 B01 C02 E12 
It was necessary to adopt the search parameter Bfl# since this overcame 
the necessity of searching all the Section B classifications (BO19 802, 
B03, B0I, 805, B06 and B07) in an "Oft" relationship. 
354 
- 
Where the number of citations retrieved in (a) above was relatively 
low, i. e., less that 25, the abbreviated citations printed out online 
were visually scanned to determine how many had been classified into 
Section B. 
The validity of the searches carried out in (a) and (b) above was 
checked on several occasions by printing of more citations and carrying 
out visual scanning. For example, the retrieval: 
ASAH/PC AND NOT 8.0/AY 
retrieved 8910 citations, and stringsearching of these with: 
STRS/CC : B##: 
retrieved 498 citations. The first five of these citations were 
printed online and had Derwent CPI accession numbers: 
92168B/51 
92023B/51 
91909B/51 
91800B/51 
and 91708B/51 
A retrieval for all ASAH patents ("ASAH/PC") retrieved 9185 citations; 
AN and CC lines were printed for groups of these. The first 275 
citations had accession numbers ranging from 000193C/01 to 39249C/22, 
i. e., they had been added to the file in 1980 (accession number series 
C). The next thirteen citations and their classifications were: 
92705B/51 M13 M24 P73 
92169B/51 A31 B05 D13 J04 
92090B/51 A85 E19 L03 R47 
92088B/51 A82 G02 A21 
92051B/51 A02 E141 G02 All A14 E12 
92023B/51 B03 
91951B/51 M21 M23 P51 P55 
91909B/51 B07 D22 
91885B/51 A89 C06 R23 
918688/51 D15 
91847B/51 A32 A13 A23 
918008/15 B02 
917980/51 B02 
- 
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Thus it was confirmed that only citations with accession numbers in the 
accession number B-series (1979) and earlier had been retrieved in the 
first search phase, and of these only those classified into CPI Section 
B were retrieved in the second phase. 
Stringsearching is a somewhat time consuming searching technique and, 
in the majority of searches conducted as in (a) and (b) above, several 
"time overflow" conditions were experienced. For example, the retrieval 
of the 8154 pre-1980 ICIL patentee coded citations took 0.54 hours 
during which period there were 137 time overflow conditions. The total 
retrieval of all the data necessary for (a) and (b) consumed 17.45 
hours of online usage. 
Time overflow conditions arise under the following circumstances: each 
simultaneous user of the ORBIT program is allotted a certain amount of 
processing time; most searches are easily accomplished within this 
time. Some search functions require more processing time than others 
(e. g., stringsearching), however to maintain an "equal-attention-to-all 
-users" concept, a capability called time-slicing has been introduced. 
When such a situation does occur, the user is sent an online message 
which requires him to respond if he requires searching to continue. 
Updated Data Set 
In early August, 1981, a further retrieval of Cephalosporins patents 
was conducted on the WPI and WPIL online files. The same search logic 
was used as described earlier. This search resulted in 2874 and 33 
hits from the WPI and WPIL files respectively. Again, allowing for 
"missed" equivalents on the one hand, and multiple patentees on the 
other, this resulted in a data set containing 29411 references with 216 
patentees, i. e., a further 3115 patents and 24 patentees than the 
original Cephalosporins data set. 
In the interval between running the original retrieval and the update, 
improvements had been made to SDC's ORBIT program suite which, inter 
alia, allowed for the sorting of retrieved data prior to offline 
citation printing. The additional data retrieved in the update was 
therefore sorted by (a) patentee codes, and (b) priority date prior to 
printing thereby giving no need to go through the lengthy routine for 
analysis required for the original data set. 
I., 
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APPENDIX II: AIR CUSHION VEHICLES 
Sometimes also referred to as ground effect machines or hovercraft, the 
air cushion vehicle essentially "traps" a volume of air between itself 
and the ground or water beneath it. Depending upon the design, the 
vehicle can be lifted from a fraction of an inch up to several feet 
above the underlying surface, with sustaining pressures, or the equiva- 
lent in lifting force, of some 36 psi or more. Normally, operational 
economy requires that the machine be kept as close to the surface over 
which it is to travel as may be possible. 
Although mathods have been suggested for supporting a vehicle on a 
cushion of air for a long time, only in the present century have 
workable machines been built. Three basic types have appeared: the 
fully amphibious, which use a flexible rubber skirt around the peri- 
phery of the craft to retain the air cushion that is produced by fans 
blowing air underneath it; the purely sea-going, which has side-walls 
extending into the water to retain the similarly produced cushion, plus 
flexible skirts at the bow and stern; and the ram wing, which rides on 
a cushion produced by its own movement. 
Machines of these types created much interest in the late 1950s and 
early 1960s and they aroused great expectations. As of the early 
1980s, however, air cushion vehicles enjoy only limited and very 
specialised applications. The ground-effect principle has been employed 
in vehicles of the types mentioned and for conveyors and industrial 
towing vehicles, but numerous practical problems remain to be worked 
out prior to a widespread application of this principle. These problems 
continue to receive the attention of industry, with a resultant steady 
flow of patents; for this reason such documents were included in this 
study. 
The retrieval of Air Cushion Vehicle patents from the WPI online 
database was conducted on 22 June, 1981; at that time the files had 
been updated with data on basics and equivalents to Derwent Week D12. 
The retrieval was carried out using the IPC B60V (Air Cushion Vehicles) 
as the only search parameter. This gave a total of 460 citations 
which, on analysis showed a total of 233 patentees. 
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APPENDIX III: CYCLOPROPANE DERIVATIVE INSECTICIDES 
Around 1820 the dried heads of Pyrethrum flower were introduced into 
Europe from Asia for use. in dust or liquid extract form as an insecti- 
cide especially for horticultural purposes. Pyrethrum flower owes its 
insecticidal properties to two groups of esters. One group consists of 
pyrethrin I and cinerin I, both of which have chrysanthemic acid 
(chrysanthemum monocarboxylic acid) as their acid component. The 
second group of esters consists of pyrethrin II and cinerin II, both of 
which have pyrethric acid (monomethyl ester of chrysanthemum dicarb- 
oxylic acid) as the acid component. 
CH9 
j C=CH 
CHs 
COON 
CH3 CH3 
Chrysanthemic Acid 
The recognition of the fact that the activity resided in a eyclopropane 
derivative led to the search for synthetic analogues which would be 
both more efficacious and more selective in action. Such synthetic 
compounds include Bioresmethrin and Phenothrin, both of which are 
commercially available. 
Me2C=CH 0 
7- 
C. O. CH2 
Me *Me I 
0 CH2Ph 
Biosresmethrin 
Me2C=CH /\ 
000C112 
Me 
Me 
OPh 
Phenotbrin 
The search for further cyclopropane derivatives with insecticidal 
properties *continues, with a resultant steady flow of patent applica- 
tions; for this reason these compounds were considered to represent a 
suitable technology in the present study. 
The retrieval for Cyclopropane Derivative Insecticides from the WPI 
online database was conducted on 6 July, 1981; at-that time the files 
had been updated with data on basics and equivalents as to Derwent Week 
D12. The retrieval was carried out using the single search statement: 
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1 O6/C, C1 AND C12-N02/MC 
in which /C, C1 are the qualifiers for the fragmentation codes applied 
to CPI Section C (Agdoc), and 406 the fragmentation code for the 
cyclopropane ring system. /MC is the qualifier for Manual Codes, and 
C12-N'02 the Section C Manual Code for insecticides. 
The search gave 1106 answers which, on analysis, showed that there were 
168 patentees. 
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APPENDIX IV: VIDEODISCS 
Recent advances in the mass storage of graphic and textual material 
have centred upon the development of videodiscs. Videodiscs and 
optical discs are basically a thin plastic or, in some cases, glass 
layer which carry data either impressed into the disc or recorded on a 
coating laid on the disc. There are two fundamental types: the disc 
which is used to play through a television monitor which is referred to 
as a videodisc; and the disc which is used to store data for computer 
systems, which is often referred to as an optical disc; however, it 
should be noted that often the two terms are confused and used synony- 
mously. Generally speaking, the former record analogue data and the 
latter digital data, although neither are intrinsic properties. 
Videodiscs utilise a laser with an extremely fine beam (about one 
thousandth of a millimetre in diameter) flashing on and off for one 
ten-millionth of a second or less. The intense light "burns" microsco- 
pic marks along a spiral track on the disc's sensitive recording 
medium, and the pattern of marks stores the information. 
The storage capacity of videodiscs has been estimated to be 1011 bits, 
which is a substantial order of magnitude greater than more conventio- 
nal magnetic tape. 
. 
Because videodiscs show great promise both as a mediura for home enter- 
tainment programmes and as a mass information storage device, they have 
attracted the interest of a large number of research teams in industry. 
It was therefore considered appropriate to include patents on videodisc 
technology in this study. 
The retrieval for Videodisc patents from the WPI online database was 
carried out on 22 June, 1981; at that time the database had been 
updated with data on basics and equivalents to Derwent Week D12. The 
retrieval was carried out using the following four-step search logic: 
Search statement 1: 
G11B-007/24/IC OR G11B-007/26 OR ALL G11B-009: /IC 
Search statement 2: 
W0$-COi/MC 
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Search statement 3: 
G11B-003/68/IC OR G11B-003/80/IC 
Search statement 4: 
SEARCH STATEMENTS 1 OR 2 OR 3 
In these searches /IC and /MC are the qualifiers for IPCz and Manual 
Codes respectively. The search parameters utilised are: 
- 
G11B-007/24 
= IPC for optical record carriers characterised by the 
selection of the material or by the structure. 
G11B-007/26 
= IPC for apparatus or processes especially adapted for 
the manufacture of optical record carriers. 
G11ß-009 
= 
IPC for recording information otherwise than by 
cutting grooves, by magnetisation, or by optical 
means; record carriers therefor, reproducing by using 
means other than styli, magnetic means or optical 
means. 
- 
G11B-003/68 
= 
IPC for recording information by cutting, deforming, 
or pressing grooves, e. g., by stylus, etc., onto 
record carriers. 
G11B-003/80 
= 
IPC for record carriers incorporating subsidiary guide 
means for heads other than modulated grooves; part- 
formed unmodulated grooves for conversion into trans- 
ducing grooves. 
W04-C01 
= Derwent Manual Code for record carriers using optical 
methods. 
The search gave 548 citations which, on analysis, showed a total of 162 
patentees. 
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APPENDIX V: GENETIC ENGINEERING 
The term "genetic engineering" refers to the relatively new laboratory 
techniques used to change the hereditary endowment of living cells. It 
is popularly associated with the transfer into and multiplication 
(cloning) of "foreign" genes in single cell micro-organisms, and 
includes the synthesis of the foreign gene product by the resulting 
organisms. It should be noted, however, that the technology is also 
used to modify higher plant and animal cells genetically. 
Present day genetic engineering techniques owe their origin to the 
results of basic research into genetics and biochemistry carried out 
over the past 35 years. The laboratory manipulations employed are 
revolutionary: they permit the production of hybrid organisms with a 
genetic make-up composed of a mixture of genes of species as diverse as 
bacteria and man. In such organisms the genetic material (DNA) of each 
species is covalently linked 
- 
hence the term "recombinant DNA". It 
will be appreciated that such techniques have provided a means to 
overcome the well known natural morphological and physiological bar- 
riers evolved to prevent hybridisation between different species. 
However, the possibility should be borne in mind that the genetic 
engineer could be mimicking natural processes which occur, albeit 
probably rarely. For example, it is conceivable that the DNA of a 
lysed bacterium in the gut of man could become integrated into his DNA, 
or that a virus particle could carry a piece of host DNA from one 
infected individual to another. 
This new technology has captured the imagination of industrial managers 
and entrepreneurs; without doubt it is a technology holding much 
promise for the future and one in which there is a great deal of 
industrial activity which is growing in impetus. It was therefore 
considered appropriate to include genetic engineering patents as one of 
the data sets for this study. 
The retrieval of Genetic Engineering patents from the WPI online 
database was conducted on 22 June, 1981; at that time the files had 
been updated with data on basics and equivalents to Derwent Week D12. 
The retrieval was carried out using the following multi-step search 
logic: 
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Search statement 1: 
C12K-001/02/IC OR C1'N-015/00/IC OR AO1H/IC OR D05-H03/MC 
Search statement 2: 
PLASMID/IT, TI OR GENETIC/IT, TI OR CUUROMOSOME/IT, TI OR RIBOSOME/IT, TI 
OR MUTANT/IT, TI OR MUTAGEN/IT, TI 
Search statement 3: 
TRANSMUTATION/IT, TI OR DNA/IT, TI OR RNA/IT, TI OR GENE/IT, TI OR 
GENOTYPE/IT, TI OR BIOGENIC/IT, TI OR CLONE/IT, TI 
Search statement u: 
C12K/IC OR C12N/IC OR D05-H/MC OR D05-H08/MC OR 540/B, B1, B2, C, C1, C2, E3 
Search statement 5: 
HYBRID/IT, TI OR DOMINANT/IT, TI OR TRANSFORM/IT, TI 
Search statement 6: 
SEARCH STATEMENTS 1 OR 2 OR 3 OR 4 AND 5 
In these searches /IC, /MC, /IT and /TI are the qualifiers for IPCs, 
Manual Codes, Index Terms and Title Terms respectively; /B, B1, B2, C, 
C1, C2 and E3 are the qualifiers for the relevant CPI sectional frag- 
mentation codes. The search parameters utilised are: 
C12K-001/02 
= IPC2 for mutation or genetic engineering 
C1211-015/00 
=-IPC3 for mutation or genetic engineering 
A01H 
= 
IPC for new plants 
C12K 
- 
IPC2 for methods and apparatus for microbiological 
research; isolation, identification and preparation of 
micro-organisms, including viruses; cell or tissue 
culture; microbiological materials and apparatus 
C1211 
= IPC3 for micro-organsims or enzymes; compositions 
thereof 
D05-H 
= 
Derwent Manual Code for microbiology 
D05-H03 
= 
Derwent Manual Code for formation of microbial mutants 
D05-H08 
= Derwent Manual Code for cell or tissue culture 
540 
= 
Derwent fragmentation code for fermentation, attenua- 
tion, use of enzymes and culture 
The search gave 1308 citations which, on analysis, showed a total of 
665 patentees. 
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APPENDIX VI: PRESSURE SENSITIVE ADHESIVES 
Pressure sensitive adhesives are viscoelastie materials which in 
solvent-free form remain permanently tacky. They adhere instantaneously 
to most solid surfaces with the application of very slight pressure. 
The important requirements for these adhesives are: thorough and rapid 
wetting, tackiness, adhesive and cohesive strength and creep resist- 
ance. These properties are dependent upon the adhesive formulation 
which may include the polymer, modifier, tackifying agent, plasticiser, 
filler, antioxidant and UV stabiliser. 
The earlier solution based pressure sensitive adhesives were largely 
replaced by acrylic emulsions, which were followed by the more recent, 
commercially available, hot melt pressure sensitive adhesives. The 
latter products include Kratom G which is a block copolymer elastomer 
of styrene with butadiene or isoprene, and Hytrel which is a polyether- 
ester elastomer containing blocks of aromatic esters with short and 
long glycol segments. Significant developments are taking place in 
this art, e. g., UV-curable liquid adhesives especially acrylics based, 
and chemically cured systems especially liquid polyurethanes. The 
number of patent filings shows continued interest of the plastics 
industry in this area. Thus, it was considered appropriate to include 
patents on Pressure Sensitive Adhesives from mono-olefinic polymers in 
the data sets used in this study. 
The retrieval for these patents from the WPI online database was 
carried out on 1 July, 1981; at that time the files had been updated 
with data on basics and equivalents to Derwent Week D12. The retrieval 
was conducted using the following four-step search logic: 
Search statement 1: 
/A 35& LINK 074 
Search statement 2: 
/A 609 LINK 074 LINK 01& 
Search statement 3: 
SEARCH STATEMENT 2 AND ALL PRESSURE: /IT, TI 
Search statement 4: 
SEARCH STATEMENTS 1 OR 3 
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In these searches /A is the qualifier for CPI Section A (Plasdoc) 
rmultipunch code; /IT, TI are the qualifiers for Index Terms and Title 
Terms respectively. LINK is the hierarchical operator which retrieves 
terms in the same subfield or subrecord, or between the main record and 
one subrecord. The search parameters are as follows: 
35& 
= Fragmentation code for pressvre sensitive adhesives (from 
Accession Number 60,001Q) 
609 
= Fragmentation code for adhesives 
074 c Fragmentation code for mono-olefinic acrylics 
01& 
= Fragmentation code control for Accession Numbers 60,001P to 
60,000Q 
The search gave 1126 citations which, on analysis, showed a total of 
427 patentees. 
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APPENDIX VII: PRODUCTION OF TEREPHTHALIC ACID 
Terephthalic Acid (TFA) is a high tonnage chemical useful in the 
manufacture of synthetic polymers especially polyethylene terephthalate 
polyester (PET) whose consumption world-wide amounts to billions of 
pounds. Although PET can be produced using dimethyl terephthalate or 
TPA, the trend is towards the use of TPA, as a result of technological 
advances which permit both better purification of TPA and its use in 
polymer production. 
Many processes are available for making TPA on a commercial scale. 
These include: (1) Solid phase disproportionation of the alkali metal 
salts of benzoic acid, phthalic acid and other benzene carboxylic 
acids, especially of potassium benzoate in the presence of carbon 
dioxide at approximately 1l00'C using cadmium or zinc compounds as 
catalysts; the TPA is obtained by mineral acid treatment and the 
by-product salt is recycled. (2) Oxidation of paraxylene using air or 
oxygen using suitable catalysts in acetic acid reaction solvent. 
Because of the continued popularity of PET fibre, the production 
technology for TPA remains an important subject to be included in the 
data sets used for this study. 
The retrieval of patents relating to Terephthalic Acid Production from 
the WPI online database was conducted on 16 July, 1981; at that time 
the files had been updated with data on basics and equivalents to 
Derwent Week D13 and Week D17 respectively. The retrieval was carried 
out using the following multi-step search logic after having instructed 
the system to search only in the relevant Section E (Chemdoc) fragmen- 
tation codes and instructing the computer to recognise "+" for "AND" 
and "<" for "NOT": 
Search statement 1: (pre-1972 search logic) 
373+378+473+715+659 
Search statement 2: (restriction by essential groups absent) 
1+<01&+<01-+<010+<012+<013+<014+<015+<016+<017+<018+<019 
Search statement 3: (total 1970-1971 references) 
SEARCH STATEMENT 2+ 70/AY OR SEARCH STATEMENT 2+ 71/AY 
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Search statement, 4: (post-1971 logic) 
SEARCH STATEMENT 2+ 058+059+616+<595 
Search statement 5: (total references 1970 to search date) 
SEARCH STATEMENTS 3 OR 4 
The complexity of the search was necessary because of changes in the 
code introduced in 1972. In these searchos /AY is the qualifier for 
accession number years. The fragmentation codes searched are as 
follows: 
373+378 
= One benzene ring present 
473 
= 
-COOH groups 
715 
= Basic Group (carbocyclic aromatic compound) 
659 
= Production of known compound 
01& to 019 = Codes for essential groups (which are negated in this 
search as they should be absent) 
058+059 
= Absence of carbon chains 
616 
= Two 
-COOH groups present 
595 
= 
-OH or ether (which are negated in the logic used) 
The retrieval gave 722 references which, on examination, showed 159 
patentees. 
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APPENDIX VIII 
- 
PHARMACOLOGICALLY ACTIVE PYRAZOLONES 
Antipyretics are drugs which set the "thermostat" in the hypothalamus 
back to normal in a feverish organism. They do not lower normal body 
temperatures and differ in this respect from hypothermic agents, such 
as clorpromazine, which aid in maintaining physiological conditions at 
subnormal level if the body has been artificially chilled several 
degrees below normal. 
The use of pyrazolones in this field was opened by the discovery in the 
1880s of Knorr261 that a compound to which he had attributed faultily a 
quinine-like structure was actually a pyrazolone derivitive. He called 
it antipyrine and found it to have a strong febrifuge action even 
before its correct chemical structure had been ascertained. Subsequent 
to this finding many other derivatives of pyrazolone were prepared and 
tested, primarily for antipyretic activity but incidentally also for 
analgesic and other effects. In this group of compounds, antipyrine 
and aminopyrine have been most successful. 
C IT 
3 CH, 
I 
NI ý 
-, 
f CH3 NýI-C6H3 CH3 N-C6H3 
'0 (CH3)2N 0 
Antipyrene Aminopyrene 
The pharmaceutical industry continues to patent new pyrazolone deriva- 
tives in large numbers and it was therefore decided that such patents 
should be included in the data sets used for this study. 
Pharmacologically Active Pyrazolone patents were retrieved from the WPI 
online database on 13 July, 1981. At that time the files had been 
updated with data on basics and equivalents to Derwent Week D12. The 
retrieval was carried out using CPI Section B (Farmdoc) multipunch data 
with the following two step search logic: 
Search Statement 1: 
321/B, B2 
Search Statement 2: 
1 AND 619/B, B2 OR 1 AND 617/B, B2 OR 1 AND 611/B, B2 
I 
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In this logic B and B2 are the qualifiers for the relevant fragmenta- 
tion code; the search parameters utilised are: 
321 = Fragmentation code for five membered ring 
with two nitrogen atoms in 1,2-positions 
611 ý Fragmentation code for analgesic 
617 Fragmentation code for anti-inflammatory activity 
619 Fragmentation code for antirheumatic activity 
This search gave 243 citations which, on analysis, showed 130 patentees. 
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APPENDIX IX 
- 
OLIVANIC ACID 
Just as the search for further ß 
-laetam antibiotic substances led to 
research programmes for cephalosporin analogues and to the isolation of 
Clavulanic Acid (See Appendix X), studies by Hood, Box and Verral262 
led to the isolation of the olivanic acids, a family of ß-lactam 
antibiotics with ý-laetamase inhibitory properties, from Streptomrces 
olivaceus. 
Before any structures had been established, three components were 
identified, these being known as MM13902, MM4550 and MM17880. Despite 
early difficulties in handling these substances owing to their high 
chemical lability, the structures were established early in 1976 to be 
263 
, 
264. the novel bicyclic derivatives (1), (2) and (3) respectively 
CH3 (0) 
HO3SO ýý. 
N NHCO CH-9 
0 
CU3 
HO3SO 
N NHCOCH3 
0 
(1) n=0, MM13902 (3) MM17880 (2) n=1, MM4550 
Here again, the discovery of this group of antibiotic substances has 
initiated research programmes leading to patent applications. Such 
applications were therefore thought to be appropriate for the biblio- 
metric investigations in this study. 
Olivanic acid patents were retrieved from the WPI online database on 30 
July, 1981; at that time the files had been updated with data on basics 
and equivalents to Derwent Week D18. The retrieval was carried out 
using the search statement: 
41252/RR OR OLIVANIC/IT, TI 
In this statement, /RR represents the search qualifier for CPI Section 
B Ring Index Numbers; 4152 is the Ring Index Number for the structure: 
Elf::: ý 
/IT, TI are the search qualifiers for Index Terms and Title Terms 
respectively, these being the fields in which the term OLIVANIC'mnight 
occur. The search gave 118 citations which, on analysis, showed 13 
patentees. i 
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APPENDIX X- CLAVULANIC ACID 
In addition to the considerable effort exerted by industry to develop 
new 0-laetam antibiotics related to cephalosporins, the possibility 
that new and more effective ß-lactamase inhibitors might occur in 
nature initiated further programmes of screening micro-organisms for 
such compounds. This resulted in the detection and isolation from 
Streptomyces clavuligeus, of a potent, irreversible ß-lactamase inhibi- 
tor named clavulanic acid by Brown et a] 265 in 1976. These workers 
showed that the structure of clavulanic acid was: 
CH2OH 
0 000H 
Clavulanic-Acid 
Brown et al reported that this compound was effective as a a-lactamase 
inhibitor in combination with ampicillin against a number of organisms, 
e. g., Serratia marescens, normally resistant to ampicillin, but in the 
presence of 1ug ml-1 of sodium clavulate the minimum inhibitory 
concentration of ampicillin was considerably reduced. 
As a result of this work, further research has been carried out on 
clavulanic acid and its derivatives which has led to patent applica- 
tions. As patents relating to this compound could be considered to be 
a "new technology", and as the compound is related to the cephalospor- 
ins, they were considered to *be appropriate for inclusion in this 
study. 
Clavulanic acid patents were retrieved from the WPI online database on 
30 July, 1981; at that time the files had been updated with data on 
basics and equivalents to Derwent Week D18. The retrieval was carried 
out using the search statement: 
41250/1R OR CLAVULANIC/IT, TI 
In this statement /RR represents the search qualifier for the CPI 
Section B Ring Index Numbers; 41250 in the Ring Index Number for the 
structure: 
371 
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/IT, TT are the search qualifiers for Index Terms and Title Terms 
respectively, these being the fields in which the term CLAVULANIC might 
occur. 
The search gave 133 citations which, on analysis, showed 16 patentees. 
p 
-- 
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APPENDIX XI: LOTKA'S LAW 
A review of Lotka's Law, its theory and application, has recently been 
266 given by Potter 
The generalised expression for Lotka's Law is: 
y=AxB 
Writing the: expression as: In y= In A-B ln(x), one can calculate A 
and B from a graph of In y against In x, when In A= intercept and 
-B 
gradient. 
An alternative treatment of Lotka's Law is to calculate the value of A 
from the value of B (i. e. 
- 
gradient) and total number of authors. In 
this case total authors expected is equal to total authors observed, 
and: 
- 
total authors Ax-B 
_AE1 
x 
A_ total authors 1 
B 
x 
Programs to calculate A have been developed by Brand 
267 in FORTRAN IV 
and Coile171 in BASIC. These programs perform the calculation of A for 
values of xi from 1 to I such that: 
- 
total authors total authors 
x=i-1 x=i 
1-1 <(0.000005 x total authors) 
XB XB 
X=1 x=1 
After xi iterations the value of constant A converges to at least 
three significant figures. 
For the present study, the. Coile program has been modified for the EG 
3003 microcomputer; the program developed is given in Figure 82 and a 
typical run for the original Cephalosporins data set in Figure 83. 
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The program requires that the slope (B) is input before running. 
Values of B have been calculated by regression analysis using a 
programmable Sharp EL-5100 calculator; an illustrative calculation for 
the original Cephalosporins is given in Table 58. Note that the 
program run was aborted (by depressing the "BREAK" key on the computer) 
when convergence was observed; in the sample run this was after 222 
iterations. 
Lotka's Lair plots, on log-log graph paper, have been prepared and, 
using the calculated value of B, lines of best fit passing through the 
mean point have been constructed. Such plots are illustrated in Figure 
84 using the original Cephalosporins data set. 
A second BASIC program, again modified from Coi1e171, was then used 
to calculate the expected frequency distributions of the y patentees 
making x contributions. This program, shown in Figure 85, and a 
typical run, again using the original Cephalosporins data, is shown in 
Figure 86. 
10 REM DETERMINATION OF LOTKA'S CONSTANT 
20 REM COILE'S PROGRAM A-3 MODIFIED BY MDD 
30 REM B=LOTKA'S SLOPE EXPONENT 
40 REM A=LOTKA'S CONSTANT 
50 REM 
60 REM CLEAR DISPLAY 
70 CLS: F'RINT: PRINT: PRINT 
80 LET 7_=0 
90 INPUT"INPUT VALUE FOR SLOPEW 
100 REM CHANGE X(MAX) IN LINE 120 IF X>200 
110 REM X=NUMBER OF ITERATIVE CAL. CULATIONS 
120 FORX=1T0200 
1.30 LET O=1/XCB: REM C=EXPONENTIATION SYMBOL 
140 LET 7=74+O 
150 LET A=1/7_ ý 
160 REM CLEAR 
-DISPLAY 
170 CLS 
' 180 REM ARRANGE DISPLAY AT BOTTOM OF SCREEN 
190 PRINTPR4o, 'X"; 2F'RINTPO50r'A' 
200 PRINT@968, X;: PRINTfa978vA 
210 REM TIME DELAY TO MANUALLY RECORD RESULTS 
220 FOR T =1T0 i0 STEP 
. 
0l: NEXT T 
230 NEXT X 
"999 END 
Figure 82: Program in BASIC to calculate I, otka's Constant 
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INPUT VALUE FOR SLOPE? 1.19792 ; 
X A 
1. 1 
2 
. 
696429 
3 
. 
586822 
4 #527954 
5 #490306 
6 
*463725 
7 
. 
443726 
a 
. 
427996 
9 
. 
415214 
10 
. 
404565 
11 
. 
395515 
12 
. 
387701 
13 
. 
3801364 
14 
. 
374816 
15 
. 
36941.5 
16 #364553 
17 
. 
3601.4 
18 
. 
3561.24 
19 
. 
35243; 
20 
. 
349036 
v v 
v v 
205 
. 
257536 
206 
. 
257424 
207 
. 
257313 
208 #257202 
209 
. 
257092 
210 
. 
256903 
211. 
. 
256875 
212 
. 
256767 
213 
.i 666 
21.4 #256553 
21.5 
. 
256448 
216 #256343 
21.7 
. 
256230 
218 
. 
256134 
219 
. 
256031. 
220 
*255929 
221 #255827 222 #255726 223 
#255626 
224 
. 
255526 
225 #255426 226 f255328 
BREAK IN 220 
Figure 83: Computer run to determine Lotka's Constant for Original 
Cephalosporins Data Set (note run aborted after 226 iterations, 
convergence having been noted at iteration 222) 
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X 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
21 
25 
28 
N(X) %N(X) log X log N(X) 
83 43.23 0.000000 1.919078 
24 12.50 0.301030 1.380211 
16 8.33 0.477121 1.204120 
8 4.17 0.602060 0.903090 
5 2.60 0.698970 0.698970 
6 3.13 0.778151 0.778151 
2 1.04 0.845098 0.301030 
5 2.60 0.903090 0.698970 
1 0.52 0.954243 0.000000 
1 0.52 1.000000 0.000000 
1 0.52 1.041393 0.000000 
1 0.52 1.079181 0.000000 
3 1.56 1.113943 0.477121 
2 1.04 1.146128 0.301030 
1 0.52 1.176091 0.000000 
1 0.52 1.204120 0.000000 
3 1.56 1.230449 0.477121 
2 1.04 1.322219 0.301030 
2 1.04 1.397940 0.301030 
2 1.04 1.447158 0.301030 
LOTKA'S EXPONENT (FIRST 20 DATA POINTS) 
_ 
-1.197925 
Mean log X=0.935919 = 8.628182 
Mean log N(X) = 0.502099 = 3.177599 
Table 58: Determination of Lotka's Exponent and Mean Points 
for Lotka plot using EL-5100 programmable calculator for 
Original Cephalosporins Data Set 
i 
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100 
10 
ur 
w 
w I 
z 
uJ 
0.5 
Q1 
Figure 811: Lotka's Law'Graph for Original Cephalosporins Data Set 
showing line of Slope 
-1.198 passing through Mean Point 
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NUMBER OF BASIC PATENTS 
1.0 REM LOTKA'S DISTRIBUTION OF SCIENTIFIC PRODUCTTVTTY 
20 REM COILE'S PROGRAM A-3 MODIFIED BY MDD 
30 REM Y DISTRIBUTION OF AUTHORS MAKING X cnNTRTBUTTONS 
40 REM T=TOTAL PATENTEES, A=LOTKA' , CONSTANT Y 
50 REM B=LOTKA'S SLOPE EXPONENT 
60 REM 
70 REM CLEAR DISPLAY 
80 CI_S: 1 RINT: PRINT: PRINT 
90 INPUT 'TOTAL. PATENTEES" ;T 
100 INPUT ' L_OTKA' S CONSTANT" yA 
110 INPUT ' LOTKA' S SLOPE EXPONENT' ;B 
120 REM CHANGE X(MAX) IN LINE 130 IF X>25 
130 FOR X=1T025 
140 LET Y=T*A/XCFJ: REM C= EXPONENTIATION SYMBOL 
150 I_ET P=Y*100/T 
160 REM CLEAR DISPLAY 
]. 70 CLS 
100 REM ARRANGE DISPLAY AT BOTTOM OF SCREEN 
190 F RINT0832r'X" i : F'F.? NT@f: 340r "Y' 9 2F'1`, T. NTPf3 09 "F'ER CENT' 
200 PRINT@960, X;: PRINTP96ß, Y;: PRTNTP97A, F' 
210 REM TIME BELAY TO MANUALLY RECORD RESULTS 
220 FOR 0=1T050 STEP 
. 
01: NEXT 0 
230 NEXT X 
999 END 
Figure 85: Program in BASIC to calculate Lotka's Distribution 
of Scientific Productivity 
TOTAL PATENTEES? 192 
LOTKA' S CONSTANT?. 2 ; 5726 
LOTKA' S SL. OPE EXPONENT? 
-I. 197925 
X Y PER CENT 
1 49.0994 25.726 
2 21#4025 1.1.. 1.471. 
3 1.3.1.68 6.8 5833 
4 9.32939 4,85906 
5 7.14106 3.7193 
6 5.73997 2.98957 
7 4.7721.3 2.48548 
8 4.0667 2.11.1307 
9 3453155 1.83935 
10 3.1.1.28 1.62125 
11 2.77693 1.44632 
12 2.50206 1.. 3031.6 
13 2.27329 1.1.8401 
1.4 2.08018 1.08343 
1.5 1.91.51.7 
. 
997404 
16 1.77268 
. 
923271 
17 1.64851. 4858599 is 1453941 
. 
801.776 
19 1#44286 s751.49 
20 1.. 35687 
. 
706703 
Figure 86: Computer run to calculate Lotka's Distribution for 
Original Cephalosporins Data Set 
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APPENDIX XII: THE SIMON-YULE DISTRIBUTION 
From observation and analysis of the frequency of different words in 
long sequences of text, the approximate formula: 
nr a r-(P+1) (r 1,2,...; p > 0) 
for nr the number of words appearing r times, was found to give a 
usefully accurate fit. In order to define a probability distribution 
appropriate, to such a situation, one may define 
P(x) = er- (A+1) (r = 1,2,... ) 
with c=IIr 
(p+1) 
=L (P+1)1- 1 
r=l 
where C ("), denotes the Riemann zeta function. This distribution is 
called the zeta distribution. When used in linguistic studies, it is 
often called the Zipf-Estoup Law (Estoup268, Zipf143). The use of the 
distribution in this connection has also been studied by Good269. It 
is found that p very often has values slightly in excess of 1. Seal 270 
has applied the distribution to the. number of insurance policies held 
by individuals. 
The distribution is analagous to the continuous Pareto distribution; it 
is sometimes called the discrete Pareto distribution. 
Simon159 noted that, for many distributions of word frequencies, a very 
good fit of this distribution could be obtained for the larger (>3) 
values of r, with p=1. For r=1,2, however, this was not the case. 
If p=1, the ratio of relative frequencies of 1's and 2's should be 
1: 2 -2 
= 
4: 1. Observed values of this ratio (in the data studied by 
Simon) were nearer to 3: 1, sometimes even less. Simon suggested 
consideration be given to distributions of form. 
P(x) 
= ApB(r, p + 1) (r = 1,2) 
where A and p are constants and B(r, p + 1) is the Beta function of i, 
p+1: 
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1 
B(i, p+1) aX-1(1 XP)dx 
0 
r(x)r(p+1) 
(x+p+1) 
Simon derived estimated frequencies from: 
ß (x) 
_ 
(1-a) (x-1) P*(x) 
1+(1-a)x P*(x-1) 
and P*(x) ký = 
nk 
= 2_a 2_a 
where nk = total authors 
k= total papers 
n 
a= k/k 
and 1 
P=1 
(o<x, o<p, <Co) 
Simon gave the name Yule Distribution to this function because it was 
obtained by Yu1e170 in 1923 as the limiting case of a distribution in 
mathematical genetics. Some examples of applications of the Yule 
27 distribution have been given by Kendall1. 
The BASIC program given in Figure 87 adapated from Coile171, allows 
computation of the Simon-Yule function; in the program 
N = nk 
K 
=k 
A a 
I x 
R p 
and F = P'(x) 
A sample run is given for the Cephalosporin data in Figure 88. 
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10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
120 
130 
140 
150 
160 
170 
180 
190 
200 
210 
220 
230 
240 
250 
260 
270 
280 
290 
300 
310 
320 
330 
999 
REM SIMON-YULE DISTRIBUTION FUNCTION PROGRAM 
REM COILE'S PROGRAM 6-1 MODIFIED BY MDD 
REM A=N/K WHERE N=TOTAL PATENTEE SP A=TOTAL BASICS 
REM R=1/(1-A) 
RE M 
REM CLEAR DISPLAY 
CLS: PRINT: PRINT: P'R I NT 
INPUT 'TOTAL. NUMBER OF 
INPUT "TOTAL NUMBER OF 
PATENTEES = "; N 
BASIC PATENTS = '; A 
LET A=N/K 
LET R=1/(1-A) 
LET F=N/ (2-A ) 
REM CLEAR DISPLAY 
CLS 
REM ARRANGE DISP'I... AY AT BOTTOM OF SCREEN 
PRINT(a832, "I';: FRINT@540r'F'; 2PR. T. NT@(3 i0, 'PER 
PRINT@960 r' 1' ; : PRINT@968 F; : PRINT(? 978, i. 00*F/N 
REM TIME DELAY TO MANUALLY RECORD RESULTS 
FOR0=lT050STEP. Oi: NEXTO 
LET 1=2 
LET F=F*(1-A)*(I-1)/(l+(1. 
-A)*I) 
LET X=100*F/N 
REM CLEAR DISPLAY 
CLS 
REM ARRANGE DISPLAY AT BOTTTOM OF SCREEN 
PRINTt 832, ' I'; : PRINT@f40Y'F'; : PRINT(PG5Or'PER 
F'RINT(@960ºI;: pRIwT@968 F;: PRINT(P978, X 
REM TIME DELAY TO MANUALLY RECORD Rl::.. c; Lll. 
-TS FORZ=1TO50STEP. 01: NEXTZ 
LET 1=1+1 
REM CHANGE I(MAX) IN LINE 320 IF 1>20 
IF I=21 THEN 999 
GOT0210 
END 
CENT 
CENT' 
Figure 87: Program in Basic to Calculate the Simon-Yule Distribution 
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INPUT TOTAL NUMBER f-ATEMTEE ä? 1.92 
INPUT TOTAL NUMBER BASIC PATENTS? 2599 
I F PER CENT 
1 99.682 51.9177 
2 32.3667 16.8577 
3 15.8669 8.6403 
4 9437067 4. E38056 
5- 6.1651.5 3.21.1.02 
6 4.35406 2.26774 
7 3.23331 1.. 68401 
8 2#4927 1.29828 
9 1.97838 1.03041. 
10 1.60702 
. 
1336991 
11. 1.33034 
. 
692886 
12 1.11.881 
. 
58771.3 
13 #953546 . 496639 
14 
. 
82203 
. 
4281.43 
15 
. 
715713 
. 
372767 
16 
. 
628562 
. 
317376 
1.7 
. 
556257 
. 
28971.7 
1.8 
*495622 . 258137 
19 
. 
444288 
. 
231.4 
20 
. 
400454 
. 
20857 
READY 
}_ 
Figure 88: Computer run to calculate the Simon-Yule Distribution 
for Original Cephalosporins Data Set 
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APPENDIX XIII: PRICE'S PARETO-TYPE DISTRIBUTION 
In 1962 Professor Derek J. de Solla Price, of Yale University, gave a 
series. of lectures at the Brookhaven National Laboratory dealing with 
the sociology of science. These lectures have been printed in a book, 
Little Science, Big Science272. In his lecture entitled "Calton 
Revisited", Price examined and compared the scientific productivity of 
the authors listed in the first index volume of the abridged Philosoph- 
ical Transactions of the Royal Society of London (17th and early 18th 
centuries) with the authors listed in the 1907-1916 decennial index of 
Chemical Abstracts, which had been studied by Lotka. 
Price expressed the opinion that Lotka's crude, simple inverse-square 
law of scientific productivity needed modification to reduce the 
proportion of high scorers since, otherwise, the maximum number of 
published papers in a lifetime would be in the thousands rather than in 
the hundreds that were observed with even the most prolific scientists. 
He therefore derived a distribution law of the Pareto type: 
- 
Nk-= ak 
p a+p p a+p) 
where N is the number of authors publishing "at least" p scientific 
papers within a given interval of time (which Price took as a life- 
time). The parameter, a, was estimated by Price as 15 papers per 
lifetime (this being his estimate of the boundary between high and low 
productivity). The arbitary constant of proportionality, k, can be 
calculated from the above equation by rearranging as follows: 
k_ Np(a + p) 
a 
Since Price preferred to reduce all data to a basis of 100 authors 
publishing but a single paper, one can set N= 100 for p=1. Then for 
a 15: 
k_ 100(1) (15 + 1) 106.667 15 
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For patenting activity studied in the present work, rather than use a= 
15, it was considered appropriate to equate a, Price's "boundary", with 
the average number of patents per patentee. A program in BASIC to 
calculate Price's Pareto-type distribution has been written based upon 
a similar program given by Coile171. The program is given in Figure 
89; in the computer nomenclature used a is represented by A, p by P 
and k by K. A typical run, using the original Cephalosporin data as 
the examplc is given in Figure 90. 
Price preferred to discuss productivity in the sense of "at least" p 
papers in the Pareto fashion rather than in the Lotka sense of pub- 
lishing "exactly" so many papers. In order to compare Price's distri- 
bution with other theoretical approaches, it is necessary to convert 
Price's "at least" data into "exactly" as many papers data; this is 
shown (for the example run) in Table 59. 
10 REM PRICE'S PARETO-TYPE DISTRIBUTION 
20 REM MODIFIED FROM COILE'S PHD THESISr PAGE 160 
30 REM TOTAL PATENTS=S 
40 REM TOTAL PATENTEES=M 
50 REM PRICE'S 'BOUNDARY' FOR HIGH/LOW, PRODUCTIVITY =A=S/M 
60 REM PRICE'S CONSTANT=K=100*(A+1)/A 
70 REM N=A*K/P*(A+P) 
80 REM N PATENTEES PUBLISHING AT LEAST P PATENTS 
90 CLSSINPUT"TOTAL NUMBER OF PATENTS ='+S 
100 INPUT 'TOTAL NUMBER OF PATENTEES ='; M 
110 LET A=S/M 
120 LET K=100*(A+1)/A 
130 PRINT: PRINT"PRICE'S BOUNDARY (A) 
_ 
'+A 
140 PRINT'PRICE'S CONSTANT (K) = ': K 
150 FOR B=1T025STEP. 01: NEXTB 
160 CLSSLET X=A*K 
170 FOR P=1T025 
180 LET Y=X/P 
190 LET N=Y/(A+P) 
200 PRINTP841r"P';: PRINTP846r'N' 
21.0 PRINTP968, P;: PRINTP9739N 
220 FOR C=1T050STEP. 012NEXTC 
230 NEXTP 
999 END 
Figure 89: Program In BASIC to calculate Price's 
Pareto-type Distribution 
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TOTAL NO. OF PATENTS 
= ? 2599 
TOTAL NO. OF PATENTEES = ? 192 
PRICE'S BOUJNr1ARY (A) = 13.5365 
PRICE'S CONSTANT (K) = 107.387 
PN 
1 100 
2 46.7818 
3 29.3018 
4 2097232 
5 15.6842 
6 12.4011 
7 10.112 
8 8.43712 
9 7.16688 
10 6.17615 
11 5#38505 
12 4.74369 
13 4.21378 
14 3,7707 
15 3.396 
16 3.07596 
17 2.80021 
18 2.56079 
19 2.35144 
20 2.16726 
21 2.00429 
Figure 90: Computer run to calculate Price's Pareto-type Distribution 
for Original Cephalosporins Data Set 
N ACTUAL 
p [not less than] % FREQUENCY 
1 100.0000 53.2182 102.1789 
2 46.7818 17.4800 33.5616 
3 29.3018 8.5786 16.4709 
4 20.7232 5.0390 9.6749 
5 15.6842 3.2831 6.3036 
6 12.4011 2.2891 4.3951 
7 10,1120 1.6749 3.2158 
8 8.4371 1.2702 2.4388 
9 7.1669 0.9907 1.9021 
10 6.1762 0.7903 1.5174 
11 5.3859 0.6422 1.2330 
12 4.7437 0.5299 1.0174 
13 4.2138 0.4431 0.8508 
14 3.7707 0.3747 0.7194 
15 3.3960 0.3200 0.6144 
16 3.0760 0.2758 0.5295 
17 2.8002 0.2394 0.4596 
18 2.5608 0.2094 0.4020 
19 2.3514 0.1841 0.3525 
20 2.1673 0.1630 0.3130 
21 2.0043 
- 
- 
Table 59: Conversion of Price's "Not-less-than" data to Theoretical 
Frequency Distribution for Original Cephalosporins Data Set 
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APPENDIX XIV: WILLIAMS' GEOMETRIC SERIES 
J. Dufrenoy273 has discussed the number of papers published by diffe- 
rent authors which were reviewed in single years in the Review of 
Applied Mycology, particularly for the years 1932,1934 and 1935. 
Dufrenoy suggested that if the probability of an author to produce 1 
paper was p, then the probability to produce z, s or 4 papers woula oe 
(P1) 2, ip1) 
, 
(pß)4, etc., and so the frequency of publication of 
papers should be on a geometric series. Williams167 expressed this 
geometric series as 
n,, n1x, nlx2, 
.... 
etc. 
If N is the total number of papers (patents in this study) and S the 
total number of authors (patentees in this study), then it can be shown 
that 
S2 
ni N 
and 
(N-S) 
N 
Williams applied the geometric series to Dufrenoy's data and to data of 
the number of papers published by authors in the Review of Applied 
Entomology. Williams found that the geometric series tended to under- 
estimate the number of authors with a single publication and those with 
5 or more, but to overestimate authors with 2 to 4 papers. 
A program in BASIC to calculate the geometric series has been described 
by Coile171. For the present study this program has been modified and 
is shown In Figure 91; In the program nomenclature M, S and X are used 
respectively for n1, S and X. A typical run, using the original Ceph- 
alosporins data set, is given in Figure 92. 
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10 
20 
30 
40 
50 
60 
64, 
70 
80 
90 
100 
1.1.0 
1.20 
130 
140 
150 
1.60 
170 
175 
180 
190 
200 
210 
220 
999 
Figure 91: Program in BASIC to calculate Williams' Geometric 
Series Distribution 
TOTAL PATENTEES = ? 192 
TOTAL PATENTS 
= T2599 
CALCULATED VALUE OF N= 14.1.839 
CALCULATED VAI... UE OF X o926125 
NO. SERIES PERCENT 
1 14.1839 7.38746 
2 13.1361 6.84171 
3 12.1657 6.33629 
4 11.2669 5.8682 
5 10.4346 5.43469 
6 9#66375 5.0332 
7 8.94984 4.661.38 
8 8.28868 4.31702 
9 7.67636 3.9981. 
10 7.10927 3#70275 
11 6.58408 3#42921 
12 6.09769 3.17588 
13 5.64722 2.94126 
14 5.23004 2.72398 
I5 4.84367 2*52275 
16 4.48585 2.33638 
17 4.15446 2.16370 
18 3.84755 2.00393 
19 3.56331 1,85589 
20 3.30008 1.71.879 
REM WILLIAMS' GEOMETRIC SERIES 
REM COILE'S PRnGRAM (P. 121 P TABLE E-4) MODIFIED 
REM SERIES IS: N, N*X, N*Xr 
, 
N*Xr3r ETC. ETC. 
REM S=TOTAL PATENTEES Y M-TOTAL PATENTS REM N= C2/M 
REM X=(M-S)/M 
CLS 
INPUT 'TOTAL PATENTEES = '; S 
INPUT 'TOTAL PATENTS = ;M 
LE1 N=SE /M 
LET X=(M-S)/M 
PR INT : FRTNT 'CALCULATED VALUE OF N="; N 
PRINT 'CALCULATED VALUE OF X='; X 
FOR B=ITO SSTEF'. O1: NEXTft 
FORQ=IT025 
LET 7=N*XCO 
LET P=100*Z/ S 
PRINT@832, 'NO. '; 
PRINT(O40s'SERIES';: PRINTPO y4, 'PER CENT' 
PRINT@967,7; : FRINT(@980. P 
; P'RINT@96O, f+1; 
IF0=2STHEN999 
FORA-lTO50STEP. 01: NEXTA 
CLS: NEXTO 
STOP 
Figure 92: Computer run to calculate Williams' Geometric Series 
Distribution for Original Cephalosporins Data Set 
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APPENDIX XV: FISHER'S LOGARITHMIC SERIES 
Fisher, Corbett and Williams168 first suggested in 1943 that a logar- 
ithmic series could be applicable in biological problems of sampling, 
such as the frequency of species with different numbers of individuals, 
or genera with different numbers of species. These authors demonstrated 
that there was a relationship between the logarithmic and the Negative 
Binomial distribution. In 1944, Williams 167 tested whether the loga- 
rithmic series could be applicable to data on the numbers of publica- 
tions written by biologists and found that this fitted the observed 
frequencies better than the geometric series. 
In 1947, Williams274 reported that the logarithmic series could be 
applied to a wide range of biological applications such as the numbers 
of individuals classified into species, species identified in a geogra- 
phic area, the numbers of parasites on hosts, etc. 
The logarithmic series is: 
- 
234 
ln(1+x) x-x+3-4...., etc. 
As negative terms have little meaning in biology, this can be written 
as: 
x2 x3 x4 
or as a more general frequency it can be written: 
nlr nix s 
nlx2 
r 
nix3 
23u 
where n1 is the number of groups with 1 unit, and the successive terms 
those with 2,3,4, etc., units. The series is discontinuous and has 
an infinite number of terms. 
The sum of all terms to infinity, which is the total number of groups, 
is given by: 
S Xý (-ln(1-x)) 
(L1) 
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This is finite if x<1; that is to say, the series is then convergent. 
The total number of units, N, is given by: 
ni 
N (1-x) (L2) 
If S and N are known, n1 and x, and hence the whole series, can be 
calculated. 
For equations L1 and L2 it follows that the average number of units per 
group (NIS) is given by: 
Nx (L3) 
S- (1-x)(-ln(1-x)) 
Thus for any average number of units per group there is only one 
possible value of x; when this has been calculated, n1 can be obtained 
by multiplying N by (1-x). 
Equation L3 may be solved for x using methods described by Herdan275a 
and Chatfield et a1276. The method relies upon solving the equation 
with trial values of x to make the right hand expression equal to the 
observed value of N/S. Coile171 has developed a BASIC program to 
achieve this; for the present study this program has been modified for 
the EG3003 system and is given in Figure 93. An example run to 
determine x (Fisher's Constant) for the original Cephalosporins data 
set is given in Figure 94. 
Figure 95 gives a BASIC program, modified from that given by Coile, to 
calculate Fisher's logarithmic series distribution. The program uses 
the terminology P for total patents instead of N, A for total patentees 
instead of S, and X for Fisher's Constant determined as above. An 
example run, using the original Cephalosporins data set is given in 
Figure 96. 
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10 REM DETERMINATION OF FISHER'S CONSTANT, X 
20 REM TOTAL NUMBER OF F'APE_RS =N (I. E. BASIC PATENTS) 
30 REM TOTAL NUMBER OF PATENTEES =S 
40 REM DETERMINE X BY TRIAL, USING VALUES UNTIL CALCULATED 
50 REM VALUE OF N/S APPROXIMATES OBSERVED VALUE 
60 CLS: CLEAR 1000 
70 INPUT 'TOTAL NUMBER OF PATENTS = 'ON 
80 INPUT 'TOTAL NUMBER OF PATENTEES = '; S 
90 LET Q=N/S: PRINT: PRINT 
100 PRINT 'OBSERVED VALUE OF N/S = '; Q 
110 PRINT: PRINT 
120 INPUT 'TRIAL VALUE OF X='; X 
130 LET Z=(1-X): LET T=(-LOG(Z)) 
140 LET R=z*T: LET W=X/R 
150 PRINT: PRI_NT_'CALCULATFD VALUE OF S/N = '; W; 
' (OBS. S/N =_ '; G; ' )' 
160 PRINT: PRINT 'FOE ANOTHER ITERATION ENTER' 
170 PRINT''O'; FOR ANOTHER SERIES OF TRIALS' 
180 INPUT 'ENTER '1'r TO STOP ENTER '2''iY 
190 IF Y=OGOTOI. 1.0 
200 IF Y=IGQTA60 
210 IF Y=2GOT0999 
999 PRINT 'NORMAL END OF JOB': EN%t 
Figure 93: Program in BASIC to determine Fisher's Constant 
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TOTAL NUMBER OF PATENTS? 2599 
TOTAL NUMBER OF PATENTEES? 192 
OBSERVER VALUE OF N/5 = 1.3.365 
TRIAL VALUE OF X 
. 
98 
CALCULATED VAL. U OF N/S = 12.525 ä (OBS, N/S = 13.5365 ) 
FOR ANOTHER ITERATION ENTER 
'0'; FOR ANOTHER SERIES OF TRIALS 
ENTER '1'; TO STOP ENTER ' ?' ?O 
TRT L VAULE OF X=? #982 
CALCULATED VALUE OF Nis = 13. ; 799 (OBS, N/S = 13.5365) 
FOR ANOTHER ITERATION ENTER 
'0'; FOR ANOTHER SERIES OF TRIALS 
ENTER '1'; TO STOP ENTER ' 2' ?0 
TRIAL VALUE OF XT 
. 
9818 
CALCULATED VALUE OF N/S = 13.4619 (OBS. N/S 13.5365) 
FOR ANOTHER ITERATION ENTER 
'0'; FOR ANOTHER SERIES OF TRIALS 
ENTER '1's TO STOP ENTER '2'? 0 
TRIAL VALUE OF X=? 
. 
9819 
CALCULATED VALUE OF N/, 13.5221 (OBS. N/S = 13.5365) 
FOR ANOTHER ITERATION ENTER 
'0'; FOR ANOTHER SERIES OF TRIALS 
ENTER '1'; TO STOP ENTER '2'? 0 
TRIAL VALUE OF X= 
. 
98192 
CALCULATED VALUE OF N/5 = 13.5337 (OBS. N/S = 13.5365) 
FOR ANOTHER ITERATION ENTER 
'0'; FOR ANOTHER SERIES OF TRIALS 
ENTER '1'i TO STOP ENTER '2'? 0 
TRIAL VALUE OF X=?. 98193 
CALCULATED VALUE OF N/S = 13.5394 (OBS. N/S = 13,5365) 
FOR ANOTHER ITERATION ENTER 
'0"; FOR ANOTHER SERIES OF TRIALS 
ENTER '1'i TO STOP ENTER '2'? 0 
TRIAL VALUE OF X ?. 981925 
CALCULATED VALUE OF N/S = 13.4 365 (ORS, NI S= 130365) 
FOR ANOTHER ITERATION ENTER 
'0'; FOR ANOTHER SERIES OF TRIALS 
ENTER 'I': TO STOP ENTER '2'? 2 
END OF JOB 
Figure 94: Computer run to determine Fisher's Constant for 
Original Cephalosporins Data Set 
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10 REM FISHER'S LOGARITHMIC: SERIES DISTRIBUTION 
20 REM COILE'S PROGRAM (P. 1 '. 8, TABLE F-5) MODIFIED 
30 REM FOR E63003 BY M Ii DIXON 
31 REM P= TOTAL NUMBER OF PATENTS 
32 REM A= TOTAL NUMBER OF PATENTEES 
33 REM X= CONSTANT DETERMINED TO MAKE W=O 
34 REM 0= P/A 
40 CLS f INPUT 'TOTAL NUMBER OF PATENTS = '; P 
41 INPUT 'TOTAL NUMBER OF PATENTEES = '; A 
42 INPUT 'FISHER'S CONSTANT (X) = ': X 
60 LET W= (-1)*X/(1-X)/LOG(1. 
-X) 
70 LET Q=P/A 
80 PRINT! PRT. NT 
90 PRINT 'CALCULATED VALUE (W) FOR P/A = ': W 
91 PRINT 'OBSERVED VALUE (0) FOR P/A = 000 
92 PRINT: PRINT 'ARE W AND 0 SUFFICIENTLY CLOSE' 
93 PRINT "TO PROCEED WITH THE CALCULATION" 
94 INPUT 'TYPE IN 'YES' OR ' NO' '; A$ 
95 IF LEFT$(A$, 1) = 'Y' GOT0 105 
96 IF LEFT$(A$, 1) = 'v' GOTO 105 
97 IF LEFT$ (A$ v 1. ) = IN' COTO 999 
98 IF LEFT$ (A$ s 1. ) _' n' GOTO 999 
105 CLS: LET Ii= P* (1-X ) 
106 PRINT "FISHER'S DISTRIBUTION IS ': PRINT 
103 LET C= BMX/2 
110 LET B 
_- 
B*XE2/3 
120 LET E= B*XC3/4 
130 LET F= B*XC4/ i 
1.40 LET G= B*X C5/6 
150 LET H= B*XC6/7 
160 LET I= B*XC7/8 
170 LET J= B*XC8/9 
180 LET K= B*XC9/10 
190 LET L= B*XC10/11 
200 LET M= B*XC11/12 
210 LET N= B*X[12/13 
220 LET 0= B*XC13/14 
230 LET R= B*XC 1.4/1 
240 LET S= Ei*X C 15/16 
250 LET T= B*XC 16/17 
260 LET U= B*XC17/18 
270 LET ,V= B*XC 1. A/19 
280 LET W= D*XC19/20 
290 LET Y= B*XC20/21. 
300 PRINT B. C, D, E 
310 PRINT Fr6, H+I 
320 PRINT J K'LPM 
330 PRINT N, O, R, S 
340 PRINT T, L. I, V. W 
350 PRINT Y 
360 PRINT: PRINT 'TO RE-RUN PROGRAM ENTER 0' 
7.. 370 INPUT-"TO STOP PROGRAM ENTER II Q 
380 IF 7_=0 THEN 10 ELSE 999 
999 PRINT 'END OF 
. 
IoB' : ENii 
Figure 95: Program in BASICS to calculate Fisher's Logarithmic 
Series Distribution 
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TOTAL NUMBER OF PATENTS = ? 2599 
TOTAL NUMBER OF PATENTEES = ? 192 
FISHER'S CONSTANT (X) = ?, 981925 
CALCULATED VALUE (W) FOR P/A =113. Siff 
OBSERVED VALUE (0) FOR F'/A = 13.5365 
ARE W AND 0 SUFFICIENTLY CLOSE 
TO PROCEED WITH THE CALCULATION 
TYPE IN 'YES' OR ' NO' ? YES 
FISHER'S DISTRIBUTION IS 
46.9769 23,0639 15.098 11.1188 
8.7343 7.14702 6.01.529 5.16825 
4.51096 3.98648 3.55857 3.20306 
2.90323 2.6471.3 2.426 2.23327 
2.06391 1.91401 1.780 116609 
1.55231 
TO RE-RUN PROGRAM ENTER 0 
TO STOP PROGRAM ENTER 1.? 1. 
END OF JOB 
Figure 96: Computer run to calculate Fisher's Logarithmic Series 
Distribution for Original Cephalosporins Data Set 
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APPENDIX XVI: SHOCKLEY'S LOGNORMAL DISTRIBUTION 
In 1957, Shockley166 reported on a study of the scientific productivity 
of physicists in several research institutes. Using graphic techniques 
he showed that the cumulative distribution of the number of journal 
publications on a logarithmic scale (to the base 10) versus cumulative 
number of authors on a linear scale indicated a more or less normal 
distribition of the logarithm of rate of publication, i. e., a "log- 
normal" distribution. However, Shockley described some of these 
lognormal fits as "very jumpy". Shockley was able to demonstrate 
similar lognormal distributions for patent applications filed during 
five and ten year periods respectively by physicists at two large 
industrial laboratories. 
Following procedures outlined by Bliss277, Coile171 developed a com- 
puter program in BASIC to calculate lognormal estimates of the numbers 
of authors publishing papers. In this program the lognormal distribu- 
tion is fitted to- discrete data by placing class boundaries such as 
0.5,1.5,2.5,3.5, etc., midway between successive. integers, transfor- 
ming these boundaries to logarithms, and assuming that the frequency, 
F, in each interval is concentrated halfway between the transformed 
boundaries. Above 5, grouping is introduced with class boundries that 
increase by an approximately uniform percentage of about 40%, and the 
pooled frequencies in each interval assigned a value halfway between 
class boundaries in logarithms; class boundaries of 5.5,7.5,10.5, 
14.5,20.5,28.5,39.5,55.5,77.5 and 108.5 are used. 
The mean y (M in computer notation) and variance a2 (S2 in computer 
notation) are computed from the log-midpoints, Y, of the grouped 
distribution. The point of truncation is at K0 : log 0.5 = 
-0.301031, 
and the logs of the mid points of the smaller classes are 
-0.0624695, 
0.287016,0.471005, etc. The mean is 
M_E (FY) 
EF 
where F is frequency 
and Y is midpoint of logs of class boundaries 
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The variance S2 is 
22 FY) 
S2 
_E 
(FY )-F 
-r 
F-1 
Bliss stated that proposed improvements to this rather arbitrary 
procedure seem to be second order corrections and did not adopt them. 
Bliss estimated the parameters of the complete normal population in 
units of the variate Y from the first and second moments of the trun- 
cated sample. With the point of truncation K0 equal to 
-0.301031, 
Cohen's278 ratio y (N in computer notation) 
s2 N(M-Ko 
is entered in a table given by Cohen (and reproduced by Coile171), to 
obtain by interpolation Cohen's auxiliary estimation function e (H in 
computer notation). The population mean ý (D in computer notation) is 
then estimated as 
D 
. 
M-H (M- I( ) 
and its variance 62 (V in computer notation) as 
S2+H (M 
- 
I( ) 
with standard deviation 8= Q2 
To obtain the expected frequencies, first the class limits YL are 
converted to standard measure 
YL 
XL 
- 
-C8) +8 
or in computer notation 
XL 
= 
K(z) 
-D 
. v7 
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The program thus generates a table of Y(L) and X(L). This program has 
been modified to run on the EG 3003 microcomputer, the program listing 
is given in Figure 97. Before running the program the observed fre- 
quency distribution is entered as a series of DATA elements in lines 
650 to, if necessary, 890. 
In Coile's studies, the proportionate areas for each XL was then 
interpolated from a table of the normal probablity *integral such as 
F(t) of Table 1 in Bennett and Franklin279, however in the present 
study, the proportionate area was calculated using the NORMAL program 
written in BASIC by van Tassel280. The proportionate area was then 
multiplied by the total number of authors to obtain the cumulative 
expected frequencies in the truncated sample. Finally, the differences 
between successive terms are the expected frequencies for comparison 
with the observed frequencies. 
A sample run using the modified Coile program with the original Ceph- 
alosporins data is given in Figure 98 and interpolation of the results 
obtained to give the expected frequency in Table 60. 
10 REM SHOCKLEY'S LOGNORMAL DISTRIBUTION 
. 20 REM COILE'S PROGRAM (P. 152r TABLE H-3) MODIFIED FOR ANY 
25 REM DATA SET AND FOR EG3003 SYSTEM BY H I1 IiixnN 
30 CL. SIPRINT '***k: * IMPORTANT *****": PRINTSPRINT 
40 PRINT *IF DATA NOT YET ENTERED PRESS <BREAK>' 
50 PRINT 'KEY AND LIST PROGRAM LINES 560-640. ' 
60 FORC=1TOS0STFP. 0I.: NFXTC. CLS 
70 INPUT 'NO. OF SETS OF BATA' 4 (O 
80 DIM I(0 1), K((I+1)v Y(0+1. ) 
90 REM COMPUTATION OF MID-POINTS OF LOGS 
100 LET 11=0 
11.0 FOR X=. 5Tß(0+. 5 ) 
120 LFTI1=I1*1 
130 LFTK(I1)=LOG(X)/2.3025£3 
140 LETJ=LOG (X+1. ) /2.30: 
_'58 150 REM I 16 INTERVAL BETWEEN LOGS 
1.60 LET I (I 1. ) =J-K (I 1) 
1.70 REM Y IS MID-POINT OF LOGS OF X 
180 LET Y(Il)=K(I1)+I(Ii. )/2 
190 NEXTX 
200 LET S1. =S2=S3=S4=S5=S6=S7=S8=Ai=A2=A3=A4=A5=T=0 
210 FOR 7.. =1TOR 
Figure 97: Program in BASIC to calculate Shockley's Lognormal 
Series Distributions 
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220 REM F=FREQUENCY (OBSERVED AND INPUT AS DATA STATEMENTS 
-230 REM IN LINES 650 ONWARDS BEFORE RUNNING PROGRAM!! !! ) 
240 READF 
250 LET S1. =F*Y(Z) 
260 LET S2=F*(Y(Z)C2 ) 
270 LET S3=F*I(Z.. ) 
280 LET . S4=F* (I (Z_) C2 ) 
290 REM Ai-=N=SUM OF F 
300 LET A1. =AI+F 
310 LET A2=A2+Si. 
320 LET A3=A3+92 
330 LET A4=A4+S3 
340 LET A 5=AS+S4 
350 NEXTZ 
360 REM MEAN (M) IS SUM OF F*Y/N 
370 LET M=A2/A1 
380 LET S5=(A3-(A2C2)/(A1-1)) 
390 REM S6 IS VARIANCE S SQUARED 
400 LET S6=S5/(A1-1) 
410 REM S7 IS STANDARD DEVIATION 
420 LET S7=SOR(S6) 
430 REM E IS STANDARD ERROR 
440 LET E=57/SQR(A1) 
450 PRINT 'SUM OF FREQUENCIES N='; Al 
460 PRINT 'MEAN Y= ;M 
470 PRINT 'VARIANCE S SQUARED = '; S6 
480 PRINT 'STANDARD DEVIATION = '; S7 
490 PRINT "STANDARD ERROR = '; E: PRINT: PRINT 
500 LET SR=S6-(A5)/12/A1 
510 LET T=SQR (SF3 ) 
520 PRINT "ADJUSTED VARIANCE = ''; S8 
530 PRINT 'ADJUSTED STANDARD" 
540 PRINT ' DEVIATION = ': T 
550 FOR W=1T01.00STEP. 01: NEXTW: CLS 
--- --- --- -- -- 560 REM #ý ########## Ik#ý ######44 4ý4#### 1 ##ýI ########-0 #P ##### 
570 REM # BEFORE RUNNING THE OBSERVED FREQUENCIES, Fy # 
580 REM # INCLUDING ZERO VALUES, MUST BE ENTERED AS TIATA# 
590 REM # STATEMENTS COMMENCING IN LINE 650. FOR EXAMPLE* 
600 REM : 1: 650 DATA 325 # 
61: 0 REM * 660 DATA 155 # 
620 REM 4 670 DATA 75 # 
630 REM # 680 DATA 0# 
640 REM ############# #####p#ý4###########ý### ##A###ý #ý# 
900 CLS: LET N=S6/(M+. 301031)C2 
910 PRINT: PRINT'COHEN'S RATIO N='; N: PRINT 
920 PRINT 'PLEASE INPUT COHEN'S AUXILLIARY' 
930 INPUT 'ESTIMATION FUNCTION THETA"; H 
940 FOR Z=i. TO (P+i. ) 
950 LET Ii=M-H*(M+. 301031) 
960 LET V=S6+H*(M+. 301031) 
970 LET R=(h: (Z)-It)/SOR(V) 
980 FRINT0842, 'Y(L)';: PRINT(a8 7r'X(L)' 
990 FRINTP964. K(Z);: PRINT@979,8 
1000 FARG=1T050STEP. 01 ! NEXTC 
1010 NEXTZ 
1020 END 
Figure 97: Program in BASIC to calculate Shockley's Lognormal 
Series Distribution (continued) 
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***** IMPORTANT ***** 
'IF DATA NOT YET ENTE RED PRESS CF(REAK: " 
KEY AND LIST PROGRAM LINES 560-640. 
NO. OF SETS OF DATAT 20 
SLIM OF FREQUENCIES N = 163 
MEAN Y = 
. 
270844 
VARIANCE S SQUARED = 
. 
161.1.28 
STANDARD DEVIATION = 
. 
401.408 
STANDARD ERROR = . 0314407 
ADJUSTED VARIANCE =. 15058h 
ADJUSTED STANDARD 
DEVIATION =. 308054 
COHEN'S RATION N=. 492685 
ESTIMATION FUNCTION THETA?. 566846 
Y(L) X(L) 
1 
-. 
355583 
2 
. 
32931.8 
3 
. 
647779 
4 
. 
857543 
5 1.01422 
6 1.13932 
7 1,24347 
8 1.33268 
9 1.41.071 
10 1.48005 
11 1.54244 
12 1.59916 
13 1.6511.4 
14 1.6991.2 
15 1.74367 
16 1.73; 25 
17 14B2422 
1e 1.86091 
19 1#89555 
20 1.92037 
21 1 
-*95955 
REAI: DY 
Figure 98: Computer run to calculate Shockley's Lognormal Series 
Distribution for-Original Cephalosporins Data Set 
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PROPORTIONATE EXPECTED 
X(L) F(t) FREQUENCY FREQUENCY 
-0.355583 0.361076 0.267967 51.449664 
0.329318 0.629043 0.112393 21.579456 
0.647779 0.741436 0.062992 12.094464 
0.857543 0.804428 0.040333 7.743936 
1.01422 0.844761 0.027955 5.367360 
1.13932 0.872716 0.020437 3.923904 
1.24347 0.893153 0.015528 2.981376 
1.33268 0.908681 0.012153 2.333376 
1.41071 0.920834 0.009736 1.869312 
1.48005 0.930570 0.007947 1.525824 
1.54244 0.938517 0.006591 1.265472 
1.59916 0.945108 0.005537 1.063104 
1.65114 0.950645 0.004707 0.903744 
1.69912 0.955352 0.004039 0.775488 
1.74367 0.959391 0.003498 0.671616 
1.78525 0.962889 0.003052 0.585984 
1.82422 0.965941 0.002681 0.514752 
1.86091 0.968622 0.002369 0.454848 
1.89555 0.970991 0.002105 0.404160 
1.92837 0.973096 0.001880 0.360960 
1.95955 0.974976 
Table 60: Conversion of Shockley's Lognormal Series Program 
Output to Theoretical Frequency Distribution for 
Original Cephalosporins Data Set 
0 
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APPENDIX XVII: THE BOREL-TANNER DISTRIBUTION 
The Borel-Tanner Distribution describes the distribution of the total 
number of customers served before a queue vanishes under condition of a 
single queue with random arrival times (at constant rate A ), of cus- 
tomers and a constant time (ß) occupied in serving each customer. It 
supposes that the probablity of arrival of a customer during the period 
(t, t + (At)) is x(pt) + o(pt) and that the probability of arrival of 
two, or more, customers in the period is ot. If there are initiall 
, 
(D )Y 
M customers in the queue, then the probablity that the total number (x) 
of customers before the queue vanishes is equal to k is: 
P(x=k) =M kk-M-1 (Aß )k-M e Aßk (k-M)! 
k=M, M+1, M+2....; M is an integer 
For this equation to represent a proper distribution it is necessary 
that ) be less than 1. If Aß>1, then CO (x=k)<1. 
k=m 
The parameters A and ß appear only as their product, X$ ; it is conve- 
nient to use a single symbol, say a, for this product (a <1). The 
distribution was obtained in 1943 by Bore1281 for the case M=1 in a 
consideration of the delay to pedestrians crossing a road, and for 
general values of M by Tanner282 in 1953 in consideration of delays 
that occur when two opposing streams of vehicles are trying to pass 
along a length of road only wide enough for one vehicle at a time. 
Haight and Breuer176 have studied the Borel-Tanner distribution and 
have published tables of the cumulative distribution function P(xý<k) to 
five decimal places for M=1; a =0.01(0.01)0.62. Owen283 has published 
similar tables whilst Haight 284 has described an analogous distribu- 
tion. Rao285 has written a program in FORTRAN for the Borel-Tanner 
distribution, however this was not suitable for the EG3003. 
For this distribution: 
Mean = M(1-a)-1 
Variance 
=M (1-a)-3 
- 
uoo 
- 
The distribution can be calculated by equating a to the sample mean172, 
since if M=1, a 
The EG 3003 program written to calculate the Borel-Tanner distribution 
is given in Figure 99; a computer run using the original Cephalospo- 
rins data as an example is given in Figure 100. In the program the 
sample mean is represented by M, the Borel-Tanner constant a by A, the 
number of patents per patentee as F and the frequency by R. 
-1 o1 - 
10 
20 
30 
40 
50 
60 
y0 
80 
110 
120 
130 
140 
1.50 
160 
170 
1.80 
190 
200 
210 
220 
230 
240 
250 
260 
270 
280 
`90 
300 
31.0 
320 
330 
340 
350 
360 
370 
380 
390 
400 
410 
420 
430 
440 
450 
460 
470 
400 
490 
500 
`; 10 
520 
530 
540 
550 
560 
570 
500 
590 
999 
CLEAR 1000 : CLS 
REM BASIC PROGRAM TO CALCULATE BOREL.. 
-TANNER FREQUENCY 
REM DISTRIBUTION FROM OBSERVED DTSTRTBUTTnN 
REM BY MICHAEL D DIXON, APRIL. 1982 
REM PROGRAM SECTOR FOR CALCULATING MEAN TAKEN FROM 'CLASS' 
REM FFOGRAM BY DENNIE VAN TASSEL. SECTOR FOR CALCULATING 
REM FACTORIALS FROM 'N! ' PROGRAM ON P. 199 IN 
REM 'BASIC BASIC' BY COAL! 
DIM X(100), F(100), F(100) 
REM INTTIALT. SE 
S=0 : F=O: N=0 : A=0 : E=2.718287 
PRINT: PRINT 
PRINT R dk #ik 14 1k ý4 ý1k1k ik 4*i . 
PRINT ' DETERMINATION OF THE" 
PRINT ' BOREL-TANNER' 
PRINT " FREQUENCY DISTRIBUTION' 
PRINT ' 1k 1k ý Jk 14 q 
-1k Ik 1k iF ýk iF ýk dGý 1F ý' 
PRINT: PRINT 
INPUT 'HOW MANY DATA CLASSES'; C 
FRINT: INPUT 'TOTAL NO, PATENTEES '; T 
PRINT 'FOR EACH CLASS GIVE: 
-' 
PRINT ' THE VALUE = X' 
PRINT ' THE FREQUENCY = F' 
FORH=i. TO2OSTEF. Oi : NEXTH: CL. S 
FORI=1TOC: PRINT 'FOR CLASS NO. *; I 
INPUT 'X='; X(I) 
INPUT "F='; F(I) 
N=N+F(I) 
S=S+X(I)*F(I) 
NEXTI 
REM CALCULATE AND DISPLAY MEAN (M) 
M=S/N 
PRINT 'CALCULATED VALUE OF MEAN = '+M 
REM CALCULATE AND DISPLAY BOREL-TANNER CONSTANT (A) 
, 
PRINT 'CALCULATED VALUE BOREL-TANNER' 
PRINT'' CONSTANT (A). = "; A' 
REM CALCULATE THEORETICAL DISTRIBUTION INITIAL CLASS 
R(1)=T*(EC-A) 
REM CALCULATE DISTRIBUTION FOR REMAINING CLASSES 
FORI=2TOC 
REM CALCULATE (X-M)! 
LET F=1: FOP: X=(I-1)T0ISTEP-1: LETF=F*X: NEXTX 
REM SUBSTITUTE VALUES IN EQUATION 
R(I)=T*(1/F)*IC(I-2)*AE(I-1)*Et(-AKI) 
NEXTI 
REM DISPLAY RESULTS 
PRTNT TAB (S) 'CLASS' ;: PRINT TAB (13) 'FREQUENCY' 
FORI=1TOC 
PRINT TAB(5) I; 
PRINT USING 'ýJka ik ý' TAB(13) R(I) 
FORH=1. TO5STEF. 01: NEXTH 
NEXTI 
PRTNT: PRINT "DO YOU WANT TO DO ANOTHER' 
INPUT 'CALCULATION (YES/NO)'; V$ 
IF LF_FT$(V$, 1)="Y'THEN10ELSE590 
CLS: PRINT: PRINT 'NORMAL END OF 
. 
JOB' 
END 
Figure 99: Program in BASIC to calculate the Borel-Tanner 
. 
Frequency Distribution 
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1: 1ý1: p:: 1: A: 44414444*444: 1gip: gip::: 14 
TiETERMTNATION OF THE 
BOREL-TANNER 
FREQUENCY D sTRIBUTION 
NOW MANY DATA CL_ASSE ? 20 
TOTAL. NUMBER OF PATENTEES ? 192 
FOR EACH CLASS GIVE: 
- THE VALUE =X 
THE FREQUENCY =F 
FAR CLASS NO. 1 
X_ ?1 
F= ? ß3 
FOR CLASS NO. 2 
X_ ?2 
F= ? 24 
FOR CLASS NO. 3, 
X= ?3 
F= ? 16 
FOR CLASS NO. 4 
X= ?4 
F 
-- 
?8 
FOR CLASS NO. 5 
X-? 5 
F_ TC 
FOR CLASS NO. 6 
X= 76 
F=? h 
FOR CLASS NO. 7 
X= 77 
F ?i 
FOR CLASS NO. 0 
X= ? i3 
F= ?S 
FOR CLASS NO. 9 
X= 79 
F» ?1 
FOR CLASS NO. 1.0 
X= ? 10 
F= ? ]. 
FOR CLASS NO. 11 
X 
-- 
T il 
F ? 1. 
FOR CLASS NO, 12 
X ? 12 
F= ?1 
FOR CLASS NO. 13 
X= ? i. 3 
F=? 3 
FOR CLASS NO. 1.4 
X= ? 14 
F_ ?2 
FOR CLASS NO. 15 
X_ T15 
F= ? 1. 
FOR CLASS NO. 16 
X ? 16 
F= ?1 
FOR CLASS NO* 17 
X= ? 17 
F= 73 
FOR CLASS NO. 18 
X= 18 
F_ TO 
FOR CLASS NO. ' 19 
X 
"= 
? 1.9 
F= ?0 
FOR CLASS NO. 20 
X= ? 20 
F ?0 
CALCULATED VALUE OF 
MEAN = 3.17178 
CALCULATED VALUE 
BOR EL-TANNER 
CONSTANT (A) = *68472 
CLASS FREQUENCY 
1 96.81.25 
2 33.4252 
3 17*3105 
4 10.6250 
5 7.1648 
6 5.1.294 
7 3. f27ß 
8 2.9447 
9 '. 3187 
10 1.8 º97 
11 1. ; 1.40 
12 1.2478 
13 1.0392 
14 0.8731. 
15 0.7391. 
16 0.6299 
17. 0.5399 
18 0.4652 
19 0.4027 
20 003500 
DO YClt. l WANT TO DO ANOTHER 
CALCUL.. ATJON (YES/NO)? NO 
NORMAL END OF JflF 
Figure 100: Computer run to calculate the Borel-Tanner Distribution 
for Original Cephalosporin Data Set 
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APPENDIX XVIII: THE NEGATIVE BINOMIAL DISTRIBUTION 
Special forms of the Negative Binomial distribution were discussed by 
Pascal286 in 1679. There is a derivation by Montmort287, published in 
1714. 'Student' 288 in 1907, used the distribution as an alternative to 
the Poisson distribution in describing counts in the plates of a 
haemacytometer. 
Greenwood and Yule289 in 1920 obtained the distribution as a conse- 
quence of certain simple assumptions in accident proneness models, 
while Eggenberger and Polya290, in 1923, obtained the distribution as a 
limiting case of an 'urn-scheme' 
Since this time, there has been an increasing number of applications of 
the Negative Binomial, and an associated development of statistical 
techniques based on this distribution. 
The expression for the Negative Binomial distribution is: 
P(r. ) r (c+x-1) Xccxw (x-1) r(e) r (x) w+c w+c 
where P(x) is the probablity of an author producing x articles, r is a 
gamma function, and c, w >0. 
The number of authors expected producing x articles is given by: 
P(x) x total authors 
The mean of the Negative Binomial distribution is w, and the variance 
is given by w 
(0+c). Now, since the Negative Binomial distribution 
starts at x=0, while the author productivity distribution starts at x 
1, sample mean =w+1. Hence: 
2=W+1 
and S2 
_ 
(x 
- 
1) ((z 
- 
1) + a) 
c 
where x is sample mean 
and S2 is sample variance 
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Thus w and c can be calculated from: 
w x. 
- 
1 (NB1) 
(NB2) 
S2 
- 
(X 
- 
1) 
The Negative Binomial distribution is frequently used as a substitute 
for the Poisson distribution when it is doubtful whether the strict 
requirements, particularly independance, for a Poisson distribution 
will be satisfied. The occurrence of Negative Binomial distributions 
as mixtures of Poisson distributions has already been noted. 
Among specific fields where Negative Binomial distributions have been 
, found to provide useful representations may be mentioned accident 
statistics (Arbous and Kerrich291, Greenwood and Yule 289), in birth- 
and-death processes (Furry292, Kendall293), in psychological data 
(Sichel294), in demand (by households) for 'frequently bought pro- 
ducts', observed distributions of consumer expenditure (Chatfield et 
al. 
276), 
and as weights (lag distributions) for times series in econo- 
mics (Solow295). Medical and military applications have been described 
296 by Chew and by Bennett and Birch297.. 
O'Neill298 found that the Negative Binomial distribution fitted the 
number of interlibrary loan requests for journals which could not be 
filled in Western New York; Altman and Lazorick299 have proposed the 
use of this distribution to describe interlibrary loan journal photo- 
copying, and Lazorick300 has applied it to the frequencies with which 
groups of books with defined characteristics are likely to be used in a 
research library. Tague and Farradane301 have successfully used the 
Negative Binomial in a study of literature retrieval effectiveness 
measures. 
Bird302 has examined five different indexing systems and found that a 
reasonable statistical fit could be made to the Negative Binomial 
distribution. Brand267 has found that the Negative Binomial distri- 
bution did not fit author productivity data from Geo Abstracts for the 
1966-75 period. 
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It may be noted that the Negative Binomial distribution is a mathema- 
tical representation of the "success-breeds-success" phenomenon; Rao 
has derived the Negative Binomial* distribution by assuming that the 
probability that an author of x papers will publish one more between 
time t and t 
.+ dt, is a linear funtion of x. Rao also shows that the 
Negative Binomial distribution describes a pattern of scientific 
productivity under a wide range of socic'Ll conditions. 
Davies303, Brand267, Wyshak304 and Rao285 have each derived programs, 
written in FORTRAN IV, to determine Negative Binomial distributions. 
However, because of the limitations of the microcomputer available for 
this study, a further program in BASIC has been written. The program 
is listed in Figure 101; the basis of the calculations is as follows: 
the required values of sample mean and sample variance may be found as 
follows: Patentee productivity data of number of patentees observed 
contributing x basic patents Is a frequency distribution, such that 
number of basic patents x1 x2 
... 
have respective frequencies f1 f2 
..., 
(where f1 f2 
... 
are numbers of patentees observed). The mean of 
- 
x2 the frequency distribution is E fx and the variance is: E fx 
Ef Ef 
Therefore E(patentees observed x patents) 
total patentees 
and S2 =E 
(patentees observed x (patents)2) - x2 
total patentees 
The values of x and S2 are then substituted in the equations NB1 and 
NB2 given above. 
A computer run using the original Cephalosporins data as an example is 
given in Figure 102. 
10 CLEAR10000 
20 REM BASIC PROGRAM TO CALCULATE NEGATIVE BINOMIAL FREQUENCY 
30 REM DISTRIBUTION FROM OBSERVED FREQUENCY DISTRIBUTION. BY 
40 REM MICHAEL D. DIXON, MARCH/APRIL, 1982. 
50 REM PROGRAM SECTOR FOR CALCULATING MEAN AND VARIANCE (LINES 
60 REM 250-400) ADAPTED FROM 'CLASS' PROGRAM BY VAN TASSEL 
70 REM CALCULATION OF 'W' AND 'K' AS PER S. BRAND MSC THESIS 
80 REM CITY UNIVERSITY, 1980. CALCULATION OF THEORETICAL 
90 REM DISTRIBUTION ADAPTE_a FROM FORTRAN IV PROGRAM, PP366-375 
100 REM IN 'COMPUTER PROGRAMMING IN QUANTITATIVE BIOLOGY' BY 
105 REM R. G. NAVIES, ACADEMIC PRESS. LONDON 1971. 
108 CLS 
110 DIM X(100). F(100). W(100) 
120 S=O: o=0: N=02K=O: P=O: R=0: 8=0: U=0 
Figure 101: Program in BASIC to calculate the Negative Binomial 
Frequency Distribution 
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130 PRINT: PRINT 
140 PRINT "####################ýF##' 
150 PRINT ' DETERMINATION OF THE' 
1.60 PRINT ' NEGATIVE BINOMIAL' 
170 PRINT "FREQUENCY DISTRIBUTION" 
180 PRINT 'ik####################ýk' 
190 PRINTSPRINT 
200 INPUT 'HOW MANY CLASSES'; C: INPUT 'TOTAL PATENTEES"; T 
210 PRINT: PRINT 
220 PRINT ' FOR EACH CLASS GIVE. 
-' 
230 PRINT' THE VALUE = X' 
240 PRINT' THE FREQUENCY = F' 
250 FOR H=1T0205TEP*0I: NEXTH*CLS 
260 FORI=ITOC 
270 PRINT 'FOR CLASS NO. '. I 
280 INPUT 'X='. X(I) 
290 INPUT 'F='; F(I) 
300 N=N+F(I) 
310 S=S+X(I)*F(I) 
320 O=0+F(I)*X(I)12 
330 NEXT I 
340 REM CALCULATE MEAN 
350 M=S/N 
360 REM CALCULATE VARIANCE 
370 V=(Q-SC2/N)/N 
380'REM DISPLAY MEAN AND VARIANCE 
390 PRINT 'MEAN = '; M 
400 PRINT 'VARIANCE = ': V 
480 P=M-1 
490 PRINT 'CALCULATED VALUE OF. W = 'iP 
500 K=(PC2)/(V-(M-1)) 
1060 REM CALCULATE THEORETICAL DISTRIBUTION 
1080 PRINT 'CALCULATED VALUE OF K= 'iK 
1090 W(1)=N/((1+(M-1)/K)CK) 
1100 SW=W(1) 
1110 FOR I=2TOC 
1120 U=(I-1) 
1130 W(I)=W(I-1)ß(K+(U-1))ß(M-1)/(K+(M-1))/U 
1140 SW=SW+W(I) 
1150 W(C+1)=T-SW 
1160 NEXT I 
1170 REM DISPLAY THEORETICAL DISTRIBUTION 
1180 PRINT TAB(5) 'CLASS'; 
1190 PRINT TAB(15) 'FREQUENCY' 
1195 FOR I=1TO(C+1) 
1200 PRINT TAB(7) I; 
1210 PRINT TAB(16) USING '####. ####'. W(I) 
1212 FCRJ=1T020STEP. 01*'NEXTJ 
1215 NEXT I 
1220 PRINT 
1230 PRINT 'Lt0 YOU WISH TO CALCULATE' 
1240 INPUT "ANOTHER DISTRIBUTION'; Ws 
1250 IF LEFTS(W$, 1)='Y'THEN]. 260ELSE1270 
1260 CLS: GQT010 
1270 PRINT 'NORMAL END OF JOB' 
1280 FOR Li=1T025STEP. 01**NEXTD*CLS 
9999 END 
Figure 101: Program in BASIC to calculate the Negative Binomial 
Frequency Distribution (continued) 
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4 4: 1: 1 : 141446-4 4"tt4t444i444 
DETERMINATION OF THE FOR CLASS NO. 14 
NEGATIVE BINOMTAl.. X= ? 14 
FREQUENCY DTSTRTRUTION F= ?2 
ikiý it 1ý A Jk Q iFih Jý FOR CLASS NO " 15 
X= ? 15 
F Ti 
HOW MANY CLASSES? 20 FOR CLASS NO. 16 
TOTAL PATENTFES? 192 X= ? 16 
F- ?1 
FOR EACH CLASS GIVE: 
- 
FOR CLASS NO. 17 
THE VALUE =X X= ? 17 
THE FREQUENCY =F F= ?3 
FOR CLASS NO. 1S 
FOR CLASS NO. 1 X= 718 
X= ?1 F- ?0 
F= 783 FOR CLASS NO. 19 
FOR CLASS NO. 2 X= ? 19 
X= ?2 F= ?0 
F= 724 FOR CLASS NO. 20 
FOR CLASS NO. 3 X= 720 
X= ,? 3 F. = ?0 
F= ? 16 MEAN = 3.17178 
FOR CLASS NO. 4 VARIANCE = 13.8846 
X= ?4 CALCULATED VALUE OF W=2,1.7178 
F= ?8 CALCULATED VALUE OF K= 
. 
402689 
FOR CLASS NO. 5 
X= ?5 CLASS FREQUENCY 
F= 75 1 77.2208 
FOR CLASS NO. 6 2 26.2320 
X= 76 
.3 
15.5200 
F= 76 4 10.4857 
FOR CLASS NO. 7 5 7.5246 
X =07 6 5.5894 
F= 72 7 4.2457 
FOR CLASS NO. 8 8 3.2 760 
X= ?8 9 2.5572 
"F = ?5 10 2.0141 
FOR CLASS NO. 9 11 1.5975 
X= 79 12 1.274; 
F= ?1 13 1.0216 
FOR CLASS NO. 10 14 0.8222 
X= ? 10 15 0.6640 
F= ?1- 16 0.5379 
FOR CLASS NO. 11 17 0.4368 
X= ? 11 18 013555 
F= ?1 19 0.2900 
FOR CLASS NO. 12 20. 0.2369 
X= ? 12 
'F "= 71 IDO YOU WISH TO CALCULATE 
FOR CLASS NO. 13 ANOTHER rIISTRIBUTTCN? NO 
X= ? 13 NORMAL END OF JOB 
F= ?3 
Figure 102: Computer run to calculate the Negative Binomial 
Distribution for Original Cephalosporins Data Set 
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APPENDIX XIX: THE KOLMOGOROV-SMIRNOV ONE-SAMPLE TEST 
The Kolmogorov-Smirnov test has been described by Birnbaum 205,206 
Birnbaum and Tingey307, Goodman308, Massey309, and Siegel173. Also, 
Robertson253 has confirmed Coile's view that the test is more suitable 
than the X2 test for goodness of fit in studies of frequency distribu- 
tions on scientific productivity. 
The test is concerned with the degree of agreement between the distri- 
bution of a set of sample values (observed scores) and a specified 
theoretical distribution. It determines whether the scores in the 
sample can reasonably be considered to have come from a population 
having the theoretical distribution. 
To achieve this, the test involves specifying the cumulative freqency 
distribution which would occur under the theoretical distribution and 
comparing that with the observed cumulative frequency distribution. 
The point at which these distributions show the greatest divergence is 
determined. Reference to the sampling distribution indicates whether a 
divergence of the magnitude calculated is likely on the basis of 
chance. 
Let F0(X) represent the theoretical cumulative frequency distributions. 
For any value of X, the number of patents, the value of F0(X) is the 
fraction of total patentees predicted to have X or fewer patents. 
SN(X) represents the observed cumulative frequency distrubution of the 
total of N patentees. 
Under the null hypothesis that the sample has been drawn from the 
theoretical distribution, it is expected that for every value of X, 
SN(X) should be fairly close to F0(X); that is to say the differences 
between SN(X) and F0(X) are expected to be small and within the limits 
-of random errors. The Kolmogorov-Smirnov tests these absolute value 
differences; the largest value of F0(X) 
- 
SN(X) is called the maximum 
deviation, D, which is: 
D= maximum I F0(X) 
- 
SN(X) 
Massey309 gives critical values of D which are reproduced in Table 
62. 
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Sample Level of Significance for 
Size D= maximum IF (X) 
-S (X)I 0 n (N) 
. 
10 
. 
05 
. 
01 
1 
. 
950 
. 
975 
. 
995 
2 
. 
776 
. 
842 
. 
929 
3 
. 
642 
. 
708 
. 
828 
4 
. 
564 
. 
624 
. 
733 
5 
. 
510 
. 
565 
. 
669 
6 
. 
470 
. 
521 
. 
618 
7 
. 
438 
. 
486 
. 
577 
8 
. 
411 
. 
457 
. 
543 
9 
. 
388 
. 
432 
. 
514 
10 
. 
368 
. 
410 
. 
490 
11 
. 
352 
. 
391 
. 
468 
12 
. 
338 
. 
375 
. 
1150 
13 
. 
325 
. 
361 
. 
433 
14 
. 
314 
. 
349 
. 
418 
15 
. 
304 
. 
338 
. 
404 
16 
. 
295 
. 
328 
. 
392 
17 
. 
286 
. 
318 
. 
381 
18 
. 
278 
. 
309 
. 
371 
19 
. 
272 
. 
301 
. 
363 
20 
. 
264 
. 
294 
. 
356 
25 
. 
24 
. 
27 
. 
32 
30 
. 
22 
. 
24 
. 
29 
35 
. 
21 
. 
23 
. 
27 
Table 61: Critical Values of D in the Kolmogorov-Smirnoy 
One-Sample Test (Adapted from Massey309) 
If N, the sample size, is greater than 35, critical values of D are 
calculated as follows: 
At 0.10 Level of Significance, D=1.22/ N 
At 0.05 Level of Significance, D=1.36/, / N 
At 0.01 Level of Significance, D=1.63/t/ N 
Using the observed Cephalosporins (original set) data and the theore- 
tical distribution determined by the Negative Binomial frequency 
distribution, Table 63 illustrates how D may be calculated. 
Brand267 has described a computer program, written in FORTRAN IV, to 
perform the Kolmogorov-Smirnov Test. For the present study a program, 
given in Figure 103, has been written in BASIC which will calculate D 
and the corresponding critical values, for up to 100 pairs of theore- 
tical and observed data. The program places the observed and thebre- 
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PATENTS THEORETICAL OBSERVED 
PER PATENTEE % F (X) % SN(X) Fo(X)-SN(X) 
0 
1 40.22 0.4022 43.23 0.4323 
-0.0301 
2 13.66 0.5388 12.50 0.5573 
-0.0185 
3 8.08 0.6196 8.33 0.6406 
-0.0210 
4 5.46 0.6742 4.17 0.6823 
-0.0081 
5 3.92 0.7134 2.60 0.7083 0.0051 
6 2.91 0.7425 3.13 0.7396 0.0029 
7 2.21 0.7646 1.04 0.7500 0.0146 
8 1.71 0.7817 2.60 0.7760 0.0057 
9 1.33 0.7950 0.52 0.7812 0.0138 
10 1.05 0.8055 0.52 0.7864 0.0191 
11 0.83 0.8138 0.52 0.7916 0.0222 
12 0.66 0.8204 0.52 0.7968 0.0236 
13 0.53 0.8257 1.56 0.8124 0.0133 
14 0.43 0.8300 1.04 0.8228 0.0072 
15 0.35 0.8335 0.52 0.8280 0.0055 
16 0.28 0.8363 0.52 0.8332 0.0031 
17 0.23 0.8386 1.56 0.8488 
-0.0102 
18 0.19 0.8405 0.00 0.8488 
-0.0083 
19 0.15 0.8420 0.00 0.8488 
-0.0068 
20 0.12 0.8432 0.00 0.8488 
-0.0056 
Dmax 
= 0.0301 N= 192 
0.10 Level of significance = 1.22 / 192 = 0.0880 
0.05 Level of significance = 1.36 / 192 = 0.0981 
0.01 Level of significance = 1.63 / 192 = 0.1176 
Table 62: Determination of Kolomogorov-Smirnov D_ax for Cephalosporins 
Original Data set observed Frequency Distribution and Negative Binomial 
Theoretical Frequency Distribution 
tical distributions . in arrays and, having calculated F0(X) 
- 
SN(X), 
sorts these values in ascending order. The highest values, i. e., Dmax' 
is selected and printed together with the critical values at 0.1,0.05 
and 0.01 levels of significance. The validity of the program was 
checked by comparing results with selected mathematical calculations of 
D. The computer determination of Dmax for the original set of Cephalo- 
sporin data and the calculated Negative Binomial distribution is given 
in Figure 104. 
- 
411 
- 
10 CLEAR 10000 
20 CLS 
30 REM SET ARRAYS 
40 DIM. 0(100)YE(100). D(100), T(i00), 7_(100) 
50 PRINT **ýc***ýk* % ýcýckcý Xcýcýcýc**ýcýc ýcýcýc* "
60 PRINT' CALCULATION OF D(MAX) FOR' 
70 PRINT ' KQLMQGoRoV-SMII; NQV' 
80 PRINT ' ONE SAMPLE TEST' 
90 PRINT *ýCýC*ýCýkýc*ýCý***ýcýcýýcýC*ýKWýC*ýc" 
100 PRINT: PRINT: PRINT 
110 PRINT 'ARE YOU READY TO' 
120 INPUT' INPUT YOUR DATA (YES/NQ)'; As 
130 IF LEFT$(A$r1)='Y' THEN 140 ELSE 110 
140 CLS 
150 INPUT'TOTAL NUMBER PATENTF_F_S'iN 
160'PRINTSINPUT'NUMBER OF PAIRS OF DATA'; 0 
170 PRINT: PRINT'PLEASE INPUT YOUR DATA' 
180 FOR I=1T0(1 
190 PRINT: PRINT 'PAIR'; I 
200 INPUT 'OBSERVED FREQUENCY = '; 0 
210 CS(I)=O/N 
220 INPUT 'EXPECTED FREQUENCY = 'iE 
230 E(I)=E/N 
240 NEXT I 
250 REM CALCULATE F0(X), SET IN ARRAY D 
260 FOR I=1TOO 
270 U(I)=0 
280 I1(I)=0(I)+D(I-1) 
290 NEXT I 
300 REM CALCULATE SN(X). SET IN ARRAY T 
310 T(I)=0 
320 T(I)=E(I)+T(I-1) 
330 NEXT I 
340 REM CALCULATE ABSOLUTE VALUE OF 
350 REM (F0(X)-SN(X)), SET IN ARRAY Z 
360 FOR I=1T00 
370 LET Z(I)=ABS(tI(I)-T(I)) 
380 NEXT I 
390 REM SORT Z(I) VALUES INTO ASCENDING ORDER 
400 FOR I=1TO(O-1) 
410 FOR J=QTO(I+1)STEP-1 
420 IF Z(J)C=Z(J-1) THEN 460 
430 LET F=Z(J-1) 
440 LET Z(J-1)=Z(J) 
450 LET Z(J)=F 
460 NEXT Jt 
470 NEXT I 
480 REM SELECT HIGHEST VALUE OF Z(I)v I. E. r Il(MAX) 
490 FOR I=1TAOSTEP-Q 
500 CLS 
510 PRINT: PPINT 'A(MAX) = 'i 
515 PRINT USING '#. ####'iZ(I) 
516 PRINT 
520 REM CALCULATE AND DISPLAY CRITICAL_ VALUES OF D(MAX ) 
530 PRINT 'CRITICAL VALUES OF D (WHEN' 
Figure 103: Program in BASIC to determine D for Kolmogorov-Smironoy 
max 
One Sample Test 
- 
412 
- 
540 PRINT'N IS >=35 
- 
ELSE REFER TO' 
550 PRINT 'TABLES) ARE 2-' 
560 PRINT 
570 PRINT 'AT 0.10 SIGNIFICANCE' 
580 PRINT ' LEVEL = ': 
585 PRINT USING 0*. ##*#'; 1.22/SQR(N) 
590 PRINT 'AT 0.05 SIGNIFICANCE' 
600 PRINT ' LEVEL 
_ 
'+ 
605 PRINT USING '#. ####'; 1.36/SOR(N) 
610 PRINT 'AT 0.01 SIGNIFICANCE' 
620 PRINT ' LEVEL = '+ 
625 PRINT USING '#. #4##'i1.63/SCOR(N) 
630 PRINT 
640 PRINT 'DO YOU WANT TO RUN ANOTHER" 
650 INPUT 'TEST? TYPE 'YES' OR 'NO " +B$ 
660 IF LEFT$(B$, 1)='Y' THEN 140 ELSE 670 
670 PRINT "END OF-JOB" 
680 FOR P=1T010STEP. 0I: NEXTPSCLS 
999 END 
Figure 103: Program in BASIC to determine D for Kolmogorov-Smironov 
ax 
One Sample Test (continued) 
- 
413 
- 
CALCULATION OF D(MAX) FOR 
KOLMO60ROV-SMIRNOV 
ONE SAMPLE TEST 
ARE YOU READY TO 
INPUT YOUR DATA (YES/NO)? YES 
TOTAL. NUMBER OF PATENTEES? 192 
NUMBER OF PAIRS OF DATA? 20 
PLEASE INPUT YOUR DATA 
FAIR 1 
OBSERVED FREQUENCY = ? 83 
EXPECTED FREQUENCY = ? 77.2208 
PAIR 2 
OBSERVED FREPUENCY = ? 24 
EXPECTED FREOLIENCY = ? 26.232 
PAIR la. 
OBSERVED FREQUENCY 
. 
EXPECTED FREQUENCY = "7 ý..::, ýý , 
FAIR 12 
OBSERVED FREQUENCY = M. 
EXPECTED FREQUENCY = ? 1.274 
PAIR 13 
OBSERVED FREQUENCY = ?3 
EXPECTED FREQUENCY = ? 1.0716 
PAIR 14 
OBSERVED FREQUENCY = ?2 EXPECTED FREQUENCY = ? *0222. 
PAIR 15 
OBSERVED FREQUENCY = ?I EXPECTED FREQUENCY = ?. 664 
PAIR 16 
OBSERVED FREQUENCY = ? 1. EXPECTED FREQUENCY = ? #5379 
PAIR 3 FAIR 17 
OBSERVED FREQUENCY = T16 OBSERVED FREQUENCY = ?3 
EXPECTED FREQUENCY = ? 15.52 
EXPECTED FREQUENCY 
= ? 44368 
PAIR 4 PAIR 18 
OBSERVED FREQUENCY = ?8 
OBSERVED FREQUENCY = 70 
EXPECTED FREQUENCY = ? 10.487 
EXPECTED FREQUENCY = ?.; i 55 
PAIR 5 
OBSERVED FREQUENCY n ?5 
EXPECTED FREQUENCY = ? 7.5246 
PAIR 6 
OBSERVED FREQUENCY 
= ?h 
EXPECTED FREPUJE. NCY = ? 5.5894 
PAIR 7 
OBSERVED FREQUENCY = ?i 
EXPECTED FREQUENCY = ? 4.2457 
PAIR 8 
OBSERVED FREQUENCY = ?r 
EXPECTED FREQUENCY 
= ? 3.276 
FAIR 9 
OBSERVED FRFOUFNCY 
= ?I 
EXPECTED FREPUENCY 
= ? 2.5572 
FAIR 1.9 
OBSERVED FREM. WNCY = ?0 
EXPECTELI FREPIJENCY = ? #29 
PAIR 20 
OBSERVED FREQUENCY = ?0 
EXPECTED FREQUENCY ? #2369 
D (MAX) 0.0301 
CRITICAL VALUES OF D (WHEN 
N IS >=35 
- 
ELSE REFER TO 
TABLES) ARE :. 
- 
AT 0.10 SIflNIFICANCE 
LEVEL_ 
= 0.0880 
AT 0.05 SIGNIFICANCE 
LEVEL = 0.0981 
AT 0.01. SIGNIFICANCE 
LEVEL 
= 0#11.76 
PAIR 10 
'AFBSFRVFri FREQUENCY = ?i 
EXPECTED FREOUENCY w ? 2.4141 
tb YOU WANT TO RI. IN ANOTHER 
TEST? TYPE 'YES' OR 'NO'? NO 
END OF JOB 
Figure 104: Kolmogorov-Smirnov Test computer run for Observed 
Distribution Original Cephalosporins Data Set and calculated 
Negative Binomial Distribution 
-414-- 
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